Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.

Overview for Request: cder_mpl1r_wp271

Request ID: cder_mpl1r_wp271_nsdp_v01

Request Description: In this report, we counted and described individuals in the Rapid Sentinel Distributed Database (SDD) with evidence of coronavirus disease 2019 (COVID-19) vaccinations. We identified individuals with at least one COVID-19 vaccination and calculated the timing between doses, overall and by brand. We additionally identified individuals with at least two COVID-19 vaccinations and characterized the timing between doses. We finally identified individuals with evidence of a booster COVID-19 vaccination.

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 13.0.1

Data Source: We distributed this request to six Sentinel Rapid COVID Database Data Partners (DPs) on May 17, 2024. The study period included data from November 1, 2020, to February 29, 2024. Please see Appendix A for a list of available data dates for each Data Partner.

Study Design: We identified individuals of all ages in the Sentinel Rapid COVID Distributed Database who received COVID-19 vaccines. This is a Type 2 analysis in the Query Request Package (QRP) documentation. We conducted these analyses in four

Run 1 (r01): We examined patients who received at least one COVID-19 vaccine overall and stratified by age group, sex, year, calendar month, geographic region, and year-month-age group. We characterized the demographic and clinical characteristics of this cohort. We also summarized the time interval between the first and second doses.

Run 2 (r02): We examined patients who received at least two COVID-19 vaccines overall and stratified by sex, U.S. State and territory, and year-month-age group. We characterized the demographic and clinical characteristics of this cohort. We also summarized the time interval between the first and second doses.

Run 3 (r03): We examined patients who received at least one COVID-19 vaccine by vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax, or unspecified]) or by data source (only immunization information systems [IIS] data, only claims data, or both IIS and claims data). We summarized the time interval between first and second doses for all possible combinations of brand or data source.

Run 4 (r04): We examined the number of patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021. We defined boosters using four different cohorts:

Cohort 1: Individuals with evidence of at least two vaccine codes more than four days apart prior to their booster dose.
Cohort 2: Individuals with a history of an immunocompromising condition, and evidence of at least three vaccine codes more than four days apart prior to their booster dose.
Cohort 3: Individuals without a history of an immunocompromising condition, and evidence of at least two vaccine codes more than four days apart prior to their booster dose.
Cohort 4: Individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine.

We examined the overall patient count in each cohort. Cohort 1 was further stratified by sex, geographic region, and year-month-age group. For this cohort, we additionally described the demographic and clinical characteristics.

Overview for Request: cder_mpl1r_wp271

Exposures of Interest: Our exposure of interest was any brand and type of COVID-19 vaccine administered or dispensed in any care setting in the United States (Pfizer-BioNTech, Moderna, Janssen, Novavax, or unspecified). These were defined using Healthcare Common Procedure Coding System (HCPCS) procedure codes, Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, National Drug Codes (NDCs), and IIS Vaccine Administered Code Set (CVX)[1] codes. Please see Appendix B for a list of non-proprietary and proprietary names of medical products, and Appendix C for a list of procedure codes used to define exposures in this request.

We included only the first valid index date during the query period for each patient; cohort re-entry was not allowed. If more than one vaccine code appeared on the index day, the patient still only contributed one exposure episode, but all codes were taken into account for brand and data source analyses. Additional details on exposures and index dates for each run are defined below:

Run 1 (r01): The index date was the date of the first COVID-19 vaccine. The first COVID-19 vaccination was identified as the first instance without any previous COVID-19 vaccination records.

Run 2 (r02): The index date was the date of the first COVID-19 vaccine. The first COVID-19 vaccination was identified as the first instance without any previous COVID-19 vaccination records. Individuals were also required to have evidence of a second dose at least four days after the index date.

Run 3 (r03): The index date was the date of the first COVID-19 vaccine with a given brand or data source for a given cohort. The first COVID-19 vaccination was identified as the first instance without any previous COVID-19 vaccination records. We included 16 cohorts based on brand combinations for first and second dose (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for first and second dose (Only IIS-Only IIS, Only IIS-IIS&Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS&Claims, Only Claims-Only IIS, IIS&Claims-Only IIS, IIS&Claims-Only Claims, and IIS&Claims-IIS&Claims).

Run 4 (r04): The index date was the date of the COVID-19 vaccine booster. For cohorts 1-3, the COVID-19 vaccine booster was defined as any COVID-19 vaccine observed after September 1, 2021, with two prior vaccine codes (for all and non-immunocompromised cohorts) or three prior vaccine codes (for immunocompromised cohorts) more than four days apart. For cohort 4, the COVID-19 vaccine booster was defined as any COVID-19 vaccine after September 1, 2021, where the code description specified that it was for a booster or bivalent COVID-19 vaccine.

Cohort Eligibility Criteria: We required members to have medical and drug coverage for a minimum of 183 days before the index date; gaps in coverage of up to 45 days were allowed and considered continuous enrollment. Individuals of the following ages were included in the cohorts: 0-6 months, 6 months-4 years, 5-11, 12-15, 16-39, 40-64, and ≥ 65 years.

Overview for Request: cder_mpl1r_wp271

Inclusion/Exclusion Criteria: In Runs 1, 2, and 3 we excluded evidence of any prior COVID-19 vaccination records before the index date. This was to ensure that the first dose index date was date of the first ever COVID-19 vaccination record to occur. In Run 2, we added an inclusion criteria so that individuals were also required to have received a second COVID-19 vaccine dose at least four days after their first dose. We also excluded patients that had a duplicate vaccine code in the days 1-4 after the index event. This was to remove competing censoring events when evaluating the timing between the first and second dose (see Follow-up Time section below).

For Run 4, we had different inclusion criteria requirements for each of the four cohorts. For the overall booster cohort (cohort 1), we required patients to have two previous COVID-19 vaccine codes at least four days apart, at least four days before the index dose. For the immunocompromised cohort (cohort 2), we required patients to have three previous COVID-19 vaccine codes at least four days apart, at least four days before the index dose. We also required patients to have evidence of an immunocompromising condition in their enrollment history. We defined immunocompromised as any evidence of HIV/AIDS, hematological malignancy, treatment-independent immune deficiencies, dialysis, chemotherapeutic agents/diagnoses and procedures, immunosuppressant therapeutic agents/diagnoses and procedures, steroid diagnoses and procedures, organ transplant diagnoses and procedures, or solid malignancies. For the non-immunocompromised cohort (cohort 3), we required patients to have two previous COVID-19 vaccine codes at least four days apart, at least four days before the index dose. We also required patients to not have any evidence of an immunocompromising condition in their enrollment history. For the booster-specific code cohort (cohort 4), we did not have any additional inclusion or exclusion criteria. Please see Appendix D for a list of the codes used to define the inclusion and exclusion criteria.

Follow-up Time: For all cohorts where we evaluated the timing between first and second COVID-19 vaccine doses, any COVID-19 vaccine codes that occurred within 1-4 days after the index date were defined as duplicate first dose codes and subsequently ignored when assessing timing to second dose. Therefore, follow-up began on day five after the index dispensing and continued until the first occurrence of any of the following: 1) evidence of a second dose; 2) disenrollment; 3) death; 4) the end of the data provided by each Data Partner; or 5) the end of the query period.

Overview for Request: cder_mpl1r_wp271

Baseline Characteristics: Baseline characteristics were included for the cohorts in Run 1, Run 2, and the overall booster cohort from Run 4. We described demographic characteristics (such as sex, age, race, and ethnicity) and calendar year of the index date. We also assessed clinical characteristics in the 183 days prior to and including the index date. These characteristics included health conditions associated with severe COVID-19 outcomes (reactive airway disease and lung diseases, other chronic respiratory diseases, sickle cell disease, liver disease, tuberculosis, cystic fibrosis, congenital or acquired heart disease, lung cancer, breast cancer, colorectal cancer, prostate cancer, endometrial cancer, other cancer, asthma, chronic obstructive pulmonary disease [COPD] and bronchiectasis, diabetes, chronic kidney disease, hypertension, acute myocardial infarction, atrial fibrillation, heart failure, ischemic heart disease, stroke/transient ischemic attack, history of cardiac arrest, history of coronary angioplasty or bypass, Alzheimer's disease/dementia, depression, bipolar or other depressive mood disorders, attention-deficit/hyperactivity disorder, alcohol abuse or dependence, drug abuse or dependence, obesity, smoking, and immunocompromised (HIV/AIDS, hematological malignancy, treatment-dependent immune deficiencies, dialysis, chemotherapeutic agents, immunosuppressant treatments, steroids, organ transplant, or solid malignancies) and other general health indicators (hyperlipidemia, rheumatoid arthritis/osteoarthritis, acquired hypothyroidism, glaucoma, osteoporosis, anemia, benign prostatic hyperplasia, hip/pelvic fracture, cataracts, and Parkinson's disease/secondary parkinsonism). We assessed evidence of cerebral palsy, spinal cord injuries, and Down syndrome in patients' entire available history. We further evaluated COVID-19 diagnoses and related treatments (including lopinavir/ritonavir, remdesivir, hydroxychloroquine, chloroquine, azithromycin, ivermectin, dexamethasone, other corticosteroids, inhaled corticosteroids, Paxlovid, baricitinib, tocilizumab, bamlanivimab, casirivimab/imdevimab, bamlanivimab/etesevimab, sotrovimab, non-steroidal anti-inflammatory drugs, and antidepressants) in the 183 days before and including the index date, and separately in the 183 days after the index date. We reported additional details about the index COVID-19 vaccine at the index date, such as brand (Pfizer-BioNTech, Moderna, Janssen, Novavax, or unspecified), COVID-19 vaccine code type (CVX codes or NDC/CPT-4/HCPCS codes), monovalent or bivalent (only in Pfizer-BioNTech, Moderna vaccines), and percentage of duplicated codes in the 1-4 days after the index date.

We used International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes, HCPCS procedure codes, CPT-4 procedure codes, and NDCs to define the clinical characteristics and treatments. Please see Appendix E for a list of diagnosis and procedure codes used to define baseline characteristics in this request, Appendix F for a list of non-proprietary and proprietary names of medical products.

Please refer to Appendices G, H, I and J for the specifications of parameters used in this request and a design diagram.

Limitations: Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (https://dev.sentinelsystem.org/projects/SETINEL/repos/sentinel-routine-querying-tool-documentation/browse).

[1] Schneider, Karen L et al. "Use of Immunization Information Systems in Ascertainment of COVID-19 Vaccinations for Claims-Based Vaccine Safety and Effectiveness Studies." JAMA Network open vol. 6,5 e2313512. 1 May. 2023, doi:10.1001/jamanetworkopen.2023.13512

Sentinel

Table of Contents

Glossary (CIDA) List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report

Patient Characteristics Tables

Table 1 r01 Aggregated Characteristics of Patients With At Least One Dose of Coronavirus Disease 2019 (COVID-19) Vaccination in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Table 1 r02 Aggregated Characteristics of Patients With at Least Two Coronavirus Disease 2019 (COVID-19) Vaccines in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Table 1 r04 Aggregated Characteristics of Patients with Booster Coronavirus Disease 2019 (COVID-19) Vaccine in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024

Summary of Exposures of Interest

Table 2 r01 Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine) in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Table 2 r02 Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines) in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Table 2 r03 Summary of Exposures of Interest (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Table 2 r04 Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine) in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024

Stratified Tables for Run 1 (At Least One COVID-19 Vaccine)

Table 3a r01 Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine) in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Sex

Table 3b r01 Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine) in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group

Table 3c_r01 Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine) in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Year

Table 3d r01 Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine) in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Year and Month

Table 3e r01 Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine) in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by US State and Territory

Table 3f r01 Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19} Vaccine) in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

Stratified Tables for Run 2 (At Least Two COVID-19 Vaccines)

Table 3a r02 Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines) in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Sex

Table 3b r02 Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines) in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by US State and Territory

Table 3c r02 Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines) in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

Stratified Tables for Run 4 (Booster COVID-19 Vaccine)

Table 3a r04 Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine) in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Sex

Table of Contents

Table 3b r04 Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine) in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by US State and Territory

Table 3c r04 Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine) in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

Interval Time Between the First and Second Vaccine

Table 4 r01 Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations Among Patients With at Least One COVID-19 Vaccine in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Table 4 r02 Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations Among Patients With At Least Two COVID-19 Vaccines in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Table 4 r03 Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code Distribution Tables for Runs 1 (At Least One COVID-19 Vaccine) and 2 (At Least Two COVID-19 Vaccines)

Table 5a r01 Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine) in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Table 5a r02 Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines) in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Table 5b r01 Total Code Counts of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine) in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Table 5b r02 Total Code Counts of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines) in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Cohort Attrition Tables

Table 6 r01 Summary of Patient-Level Cohort Attrition (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine) in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Table 6 r02 Summary of Patient-Level Cohort Attrition (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines) in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Table 6 r03 Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Table 6 r04 Summary of Patient-Level Cohort Attrition (Booster Coronavirus Disease 2019 [COVID-19] Vaccines) in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024

Appendices

Appendix A Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (May 17, 2024)

Appendix B List of Non-proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Appendix C List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

Appendix D List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Table of Contents

Appendix E List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Appendix F Technical Specifications Used for this Request

Appendix G r01 Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

Appendix G r02 Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Appendix G r04 Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Appendix H Design Diagram Used for this Request

Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.
Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.
Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.
Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.
Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.
Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.
Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).
Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.
Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.
Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.
Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.
Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.
Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.
Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.
Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.
Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).
Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."
Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.
Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.
Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.
Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.
Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.
Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.
Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.
Query Period - period in which the modular program looks for exposures and outcomes of interest.
Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).
Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.
Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.
Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.
Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.
Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.
Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1 r01. Aggregated Characteristics of Patients With At Least One Dose of Coronavirus Disease 2019 (COVID-19) Vaccination [1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	Coronavirus Disease 2019 (COVID-19) Vaccination	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[2]**
Unique patients	15,530,103	N/A
Demographic Characteristics		
Age (Years)	46.2	20.6
Age Group (Years)		
0-6 months	14,467	0.1%
7-59 months	181,904	1.2%
5-11 years	712,634	4.6%
12-15 years	637,777	4.1%
16-39 years	4,609,862	29.7%
40-64 years	5,979,219	38.5%
≥ 65 years	3,394,240	21.9%
Sex		
Female	8,258,723	53.2%
Male	7,271,380	46.8%
Race[3]		
American Indian or Alaska Native	16,778	0.1%
Asian	380,392	2.4%
Black or African American	520,287	3.4%
Multi-racial	395,811	2.5%
Native Hawaiian or Other Pacific Islander	21,645	0.1%
Unknown	10,374,231	66.8%
White	3,820,959	24.6%
Hispanic origin		
Yes	362,613	2.3%
No	1,778,839	11.5%
Unknown	13,388,651	86.2%
Year		
2020	204,535	1.3%
2021	12,795,346	82.4%
2022	2,262,353	14.6%
2023	267,830	1.7%
2024	39	0.0%
COVID-19 Vaccination		
Duplicated COVID-19 vaccine records *(having evidence of days with any COVID-19 vaccine codes 1-4 after the index date [not including the index])*	172,654	1.1%
COVID-19 Vaccine Brand for the First Observed Record		
Pfizer at index	9,114,170	58.7%
Moderna at index	5,584,660	36.0%
Jannsen at index	818,691	5.3%
Novavax at index	3,048	0.0%
Unspecified at index	64,244	0.4%
Other (including Janssen, Novavax, or Unspecified) at index	883,480	5.7%
Having both Pfizer and Moderna at the index	21,352	0.1%

Table 1 r01. Aggregated Characteristics of Patients With At Least One Dose of Coronavirus Disease 2019 (COVID-19) Vaccination [1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	Coronavirus Disease 2019 (COVID-19) Vaccination	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[2]**
Having both Pfizer and Other at the index	16,829	0.1%
Having both Moderna and Other at the index	14,116	0.1%
Having both Pfizer and Moderna 1-4 days after the index	269	0.0%
Having both Pfizer and Other 1-4 days after the index	90	0.0%
Having both Moderna and Other 1-4 days after the index	72	0.0%
Only Pfizer at index	9,076,079	58.4%
Only Moderna at index	5,549,282	35.7%
Only Jannsen at index	811,984	5.2%
Only Novavax at index	2,917	0.0%
Only Unspecified at index	35,235	0.2%
Only Other (including Janssen, Novavax, or Unspecified) at index	852,625	5.5%
COVID-19 Vaccine Code Type for the First Observed Record		
Insurance claims data (National Drug Codes[NDC]/Current Procedural Terminology[CPT]/Healthcare Common Procedure Coding System [HCPCS] codes) at index	12,228,574	78.7%
State-based Immunization Information Systems (IIS) (Vaccine Administered Code Set [CVX] codes) at index	7,527,550	48.5%
Having both IIS and insurance claims data at index	4,226,021	27.2%
Only Insurance claims data at index	8,002,553	51.5%
Only IIS data at index	3,301,529	21.3%
Having both insurance claims and IIS data 1-4 days after the index	21,294	0.1%
COVID-19 Vaccine for the First Observed Record; Monovalent or Bivalent (only Pfizer and Moderna)		
Monovalent at index	13,522,180	87.1%
Bivalent at index	1,166,502	7.5%
Having both Monovalent and Bivalent at index date	11,204	0.1%
Only Monovalent at index date	13,510,976	87.0%
Only Bivalent at index date	1,155,298	7.4%
Monovalent and Bivalent 4 days of index	93	0.0%
COVID-19 Vaccine for the First Observed Record; Whether the "dose1" is Mentioned in the Code Description		
Covid-19 Vaccine Dose 1	6,694,869	43.1%
COVID-19 Vaccine for the Second Observed Record; Whether the "dose2" is Mentioned in the Code Description		
Covid-19 Vaccine Dose 2	3,770,691	24.3%
Total Number of Observed Days with Records for the COVID-19 Vaccination after Index, Including the First Record		
With at least one COVID-19 vaccine codes	15,530,103	100.0%
With at least two COVID-19 vaccine codes in two separate days	12,087,681	77.8%
With at least three COVID-19 vaccine codes in three separate days	6,602,626	42.5%
With one COVID-19 vaccine	3,442,422	22.2%
With two COVID-19 vaccine in two separate days	5,485,055	35.3%
With three COVID-19 vaccine in three separate days	3,727,566	24.0%
With ≥4 COVID-19 vaccine codes in ≥4 separate days	2,875,060	18.5%
Health Characteristics		
Reactive Airway and Lung Diseases	2,054	0.0%
Other Chronic Respiratory Diseases (e.g., Pneumonia and Bronchitis)	352,467	2.3%
Sickle Cell Disease	8,353	0.1%
Liver disease (severe/moderate)	369,370	2.4%

Table 1 r01. Aggregated Characteristics of Patients With At Least One Dose of Coronavirus Disease 2019 (COVID-19) Vaccination [1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	Coronavirus Disease 2019 (COVID-19) Vaccination	
Patient Characteristics	Number/Mean	Percent/ Standard Deviation[2]
Tuberculosis	6,655	0.0%
Cystic fibrosis	3,847	0.0%
Congenital or Acquired Heart Disease	62,717	0.4%
Lung Cancer	29,908	0.2%
Breast Cancer	140,063	0.9%
Colorectal Cancer	36,383	0.2%
Prostate Cancer	106,649	0.7%
Endometrial Cancer	12,326	0.1%
Other cancer	696,082	4.5%
Asthma	278,451	1.8%
Chronic obstructive pulmonary disease (COPD) and Bronchiectasis	306,061	2.0%
Diabetes types 1 and/or 2	1,244,719	8.0%
Chronic Kidney Disease	548,664	3.5%
Hypertension	2,386,117	15.4%
Acute Myocardial Infarction	22,343	0.1%
Atrial Fibrillation	313,959	2.0%
Heart Failure	361,513	2.3%
Ischemic Heart Disease	775,170	5.0%
Stroke/Transient Ischemic Attack (TIA)	87,882	0.6%
History of Cardiac Arrest	3,780	0.0%
History of Coronary Angioplasty or Bypass	187,611	1.2%
Alzheimer's Disease and related conditions	154,755	1.0%
Depression	1,526,035	9.8%
Bipolar or Other Depressive Mood Disorders	225,882	1.5%
Attention-deficit/hyperactivity disorder (ADHD)	399,856	2.6%
History of Cerebral palsy	114,626	0.7%
History of Spinal cord injuries	73,725	0.5%
History of Down syndrome	6,914	0.0%
Alcohol Abuse or Dependence	153,443	1.0%
Drug Abuse or Dependence	157,641	1.0%
Obesity/overweight	2,406,256	15.5%
Smoking	946,652	6.1%
Immunocompromised	2,393,233	15.4%
Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)	36,386	0.2%
Hematological Malignancy	87,113	0.6%
Treatment-Independent Immune Deficiencies	66,679	0.4%
Dialysis	29,130	0.2%
Chemo Therapeutic Agents	249,634	1.6%
Immunosuppressant Therapeutic Agents	231,076	1.5%
Steroid/Corticosteroid Diagnoses and Procedures and Dispensings	1,275,380	8.2%
Organ Transplant Diagnoses and Procedures	33,800	0.2%
Solid Malignancies	948,149	6.1%
Hyperlipidemia	1,968,830	12.7%
Rheumatoid Arthritis/Osteoarthritis	829,640	5.3%

Table 1 r01. Aggregated Characteristics of Patients With At Least One Dose of Coronavirus Disease 2019 (COVID-19) Vaccination [1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	Coronavirus Disease 2019 (COVID-19) Vaccination	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[2]**
Acquired Hypothyroidism	627,667	4.0%
Glaucoma	559,601	3.6%
Osteoporosis	170,598	1.1%
Anemia	426,144	2.7%
Benign Prostatic Hyperplasia	206,782	1.3%
Hip/Pelvic Fracture	21,702	0.1%
Cataract	787,839	5.1%
Parkinsons Disease and Secondary Parkinsonism	33,394	0.2%
Comorbidity score		
Charlson/Elixhauser combined comorbidity score[4]	0.5	1.4
Medical Product Use		
Pre-Index		
COVID-19 diagnosis	747,934	4.8%
Lopinavir/Ritonavir	131	0.0%
Remdesivir	28,869	0.2%
Hydroxychloroquine	78,232	0.5%
Chloroquine	224	0.0%
Azithromycin	531,522	3.4%
Ivermectin	14,372	0.1%
Dexamethasone	541,773	3.5%
Other Corticosteroids	1,622,868	10.4%
Inhaled Corticosteroids	530,645	3.4%
Paxlovid	38,582	0.2%
Baricitinib	1,738	0.0%
Tocilizumab	2,732	0.0%
Bamlanivimab	8,236	0.1%
Casirivimab/Imdevimab	9,816	0.1%
Bamlanivimab/Etesevimab	1,825	0.0%
Sotrovimab	790	0.0%
Non-steroidal anti-inflammatory drugs (NSAIDs)	1,516,756	9.8%
Antidepressants	2,624,805	16.9%
Post-Index		
COVID-19 diagnosis	422,321	2.7%
Lopinavir/Ritonavir	97	0.0%
Remdesivir	6,797	0.0%
Hydroxychloroquine	75,806	0.5%
Chloroquine	277	0.0%
Azithromycin	527,759	3.4%
Ivermectin	7,738	0.0%
Dexamethasone	519,781	3.3%
Other Corticosteroids	1,680,620	10.8%
Inhaled Corticosteroids	516,747	3.3%
Paxlovid	38,222	0.2%
Baricitinib	687	0.0%

Table 1 r01. Aggregated Characteristics of Patients With At Least One Dose of Coronavirus Disease 2019 (COVID-19) Vaccination [1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	Coronavirus Disease 2019 (COVID-19) Vaccination	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[2]**
Tocilizumab	2,700	0.0%
Bamlanivimab	849	0.0%
Casirivimab/Imdevimab	12,469	0.1%
Bamlanivimab/Etesevimab	2,021	0.0%
Sotrovimab	1,608	0.0%
Non-steroidal anti-inflammatory drugs (NSAIDs)	1,464,631	9.4%
Antidepressants	2,649,157	17.1%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	5.9	8.5
Mean number of emergency room encounters	0.1	0.7
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	2.1	4.0
Mean number of filled prescriptions	7.5	10.4
Mean number of generics dispensed	3.7	3.8
Mean number of unique drug classes dispensed	3.5	3.5

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051)

N/A: Not Applicable

Table 1 r02. Aggregated Characteristics of Patients With at Least Two Coronavirus Disease 2019 (COVID-19) Vaccines[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With at least two Coronavirus Disease 2019 (COVID-19) vaccine	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[2]**
Unique patients	11,915,048	N/A
Demographic Characteristics		
Age (Years)	45.1	21.1
Age Group (Years)		
0-6 months	12,229	0.1%
7-59 months	153,889	1.3%
5-11 years	608,742	5.1%
12-15 years	561,943	4.7%
16-39 years	3,532,172	29.6%
40-64 years	4,735,469	39.7%
≥ 65 years	2,310,604	19.4%
Sex		
Female	6,349,302	53.3%
Male	5,565,746	46.7%
Race[3]		
American Indian or Alaska Native	11,093	0.1%
Asian	298,504	2.5%
Black or African American	324,600	2.7%
Multi-racial	318,463	2.7%
Native Hawaiian or Other Pacific Islander	8,940	0.1%
Unknown	8,245,710	69.2%
White	2,707,738	22.7%
Hispanic origin		
Yes	276,968	2.3%
No	1,009,663	8.5%
Unknown	10,628,417	89.2%
Year		
2020	189,642	1.6%
2021	10,998,309	92.3%
2022	704,592	5.9%
2023	22,505	0.2%
2024	0	0.0%
COVID-19 Vaccination		
COVID-19 Vaccine Brand for the First Observed Record		
Pfizer at index	7,361,386	61.8%
Moderna at index	4,178,262	35.1%
Jannsen at index	369,345	3.1%
Novavax at index	1,770	0.0%
Unspecified at index	51,642	0.4%
Other (including Janssen, Novavax, or Unspecified) at index	421,281	3.5%
Having both Pfizer and Moderna at the index	18,957	0.2%
Having both Pfizer and Other at the index	14,954	0.1%
Having both Moderna and Other at the index	12,052	0.1%
Only Pfizer at index	7,327,557	61.5%

Table 1 r02. Aggregated Characteristics of Patients With at Least Two Coronavirus Disease 2019 (COVID-19) Vaccines[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With at least two Coronavirus Disease 2019 (COVID-19) vaccine	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[2]**
Only Moderna at index	4,147,335	34.8%
Only Jannsen at index	365,086	3.1%
Only Novavax at index	1,677	0.0%
Only Unspecified at index	26,129	0.2%
Only Other (including Janssen, Novavax, or Unspecified) at index	394,357	3.3%
COVID-19 Vaccine Code Type for the First Observed Record		
Insurance claims data (National Drug Codes[NDC]/Current Procedural Terminology[CPT]/Healthcare Common Procedure Coding System [HCPCS] codes) at index	8,983,873	75.4%
State-based Immunization Information Systems (IIS) (Vaccine Administered Code Set [CVX] codes) at index	6,640,068	55.7%
Having both IIS and insurance claims data at index	3,708,893	31.1%
Only Insurance claims data at index	5,274,980	44.3%
Only IIS data at index	2,931,175	24.6%
COVID-19 Vaccine for the First Observed Record; Monovalent or Bivalent (only Pfizer and Moderna)		
Monovalent at index	11,464,761	96.2%
Bivalent at index	58,258	0.5%
Having both Monovalent and Bivalent at index date	2,328	0.0%
Only Monovalent at index date	11,462,433	96.2%
Only Bivalent at index date	55,930	0.5%
COVID-19 Vaccine for the First Observed Record; Whether the "dose1" is Mentioned in the Code Description		
Covid-19 Vaccine Dose 1	6,046,197	50.7%
COVID-19 Vaccine for the Second Observed Record; Whether the "dose2" is Mentioned in the Code Description		
Covid-19 Vaccine Dose 2	3,732,590	31.3%
Total Number of Observed records for the COVID-19 Vaccination after Index, Including the First Record		
With at least one COVID-19 vaccine codes	11,915,048	100.0%
With at least two COVID-19 vaccine codes in two separate days	11,915,027	100.0%
With at least three COVID-19 vaccine codes in three separate days	6,447,015	54.1%
With one COVID-19 vaccine [4]	21	0.0%
With two COVID-19 vaccine in two separate days	5,468,012	45.9%
With three COVID-19 vaccine in three separate days	3,696,070	31.0%
With ≥4 COVID-19 vaccine codes in ≥4 separate days	2,750,945	23.1%
Health Characteristics		
Reactive Airway and Lung Diseases	1,482	0.0%
Other Chronic Respiratory Diseases (e.g., Pneumonia and Bronchitis)	228,915	1.9%
Sickle Cell Disease	5,904	0.0%
Liver disease (severe/moderate)	264,957	2.2%
Tuberculosis	4,749	0.0%
Cystic fibrosis	2,987	0.0%
Congenital or Acquired Heart Disease	47,716	0.4%

Table 1 r02. Aggregated Characteristics of Patients With at Least Two Coronavirus Disease 2019 (COVID-19) Vaccines[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With at least two Coronavirus Disease 2019 (COVID-19) vaccine	
Patient Characteristics	Number/Mean	Percent/ Standard Deviation[2]
Lung Cancer	19,448	0.2%
Breast Cancer	101,841	0.9%
Colorectal Cancer	25,273	0.2%
Prostate Cancer	72,931	0.6%
Endometrial Cancer	8,748	0.1%
Other cancer	511,232	4.3%
Asthma	204,925	1.7%
Chronic obstructive pulmonary disease (COPD) and Bronchiectasis	189,576	1.6%
Diabetes types 1 and/or 2	856,510	7.2%
Chronic Kidney Disease	347,881	2.9%
Hypertension	1,644,206	13.8%
Acute Myocardial Infarction	14,354	0.1%
Atrial Fibrillation	209,356	1.8%
Heart Failure	227,792	1.9%
Ischemic Heart Disease	519,797	4.4%
Stroke/Transient Ischemic Attack (TIA)	58,960	0.5%
History of Cardiac Arrest	2,465	0.0%
History of Coronary Angioplasty or Bypass	124,543	1.0%
Alzheimer's Disease and related conditions	96,340	0.8%
Depression	1,094,617	9.2%
Bipolar or Other Depressive Mood Disorders	159,005	1.3%
Attention-deficit/hyperactivity disorder (ADHD)	304,023	2.6%
History of Cerebral palsy	78,150	0.7%
History of Spinal cord injuries	51,054	0.4%
History of Down syndrome	5,356	0.0%
Alcohol Abuse or Dependence	104,532	0.9%
Drug Abuse or Dependence	101,243	0.8%
Obesity/overweight	1,708,758	14.3%
Smoking	639,446	5.4%
Immunocompromised	1,731,945	14.5%
Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)	26,186	0.2%
Hematological Malignancy	63,036	0.5%
Treatment-Independent Immune Deficiencies	45,673	0.4%
Dialysis	16,825	0.1%
Chemo Therapeutic Agents	180,928	1.5%
Immunosuppressant Therapeutic Agents	172,323	1.4%
Steroid/Corticosteroid Diagnoses and Procedures and Dispensings	910,466	7.6%
Organ Transplant Diagnoses and Procedures	24,518	0.2%
Solid Malignancies	691,917	5.8%
Hyperlipidemia	1,357,835	11.4%
Rheumatoid Arthritis/Osteoarthritis	567,392	4.8%
Acquired Hypothyroidism	443,316	3.7%

Table 1 r02. Aggregated Characteristics of Patients With at Least Two Coronavirus Disease 2019 (COVID-19) Vaccines[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With at least two Coronavirus Disease 2019 (COVID-19) vaccine	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[2]**
Glaucoma	400,867	3.4%
Osteoporosis	114,573	1.0%
Anemia	296,529	2.5%
Benign Prostatic Hyperplasia	138,334	1.2%
Hip/Pelvic Fracture	14,144	0.1%
Cataract	554,723	4.7%
Parkinsons Disease and Secondary Parkinsonism	22,086	0.2%
Comorbidity score		
Charlson/Elixhauser combined comorbidity score[5]	0.4	1.3
Medical Product Use		
Pre-Index		
COVID-19 diagnosis	558,020	4.7%
Lopinavir/Ritonavir	115	0.0%
Remdesivir	23,358	0.2%
Hydroxychloroquine	57,519	0.5%
Chloroquine	168	0.0%
Azithromycin	374,455	3.1%
Ivermectin	11,173	0.1%
Dexamethasone	389,579	3.3%
Other Corticosteroids	1,158,092	9.7%
Inhaled Corticosteroids	389,432	3.3%
Paxlovid	3,454	0.0%
Baricitinib	1,256	0.0%
Tocilizumab	2,140	0.0%
Bamlanivimab	7,462	0.1%
Casirivimab/Imdevimab	6,061	0.1%
Bamlanivimab/Etesevimab	1,202	0.0%
Sotrovimab	388	0.0%
Non-steroidal anti-inflammatory drugs (NSAIDs)	1,111,404	9.3%
Antidepressants	1,922,363	16.1%
Post-Index		
COVID-19 diagnosis	291,538	2.4%
Lopinavir/Ritonavir	86	0.0%
Remdesivir	3,955	0.0%
Hydroxychloroquine	56,373	0.5%
Chloroquine	212	0.0%
Azithromycin	376,818	3.2%
Ivermectin	5,998	0.1%
Dexamethasone	379,671	3.2%
Other Corticosteroids	1,245,372	10.5%
Inhaled Corticosteroids	382,478	3.2%
Paxlovid	9,903	0.1%
Baricitinib	388	0.0%
Tocilizumab	2,121	0.0%

Table 1 r02. Aggregated Characteristics of Patients With at Least Two Coronavirus Disease 2019 (COVID-19) Vaccines[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With at least two Coronavirus Disease 2019 (COVID-19) vaccine	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[2]**
Bamlanivimab	756	0.0%
Casirivimab/Imdevimab	8,632	0.1%
Bamlanivimab/Etesevimab	1,378	0.0%
Sotrovimab	972	0.0%
Non-steroidal anti-inflammatory drugs (NSAIDs)	1,102,267	9.3%
Antidepressants	1,979,307	16.6%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	5.8	8.3
Mean number of emergency room encounters	0.1	0.6
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.3	3.9
Mean number of filled prescriptions	7.1	10.1
Mean number of generics dispensed	3.4	3.7
Mean number of unique drug classes dispensed	3.2	3.4

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]In the covariate "Total number of observed records for the COVID-19 vaccination" after index, a small number of patients are recorded as having received only one COVID-19 vaccine. However, our cohort inclusion criteria require at least two COVID-19 vaccines (including index and after). This discrepancy arises because the assessment of covariates requires that claims occur during a valid enrollment span. For this query, both medical and drug coverage enrollment were necessary, meaning that any claim made during the enrollment period with only medical coverage, for instance, was not counted. This is the case for those few patients. Our cohort inclusion criteria consider all claims without restricting to those occurring during enrollment, which is why these patients are included in our cohort but not in our covariate.

[5]Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749-759. Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046-1051.

N/A: Not Applicable

Table 1 r04. Aggregated Characteristics of Patients with Booster Coronavirus Disease 2019 (COVID-19) Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024

	With Booster Coronavirus Disease 2019 (COVID-19) Vaccine	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[2]**
Unique patients	7,730,120	N/A
Demographic Characteristics		
Age (Years)	49.9	20.6
Age Group (Years)		
0-6 months	73	0.0%
7-59 months	84,563	1.1%
5-11 years	212,265	2.7%
12-15 years	240,557	3.1%
16-39 years	1,948,397	25.2%
40-64 years	3,222,250	41.7%
≥ 65 years	2,022,015	26.2%
Sex		
Female	4,218,077	54.6%
Male	3,512,043	45.4%
Race[3]		
American Indian or Alaska Native	6,805	0.1%
Asian	246,382	3.2%
Black or African American	218,881	2.8%
Multi-racial	214,471	2.8%
Native Hawaiian or Other Pacific Islander	3,781	0.0%
Unknown	5,039,010	65.2%
White	2,000,790	25.9%
Hispanic origin		
Yes	167,731	2.2%
No	581,706	7.5%
Unknown	6,980,683	90.3%
Year		
2021	4,840,292	62.6%
2022	2,680,811	34.7%
2023	*****	*****
2024	*****	*****
COVID-19 Vaccination		
COVID-19 Vaccine Booster Brand		
Pfizer at index	4,692,528	60.7%
Moderna at index	3,048,757	39.4%
COVID-19 Vaccine Booster Code Type		
Insurance claims data (National Drug Codes[NDC]/Current Procedural Terminology[CPT]/Healthcare Common Procedure Coding System [HCPCS] codes) at index	6,319,952	81.8%
State-based Immunization Information Systems (IIS) (Vaccine Administered Code Set [CVX] codes) at index	4,682,131	60.6%
COVID-19 Vaccine Booster; Monovalent or Bivalent (only Pfizer and Moderna)		
Monovalent at index	6,897,184	89.2%
Bivalent at index	851,190	11.0%
COVID-19 Vaccine Booster; Whether the "Booster" or "Bivalent" is Mentioned in the Code Description		

Table 1 r04. Aggregated Characteristics of Patients with Booster Coronavirus Disease 2019 (COVID-19) Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024

	With Booster Coronavirus Disease 2019 (COVID-19) Vaccine	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[2]**
Booster or Bivalent COVID-19 Vaccine based on code description	2,476,046	32.0%
Total Number of Observed Records for the COVID-19 Vaccination Before Index, Including the Booster Record		
With at least one COVID-19 vaccine codes	7,730,120	100.0%
With at least two COVID-19 vaccine codes in two separate days	7,499,536	97.0%
With at least three COVID-19 vaccine codes in three separate days	452,234	5.9%
With one COVID-19 vaccine[4]	230,584	3.0%
With two COVID-19 vaccine in two separate days	7,047,302	91.2%
With three COVID-19 vaccine in three separate days	318,697	4.1%
With ≥4 COVID-19 vaccine codes in ≥4 separate days	133,537	1.7%
Health Characteristics		
Reactive Airway and Lung Diseases	1,169	0.0%
Other Chronic Respiratory Diseases (e.g., Pneumonia and Bronchitis)	191,298	2.5%
Sickle Cell Disease	3,590	0.0%
Liver disease (severe/moderate)	211,682	2.7%
Tuberculosis	4,189	0.1%
Cystic fibrosis	1,981	0.0%
Congenital or Acquired Heart Disease	34,345	0.4%
Lung Cancer	17,186	0.2%
Breast Cancer	88,360	1.1%
Colorectal Cancer	20,512	0.3%
Prostate Cancer	64,925	0.8%
Endometrial Cancer	7,437	0.1%
Other cancer	435,633	5.6%
Asthma	146,135	1.9%
Chronic obstructive pulmonary disease (COPD) and Bronchiectasis	151,804	2.0%
Diabetes types 1 and/or 2	689,850	8.9%
Chronic Kidney Disease	293,237	3.8%
Hypertension	1,319,024	17.1%
Acute Myocardial Infarction	10,075	0.1%
Atrial Fibrillation	182,483	2.4%
Heart Failure	188,816	2.4%
Ischemic Heart Disease	433,984	5.6%
Stroke/Transient Ischemic Attack (TIA)	47,498	0.6%
History of Cardiac Arrest	2,002	0.0%
History of Coronary Angioplasty or Bypass	101,683	1.3%
Alzheimer's Disease and related conditions	82,770	1.1%
Depression	805,540	10.4%
Bipolar or Other Depressive Mood Disorders	109,732	1.4%
Attention-deficit/hyperactivity disorder (ADHD)	198,654	2.6%
History of Cerebral palsy	62,549	0.8%
History of Spinal cord injuries	43,605	0.6%
History of Down syndrome	3,497	0.0%
Alcohol Abuse or Dependence	76,248	1.0%

Table 1 r04. Aggregated Characteristics of Patients with Booster Coronavirus Disease 2019 (COVID-19) Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024

	With Booster Coronavirus Disease 2019 (COVID-19) Vaccine	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[2]**
Drug Abuse or Dependence	65,566	0.8%
Obesity/overweight	1,276,949	16.5%
Smoking	459,838	5.9%
Immunocompromised	1,370,279	17.7%
Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)	21,537	0.3%
Hematological Malignancy	54,143	0.7%
Treatment-Independent Immune Deficiencies	39,958	0.5%
Dialysis	14,155	0.2%
Chemo Therapeutic Agents	148,211	1.9%
Immunosuppressant Therapeutic Agents	145,184	1.9%
Steroid/Corticosteroid Diagnoses and Procedures and Dispensings	677,443	8.8%
Organ Transplant Diagnoses and Procedures	20,647	0.3%
Solid Malignancies	591,817	7.7%
Hyperlipidemia	1,124,417	14.5%
Rheumatoid Arthritis/Osteoarthritis	488,443	6.3%
Acquired Hypothyroidism	349,971	4.5%
Glaucoma	365,388	4.7%
Osteoporosis	108,399	1.4%
Anemia	239,021	3.1%
Benign Prostatic Hyperplasia	120,592	1.6%
Hip/Pelvic Fracture	11,928	0.2%
Cataract	510,358	6.6%
Parkinsons Disease and Secondary Parkinsonism	20,542	0.3%
Comorbidity score		
Charlson/Elixhauser combined comorbidity score[5]	0.5	1.4
Medical Product Use		
Pre-Index		
COVID-19 diagnosis	242,633	3.1%
Lopinavir/Ritonavir	50	0.0%
Remdesivir	3,356	0.0%
Hydroxychloroquine	43,175	0.6%
Chloroquine	163	0.0%
Azithromycin	276,714	3.6%
Ivermectin	2,802	0.0%
Dexamethasone	268,272	3.5%
Other Corticosteroids	907,551	11.7%
Inhaled Corticosteroids	288,708	3.7%
Paxlovid	24,019	0.3%
Baricitinib	405	0.0%
Tocilizumab	1,619	0.0%
Bamlanivimab	34	0.0%
Casirivimab/Imdevimab	10,845	0.1%

Table 1 r04. Aggregated Characteristics of Patients with Booster Coronavirus Disease 2019 (COVID-19) Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024

	With Booster Coronavirus Disease 2019 (COVID-19) Vaccine	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[2]**
Bamlanivimab/Etesevimab	1,739	0.0%
Sotrovimab	1,004	0.0%
Non-steroidal anti-inflammatory drugs (NSAIDs)	772,303	10.0%
Antidepressants	1,403,750	18.2%
Post-Index		
COVID-19 diagnosis	311,106	4.0%
Lopinavir/Ritonavir	24	0.0%
Remdesivir	2,571	0.0%
Hydroxychloroquine	41,608	0.5%
Chloroquine	174	0.0%
Azithromycin	298,668	3.9%
Ivermectin	854	0.0%
Dexamethasone	263,373	3.4%
Other Corticosteroids	865,001	11.2%
Inhaled Corticosteroids	283,001	3.7%
Paxlovid	56,027	0.7%
Baricitinib	295	0.0%
Tocilizumab	1,660	0.0%
Bamlanivimab	*****	*****
Casirivimab/Imdevimab	2,975	0.0%
Bamlanivimab/Etesevimab	1,252	0.0%
Sotrovimab	3,315	0.0%
Non-steroidal anti-inflammatory drugs (NSAIDs)	705,315	9.1%
Antidepressants	1,381,179	17.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	6.6	9.0
Mean number of emergency room encounters	0.1	0.6
Mean number of inpatient hospital encounters	0.0	0.2
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	2.5	4.1
Mean number of filled prescriptions	8.3	10.7
Mean number of generics dispensed	4.2	3.9
Mean number of unique drug classes dispensed	3.8	3.6

Table 1 r04. Aggregated Characteristics of Patients with Booster Coronavirus Disease 2019 (COVID-19) Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024

	With Booster Coronavirus Disease 2019 (COVID-19) Vaccine	
Patient Characteristics	**Number/Mean**	**Percent/ Standard Deviation[2]**

[1]The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. We defined boosters using four different cohorts:

- Cohort 1: Individuals with evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 2: Individuals with a history of an immunocompromising condition and evidence of at least three vaccine codes more than four days apart prior to their booster dose.
- Cohort 3: Individuals without a history of an immunocompromising condition and evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 4: Individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine.

This table presents baseline characteristics for Cohort 1 only. Baseline tables for Cohorts 2, 3, and 4 were not produced.

[2]Value represents standard deviation where no % follows the value.

[3]Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

[4]In the covariate "Total number of observed records for the COVID-19 vaccination" before index, a small number of patients are recorded as having received only one COVID-19 vaccine. However, our cohort inclusion criteria require at least two COVID-19 vaccines prior to the index date. This discrepancy arises because the assessment of covariates requires that claims occur during a valid enrollment span. For this query, both medical and drug coverage enrollment were necessary, meaning that any claim made during the enrollment period with only medical coverage, for instance, was not counted. This is the case for those few patients. Our cohort inclusion criteria consider all claims without restricting to those occurring during enrollment, which is why these patients are included in our cohort but not in our covariate.

[5]The Combined Comorbidity Score is calculated based on comorbidities observed during a requester-defined window around the exposure episode start date. (Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A Combined Comorbidity Score Predicted Mortality in Elderly Patients Better Than Existing Scores. J Clin Epidemiol. 2011;64(7):749-759; Sun JW, Rogers JR, Her Q, Welch EC, Panozzo CA, Toh S, Gagne JJ. Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM. Med Care. 2017;55(12):1046-1051).

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
N/A: Not Applicable

Table 2 r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccination	15,530,103	47,181,063	3,291.60

[1] The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2] Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility.

Table 2 r02. Summary of Exposures of Interest (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines	11,915,048	15,600,164	7,637.77

[1]The cohort includes patients who received at least two Coronavirus Disease 2019 [COVID-19] vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2]***Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.*** This quantity does not consider age-based vaccine eligibility.

Table 2 r03. Summary of Exposures of Interest (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	Number of Patients with Only the First Component of the Combination[2]	Number of Exposure Episodes with First and Second Components of Combination[3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
Coronavirus Disease 2019 (COVID-19) Vaccine Brand for the First and Second Observed Records				
With a first Pfizer COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Pfizer-Pfizer combination)	9,114,170	7,381,915	47,181,063	1,931.74
With a first Moderna COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Moderna-Moderna combination)	5,584,660	4,146,919	47,181,063	1,183.67
With a first Janssen COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Janssen-Janssen combination)	818,691	87,221	47,181,063	173.52
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Novavax or Unspecified-Novavax or Unspecified combination)	67,284	37,807	47,181,063	14.26
With a first Pfizer COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Pfizer-Moderna combination)	9,114,170	566,454	47,181,063	1,931.74
With a first Moderna COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Moderna-Pfizer combination)	5,584,660	663,253	47,181,063	1,183.67
With a first Pfizer COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Pfizer-Novavax or Unspecified combination)	9,114,170	26,590	47,181,063	1,931.74
With a first Pfizer COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Pfizer-Janssen combination)	9,114,170	7,144	47,181,063	1,931.74
With a first Moderna COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Moderna-Janssen combination)	5,584,660	7,428	47,181,063	1,183.67
With a first Moderna COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Moderna-Novavax or Unspecified combination)	5,584,660	21,469	47,181,063	1,183.67
With a first Janssen COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Janssen-Moderna combination)	818,691	173,946	47,181,063	173.52
With a first Janssen COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Janssen-Pfizer combination)	818,691	173,801	47,181,063	173.52
With a first Janssen COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Janssen-Novavax or Unspecified combination)	818,691	2,638	47,181,063	173.52

Table 2 r03. Summary of Exposures of Interest (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	Number of Patients with Only the First Component of the Combination[2]	Number of Exposure Episodes with First and Second Components of Combination[3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Moderna COVID-19 vaccine	67,284	24,248	47,181,063	14.26
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Novavax or Unspecified-Pfizer combination)	67,284	30,790	47,181,063	14.26
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Janssen or Unspecified COVID-19 vaccine (Novavax or Unspecified-Janssen combination)	67,284	2,006	47,181,063	14.26
COVID-19 Vaccine Code Type for the First and Second Observed Records				
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only Claims-OnlyClaims combination)	7,701,405	5,075,804	39,301,804	1,959.56
With a first COVID-19 vaccine identified only by immunization information systems (IIS) codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only IIS-Only IIS combination)	1,677,891	1,364,761	33,244,650	504.71
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only Claims-Only IIS combination)	8,002,553	117,099	47,173,900	1,696.39
With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only IIS-Only claims combination)	3,301,529	368,707	47,170,266	699.92
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only Claims-Claims and IIS combination)	8,002,553	217,782	47,173,900	1,696.39
With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only IIS-IIS and Claims combination)	3,301,529	1,382,856	47,170,266	699.92
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Claims and IIS-Only IIS combination)	4,226,021	703,498	7,527,717	5,613.95
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (IIS and Claims-Only Claims combination)	4,226,021	506,255	7,527,717	5,613.95
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (IIS and Claims-IIS and Claims combination)	4,226,021	3,509,298	7,527,717	5,613.95

Table 2 r03. Summary of Exposures of Interest (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	Number of Patients with Only the First Component of the Combination[2]	Number of Exposure Episodes with First and Second Components of Combination[3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column presents the number of patients based on the brand or data source of their initial COVID-19 vaccine.

[3]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column displays the number of patients who have received both their initial and second COVID-19 vaccines, categorized by the combination of vaccine brand and data source.

[4]***Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.*** This quantity does not consider age-based vaccine eligibility. We observe differences in the number of eligible members across the Code Type cohorts. For this cohort, the Code Type of interest was used to define the cohorts. Specifically, the Claims Code Type was defined using Healthcare Common Procedure Coding System (HCPCS) codes, Current Procedural Terminology, Fourth Edition (CPT-4) codes, and National Drug Codes (NDCs). The Immunization Information Systems (IIS) Code Type was defined using Vaccine Administered Code Set (CVX) codes.

Table 2 r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine [3]	7,730,120	14,699,430	5,258.79
With Booster COVID-19 Vaccine (Including Individuals Ever Immunocompromised) [4,5]	1,752,336	4,354,091	4,024.57
With Booster COVID-19 Vaccine (Excluding Individuals Ever Immunocompromised) [4,6]	4,418,268	9,320,093	4,740.58
Code) [7]	7,210,340	45,519,460	1,584.01

[1] The cohorts include patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. We defined boosters using four different cohorts:
- Cohort 1: Individuals with evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 2: Individuals with a history of an immunocompromising condition and evidence of at least three vaccine codes more than four days apart prior to their booster dose.
- Cohort 3: Individuals without a history of an immunocompromising condition and evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 4: Individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine.

[2] ***Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.*** This quantity does not consider age-based vaccine eligibility. We observe differences in the number of eligible members across the cohorts due to varying inclusion and exclusion criteria for each cohort.

[3] The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who have evidence of receiving at least two vaccine doses more than four days apart prior to their booster dose.

[4] Including any evidence of HIV/AIDS, Hematological Malignancy, Treatment-Independent Immune Deficiencies, Dialysis, Chemo Therapeutic Agents/ Diagnoses and Procedures, Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures, Steroid Diagnoses and Procedures, Organ Transplant Diagnoses and Procedures, or Solid Malignancies any time before index.

[5] The cohort includes patients with evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals with a history of an immunocompromising condition and evidence of at least three vaccine doses more than four days apart prior to their booster dose.

[6] The cohort includes patients without evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals without a history of an immunocompromising condition and evidence of at least two vaccine doses more than four days apart prior to their booster dose.

[7] The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine. No prior evidence of having COVID-19 vaccination inclusion criteria was required for this cohort.

Table 3a r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Sex

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[1]
With At Least One COVID-19 Vaccine			
Female	8,258,723	24,210,986	3,411.15
Male	7,271,380	22,970,077	3,165.59

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility.

Table 3b r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
0-6 months	14,467	592,438	244.19
7-59 months	181,904	2,272,972	800.29
5-11 years	712,634	3,468,247	2,054.74
12-15 years	637,777	2,325,521	2,742.51
16-39 years	4,609,862	14,777,680	3,119.48
40-64 years	5,979,219	15,304,085	3,906.94
≥ 65 years	3,394,240	11,732,206	2,893.10

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility.

Table 3c r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Year

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
2020	204,535	27,512,739	74.34
2021	12,795,346	29,601,411	4,322.55
2022	2,262,353	19,187,304	1,179.09
2023	267,830	21,207,120	126.29
2024	39	5,151,275	0.08

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility.

Table 3d r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Year and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
2020			
November	5,605	26,781,805	2.09
December	198,929	27,200,396	73.13
2021			
January	1,153,185	24,625,053	468.30
February	1,288,577	23,167,300	556.21
March	3,038,814	21,921,471	1,386.23
April	2,464,384	18,865,291	1,306.31
May	993,181	16,346,566	607.58
June	407,210	15,278,308	266.53
July	446,067	16,702,805	267.06
August	643,561	16,370,020	393.13
September	406,488	15,439,234	263.28
October	392,033	15,289,261	256.41
November	864,235	14,709,786	587.52
December	697,611	14,312,317	487.42
2022			
January	412,399	12,640,145	326.26
February	128,198	12,043,800	106.44
March	75,859	12,047,906	62.96
April	118,739	12,062,588	98.44
May	100,985	12,013,384	84.06
June	110,258	11,958,983	92.20
July	169,683	14,472,871	117.24
August	109,776	14,791,763	74.21
September	231,582	14,469,994	160.04
October	377,803	14,724,271	256.59
November	255,499	14,203,300	179.89
December	171,572	14,609,197	117.44
2023			
January	80,626	13,451,635	59.94
February	36,690	13,190,805	27.81
March	30,563	13,390,207	22.82

Table 3d r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Year and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
April	21,303	13,498,581	15.78
May	22,112	13,593,723	16.27
June	14,884	13,631,607	10.92
July	15,935	17,053,416	9.34
August	21,336	17,667,643	12.08
September	8,511	17,363,809	4.90
October	8,805	17,945,894	4.91
November	4,984	17,716,682	2.81
December	2,081	13,273,215	1.57
2024			
January	*****	*****	*****
February	*****	*****	*****

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3e r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by US State and Territory [2]

	Number of Patients[3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
AK	10,299	34,934	2,948.13
AL	81,666	464,821	1,756.93
AR	45,392	241,937	1,876.19
AZ	240,282	941,382	2,552.44
CA	2,089,807	4,525,377	4,617.97
CO	709,108	1,622,552	4,370.33
CT	405,149	907,085	4,466.49
DC	32,398	70,272	4,610.37
DE	46,301	120,567	3,840.27
FL	539,102	2,927,570	1,841.47
FM	*****	*****	*****
GA	866,951	2,845,090	3,047.18
GU	2,773	25,717	1,078.28
HI	10,479	37,455	2,797.76
IA	90,806	268,911	3,376.80
ID	32,291	138,765	2,327.03
IL	402,499	1,314,258	3,062.56
IN	634,175	1,774,082	3,574.67
KS	81,115	328,765	2,467.26
KY	637,333	1,797,550	3,545.56
LA	98,022	697,193	1,405.95
MA	189,309	407,246	4,648.52
MD	189,970	418,828	4,535.75
ME	222,500	479,218	4,642.98
MH	0	12	0.00
MI	179,377	707,198	2,536.45
MN	544,675	1,252,943	4,347.17
MO	353,816	1,327,446	2,665.39
MP	3,117	9,162	3,402.10
MS	50,863	340,489	1,493.82
MT	11,856	86,829	1,365.44
NC	423,551	1,588,723	2,665.98

Table 3e r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by US State and Territory [2]

	Number of Patients[3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
ND	9,284	42,400	2,189.62
NE	64,993	187,097	3,473.76
NH	107,051	312,091	3,430.12
NJ	452,157	1,080,877	4,183.24
NM	28,099	130,049	2,160.65
NV	132,909	544,609	2,440.45
NY	947,184	2,190,259	4,324.53
OH	876,040	2,788,993	3,141.06
OK	51,281	298,252	1,719.38
OR	377,325	789,714	4,778.00
PA	462,917	1,294,866	3,575.02
PR	499	2,210	2,257.92
PW	*****	*****	*****
RI	18,739	52,213	3,588.95
SC	132,257	681,148	1,941.68
SD	17,283	73,693	2,345.27
TN	126,301	695,869	1,815.01
TX	794,978	3,404,845	2,334.84
UT	71,304	270,474	2,636.26
VA	1,040,397	2,540,591	4,095.10
VI	160	1,008	1,587.30
VT	8,153	23,314	3,497.04
WA	268,174	745,656	3,596.48
WI	240,683	834,218	2,885.13
WV	51,972	275,397	1,887.17
WY	5,795	34,055	1,701.66
Invalid	12,820	46,075	2,782.42
Missing	6,355	138,700	458.18

Table 3e r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by US State and Territory [2]

	Number of Patients[3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]American Samoa counts are included in the "Other" category.

[3] Due to data partners' data privacy restrictions, any data smaller than 25 has not been included (i.e., is regarded as 0). As a result, the sum of the numbers across all states is slightly smaller than the total number of patients.

[4] Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3f r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
0-6 months			
0-6 months, 2020			
November	0	27,837	0.00
December	0	35,144	0.00
0-6 months, 2021			
January	*****	31,980	*****
February	*****	25,866	*****
March	*****	25,581	*****
April	*****	24,501	*****
May	*****	23,161	*****
June	*****	21,188	*****
July	*****	23,685	*****
August	0	29,881	0.00
September	*****	25,747	*****
October	0	33,955	0.00
November	*****	27,659	*****
December	*****	35,630	*****
0-6 months, 2022			
January	0	33,594	0.00
February	*****	26,998	*****
March	*****	27,524	*****
April	0	26,192	0.00
May	*****	24,877	*****
June	295	22,895	128.85
July	1,162	25,941	447.94
August	1,230	31,287	393.13
September	1,247	26,436	471.71
October	1,386	33,827	409.73
November	1,329	27,502	483.24
December	1,380	34,841	396.09
0-6 months, 2023			
January	1,271	32,500	391.08

Table 3f r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
February	1,076	26,653	403.71
March	1,022	26,815	381.13
April	716	25,191	284.23
May	592	25,432	232.78
June	524	23,861	219.61
July	462	26,876	171.90
August	460	32,371	142.10
September	155	26,739	57.97
October	*****	34,294	*****
November	47	27,967	16.81
December	35	24,250	14.43
0-6 months, 2024			
January	0	3,141	0.00
February	0	1,931	0.00
7-59 months			
7-59 months, 2020			
November	*****	928,361	*****
December	*****	941,591	*****
7-59 months, 2021			
January	81	851,534	0.95
February	63	840,936	0.75
March	173	843,824	2.05
April	243	842,245	2.89
May	234	838,084	2.79
June	181	830,132	2.18
July	174	905,653	1.92
August	157	905,722	1.73
September	147	883,443	1.66
October	171	888,135	1.93
November	382	873,383	4.37
December	237	893,173	2.65
7-59 months, 2022			

Table 3f r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
January	175	830,262	2.11
February	70	819,875	0.85
March	95	829,018	1.15
April	77	831,438	0.93
May	92	832,077	1.11
June	30,132	826,955	364.37
July	54,450	889,773	611.95
August	30,202	843,133	358.21
September	16,542	794,895	208.10
October	12,749	789,683	161.44
November	10,610	766,857	138.36
December	7,291	778,393	93.67
7-59 months, 2023			
January	4,784	712,778	67.12
February	2,747	699,655	39.26
March	2,616	709,281	36.88
April	1,385	710,480	19.49
May	1,157	713,145	16.22
June	1,008	711,614	14.16
July	1,088	801,662	13.57
August	1,330	813,052	16.36
September	395	795,923	4.96
October	286	809,793	3.53
November	227	798,784	2.84
December	129	605,397	2.13
7-59 months, 2024			
January	0	76,731	0.00
February	*****	48,930	*****
5-11 years			
5-11 years, 2020			
November	68	1,681,078	0.40
December	52	1,703,432	0.31

Table 3f r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
5-11 years, 2021			
January	276	1,550,476	1.78
February	138	1,531,521	0.90
March	293	1,535,568	1.91
April	466	1,533,797	3.04
May	857	1,529,059	5.60
June	606	1,521,061	3.98
July	524	1,655,879	3.16
August	715	1,661,636	4.30
September	456	1,632,969	2.79
October	438	1,637,830	2.67
November	374,637	1,614,467	2,320.50
December	138,415	1,260,036	1,098.50
5-11 years, 2022			
January	72,545	1,040,244	697.38
February	20,552	958,646	214.39
March	10,558	950,275	111.10
April	7,351	947,345	77.60
May	8,167	947,182	86.22
June	10,590	944,105	112.17
July	14,091	1,085,212	129.85
August	13,124	1,098,554	119.47
September	5,781	1,073,339	53.86
October	6,234	1,092,414	57.07
November	8,611	1,077,910	79.89
December	5,662	1,107,956	51.10
5-11 years, 2023			
January	2,970	1,026,581	28.93
February	1,659	1,012,294	16.39
March	1,517	1,029,010	14.74
April	984	1,036,838	9.49
May	900	1,044,735	8.61

Table 3f r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
June	870	1,047,312	8.31
July	874	1,213,874	7.20
August	1,066	1,238,885	8.60
September	235	1,220,503	1.93
October	143	1,243,848	1.15
November	153	1,229,861	1.24
December	48	931,983	0.52
5-11 years, 2024			
January	0	120,756	0.00
February	0	72,380	0.00
12-15 years			
12-15 years, 2020			
November	23	1,103,218	0.21
December	25	1,116,155	0.22
12-15 years, 2021			
January	343	1,016,493	3.37
February	175	1,004,424	1.74
March	493	1,007,411	4.89
April	893	1,005,808	8.88
May	248,708	1,002,895	2,479.90
June	86,514	751,496	1,151.22
July	71,585	732,747	976.94
August	81,328	670,483	1,212.98
September	33,793	588,238	574.48
October	16,979	565,634	300.18
November	15,588	548,320	284.29
December	14,834	550,837	269.30
12-15 years, 2022			
January	22,399	499,345	448.57
February	7,108	472,896	150.31
March	3,548	474,368	74.79
April	2,582	477,239	54.10

Table 3f r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
May	2,779	479,434	57.96
June	2,895	479,396	60.39
July	3,867	570,156	67.82
August	3,251	581,840	55.87
September	2,336	571,840	40.85
October	3,662	584,194	62.68
November	3,694	575,391	64.20
December	2,780	595,446	46.69
12-15 years, 2023			
January	1,313	553,022	23.74
February	694	545,548	12.72
March	665	555,718	11.97
April	494	560,648	8.81
May	427	565,475	7.55
June	462	567,887	8.14
July	478	676,388	7.07
August	537	691,642	7.76
September	145	681,892	2.13
October	187	695,427	2.69
November	120	687,539	1.75
December	59	519,211	1.14
12-15 years, 2024			
January	0	64,523	0.00
February	0	36,680	0.00
16-39 years			
16-39 years, 2020			
November	*****	7,426,269	*****
December	67,725	7,552,610	89.67
16-39 years, 2021			
January	227,678	6,819,582	333.86
February	186,360	6,488,812	287.20
March	774,211	6,335,939	1,221.94

Table 3f r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
April	1,165,585	5,559,210	2,096.67
May	376,697	4,375,735	860.88
June	164,060	3,969,853	413.26
July	181,333	4,215,700	430.14
August	274,205	3,992,752	686.76
September	165,695	3,602,647	459.93
October	117,179	3,496,493	335.13
November	147,532	3,309,899	445.73
December	222,453	3,327,830	668.46
16-39 years, 2022			
January	137,774	2,903,098	474.58
February	45,968	2,718,187	169.11
March	26,088	2,742,793	95.11
April	18,404	2,763,471	66.60
May	18,031	2,785,809	64.72
June	14,982	2,796,462	53.57
July	18,649	3,577,969	52.12
August	15,201	3,711,509	40.96
September	41,658	3,615,735	115.21
October	59,156	3,748,655	157.81
November	48,522	3,634,339	133.51
December	35,476	3,839,229	92.40
16-39 years, 2023			
January	16,723	3,587,356	46.62
February	8,068	3,516,541	22.94
March	7,371	3,621,471	20.35
April	5,092	3,676,395	13.85
May	4,522	3,724,274	12.14
June	3,510	3,743,679	9.38
July	3,376	4,633,875	7.29
August	4,354	4,778,207	9.11
September	1,856	4,649,149	3.99

Table 3f r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
October	2,181	4,820,372	4.52
November	1,309	4,730,164	2.77
December	621	3,316,121	1.87
16-39 years, 2024			
January	*****	405,273	*****
February	*****	195,963	*****
40-64 years			
40-64 years, 2020			
November	*****	9,015,110	*****
December	109,243	9,144,453	119.46
40-64 years, 2021			
January	433,464	8,280,488	523.48
February	420,587	7,744,501	543.08
March	1,697,187	7,325,065	2,316.96
April	1,137,193	5,614,698	2,025.39
May	303,331	4,454,932	680.89
June	127,252	4,125,351	308.46
July	159,365	4,438,603	359.04
August	239,375	4,319,491	554.17
September	150,829	4,000,986	376.98
October	148,388	3,918,472	378.69
November	217,434	3,716,766	585.01
December	251,349	3,629,953	692.43
40-64 years, 2022			
January	119,385	3,118,096	382.88
February	33,351	2,943,652	113.30
March	19,338	2,942,244	65.73
April	22,238	2,947,103	75.46
May	20,549	2,941,517	69.86
June	16,469	2,937,233	56.07
July	32,640	3,755,693	86.91
August	19,426	3,876,796	50.11

Table 3f r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
September	50,154	3,799,870	131.99
October	85,908	3,887,224	221.00
November	61,072	3,759,064	162.47
December	43,046	3,889,622	110.67
40-64 years, 2023			
January	19,271	3,567,401	54.02
February	8,404	3,491,325	24.07
March	6,765	3,548,257	19.07
April	4,398	3,584,452	12.27
May	3,625	3,613,433	10.03
June	2,616	3,631,574	7.20
July	2,708	4,685,688	5.78
August	4,017	4,911,326	8.18
September	2,416	4,829,032	5.00
October	3,075	5,011,836	6.14
November	1,666	4,940,483	3.37
December	712	3,518,234	2.02
40-64 years, 2024			
January	*****	883,199	*****
February	0	156,780	0.00
≥ 65 years			
≥ 65 years, 2020			
November	4,287	6,720,062	6.38
December	21,850	6,832,192	31.98
≥ 65 years, 2021			
January	491,341	6,183,726	794.57
February	681,252	5,634,298	1,209.12
March	566,454	4,955,525	1,143.08
April	159,997	4,379,847	365.30
May	63,350	4,213,953	150.33
June	28,593	4,143,136	69.01
July	33,084	4,823,702	68.59

Table 3f r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
August	47,779	4,882,068	97.87
September	55,565	4,792,217	115.95
October	108,878	4,833,964	225.24
November	108,659	4,696,849	231.34
December	70,319	4,690,820	149.91
≥ 65 years, 2022			
January	60,117	4,282,500	140.38
February	21,144	4,165,879	50.76
March	16,228	4,150,470	39.10
April	68,086	4,135,769	164.63
May	51,363	4,070,207	126.19
June	34,895	4,018,187	86.84
July	44,824	4,646,557	96.47
August	27,342	4,727,745	57.83
September	113,864	4,664,119	244.13
October	208,708	4,664,808	447.41
November	121,661	4,433,697	274.40
December	75,937	4,437,407	171.13
≥ 65 years, 2023			
January	34,294	4,039,133	84.90
February	14,042	3,961,948	35.44
March	10,607	3,971,064	26.71
April	8,234	3,972,206	20.73
May	10,889	3,978,703	27.37
June	5,894	3,975,745	14.82
July	6,949	5,100,746	13.62
August	9,572	5,291,430	18.09
September	3,309	5,246,477	6.31
October	2,909	5,418,150	5.37
November	1,462	5,385,397	2.71
December	477	4,420,439	1.08
≥ 65 years, 2024			

Table 3f r01. Summary of Exposures of Interest (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least One Coronavirus Disease 2019 (COVID-19) Vaccine			
January	25	3,606,978	0.07
February	0	36,909	0.00

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3a r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Sex

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines			
Female	6,349,302	8,297,003	7,652.52
Male	5,565,746	7,303,161	7,621.01

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2]Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility.

Table 3b r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Member[4]
With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines			
AK	7,800	10,313	7,563.27
AL	45,547	81,909	5,560.68
AR	28,887	45,555	6,341.13
AZ	175,221	241,194	7,264.73
CA	1,790,135	2,097,567	8,534.34
CO	580,542	713,010	8,142.13
CT	296,769	406,422	7,301.99
DC	23,970	32,441	7,388.80
DE	35,632	46,460	7,669.39
FL	316,469	540,235	5,857.99
FM	0	0	NaN
GA	635,019	871,155	7,289.39
GU	1,525	2,789	5,467.91
HI	4,693	10,509	4,465.70
IA	68,294	91,205	7,487.97
ID	24,356	32,396	7,518.21
IL	293,125	403,249	7,269.08
IN	527,070	637,889	8,262.72
KS	54,461	81,470	6,684.79
KY	520,661	643,381	8,092.58
LA	52,791	98,435	5,363.03
MA	151,492	189,465	7,995.78
MD	152,619	190,237	8,022.57
ME	173,053	223,636	7,738.15
MH	0	0	NaN
MI	121,070	180,060	6,723.87
MN	456,095	547,792	8,326.06
MO	250,297	355,796	7,034.85
MP	2,548	3,119	8,169.29
MS	27,992	51,221	5,464.95
MT	5,334	11,883	4,488.77
NC	284,566	425,461	6,688.42

Table 3b r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Member[4]
With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines			
ND	6,059	9,321	6,500.38
NE	48,538	65,152	7,449.96
NH	65,201	107,732	6,052.15
NJ	383,105	453,522	8,447.33
NM	14,377	28,312	5,078.06
NV	98,913	133,614	7,402.89
NY	751,685	951,117	7,903.18
OH	653,680	880,412	7,424.71
OK	31,816	51,500	6,177.86
OR	315,529	379,382	8,316.92
PA	353,520	464,172	7,616.14
PR	334	498	6,706.83
PW	0	0	NaN
RI	11,918	18,787	6,343.75
SC	83,005	133,814	6,203.01
SD	11,756	17,367	6,769.16
TN	76,580	126,668	6,045.73
TX	583,150	797,698	7,310.41
UT	52,316	71,550	7,311.81
VA	836,723	1,046,803	7,993.13
VI	110	160	6,875.00
VT	5,195	8,180	6,350.86
WA	203,415	269,276	7,554.15
WI	175,046	241,589	7,245.61
WV	27,844	52,237	5,330.32
WY	3,936	5,803	6,782.70
Invalid	9,435	12,883	7,323.60
Missing	3,824	6,361	6,011.63

Table 3b r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Member[4]
With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines			

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2] American Samoa counts are included in the "Other" category.

[3] Due to data partners' data privacy restrictions, any data smaller than 25 has not been included (i.e., is regarded as 0). As a result, the sum of the numbers across all states is slightly smaller than the total number of patients.

[4] Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility.

*NaN: Not a number

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines			
0-6 months			
0-6 months, 2020			
November	0	3,702	0.00
December	0	4,722	0.00
0-6 months, 2021			
January	*****	4,790	*****
February	*****	3,811	*****
March	*****	3,670	*****
April	*****	3,516	*****
May	*****	3,320	*****
June	0	2,940	0.00
July	*****	3,306	*****
August	0	4,490	0.00
September	*****	3,947	*****
October	0	5,403	0.00
November	*****	4,465	*****
December	*****	5,658	*****
0-6 months, 2022			
January	0	5,617	0.00
February	*****	4,469	*****
March	*****	4,678	*****
April	0	4,520	0.00
May	*****	4,411	*****
June	282	4,111	685.96
July	1,088	4,305	2,527.29
August	1,158	4,546	2,547.29
September	1,176	3,680	3,195.65
October	1,291	4,453	2,899.17
November	1,225	3,418	3,583.97
December	1,160	3,869	2,998.19
0-6 months, 2023			
January	1,193	3,406	3,502.64
February	967	2,339	4,134.25

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines			
March	825	2,028	4,068.05
April	537	1,557	3,448.94
May	476	1,376	3,459.30
June	376	993	3,786.51
July	257	775	3,316.13
August	122	620	1,967.74
September	0	193	0.00
October	*****	85	*****
November	0	66	0.00
December	0	33	0.00
0-6 months, 2024			
January	0	0	NaN
February	0	0	NaN
7-59 months			
7-59 months, 2020			
November	*****	*****	*****
December	*****	*****	*****
7-59 months, 2021			
January	69	170,382	4.05
February	56	167,319	3.35
March	149	166,155	8.97
April	206	164,043	12.56
May	200	161,528	12.38
June	152	158,195	9.61
July	144	170,415	8.45
August	125	168,949	7.40
September	117	164,132	7.13
October	127	163,628	7.76
November	325	159,796	20.34
December	176	160,878	10.94
7-59 months, 2022			
January	128	159,845	8.01
February	49	157,811	3.10

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines			
March	76	159,454	4.77
April	56	160,157	3.50
May	64	160,729	3.98
June	28,482	160,584	1,773.65
July	50,512	144,253	3,501.63
August	26,673	89,366	2,984.69
September	13,945	58,612	2,379.21
October	10,236	42,787	2,392.32
November	8,065	29,906	2,696.78
December	4,863	20,349	2,389.80
7-59 months, 2023			
January	3,201	13,713	2,334.28
February	1,795	9,417	1,906.13
March	1,420	7,357	1,930.13
April	637	5,149	1,237.13
May	548	4,272	1,282.77
June	493	3,471	1,420.34
July	409	3,160	1,294.30
August	196	2,103	932.00
September	*****	*****	22.10
October	78	650	1,200.00
November	55	350	1,571.43
December	0	135	0.00
7-59 months, 2024			
January	0	*****	*****
February	0	*****	*****
5-11 years			
5-11 years, 2020			
November	55	580,901	0.95
December	50	588,809	0.85
5-11 years, 2021			
January	259	586,920	4.41
February	129	582,912	2.21

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines			
March	269	585,425	4.59
April	412	586,441	7.03
May	790	586,406	13.47
June	560	585,315	9.57
July	484	641,882	7.54
August	653	647,251	10.09
September	397	642,451	6.18
October	381	650,462	5.86
November	357,356	646,090	5,531.06
December	114,744	272,462	4,211.38
5-11 years, 2022			
January	60,864	138,236	4,402.91
February	16,885	69,732	2,421.41
March	8,717	54,421	1,601.77
April	6,367	48,568	1,310.95
May	6,501	45,821	1,418.78
June	7,399	42,078	1,758.40
July	8,611	50,927	1,690.85
August	7,018	40,518	1,732.07
September	2,799	29,891	936.40
October	2,199	26,936	816.38
November	1,882	20,194	931.96
December	1,118	13,648	819.17
5-11 years, 2023			
January	813	8,953	908.08
February	428	6,307	678.61
March	371	5,149	720.53
April	138	3,961	348.40
May	31	3,140	98.73
June	*****	2,458	*****
July	*****	2,302	*****
August	*****	1,462	*****
September	0	483	0.00

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines			
October	0	353	0.00
November	0	183	0.00
December	0	59	0.00
5-11 years, 2024			
January	0	0	NaN
February	0	0	NaN
12-15 years			
12-15 years, 2020			
November	22	532,029	0.41
December	24	540,572	0.44
12-15 years, 2021			
January	316	541,061	5.84
February	172	538,956	3.19
March	471	543,503	8.67
April	844	546,248	15.45
May	239,998	547,803	4,381.10
June	79,381	300,208	2,644.20
July	66,958	243,618	2,748.48
August	74,620	179,909	4,147.65
September	29,658	106,118	2,794.81
October	15,148	82,185	1,843.16
November	13,849	71,174	1,945.79
December	11,920	61,811	1,928.46
12-15 years, 2022			
January	13,881	48,629	2,854.47
February	4,173	26,353	1,583.50
March	2,030	21,025	965.52
April	1,662	18,832	882.54
May	1,639	17,263	949.43
June	1,358	15,104	899.10
July	1,442	19,116	754.34
August	984	16,832	584.60
September	361	14,424	250.28

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines			
October	298	13,165	226.36
November	228	9,387	242.89
December	121	6,574	184.06
12-15 years, 2023			
January	145	4,205	344.83
February	81	3,081	262.90
March	83	2,584	321.21
April	38	2,035	186.73
May	*****	1,637	*****
June	*****	1,305	*****
July	0	1,386	0.00
August	*****	930	*****
September	0	439	0.00
October	0	341	0.00
November	0	165	0.00
December	0	54	0.00
12-15 years, 2024			
January	0	0	NaN
February	0	0	NaN
16-39 years			
16-39 years, 2020			
November	240	3,746,294	0.64
December	62,272	3,854,327	161.56
16-39 years, 2021			
January	214,476	3,852,862	556.67
February	176,785	3,630,506	486.94
March	723,558	3,508,415	2,062.35
April	1,068,879	2,767,838	3,861.78
May	317,714	1,635,665	1,942.41
June	134,664	1,281,612	1,050.74
July	153,086	1,280,993	1,195.06
August	227,066	1,123,191	2,021.62
September	128,423	850,218	1,510.47

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines			
October	75,885	726,759	1,044.16
November	70,320	607,941	1,156.69
December	69,258	503,748	1,374.85
16-39 years, 2022			
January	43,678	303,148	1,440.81
February	15,135	181,201	835.26
March	8,586	150,249	571.45
April	6,832	134,040	509.70
May	6,436	123,926	519.34
June	5,512	115,513	477.18
July	6,113	199,203	306.87
August	4,520	209,082	216.18
September	3,296	198,426	166.11
October	2,749	169,264	162.41
November	2,038	110,534	184.38
December	1,394	74,596	186.87
16-39 years, 2023			
January	1,139	45,717	249.14
February	756	31,271	241.76
March	743	25,413	292.37
April	326	19,536	166.87
May	101	15,267	66.16
June	72	11,667	61.71
July	26	12,245	21.23
August	17	9,378	18.13
September	*****	*****	*****
October	*****	*****	*****
November	*****	*****	*****
December	0	605	0.00
16-39 years, 2024			
January	0	*****	*****
February	0	*****	*****
40-64 years			

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines			
40-64 years, 2020			
November	927	5,215,263	1.78
December	101,549	5,329,067	190.56
40-64 years, 2021			
January	413,932	5,244,012	789.34
February	402,609	4,810,853	836.88
March	1,594,970	4,429,474	3,600.81
April	1,032,123	2,750,301	3,752.76
May	247,814	1,641,181	1,509.97
June	101,382	1,355,882	747.72
July	135,161	1,395,531	968.53
August	195,758	1,258,512	1,555.47
September	112,989	1,019,443	1,108.34
October	93,215	911,509	1,022.64
November	108,323	754,716	1,435.28
December	86,117	563,569	1,528.06
40-64 years, 2022			
January	36,434	331,431	1,099.29
February	10,985	223,275	491.99
March	6,329	199,650	317.00
April	10,008	187,675	533.26
May	8,913	171,995	518.21
June	6,528	159,744	408.65
July	13,185	283,093	465.75
August	5,940	274,934	216.05
September	3,015	259,713	116.09
October	2,992	216,902	137.94
November	1,701	128,877	131.99
December	996	81,532	122.16
40-64 years, 2023			
January	555	44,570	124.52
February	348	27,344	127.27
March	305	20,851	146.28

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines			
April	132	15,543	84.93
May	70	11,794	59.35
June	20	9,232	21.66
July	26	12,823	20.28
August	18	10,961	16.42
September	*****	*****	*****
October	*****	*****	*****
November	*****	*****	*****
December	0	710	0.00
40-64 years, 2024			
January	0	*****	*****
February	0	0	NaN
≥ 65 years			
≥ 65 years, 2020			
November	4,200	2,810,752	14.94
December	20,261	2,863,237	70.76
≥ 65 years, 2021			
January	473,509	2,852,262	1,660.12
February	658,982	2,364,494	2,786.99
March	531,574	1,701,420	3,124.30
April	140,538	1,149,566	1,222.53
May	52,123	999,729	521.37
June	23,302	943,888	246.87
July	28,168	1,080,928	260.59
August	36,532	1,073,004	340.46
September	34,177	1,026,462	332.96
October	55,323	1,001,318	552.50
November	46,133	887,167	520.00
December	21,796	804,690	270.86
≥ 65 years, 2022			
January	17,826	740,890	240.60
February	7,018	685,892	102.32
March	6,803	673,374	101.03

Table 3c r02. Summary of Exposures of Interest (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With At Least Two Coronavirus Disease 2019 (COVID-19) Vaccines			
April	41,043	662,554	619.47
May	28,181	598,939	470.52
June	17,489	553,788	315.81
July	20,143	638,360	315.54
August	9,565	611,870	156.32
September	14,202	588,839	241.19
October	12,936	463,838	278.89
November	4,747	252,615	187.91
December	2,249	153,019	146.98
≥ 65 years, 2023			
January	888	85,060	104.40
February	338	54,819	61.66
March	191	42,691	44.74
April	94	33,615	27.96
May	54	24,423	22.11
June	20	15,784	12.67
July	73	22,550	32.37
August	52	16,026	32.45
September	*****	6,941	*****
October	*****	4,493	*****
November	*****	1,822	*****
December	0	535	0.00
≥ 65 years, 2024			
January	0	28	0.00
February	0	0	NaN

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2]Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 3a r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Sex

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
Female	4,218,077	7,848,989	5,374.04
Male	3,512,043	6,850,441	5,126.74
With Booster COVID-19 Vaccine (Including Individuals Ever Immunocompromised)[4,5]			
Female	1,006,255	2,499,036	4,026.57
Male	746,081	1,855,055	4,021.88
With Booster COVID-19 Vaccine (Excluding Individuals Ever Immunocompromised)[4,6]			
Female	2,313,829	4,781,086	4,839.55
Male	2,104,439	4,539,007	4,636.34
With Booster COVID-19 Vaccine (Booster Specific Code)[7]			
Female	3,946,717	23,468,755	1,681.69
Male	3,263,623	22,050,705	1,480.05

[1] The cohorts include patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. We defined boosters using four different cohorts:
- Cohort 1: Individuals with evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 2: Individuals with a history of an immunocompromising condition and evidence of at least three vaccine codes more than four days apart prior to their booster dose.
- Cohort 3: Individuals without a history of an immunocompromising condition and evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 4: Individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine.

[2] ***Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.*** This quantity does not consider age-based vaccine eligibility. We observe differences in the number of eligible members across the cohorts due to varying inclusion and exclusion criteria for each cohort.

[3] The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who have evidence of receiving at least two vaccine doses more than four days apart prior to their booster dose.

[4] Including any evidence of HIV/AIDS, Hematological Malignancy, Treatment-Independent Immune Deficiencies, Dialysis, Chemo Therapeutic Agents/ Diagnoses and Procedures, Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures, Steroid Diagnoses and Procedures, Organ Transplant Diagnoses and Procedures, or Solid Malignancies any time before index.

[5] The cohort includes patients with evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals with a history of an immunocompromising condition and evidence of at least three vaccine doses more than four days apart prior to their booster dose.

[6] The cohort includes patients without evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals without a history of an immunocompromising condition and evidence of at least two vaccine doses more than four days apart prior to their booster dose.

[7] The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine. No prior evidence of having COVID-19 vaccination inclusion criteria was required for this cohort.

Table 3b r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[5]			
AK	2,942	8,637	3,406.28
AL	18,675	57,739	3,234.38
AR	13,031	32,637	3,992.71
AZ	105,860	238,037	4,447.21
CA	1,350,555	2,214,146	6,099.67
CO	380,144	670,775	5,667.24
CT	228,676	408,105	5,603.36
DC	15,272	27,332	5,587.59
DE	24,209	44,237	5,472.57
FL	130,505	368,759	3,539.03
FM	0	0	NaN
GA	327,042	763,324	4,284.45
GU	19	1,538	123.54
HI	2,000	5,064	3,949.45
IA	44,194	77,702	5,687.63
ID	11,301	27,458	4,115.74
IL	219,593	412,909	5,318.19
IN	327,900	612,980	5,349.28
KS	25,875	60,978	4,243.33
KY	297,417	595,526	4,994.19
LA	17,351	60,180	2,883.18
MA	127,870	216,646	5,902.26
MD	122,363	204,582	5,981.12
ME	111,678	192,274	5,808.27
MH	0	0	NaN
MI	80,788	163,540	4,939.95
MN	333,121	564,423	5,901.97
MO	121,421	284,070	4,274.33
MP	341	2,639	1,292.16
MS	6,712	32,693	2,053.04
MT	1,850	6,062	3,051.80
NC	177,524	362,005	4,903.91
ND	3,072	7,576	4,054.91
NE	30,011	59,352	5,056.44

Table 3b r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[5]			
NH	32,693	75,651	4,321.56
NJ	273,919	492,780	5,558.65
NM	9,701	20,022	4,845.17
NV	64,748	134,152	4,826.47
NY	567,735	991,818	5,724.19
OH	389,673	762,011	5,113.75
OK	15,393	40,788	3,773.90
OR	174,848	359,352	4,865.65
PA	281,801	492,059	5,726.98
PR	154	379	4,063.32
PW	0	0	NaN
RI	6,565	14,679	4,472.38
SC	38,856	101,931	3,811.99
SD	5,566	12,864	4,326.80
TN	32,822	92,992	3,529.55
TX	335,789	741,335	4,529.52
UT	29,151	67,508	4,318.15
VA	540,333	975,323	5,540.04
VI	18	109	1,651.38
VT	3,614	7,034	5,137.90
WA	143,770	265,104	5,423.15
WI	105,112	215,919	4,868.12
WV	10,482	31,674	3,309.34
WY	1,482	4,386	3,378.93
Invalid	5,394	11,451	4,710.51
Missing	1,178	4,184	2,815.49
With Booster COVID-19 Vaccine (Including Individuals Ever Immunocompromised)[6,7]			
AK	341	1,202	2,836.94
AL	3,251	12,627	2,574.64
AR	2,695	8,542	3,155.00
AZ	21,223	59,375	3,574.40
CA	296,984	645,093	4,603.74
CO	87,702	197,349	4,444.01
CT	48,741	131,355	3,710.63

Table 3b r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[5]			
DC	2,874	6,886	4,173.69
DE	6,211	14,356	4,326.41
FL	20,099	87,223	2,304.32
FM	0	0	NaN
GA	72,717	227,319	3,198.90
GU	*****	*****	*****
HI	313	1,064	2,941.73
IA	11,902	26,089	4,562.08
ID	1,839	5,495	3,346.68
IL	47,577	127,149	3,741.83
IN	78,504	194,199	4,042.45
KS	4,910	15,089	3,254.03
KY	83,239	214,163	3,886.71
LA	2,324	11,393	2,039.85
MA	22,084	53,219	4,149.65
MD	30,225	65,369	4,623.75
ME	26,301	58,713	4,479.59
MH	0	0	NaN
MI	16,635	45,986	3,617.41
MN	79,153	169,832	4,660.66
MO	24,972	75,201	3,320.70
MP	26	190	1,368.42
MS	732	4,522	1,618.75
MT	240	945	2,539.68
NC	46,869	116,203	4,033.37
ND	491	1,552	3,163.66
NE	6,498	17,050	3,811.14
NH	6,065	17,831	3,401.38
NJ	53,063	149,468	3,550.12
NM	2,306	5,166	4,463.80
NV	14,911	37,360	3,991.17
NY	128,483	303,136	4,238.46
OH	103,593	258,614	4,005.70
OK	3,513	10,444	3,363.65

Table 3b r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[5]			
OR	25,885	71,789	3,605.71
PA	81,262	183,724	4,423.05
PR	*****	*****	*****
PW	0	0	NaN
RI	1,184	3,533	3,351.26
SC	5,638	24,540	2,297.47
SD	1,071	3,242	3,303.52
TN	5,970	21,069	2,833.55
TX	73,160	200,499	3,648.90
UT	5,421	15,911	3,407.08
VA	137,927	325,011	4,243.76
VI	*****	*****	*****
VT	569	1,429	3,981.81
WA	31,229	62,961	4,960.05
WI	20,267	52,024	3,895.70
WV	1,784	7,198	2,478.47
WY	213	822	2,591.24
Invalid	1,009	3,028	3,332.23
Missing	114	442	2,579.19
With Booster COVID-19 Vaccine (Excluding Individuals Ever Immunocompromised)[6,8]			
AK	2,013	6,467	3,112.73
AL	8,953	31,062	2,882.30
AR	6,436	18,409	3,496.12
AZ	65,151	166,260	3,918.62
CA	854,001	1,540,577	5,543.38
CO	228,802	445,598	5,134.72
CT	131,797	260,338	5,062.53
DC	9,857	19,103	5,159.92
DE	13,106	27,306	4,799.68
FL	60,418	203,767	2,965.05
FM	0	0	NaN
GA	144,960	393,824	3,680.83
GU	*****	*****	*****
HI	1,097	2,778	3,948.88

Table 3b r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[5]			
IA	24,759	47,967	5,161.67
ID	6,998	18,871	3,708.34
IL	134,288	279,875	4,798.14
IN	177,917	370,417	4,803.15
KS	14,058	37,299	3,769.00
KY	128,688	298,149	4,316.23
LA	7,859	29,916	2,627.02
MA	91,492	166,677	5,489.18
MD	71,845	134,705	5,333.51
ME	64,200	122,052	5,260.05
MH	0	0	NaN
MI	47,904	107,753	4,445.72
MN	210,291	394,435	5,331.45
MO	63,015	167,874	3,753.71
MP	191	1,729	1,104.68
MS	3,120	17,200	1,813.95
MT	1,123	3,953	2,840.88
NC	89,990	212,580	4,233.23
ND	1,932	5,174	3,734.05
NE	17,436	39,040	4,466.19
NH	18,342	46,951	3,906.63
NJ	163,813	331,652	4,939.30
NM	6,102	13,596	4,488.08
NV	37,767	89,672	4,211.68
NY	342,660	663,945	5,160.97
OH	180,807	410,767	4,401.69
OK	7,880	23,925	3,293.63
OR	119,884	267,918	4,474.65
PA	151,358	302,507	5,003.45
PR	103	269	3,829.00
PW	0	0	NaN
RI	3,862	9,537	4,049.49
SC	19,084	57,607	3,312.79
SD	2,912	7,519	3,872.86

Table 3b r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[5]			
TN	16,405	53,302	3,077.75
TX	186,114	470,271	3,957.59
UT	17,317	46,819	3,698.71
VA	283,379	571,723	4,956.58
VI	*****	*****	*****
VT	2,637	5,375	4,906.05
WA	98,449	194,925	5,050.61
WI	66,269	150,331	4,408.21
WV	4,677	15,687	2,981.45
WY	830	2,739	3,030.30
Invalid	3,092	7,467	4,140.89
Missing	803	3,212	2,500.00
With Booster COVID-19 Vaccine (Booster Specific Code)[9]			
AK	2,432	31,273	777.67
AL	35,172	438,365	802.35
AR	18,739	218,444	857.84
AZ	104,682	904,128	1,157.82
CA	1,078,343	4,634,405	2,326.82
CO	390,437	1,571,279	2,484.84
CT	220,778	980,685	2,251.26
DC	14,347	69,655	2,059.72
DE	21,101	115,012	1,834.68
FL	201,242	2,743,132	733.62
FM	0	*****	*****
GA	260,769	2,691,767	968.77
GU	38	23,940	15.87
HI	7,507	35,444	2,117.99
IA	52,780	253,640	2,080.90
ID	11,392	128,211	888.54
IL	216,516	1,309,317	1,653.66
IN	284,804	1,694,153	1,681.10
KS	36,242	294,936	1,228.81
KY	253,180	1,593,847	1,588.48
LA	44,470	659,175	674.63

Table 3b r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[5]			
MA	115,936	440,166	2,633.92
MD	88,999	425,826	2,090.03
ME	118,560	474,418	2,499.06
MH	0	*****	*****
MI	91,677	679,923	1,348.34
MN	320,721	1,213,358	2,643.25
MO	137,887	1,223,880	1,126.64
MP	346	8,955	386.38
MS	17,816	320,015	556.72
MT	6,581	81,425	808.23
NC	226,817	1,557,129	1,456.64
ND	5,388	40,004	1,346.87
NE	25,655	174,395	1,471.09
NH	52,088	304,464	1,710.81
NJ	176,618	1,048,449	1,684.56
NM	19,353	124,852	1,550.08
NV	61,037	521,996	1,169.30
NY	444,099	2,220,604	1,999.90
OH	391,834	2,671,861	1,466.52
OK	22,682	270,678	837.97
OR	140,261	781,724	1,794.25
PA	251,065	1,288,914	1,947.88
PR	*****	*****	*****
PW	0	*****	*****
RI	8,367	51,512	1,624.28
SC	56,584	661,589	855.27
SD	9,079	67,350	1,348.03
TN	52,538	645,586	813.80
TX	327,805	3,057,336	1,072.19
UT	26,887	254,058	1,058.30
VA	445,593	2,513,955	1,772.48
VI	*****	*****	*****
VT	4,577	23,635	1,936.53
WA	155,659	730,598	2,130.57

Table 3b r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by US State and Territory[2]

	Number of Patients [3]	Number of Eligible Members[4]	Number of Patients per 10,000 Eligible Members[4]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[5]			
WI	120,831	790,050	1,529.41
WV	23,816	258,283	922.09
WY	1,494	30,653	487.39
Invalid	5,199	43,740	1,188.61
Missing	1,357	124,316	109.16

[1] The cohorts include patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. We defined boosters using four different cohorts:
- Cohort 1: Individuals with evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 2: Individuals with a history of an immunocompromising condition and evidence of at least three vaccine codes more than four days apart prior to their booster dose.
- Cohort 3: Individuals without a history of an immunocompromising condition and evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 4: Individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine.

[2] American Samoa counts are included in the "Other" category.

[3] Due to data partners' data privacy restrictions, any data smaller than 25 has not been included (i.e., is regarded as 0). As a result, the sum of the numbers across all states is slightly smaller than the total number of patients.

[4]Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period. This quantity does not consider age-based vaccine eligibility. We observe differences in the number of eligible members across the cohorts due to varying inclusion and exclusion criteria for each cohort.

[5]The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who have evidence of receiving at least two vaccine doses more than four days apart prior to their booster dose.

[6]Including any evidence of HIV/AIDS, Hematological Malignancy, Treatment-Independent Immune Deficiencies, Dialysis, Chemo Therapeutic Agents/ Diagnoses and Procedures, Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures, Steroid Diagnoses and Procedures, Organ Transplant Diagnoses and Procedures, or Solid Malignancies any time before index.

[7]The cohort includes patients with evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals with a history of an immunocompromising condition and evidence of at least three vaccine doses more than four days apart prior to their booster dose.

[8]The cohort includes patients without evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals without a history of an immunocompromising condition and evidence of at least two vaccine doses more than four days apart prior to their booster dose.

[9]The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine. No prior evidence of having COVID-19 vaccination inclusion criteria was required for this cohort.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*NaN: Not a number

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
0-6 months			
0-6 months, 2021			
September	*****	38	*****
October	0	39	0.00
November	*****	34	*****
December	*****	46	*****
0-6 months, 2022			
January	0	49	0.00
February	*****	44	*****
March	*****	51	*****
April	*****	46	*****
May	0	40	0.00
June	*****	48	*****
July	*****	96	*****
August	0	207	0.00
September	*****	181	*****
October	*****	141	*****
November	*****	97	*****
December	*****	99	*****
0-6 months, 2023			
January	0	87	0.00
February	*****	69	*****
March	0	59	0.00
April	0	87	0.00
May	*****	90	*****
June	0	87	0.00
July	0	79	0.00
August	*****	103	*****
September	0	56	0.00
October	0	34	0.00
November	0	25	0.00
December	0	13	0.00
0-6 months, 2024			
January	0	0	NaN

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
February	0	0	NaN
7-59 months			
7-59 months, 2021			
September	127	869	1,461.45
October	145	887	1,634.72
November	125	874	1,430.21
December	161	1,060	1,518.87
7-59 months, 2022			
January	88	1,011	870.43
February	92	985	934.01
March	91	974	934.29
April	94	943	996.82
May	88	896	982.14
June	96	879	1,092.15
July	235	27,362	85.89
August	399	77,789	51.29
September	16,022	101,312	1,581.45
October	16,330	103,531	1,577.31
November	11,094	97,366	1,139.41
December	8,266	99,606	829.87
7-59 months, 2023			
January	8,481	90,894	933.06
February	5,342	85,069	627.96
March	5,231	83,172	628.94
April	3,339	79,175	421.72
May	2,770	75,906	364.93
June	2,218	72,440	306.18
July	1,337	70,995	188.32
August	1,329	69,002	192.60
September	310	65,692	47.19
October	353	63,428	55.65
November	293	60,869	48.14
December	107	41,849	25.57
7-59 months, 2024			

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
January	0	5,185	0.00
February	0	4,079	0.00
5-11 years			
5-11 years, 2021			
September	115	2,305	498.92
October	156	2,393	651.90
November	1,289	14,225	906.15
December	3,433	367,681	93.37
5-11 years, 2022			
January	1,790	449,733	39.80
February	863	494,854	17.44
March	889	512,788	17.34
April	321	515,312	6.23
May	20,534	516,710	397.40
June	41,262	494,365	834.65
July	27,254	466,238	584.55
August	24,358	442,300	550.71
September	10,373	414,726	250.12
October	15,279	403,363	378.79
November	26,788	388,667	689.23
December	16,377	364,398	449.43
5-11 years, 2023			
January	6,984	322,445	216.60
February	3,427	311,238	110.11
March	3,089	305,462	101.13
April	1,914	298,012	64.23
May	1,666	292,260	57.00
June	1,319	285,686	46.17
July	909	279,875	32.48
August	1,093	274,678	39.79
September	192	267,769	7.17
October	272	262,699	10.35
November	229	257,536	8.89
December	90	185,832	4.84

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
5-11 years, 2024			
January	0	20,417	0.00
February	0	15,469	0.00
12-15 years			
12-15 years, 2021			
September	1,111	464,811	23.90
October	634	483,797	13.10
November	769	483,703	15.90
December	1,858	494,962	37.54
12-15 years, 2022			
January	110,222	472,712	2,331.69
February	27,095	367,427	737.43
March	12,965	344,942	375.86
April	7,004	332,185	210.85
May	10,135	326,757	310.17
June	12,092	316,472	382.09
July	9,752	313,130	311.44
August	7,585	302,927	250.39
September	5,250	294,098	178.51
October	9,196	290,373	316.70
November	9,372	282,123	332.20
December	6,501	274,491	236.84
12-15 years, 2023			
January	2,612	249,847	104.54
February	1,300	244,124	53.25
March	1,199	242,000	49.55
April	761	238,352	31.93
May	694	235,665	29.45
June	679	232,339	29.22
July	503	229,600	21.91
August	511	226,769	22.53
September	172	223,020	7.71
October	282	220,012	12.82
November	198	216,907	9.13

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
December	105	162,629	6.46
12-15 years, 2024			
January	0	17,944	0.00
February	0	13,796	0.00
16-39 years			
16-39 years, 2021			
September	29,117	3,185,829	91.40
October	116,266	3,293,596	353.01
November	349,271	3,249,903	1,074.71
December	658,166	3,028,483	2,173.25
16-39 years, 2022			
January	349,462	2,311,256	1,512.00
February	92,749	1,979,275	468.60
March	48,799	1,916,819	254.58
April	30,281	1,869,780	161.95
May	29,366	1,841,472	159.47
June	23,950	1,804,088	132.75
July	20,896	1,809,622	115.47
August	15,652	1,755,387	89.17
September	33,784	1,738,539	194.32
October	47,191	1,748,868	269.84
November	37,166	1,726,906	215.22
December	26,410	1,723,100	153.27
16-39 years, 2023			
January	12,311	1,576,289	78.10
February	5,375	1,546,585	34.75
March	4,832	1,540,462	31.37
April	3,242	1,522,854	21.29
May	2,916	1,507,124	19.35
June	2,373	1,486,107	15.97
July	1,871	1,473,128	12.70
August	2,279	1,442,301	15.80
September	1,244	1,411,716	8.81
October	1,910	1,395,028	13.69

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
November	1,083	1,374,131	7.88
December	*****	998,600	*****
16-39 years, 2024			
January	*****	123,476	*****
February	*****	92,594	*****
40-64 years			
40-64 years, 2021			
September	85,461	4,349,863	196.47
October	362,216	4,398,047	823.58
November	813,662	4,170,519	1,950.98
December	934,454	3,506,231	2,665.12
40-64 years, 2022			
January	357,921	2,478,716	1,443.98
February	96,161	2,132,544	450.92
March	52,074	2,052,875	253.66
April	62,170	2,033,503	305.73
May	52,412	2,003,373	261.62
June	36,579	1,964,246	186.22
July	35,783	2,003,227	178.63
August	19,348	1,977,024	97.86
September	61,825	1,983,227	311.74
October	95,575	2,008,634	475.82
November	61,660	1,965,600	313.70
December	40,976	1,954,181	209.68
40-64 years, 2023			
January	18,120	1,795,461	100.92
February	7,434	1,764,986	42.12
March	6,090	1,758,275	34.64
April	4,192	1,743,534	24.04
May	3,741	1,730,565	21.62
June	2,716	1,712,823	15.86
July	1,838	1,710,041	10.75
August	2,669	1,699,531	15.70
September	2,007	1,679,225	11.95

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
October	2,978	1,665,083	17.88
November	1,551	1,647,874	9.41
December	*****	1,235,601	*****
40-64 years, 2024			
January	*****	148,217	*****
February	0	98,512	0.00
≥ 65 years			
≥ 65 years, 2021			
September	161,842	2,197,470	736.49
October	510,694	2,093,684	2,439.21
November	513,369	1,639,920	3,130.45
December	295,831	1,179,702	2,507.68
≥ 65 years, 2022			
January	100,541	842,545	1,193.30
February	32,519	745,431	436.24
March	23,364	722,787	323.25
April	58,815	743,727	790.81
May	36,797	719,393	511.50
June	21,901	699,799	312.96
July	20,155	758,896	265.58
August	11,264	762,094	147.80
September	46,800	787,169	594.54
October	72,266	848,418	851.77
November	38,258	830,505	460.66
December	23,740	839,316	282.85
≥ 65 years, 2023			
January	10,832	766,840	141.26
February	4,735	756,617	62.58
March	3,646	757,689	48.12
April	4,988	758,218	65.79
May	11,246	768,690	146.30
June	6,143	762,895	80.52
July	3,451	776,706	44.43
August	4,145	778,920	53.21

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
September	1,729	773,812	22.34
October	1,793	772,080	23.22
November	843	768,820	10.96
December	*****	416,736	*****
≥ 65 years, 2024			
January	*****	166,935	*****
February	*****	36,776	*****
With Booster COVID-19 Vaccine (Including Individuals Ever Immunocompromised)[4,5]			
0-6 months			
0-6 months, 2021			
September	0	0	NaN
October	0	*****	*****
November	0	*****	*****
December	0	*****	*****
0-6 months, 2022			
January	0	*****	*****
February	0	*****	*****
March	0	*****	*****
April	0	*****	*****
May	*****	*****	*****
June	0	*****	*****
July	0	*****	*****
August	0	*****	*****
September	0	*****	*****
October	0	*****	*****
November	0	*****	*****
December	0	*****	*****
0-6 months, 2023			
January	0	*****	*****
February	0	*****	*****
March	0	*****	*****
April	0	*****	*****
May	0	*****	*****
June	0	*****	*****

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
July	0	*****	*****
August	0	*****	*****
September	0	*****	*****
October	0	*****	*****
November	0	*****	*****
December	0	*****	*****
0-6 months, 2024			
January	0	0	NaN
February	0	0	NaN
7-59 months			
7-59 months, 2021			
September	*****	46	*****
October	*****	56	*****
November	11	72	1,527.78
December	*****	92	*****
7-59 months, 2022			
January	*****	86	*****
February	*****	96	*****
March	*****	107	*****
April	*****	114	*****
May	*****	117	*****
June	*****	119	*****
July	*****	139	*****
August	*****	189	*****
September	39	2,136	182.58
October	40	5,415	73.87
November	36	7,413	48.56
December	44	8,936	49.24
7-59 months, 2023			
January	57	9,677	58.90
February	*****	10,480	*****
March	77	11,311	68.08
April	89	11,710	76.00
May	128	12,011	106.57

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
June	99	12,012	82.42
July	60	11,938	50.26
August	84	11,905	70.56
September	11	11,788	9.33
October	139	11,838	117.42
November	84	11,808	71.14
December	0	8,607	0.00
7-59 months, 2024			
January	0	1,190	0.00
February	0	734	0.00
5-11 years			
5-11 years, 2021			
September	*****	61	*****
October	*****	84	*****
November	72	236	3,050.85
December	158	851	1,856.64
5-11 years, 2022			
January	95	1,108	857.40
February	38	1,200	316.67
March	58	1,410	411.35
April	*****	1,462	47.88
May	88	4,135	*****
June	168	10,943	153.52
July	127	16,105	78.86
August	118	20,863	56.56
September	51	22,781	22.39
October	1,612	25,630	628.95
November	3,079	29,909	1,029.46
December	1,950	30,456	640.27
5-11 years, 2023			
January	829	28,642	289.44
February	366	28,812	127.03
March	339	29,478	115.00
April	206	29,864	68.98

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
May	220	30,391	72.39
June	207	30,730	67.36
July	147	30,787	47.75
August	204	31,145	65.50
September	56	31,215	17.94
October	128	31,558	40.56
November	129	31,810	40.55
December	30	24,312	12.34
5-11 years, 2024			
January	0	3,051	0.00
February	0	1,986	0.00
12-15 years			
12-15 years, 2021			
September	59	1,220	483.61
October	56	1,294	432.77
November	55	1,391	395.40
December	83	1,734	478.66
12-15 years, 2022			
January	436	17,091	255.11
February	145	21,609	67.10
March	84	23,619	35.56
April	70	24,407	28.68
May	131	25,692	50.99
June	147	27,235	53.97
July	134	28,778	46.56
August	91	29,876	30.46
September	1,862	30,241	615.72
October	2,970	29,751	998.29
November	2,681	28,509	940.40
December	1,706	27,216	626.84
12-15 years, 2023			
January	585	24,631	237.51
February	229	24,342	94.08
March	236	24,526	96.22

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
April	121	24,342	49.71
May	136	24,553	55.39
June	129	24,613	52.41
July	110	24,476	44.94
August	126	24,576	51.27
September	50	24,496	20.41
October	124	24,570	50.47
November	96	24,616	39.00
December	54	18,891	28.59
12-15 years, 2024			
January	0	2,018	0.00
February	0	1,449	0.00
16-39 years			
16-39 years, 2021			
September	1,121	32,415	345.83
October	2,005	65,207	307.48
November	4,432	159,170	278.44
December	6,277	316,421	198.37
16-39 years, 2022			
January	3,926	398,312	98.57
February	1,911	421,033	45.39
March	1,559	437,191	35.66
April	2,728	446,728	61.07
May	4,285	455,971	93.98
June	4,025	461,076	87.30
July	3,773	463,593	81.39
August	2,082	463,161	44.95
September	32,274	467,575	690.24
October	42,995	450,177	955.07
November	32,142	421,633	762.32
December	20,658	404,162	511.13
16-39 years, 2023			
January	8,360	365,616	228.66
February	2,805	361,409	77.61

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
March	2,334	365,609	63.84
April	1,355	366,643	36.96
May	1,409	369,752	38.11
June	1,064	371,366	28.65
July	684	371,259	18.42
August	1,153	371,728	31.02
September	788	370,136	21.29
October	1,408	371,459	37.90
November	827	372,200	22.22
December	*****	276,942	*****
16-39 years, 2024			
January	*****	26,675	*****
February	*****	20,221	*****
40-64 years			
40-64 years, 2021			
September	4,218	120,971	348.68
October	10,494	274,756	381.94
November	19,473	633,614	307.33
December	19,725	1,029,783	191.55
40-64 years, 2022			
January	10,450	1,149,707	90.89
February	6,481	1,188,635	54.52
March	11,688	1,214,951	96.20
April	83,393	1,234,700	675.41
May	77,901	1,183,132	658.43
June	50,943	1,128,944	451.24
July	52,334	1,105,293	473.49
August	22,633	1,072,511	211.03
September	80,618	1,076,774	748.70
October	126,045	1,046,420	1,204.54
November	82,770	960,613	861.64
December	51,842	913,461	567.53
40-64 years, 2023			
January	20,564	830,407	247.64

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
February	7,698	820,122	93.86
March	5,805	827,548	70.15
April	3,795	831,062	45.66
May	3,363	836,762	40.19
June	2,256	840,726	26.83
July	1,610	844,358	19.07
August	2,494	851,301	29.30
September	2,173	853,582	25.46
October	4,099	857,828	47.78
November	2,266	859,650	26.36
December	*****	652,509	*****
40-64 years, 2024			
January	*****	61,666	*****
February	0	43,920	0.00
≥ 65 years			
≥ 65 years, 2021			
September	6,887	138,573	496.99
October	19,624	424,499	462.29
November	22,458	715,861	313.72
December	11,790	873,939	134.91
≥ 65 years, 2022			
January	5,718	888,574	64.35
February	5,619	905,812	62.03
March	18,392	920,661	199.77
April	169,675	934,808	1,815.08
May	105,142	792,633	1,326.49
June	54,253	706,665	767.73
July	49,859	686,741	726.02
August	23,230	656,042	354.09
September	54,346	658,035	825.88
October	91,243	651,982	1,399.47
November	51,759	590,680	876.26
December	30,972	565,933	547.27
≥ 65 years, 2023			

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
January	13,161	513,802	256.15
February	4,929	509,255	96.79
March	3,797	516,168	73.56
April	4,369	522,135	83.68
May	8,409	532,429	157.94
June	4,230	535,041	79.06
July	2,427	551,083	44.04
August	2,971	560,978	52.96
September	1,704	566,548	30.08
October	2,493	573,820	43.45
November	1,095	579,222	18.90
December	*****	266,569	*****
≥ 65 years, 2024			
January	*****	49,275	*****
February	0	23,732	0.00
With Booster COVID-19 Vaccine (Excluding Individuals Ever Immunocompromised)[4,6]			
0-6 months			
0-6 months, 2021			
September	*****	*****	*****
October	0	33	0.00
November	*****	31	*****
December	*****	42	*****
0-6 months, 2022			
January	0	43	0.00
February	*****	41	*****
March	*****	48	*****
April	*****	42	*****
May	0	38	0.00
June	*****	45	*****
July	*****	92	*****
August	0	198	0.00
September	*****	171	*****
October	*****	132	*****
November	*****	93	*****

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
December	*****	94	*****
0-6 months, 2023			
January	0	81	0.00
February	*****	67	*****
March	0	56	0.00
April	0	83	0.00
May	*****	84	*****
June	0	78	0.00
July	0	71	0.00
August	*****	90	*****
September	0	47	0.00
October	0	26	0.00
November	0	18	0.00
December	0	*****	*****
0-6 months, 2024			
January	0	0	NaN
February	0	0	NaN
7-59 months			
7-59 months, 2021			
September	99	701	1,412.27
October	120	725	1,655.17
November	102	713	1,430.58
December	129	862	1,496.52
7-59 months, 2022			
January	73	817	893.51
February	77	795	968.55
March	78	781	998.72
April	76	746	1,018.77
May	71	707	1,004.24
June	80	704	1,136.36
July	206	23,306	88.39
August	340	66,542	51.10
September	13,609	86,487	1,573.53
October	13,626	88,104	1,546.58

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
November	9,331	82,220	1,134.88
December	6,957	83,609	832.09
7-59 months, 2023			
January	7,147	75,941	941.13
February	4,541	70,862	640.82
March	4,502	69,108	651.44
April	2,891	65,392	442.10
May	2,407	62,443	385.47
June	1,948	59,324	328.37
July	1,157	58,195	198.81
August	1,155	56,490	204.46
September	266	53,547	49.68
October	287	51,479	55.75
November	229	49,023	46.71
December	80	33,202	24.09
7-59 months, 2024			
January	0	4,326	0.00
February	0	3,451	0.00
5-11 years			
5-11 years, 2021			
September	78	1,802	432.85
October	114	1,883	605.42
November	1,006	11,544	871.45
December	2,809	308,336	91.10
5-11 years, 2022			
January	1,367	374,895	36.46
February	675	411,158	16.42
March	664	425,627	15.60
April	233	426,600	5.46
May	17,095	426,404	400.91
June	34,505	405,600	850.71
July	22,141	382,308	579.14
August	19,866	361,736	549.19
September	8,494	337,580	251.61

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
October	12,355	326,834	378.02
November	21,681	313,106	692.45
December	13,262	291,669	454.69
5-11 years, 2023			
January	5,568	256,078	217.43
February	2,747	246,093	111.62
March	2,507	240,474	104.25
April	1,554	233,280	66.62
May	1,390	227,728	61.04
June	1,058	221,272	47.81
July	717	216,024	33.19
August	850	211,134	40.26
September	144	204,749	7.03
October	207	199,930	10.35
November	180	194,739	9.24
December	71	137,263	5.17
5-11 years, 2024			
January	0	16,297	0.00
February	0	12,519	0.00
12-15 years, 2021			
September	802	396,443	20.23
October	484	411,853	11.75
November	560	410,431	13.64
December	1,350	419,173	32.21
12-15 years, 2022			
January	93,343	398,873	2,340.17
February	22,976	308,604	744.51
March	10,965	289,019	379.39
April	5,877	277,476	211.80
May	8,443	272,159	310.22
June	10,142	262,675	386.10
July	8,101	260,269	311.25
August	6,385	251,220	254.16
September	4,484	243,059	184.48

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
October	7,684	239,198	321.24
November	7,937	231,543	342.79
December	5,440	223,896	242.97
12-15 years, 2023			
January	2,183	202,507	107.80
February	1,101	197,201	55.83
March	991	194,820	50.87
April	651	191,108	34.06
May	571	188,346	30.32
June	551	184,937	29.79
July	419	182,268	22.99
August	418	179,522	23.28
September	145	175,824	8.25
October	230	172,780	13.31
November	152	169,632	8.96
December	80	124,877	6.41
12-15 years, 2024			
January	0	15,338	0.00
February	0	11,837	0.00
16-39 years			
16-39 years, 2021			
September	17,239	2,372,171	72.67
October	77,558	2,445,332	317.17
November	246,578	2,402,152	1,026.49
December	489,008	2,240,389	2,182.69
16-39 years, 2022			
January	261,297	1,701,028	1,536.11
February	69,352	1,439,980	481.62
March	36,046	1,390,189	259.29
April	21,794	1,348,513	161.62
May	20,907	1,321,431	158.21
June	16,893	1,285,933	131.37
July	14,839	1,289,131	115.11
August	11,129	1,237,830	89.91

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
September	24,428	1,217,644	200.62
October	34,178	1,221,783	279.74
November	26,927	1,200,020	224.39
December	19,299	1,191,642	161.95
16-39 years, 2023			
January	8,862	1,081,716	81.93
February	3,764	1,052,490	35.76
March	3,413	1,043,311	32.71
April	2,307	1,024,023	22.53
May	2,010	1,006,951	19.96
June	1,710	985,672	17.35
July	1,324	971,979	13.62
August	1,575	942,242	16.72
September	819	914,253	8.96
October	1,226	897,763	13.66
November	698	877,308	7.96
December	*****	608,073	*****
16-39 years, 2024			
January	*****	90,022	*****
February	*****	69,099	*****
40-64 years			
40-64 years, 2021			
September	33,473	2,416,392	138.52
October	175,121	2,436,942	718.61
November	429,152	2,309,138	1,858.49
December	521,461	1,949,695	2,674.58
40-64 years, 2022			
January	198,161	1,356,990	1,460.30
February	52,055	1,146,430	454.06
March	26,956	1,095,794	246.00
April	30,781	1,076,412	285.96
May	26,566	1,053,595	252.15
June	18,608	1,023,431	181.82
July	17,613	1,047,740	168.10

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
August	9,548	1,025,632	93.09
September	32,211	1,020,675	315.59
October	49,981	1,032,380	484.13
November	32,326	1,003,163	322.24
December	21,533	991,803	217.11
40-64 years, 2023			
January	9,381	898,576	104.40
February	3,830	871,681	43.94
March	3,184	860,449	37.00
April	2,094	843,502	24.83
May	1,816	828,415	21.92
June	1,328	810,087	16.39
July	911	803,822	11.33
August	1,226	791,295	15.49
September	951	772,809	12.31
October	1,329	758,418	17.52
November	748	741,760	10.08
December	*****	525,059	*****
40-64 years, 2024			
January	*****	80,107	*****
February	0	57,013	0.00
≥ 65 years			
≥ 65 years, 2021			
September	56,771	971,526	584.35
October	210,404	928,922	2,265.03
November	219,484	732,393	2,996.81
December	131,113	533,281	2,458.61
≥ 65 years, 2022			
January	44,639	378,004	1,180.91
February	13,900	329,760	421.52
March	9,102	318,488	285.79
April	23,475	325,476	721.25
May	15,504	314,143	493.53
June	9,479	302,666	313.18

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
July	8,730	340,552	256.35
August	4,959	340,752	145.53
September	21,101	347,069	607.98
October	33,275	373,835	890.10
November	17,453	360,999	483.46
December	10,733	362,794	295.84
≥ 65 years, 2023			
January	4,774	325,070	146.86
February	2,080	315,368	65.95
March	1,568	312,214	50.22
April	2,134	307,655	69.36
May	4,679	307,052	152.38
June	2,482	299,448	82.89
July	1,388	303,819	45.69
August	1,579	300,515	52.54
September	725	293,645	24.69
October	770	289,126	26.63
November	339	283,384	11.96
December	*****	139,747	*****
≥ 65 years, 2024			
January	*****	57,096	*****
February	*****	16,144	*****
With Booster COVID-19 Vaccine (Booster Specific Code)[7]			
0-6 months			
0-6 months, 2021			
September	0	25,802	0.00
October	0	34,022	0.00
November	0	27,711	0.00
December	0	35,707	0.00
0-6 months, 2022			
January	0	33,677	0.00
February	0	27,069	0.00
March	*****	27,621	*****
April	0	26,278	0.00

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
May	0	24,948	0.00
June	0	22,984	0.00
July	*****	26,586	*****
August	*****	32,717	*****
September	0	27,573	0.00
October	0	35,105	0.00
November	*****	28,612	*****
December	*****	36,111	*****
0-6 months, 2023			
January	*****	33,665	*****
February	*****	27,655	*****
March	*****	27,835	*****
April	161	26,176	61.51
May	638	26,045	244.96
June	547	24,168	226.33
July	490	27,197	180.17
August	498	32,740	152.11
September	146	26,923	54.23
October	0	34,365	0.00
November	*****	28,026	*****
December	0	24,306	0.00
0-6 months, 2024			
January	0	3,142	0.00
February	0	1,931	0.00
7-59 months			
7-59 months, 2021			
September	0	884,848	0.00
October	*****	889,689	*****
November	151	875,078	1.73
December	74	895,140	0.83
7-59 months, 2022			
January	72	832,247	0.87
February	*****	821,927	*****
March	29	831,124	0.35

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
April	*****	833,605	*****
May	*****	834,294	*****
June	178	829,240	2.15
July	255	926,706	2.75
August	190	936,582	2.03
September	169	916,503	1.84
October	204	928,915	2.20
November	161	916,162	1.76
December	4,275	940,955	45.43
7-59 months, 2023			
January	8,357	863,971	96.73
February	5,448	844,373	64.52
March	5,507	851,004	64.71
April	4,530	847,141	53.47
May	5,777	843,786	68.47
June	4,397	833,812	52.73
July	2,978	920,079	32.37
August	3,013	926,235	32.53
September	677	903,037	7.50
October	32	913,197	0.35
November	*****	898,507	*****
December	0	676,377	0.00
7-59 months, 2024			
January	0	84,862	0.00
February	0	54,661	0.00
5-11 years			
5-11 years, 2021			
September	81	1,636,806	0.49
October	68	1,641,882	0.41
November	212,520	1,619,090	1,312.59
December	77,073	1,436,522	536.53
5-11 years, 2022			
January	41,040	1,259,056	325.96
February	12,046	1,203,719	100.07

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
March	5,988	1,207,425	49.59
April	4,119	1,209,761	34.05
May	6,511	1,212,464	53.70
June	11,879	1,207,615	98.37
July	13,081	1,372,176	95.33
August	12,586	1,384,986	90.87
September	5,742	1,354,121	42.40
October	14,340	1,372,207	104.50
November	25,584	1,346,015	190.07
December	16,395	1,362,750	120.31
5-11 years, 2023			
January	7,603	1,249,550	60.85
February	3,883	1,227,993	31.62
March	3,497	1,243,279	28.13
April	2,457	1,248,185	19.68
May	2,320	1,254,203	18.50
June	2,152	1,253,563	17.17
July	1,786	1,419,678	12.58
August	2,119	1,442,561	14.69
September	380	1,420,207	2.68
October	56	1,441,491	0.39
November	*****	1,425,382	*****
December	*****	1,069,961	*****
5-11 years, 2024			
January	0	136,446	0.00
February	0	81,423	0.00
12-15 years			
12-15 years, 2021			
September	142	1,078,557	1.32
October	72	1,081,263	0.67
November	427	1,065,672	4.01
December	706	1,079,185	6.54
12-15 years, 2022			
January	39,409	997,517	395.07

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
February	18,837	942,124	199.94
March	9,994	926,290	107.89
April	5,591	914,157	61.16
May	6,559	905,816	72.41
June	7,449	892,574	83.46
July	7,006	992,615	70.58
August	5,659	992,356	57.03
September	14,524	968,605	149.95
October	23,181	960,209	241.42
November	21,118	922,613	228.89
December	14,227	921,415	154.40
12-15 years, 2023			
January	5,267	840,414	62.67
February	2,422	821,555	29.48
March	2,116	825,899	25.62
April	1,325	823,403	16.09
May	1,227	821,714	14.93
June	1,335	816,851	16.34
July	1,137	919,885	12.36
August	1,151	928,400	12.40
September	201	911,128	2.21
October	*****	918,421	*****
November	0	904,586	0.00
December	*****	679,191	*****
12-15 years, 2024			
January	0	81,682	0.00
February	0	48,165	0.00
16-39 years			
16-39 years, 2021			
September	1,149	7,265,586	1.58
October	12,555	7,331,656	17.12
November	52,881	7,184,989	73.60
December	109,591	7,337,410	149.36
16-39 years, 2022			

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
January	87,122	6,778,979	128.52
February	55,231	6,587,657	83.84
March	33,210	6,629,489	50.09
April	22,270	6,626,838	33.61
May	23,672	6,621,381	35.75
June	21,187	6,581,895	32.19
July	21,201	7,408,573	28.62
August	15,848	7,424,626	21.35
September	188,778	7,236,545	260.87
October	258,047	7,177,773	359.51
November	197,795	6,813,556	290.30
December	134,936	6,878,006	196.18
16-39 years, 2023			
January	56,153	6,292,025	89.24
February	21,384	6,142,810	34.81
March	17,781	6,232,288	28.53
April	11,658	6,253,274	18.64
May	10,808	6,270,042	17.24
June	8,396	6,249,718	13.43
July	6,924	7,120,134	9.72
August	8,821	7,204,236	12.24
September	2,554	7,015,627	3.64
October	461	7,156,695	0.64
November	239	7,033,825	0.34
December	57	5,027,875	0.11
16-39 years, 2024			
January	0	578,369	0.00
February	0	325,051	0.00
40-64 years			
40-64 years, 2021			
September	2,906	9,018,274	3.22
October	45,800	9,087,159	50.40
November	147,474	8,937,831	165.00
December	187,037	8,955,941	208.84

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
40-64 years, 2022			
January	94,614	8,134,776	116.31
February	49,629	7,930,091	62.58
March	35,025	7,916,967	44.24
April	87,118	7,890,239	110.41
May	83,319	7,798,123	106.84
June	59,074	7,696,666	76.75
July	63,082	8,587,418	73.46
August	32,667	8,653,228	37.75
September	327,574	8,504,066	385.20
October	500,862	8,289,301	604.23
November	323,464	7,708,126	419.64
December	209,973	7,597,806	276.36
40-64 years, 2023			
January	83,466	6,859,232	121.68
February	31,505	6,685,913	47.12
March	23,642	6,720,461	35.18
April	14,595	6,724,405	21.70
May	11,482	6,725,346	17.07
June	8,173	6,711,003	12.18
July	6,333	7,769,566	8.15
August	9,436	7,976,294	11.83
September	3,292	7,855,834	4.19
October	881	8,015,348	1.10
November	461	7,919,627	0.58
December	*****	5,801,286	*****
40-64 years, 2024			
January	*****	1,105,862	*****
February	0	310,572	0.00
≥ 65 years			
≥ 65 years, 2021			
September	47,193	7,220,470	65.36
October	281,031	7,293,494	385.32
November	347,259	6,982,874	497.30

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			
December	203,429	6,770,275	300.47
≥ 65 years, 2022			
January	47,763	6,098,817	78.32
February	24,213	5,982,518	40.47
March	25,431	5,975,553	42.56
April	145,415	5,958,072	244.06
May	99,700	5,819,277	171.33
June	59,885	5,719,890	104.70
July	58,658	6,449,374	90.95
August	33,976	6,536,689	51.98
September	272,554	6,458,338	422.02
October	439,563	6,322,597	695.23
November	241,587	5,856,802	412.49
December	147,292	5,772,037	255.18
≥ 65 years, 2023			
January	64,309	5,210,927	123.41
February	25,526	5,094,268	50.11
March	18,950	5,099,228	37.16
April	15,025	5,093,565	29.50
May	21,356	5,093,609	41.93
June	11,671	5,077,843	22.98
July	10,248	6,261,753	16.37
August	13,761	6,454,096	21.32
September	3,884	6,399,981	6.07
October	878	6,572,824	1.34
November	323	6,538,822	0.49
December	*****	5,028,552	*****
≥ 65 years, 2024			
January	*****	3,769,464	*****
February	0	96,190	0.00

Table 3c r04. Summary of Exposures of Interest (Booster Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024, by Age Group, Year, and Month

	Number of Patients	Number of Eligible Members[2]	Number of Patients per 10,000 Eligible Members[2]
With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[3]			

[1] The cohorts include patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. We defined boosters using four different cohorts:
- Cohort 1: Individuals with evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 2: Individuals with a history of an immunocompromising condition and evidence of at least three vaccine codes more than four days apart prior to their booster dose.
- Cohort 3: Individuals without a history of an immunocompromising condition and evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 4: Individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine.

[2] ***Eligible Members are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.*** This quantity does not consider age-based vaccine eligibility. We observe differences in the number of eligible members across the cohorts due to varying inclusion and exclusion criteria for each cohort.

[3] The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who have evidence of receiving at least two vaccine doses more than four days apart prior to their booster dose.

[4] Including any evidence of HIV/AIDS, Hematological Malignancy, Treatment-Independent Immune Deficiencies, Dialysis, Chemo Therapeutic Agents/ Diagnoses and Procedures, Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures, Steroid Diagnoses and Procedures, Organ Transplant Diagnoses and Procedures, or Solid Malignancies any time before index.

[5] The cohort includes patients with evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals with a history of an immunocompromising condition and evidence of at least three vaccine doses more than four days apart prior to their booster dose.

[6] The cohort includes patients without evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals without a history of an immunocompromising condition and evidence of at least two vaccine doses more than four days apart prior to their booster dose.

[7] The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine. No prior evidence of having COVID-19 vaccination inclusion criteria was required for this cohort.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
*NaN: Not a number

Table 4a r01. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations Among Patients With at Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]						
			1-10 days		11-17 days	
	Total Number of Patients with At Least One COVID-19 Vaccine	Total Number of Patients with Two COVID-19 Vaccines[3]	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
COVID-19 Vaccination	15,530,103	12,064,594	116,351	1.0%	4,605,438	38.2%

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]Represents episodes of at least two COVID-19 vaccine codes in two separate days.

Table 4a r01. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations Among Patients With at Least One COVID-19 Vaccine1 in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]							
18-21 days		22-24 days		25-27 days		28-40 days	
Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
1,211,907	10.0%	3,227,063	26.7%	733,987	6.1%	635,382	5.3%

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]Represents episodes of at least two COVID-19 vaccine codes in two separate days.

Table 4a r01. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations Among Patients With at Least One COVID-19 Vaccine1 in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]					
41-50 days		51-60 days		61+ days	
Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
73,717	0.6%	50,123	0.4%	1,410,626	11.7%

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]Represents episodes of at least two COVID-19 vaccine codes in two separate days.

Table 4a r01. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations Among Patients With at Least One COVID-19 Vaccine1 in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]						
Distribution of At-Risk Time in Days, by Episode						
Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
1	17	22	24	1,075	46.7	78.7

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]Represents episodes of at least two COVID-19 vaccine codes in two separate days.

Table 4 r02. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations Among Patients With At Least Two COVID-19 Vaccines[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]								
			1-10 days		11-17 days		18-21 days	
	Total Number of Patients with At Least Two COVID-19 Vaccines	Total Number of Patients with Two COVID-19 Vaccines[3]	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
COVID-19 Vaccination	11,915,048	11,900,238	104,825	0.9%	4,569,072	38.4%	1,184,990	10.0%

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]Represents episodes of at least two COVID-19 vaccine codes in two separate days. A small subset of patients do not appear to have received their second COVID-19 vaccine and thus are not included in the calculation of the time interval between the first and second COVID-19 vaccines. This is despite our cohort inclusion criteria requiring at least two COVID-19 vaccines. This discrepancy arises because to assess the time between the first and second COVID-19 vaccinations, the second vaccination is considered as one of the "end of follow-up" points. For a small number of patients, an earlier "end of follow-up" point, such as disenrollment/re-enrollment, occurred before the second vaccine. Consequently, the follow-up ended at this point and did not extend until the second vaccine was observed.

Table 4 r02. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations Among Patients With At Least Two COVID-19 Vaccines1 in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]									
22-24 days		25-27 days		28-40 days		41-50 days		51-60 days	
Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
3,187,011	26.8%	706,812	5.9%	626,832	5.3%	73,016	0.6%	49,680	0.4%

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]Represents episodes of at least two COVID-19 vaccine codes in two separate days. A small subset of patients do not appear to have received their second COVID-19 vaccine and thus are not included in the calculation of the time interval between the first and second COVID-19 vaccines. This is despite our cohort inclusion criteria requiring at least two COVID-19 vaccines. This discrepancy arises because to assess the time between the first and second COVID-19 vaccinations, the second vaccination is considered as one of the “end of follow-up” points. For a small number of patients, an earlier “end of follow-up” point, such as disenrollment/re-enrollment, occurred before the second vaccine. Consequently, the follow-up ended at this point and did not extend until the second vaccine was observed.

Table 4 r02. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations Among Patients With At Least Two COVID-19 Vaccines[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]								
61+ days		Distribution of At-Risk Time in Days, by Episode						
Number of Episodes	Percent of Total Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
1,398,000	11.7%	1	17	22	24	1,075	46.8	78.9

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]Represents episodes of at least two COVID-19 vaccine codes in two separate days. A small subset of patients do not appear to have received their second COVID-19 vaccine and thus are not included in the calculation of the time interval between the first and second COVID-19 vaccines. This is despite our cohort inclusion criteria requiring at least two COVID-19 vaccines. This discrepancy arises because to assess the time between the first and second COVID-19 vaccinations, the second vaccination is considered as one of the “end of follow-up” points. For a small number of patients, an earlier “end of follow-up” point, such as disenrollment/re-enrollment, occurred before the second vaccine. Consequently, the follow-up ended at this point and did not extend until the second vaccine was observed.

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]				
			1-10 days	
	Number of Patients with Only the First Component of the Combination[3]	Number of Exposure Episodes with First and Second Components of Combination[4]	Number of Episodes	Percent of Total Episodes
COVID-19 Vaccine Brand for the First and Second Observed Records				
With a first Pfizer COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Pfizer-Pfizer combination)	9,114,170	7,381,915	49,273	0.7%
With a first Moderna COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Moderna-Moderna combination)	5,584,660	4,146,919	46,345	1.1%
With a first Janssen COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Janssen-Janssen combination)	818,691	87,221	7,590	8.7%
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Novavax or Unspecified-Novavax or Unspecified combination)	67,284	37,807	244	0.6%
With a first Pfizer COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Pfizer-Moderna combination)	9,114,170	566,454	3,080	0.5%
With a first Moderna COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Moderna-Pfizer combination)	5,584,660	663,253	3,512	0.5%
With a first Pfizer COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Pfizer-Novavax or Unspecified combination)	9,114,170	26,590	629	2.4%
With a first Pfizer COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Pfizer-Janssen combination)	9,114,170	7,144	405	5.7%
With a first Moderna COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Moderna-Janssen combination)	5,584,660	7,428	481	6.5%
With a first Moderna COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Moderna-Novavax or Unspecified combination)	5,584,660	21,469	573	2.7%
With a first Janssen COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Janssen-Moderna combination)	818,691	173,946	385	0.2%
With a first Janssen COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Janssen-Pfizer combination)	818,691	173,801	413	0.2%
With a first Janssen COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Janssen-Novavax or Unspecified combination)	818,691	2,638	355	13.5%

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]				
			1-10 days	
	Number of Patients with Only the First Component of the Combination[3]	Number of Exposure Episodes with First and Second Components of Combination [4]	Number of Episodes	Percent of Total Episodes
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Novavax or Unspecified-Moderna combination)	67,284	24,248	1,304	5.4%
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Novavax or Unspecified-Pfizer combination)	67,284	30,790	2,128	6.9%
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Janssen or Unspecified COVID-19 vaccine (Novavax or Unspecified-Janssen combination)	67,284	2,006	576	28.7%
COVID-19 Vaccine Code Type for the First and Second Observed Records				
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only Claims-OnlyClaims combination)	7,701,405	5,075,804	37,843	0.7%
With a first COVID-19 vaccine identified only by immunization information systems (IIS) codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only IIS-Only IIS combination)	1,677,891	1,364,761	7,761	0.6%
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only Claims-Only IIS combination)	8,002,553	117,099	8,962	7.7%
With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only IIS-Only claims combination)	3,301,529	368,707	16,233	4.4%
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only Claims-Claims and IIS combination)	8,002,553	217,782	1,658	0.8%
With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only IIS-IIS and Claims	3,301,529	1,382,856	9,319	0.7%
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Claims and IIS-Only IIS	4,226,021	703,498	7,404	1.1%
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (IIS and Claims-Only Claims combination)	4,226,021	506,255	1,681	0.3%

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]				
			1-10 days	
	Number of Patients with Only the First Component of the Combination[3]	Number of Exposure Episodes with First and Second Components of Combination [4]	Number of Episodes	Percent of Total Episodes
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (IIS and Claims-IIS and Claims combination)	4,226,021	3,509,298	2,717	0.1%

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column presents the number of patients based on the brand or data source of their initial COVID-19 vaccine.

[4]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column displays the number of patients who have received both their initial and second COVID-19 vaccines in two separate days, categorized by the combination of vaccine brand and data source.

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]				
	11-17 days		18-21 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
COVID-19 Vaccine Brand for the First and Second Observed Records				
With a first Pfizer COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Pfizer-Pfizer combination)	4,569,763	61.9%	1,119,772	15.2%
With a first Moderna COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Moderna-Moderna combination)	25,348	0.6%	86,793	2.1%
With a first Janssen COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Janssen-Janssen combination)	1,716	2.0%	694	0.8%
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Novavax or Unspecified-Novavax or Unspecified combination)	11,265	29.8%	3,119	8.2%
With a first Pfizer COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Pfizer-Moderna combination)	8,976	1.6%	3,005	0.5%
With a first Moderna COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Moderna-Pfizer combination)	10,791	1.6%	4,235	0.6%
With a first Pfizer COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Pfizer-Novavax or Unspecified combination)	9,939	37.4%	2,626	9.9%
With a first Pfizer COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Pfizer-Janssen combination)	789	11.0%	237	3.3%
With a first Moderna COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Moderna-Janssen combination)	235	3.2%	143	1.9%
With a first Moderna COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Moderna-Novavax or Unspecified combination)	1,047	4.9%	628	2.9%
With a first Janssen COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Janssen-Moderna combination)	228	0.1%	92	0.1%
With a first Janssen COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Janssen-Pfizer combination)	840	0.5%	373	0.2%
With a first Janssen COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Janssen-Novavax or Unspecified combination)	124	4.7%	77	2.9%
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Novavax or Unspecified-Moderna combination)	822	3.4%	514	2.1%

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]				
	11-17 days		18-21 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Novavax or Unspecified-Pfizer combination)	9,888	32.1%	3,600	11.7%
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Janssen or Unspecified COVID-19 vaccine (Novavax or Unspecified-Janssen combination)	158	7.9%	81	4.0%
COVID-19 Vaccine Code Type for the First and Second Observed Records				
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only Claims-OnlyClaims combination)	1,847,972	36.4%	484,848	9.6%
With a first COVID-19 vaccine identified only by immunization information systems (IIS) codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only IIS-Only IIS combination)	527,647	38.7%	129,792	9.5%
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only Claims-Only IIS combination)	6,119	5.2%	16,160	13.8%
With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only IIS-Only claims combination)	8,393	2.3%	7,147	1.9%
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only Claims-Claims and IIS combination)	29,870	13.7%	18,672	8.6%
With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only IIS-IIS and Claims combination)	71,249	5.2%	34,105	2.5%
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Claims and IIS-Only IIS combination)	64,575	9.2%	27,174	3.9%
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (IIS and Claims-Only Claims combination)	49,529	9.8%	17,340	3.4%
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (IIS and Claims-IIS and Claims combination)	1,478,404	42.1%	379,297	10.8%

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]				
	11-17 days		18-21 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column presents the number of patients based on the brand or data source of their initial COVID-19 vaccine.

[4]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column displays the number of patients who have received both their initial and second COVID-19 vaccines in two separate days, categorized by the combination of vaccine brand and data source.

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]				
	22-24 days		25-27 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
COVID-19 Vaccine Brand for the First and Second Observed Records				
With a first Pfizer COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Pfizer-Pfizer combination)	627,522	8.5%	165,422	2.2%
With a first Moderna COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Moderna-Moderna combination)	2,596,741	62.6%	564,323	13.6%
With a first Janssen COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Janssen-Janssen combination)	753	0.9%	585	0.7%
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Novavax or Unspecified-Novavax or Unspecified combination)	10,997	29.1%	5,476	14.5%
With a first Pfizer COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Pfizer-Moderna combination)	8,085	1.4%	2,864	0.5%
With a first Moderna COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Moderna-Pfizer combination)	7,468	1.1%	2,490	0.4%
With a first Pfizer COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Pfizer-Novavax or Unspecified combination)	1,589	6.0%	571	2.1%
With a first Pfizer COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Pfizer-Janssen combination)	159	2.2%	100	1.4%
With a first Moderna COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Moderna-Janssen combination)	557	7.5%	165	2.2%
With a first Moderna COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Moderna-Novavax or Unspecified combination)	7,309	34.0%	2,006	9.3%
With a first Janssen COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Janssen-Moderna combination)	506	0.3%	263	0.2%
With a first Janssen COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Janssen-Pfizer combination)	208	0.1%	106	0.1%
With a first Janssen COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Janssen-Novavax or Unspecified combination)	37	1.4%	48	1.8%
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Novavax or Unspecified-Moderna combination)	7,450	30.7%	2,777	11.5%

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]				
	22-24 days		25-27 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Novavax or Unspecified-Pfizer combination)	1,966	6.4%	868	2.8%
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Janssen or Unspecified COVID-19 vaccine (Novavax or Unspecified-Janssen combination)	49	2.4%	60	3.0%
COVID-19 Vaccine Code Type for the First and Second Observed Records				
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only Claims-OnlyClaims combination)	1,287,930	25.4%	262,374	5.2%
With a first COVID-19 vaccine identified only by immunization information systems (IIS) codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only IIS-Only IIS combination)	408,738	29.9%	100,073	7.3%
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only Claims-Only IIS combination)	5,015	4.3%	17,332	14.8%
With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only IIS-Only claims combination)	6,007	1.6%	6,413	1.7%
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only Claims-Claims and IIS combination)	26,627	12.2%	15,099	6.9%
With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only IIS-IIS and Claims combination)	52,350	3.8%	28,586	2.1%
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Claims and IIS-Only IIS combination)	58,441	8.3%	19,963	2.8%
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (IIS and Claims-Only Claims combination)	47,379	9.4%	9,797	1.9%
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (IIS and Claims-IIS and Claims combination)	937,150	26.7%	206,960	5.9%

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]				
	22-24 days		25-27 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column presents the number of patients based on the brand or data source of their initial COVID-19 vaccine.

[4]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column displays the number of patients who have received both their initial and second COVID-19 vaccines in two separate days, categorized by the combination of vaccine brand and data source.

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]				
	28-40 days		41-50 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
COVID-19 Vaccine Brand for the First and Second Observed Records				
With a first Pfizer COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Pfizer-Pfizer combination)	224,781	3.0%	41,469	0.6%
With a first Moderna COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Moderna-Moderna combination)	406,207	9.8%	30,352	0.7%
With a first Janssen COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Janssen-Janssen combination)	841	1.0%	352	0.4%
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Novavax or Unspecified-Novavax or Unspecified	3,047	8.1%	416	1.1%
With a first Pfizer COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Pfizer-Moderna combination)	4,180	0.7%	1,733	0.3%
With a first Moderna COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Moderna-Pfizer combination)	3,915	0.6%	1,634	0.2%
With a first Pfizer COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Pfizer-Novavax or Unspecified combination)	1,438	5.4%	649	2.4%
With a first Pfizer COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Pfizer-Janssen combination)	316	4.4%	197	2.8%
With a first Moderna COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Moderna-Janssen combination)	384	5.2%	192	2.6%
With a first Moderna COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Moderna-Novavax or Unspecified combination)	1,755	8.2%	509	2.4%
With a first Janssen COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Janssen-Moderna combination)	372	0.2%	171	0.1%
With a first Janssen COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Janssen-Pfizer combination)	268	0.2%	142	0.1%
With a first Janssen COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Janssen-Novavax or Unspecified combination)	77	2.9%	41	1.6%
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Novavax or Unspecified-Moderna combination)	2,096	8.6%	268	1.1%

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]				
	28-40 days		41-50 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Novavax or Unspecified-Pfizer combination)	1,194	3.9%	369	1.2%
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Janssen or Unspecified COVID-19 vaccine (Novavax or Unspecified-Janssen combination)	130	6.5%	41	2.0%
COVID-19 Vaccine Code Type for the First and Second Observed Records				
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only Claims-OnlyClaims combination)	227,470	4.5%	30,119	0.6%
With a first COVID-19 vaccine identified only by immunization information systems (IIS) codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only IIS-Only IIS combination)	93,569	6.9%	9,156	0.7%
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only Claims-Only IIS combination)	5,772	4.9%	1,462	1.2%
With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only IIS-Only claims combination)	6,864	1.9%	2,440	0.7%
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only Claims-Claims and IIS combination)	9,549	4.4%	1,328	0.6%
With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only IIS-IIS and Claims combination)	27,027	2.0%	6,088	0.4%
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Claims and IIS-Only IIS combination)	20,459	2.9%	5,038	0.7%
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (IIS and Claims-Only Claims combination)	10,465	2.1%	2,055	0.4%
19 vaccine also identified by claims and IIS codes (IIS and Claims-IIS and Claims combination)	187,720	5.3%	21,447	0.6%

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]				
	28-40 days		41-50 days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column presents the number of patients based on the brand or data source of their initial COVID-19 vaccine.

[4]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column displays the number of patients who have received both their initial and second COVID-19 vaccines in two separate days, categorized by the combination of vaccine brand and data source.

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]				
	51-60 days		61+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
COVID-19 Vaccine Brand for the First and Second Observed Records				
With a first Pfizer COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Pfizer-Pfizer combination)	28,597	0.4%	555,316	7.5%
With a first Moderna COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Moderna-Moderna combination)	18,627	0.4%	372,183	9.0%
With a first Janssen COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Janssen-Janssen combination)	746	0.9%	73,944	84.8%
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Novavax or Unspecified-Novavax or Unspecified combination)	437	1.2%	2,806	7.4%
With a first Pfizer COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Pfizer-Moderna combination)	1,539	0.3%	532,992	94.1%
With a first Moderna COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Moderna-Pfizer combination)	1,763	0.3%	627,445	94.6%
With a first Pfizer COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Pfizer-Novavax or Unspecified combination)	460	1.7%	8,689	32.7%
With a first Pfizer COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Pfizer-Janssen combination)	172	2.4%	4,769	66.8%
With a first Moderna COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Moderna-Janssen combination)	210	2.8%	5,061	68.1%
With a first Moderna COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Moderna-Novavax or Unspecified combination)	522	2.4%	7,120	33.2%
With a first Janssen COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Janssen-Moderna combination)	274	0.2%	171,655	98.7%
With a first Janssen COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Janssen-Pfizer combination)	297	0.2%	171,154	98.5%
With a first Janssen COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Janssen-Novavax or Unspecified combination)	37	1.4%	1,842	69.8%
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Novavax or Unspecified-Moderna combination)	241	1.0%	8,776	36.2%

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]				
	51-60 days		61+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Novavax or Unspecified-Pfizer combination)	322	1.0%	10,455	34.0%
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Janssen or Unspecified COVID-19 vaccine (Novavax or Unspecified-Janssen combination)	55	2.7%	856	42.7%
COVID-19 Vaccine Code Type for the First and Second Observed Records				
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only Claims-OnlyClaims combination)	21,277	0.4%	875,971	17.3%
With a first COVID-19 vaccine identified only by immunization information systems (IIS) codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only IIS-Only IIS combination)	5,749	0.4%	82,276	6.0%
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only Claims-Only IIS combination)	1,170	1.0%	55,107	47.1%
With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only IIS-Only claims combination)	2,154	0.6%	313,056	84.9%
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only Claims-Claims and IIS combination)	831	0.4%	114,148	52.4%
With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only IIS-IIS and Claims combination)	4,401	0.3%	1,149,731	83.1%
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Claims and IIS-Only IIS combination)	3,772	0.5%	496,672	70.6%
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (IIS and Claims-Only Claims combination)	1,648	0.3%	366,361	72.4%
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (IIS and Claims-IIS and Claims combination)	14,067	0.4%	281,536	8.0%

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]				
	51-60 days		61+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column presents the number of patients based on the brand or data source of their initial COVID-19 vaccine.

[4]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column displays the number of patients who have received both their initial and second COVID-19 vaccines in two separate days, categorized by the combination of vaccine brand and data source.

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]							
	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
COVID-19 Vaccine Brand for the First and Second Observed Records							
With a first Pfizer COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Pfizer-Pfizer combination)	1	17	17	20	1,075	35.3	65.4
With a first Moderna COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Moderna-Moderna combination)	1	24	24	26	1,058	43.4	66.8
With a first Janssen COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Janssen-Janssen combination)	1	175	224	248	934	194.8	90.8
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Novavax or Unspecified-Novavax or Unspecified combination)	1	17	24	27	1,047	38.6	66.6
With a first Pfizer COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Pfizer-Moderna combination)	1	238	285	501	1,089	352.1	184.1
With a first Moderna COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Moderna-Pfizer combination)	1	259	391	593	1,111	420.4	210.1
With a first Pfizer COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Pfizer-Novavax or Unspecified combination)	1	17	22	207	1,122	138.9	220.5
With a first Pfizer COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Pfizer-Janssen combination)	1	31	170	255	1,043	165.1	137.1
With a first Moderna COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Moderna-Janssen combination)	1	36	173	262	1,041	171.0	141.3
With a first Moderna COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Moderna-Novavax or Unspecified combination)	1	24	26	210	1,096	137.7	211.3
With a first Janssen COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Janssen-Moderna combination)	1	219	242	278	1,017	271.8	112.9
With a first Janssen COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Janssen-Pfizer combination)	1	224	256	385	1,028	316.5	154.3
With a first Janssen COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Janssen-Novavax or Unspecified combination)	1	29	231	428	1,029	277.6	261.2
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Novavax or Unspecified-Moderna combination)	1	24	27	240	1,014	126.2	163.6

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]							
	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Novavax or Unspecified-Pfizer combination)	1	17	21	225	1,074	127.2	191.2
With a first Novavax or Unspecified COVID-19 vaccine followed by a second Janssen or Unspecified COVID-19 vaccine (Novavax or Unspecified-Janssen combination)	1	8	34	204	584	92.4	103.8
COVID-19 Vaccine Code Type for the First and Second Observed Records							
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only Claims-OnlyClaims combination)	1	17	23	26	990	59.4	94.0
With a first COVID-19 vaccine identified only by immunization information systems (IIS) codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only IIS-Only IIS combination)	1	17	22	24	1,075	34.4	57.4
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only Claims-Only IIS combination)	1	20	37	272	1,093	179.1	218.4
With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only IIS-Only claims combination)	1	225	286	534	1,073	341.1	217.8
With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only Claims-Claims and IIS combination)	1	24	169	268	1,065	176.2	177.6
With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only IIS-IIS and Claims	1	216	260	321	1,052	272.8	166.1
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Claims and IIS-Only IIS	1	27	241	302	1,123	249.6	214.2
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (IIS and Claims-Only Claims combination)	1	28	253	416	1,085	275.7	213.5
With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (IIS and Claims-IIS and Claims combination)	1	17	20	24	981	39.7	71.5

Table 4 r03. Summary of the Length of the Interval Between the First and Second Observed Coronavirus Disease 2019 (COVID-19) Vaccinations (Combinations of Brand or Code Type for the First and Second COVID-19 Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Number of Patients by Length of the Interval Between First and Second Coronavirus Disease 2019 (COVID-19) Vaccines[2]							
	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]The four days after the index date are not included; therefore, the interval calculation begins on day five after the index.

[3]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column presents the number of patients based on the brand or data source of their initial COVID-19 vaccine.

[4]We first define the cohort as patients who received at least one COVID-19 vaccine. We then follow these patients for any subsequent records of a second COVID-19 vaccine. For each patient, we have information on the brand and data source of both the initial (index) and second COVID-19 vaccine. This column displays the number of patients who have received both their initial and second COVID-19 vaccines in two separate days, categorized by the combination of vaccine brand and data source.

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2,683,199	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1,080,313	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	823,172	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	648,008	N/A
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	590,516	AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	559,690	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	475,836	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	343,556	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	334,811	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	326,723	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	274,522	AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	265,527	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	231,605	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	220,745	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	182,684	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	CV	157,443	OA
0011a	Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	155,977	AV
0001a	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	145,136	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	140,046	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	139,958	OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	134,744	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	129,035	AV
0011a	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	122,965	OA
208	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	117,272	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	116,986	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	116,782	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	114,762	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	99,918	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	92,638	AV
208	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	CV		OA
0001a	Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	92,440	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	90,110	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	82,759	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	81,047	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	78,436	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	75,679	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	74,509	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	70,575	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	70,299	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	69,616	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	69,417	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	64,785	AV
0001a	Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	64,410	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	63,447	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	60,564	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	59,984	OA
207		Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	56,768	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	54,849	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	52,914	OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	52,740	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	52,446	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	49,192	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	48,479	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	47,216	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	CV	47,050	OA
0011a	Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	43,012	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	40,351	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	ND	39,459	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	39,217	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	38,360	AV
208		Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	37,680	OA
0071a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	37,616	AV
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	37,185	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	35,803	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	35,720	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	32,799	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	29,627	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	28,902	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	28,008	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	27,404	AV
0071a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	27,376	OA
0011a		Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	27,199	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	26,912	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	25,761	AV
59267100002		Procedure	ND		AV
0001a		Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	25,466	AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	25,438	AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	24,499	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	23,924	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	22,168	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	22,104	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	22,036	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	21,940	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	21,828	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	21,674	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	20,498	AV
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	20,343	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	20,120	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	19,589	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	19,278	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	18,273	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	17,847	AV
0004a	Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	17,553	AV
0004a	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	C4		AV
	Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	ND	17,428	AV
207	Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	17,228	AV
208	Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	17,048	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	16,207	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	15,758	OA
91300		Procedure	C4		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	15,727	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	15,523	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	14,683	AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	13,418	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	13,285	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
207		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13,192	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND	12,983	AV
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	12,487	OA
80777027399		Procedure	ND		AV
0011a		Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	11,508	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11,482	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	11,197	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	11,092	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10,944	OA
91300		Procedure	C4		AV
59267100002		Procedure	ND		AV
0001a		Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	10,225	OA
91300		Procedure	C4		AV
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4	10,174	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10,009	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9,880	AV
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9,499	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	9,261	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9,112	OA
91300		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9,045	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8,936	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV	8,513	OA
0124a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	8,372	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	8,313	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	8,308	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	8,201	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	8,062	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7,955	OA
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	7,521	OA
207	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	7,296	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	7,164	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	6,959	OA
59267100002	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	ND		AV
0001a	Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	6,817	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;	Procedure	CV	6,777	OA
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	6,688	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	6,560	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	6,465	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6,377	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6,135	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6,130	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6,065	OA
80777027310		Procedure	ND		AV
0011a		Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	5,779	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	5,707	OA
91300		Procedure	C4		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	5,661	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	5,545	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	5,407	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5,394	AV
91301		Procedure	C4		OA
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
91307	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5,338	AV
91307		Procedure	C4	5,334	AV
0071a		Procedure	C4		AV
91301	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5,334	AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	5,306	OA
0001a	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	C4		OA
	Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-				
	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	5,277	AV
59267100002	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	ND		AV
208	Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,				
	Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary				
	Series And Ic Dose Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-				
	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	5,237	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record	Procedure	C4		AV
	Janssen/J&j Vaccines Administered In The Us And In Non-Us				
	Locations				
	Immunization Administration By Intramuscular Injection Of				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-				
	2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike				
	Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5,229	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	CV	4,855	OA
0011a	Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4,787	AV
91301		Procedure	C4		OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4,721	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	4,708	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4,703	OA
91301		Procedure	C4		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscu				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	4,479	AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
0011a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4,478	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4,285	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	4,097	AV
208	Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3,996	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3,854	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3,848	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	3,795	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3,732	N/A
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3,604	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	CV	3,597	OA
0064a	Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3,406	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	ND	3,393	AV
207	Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3,386	AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3,383	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3,379	AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3,352	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV	3,195	OA
0124a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3,175	OA
91301		Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3,170	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND	3,101	AV
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	3,083	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3,062	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3,043	OA
91301		Procedure	C4		AV
80777027310		Procedure	ND		AV
0011a		Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	3,020	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	2,997	OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2,950	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2,799	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	2,763	OA
0124a	eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2,746	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;	Procedure	CV	2,738	OA
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	2,734	AV
207	Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2,685	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	2,643	OA
208	Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2,618	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2,515	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2,504	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2,502	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	2,483	AV
0001a	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	2,423	OA
59267100001	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	ND		OA
0001a	Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	2,409	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2,404	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2,397	OA
91301		Procedure	C4		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2,377	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2,366	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2,342	AV
59267100002		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2,293	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2,285	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	2,278	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2,239	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	ND	2,200	AV
0064a	Mcg/0.25ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2,182	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	2,150	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4	2,130	AV
59267100002		Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2,130	AV
59267100002		Procedure	ND		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2,122	OA
91300		Procedure	C4		AV
59267100002		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4	2,102	AV
59267100001		Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	2,091	OA
0071a		Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2,008	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1,985	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1,975	OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1,972	OA
91307		Procedure	C4		AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1,963	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1,952	OA
91307		Procedure	C4		AV
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1,938	AV
91307		Procedure	C4		OA
0071a		Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1,928	OA
0071a		Procedure	C4		AV
91307	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,952	OA
91307		Procedure	C4		AV
0071a		Procedure	C4		AV
91307		Procedure	C4	1,938	AV
91307		Procedure	C4		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1,918	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1,905	OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1,887	OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1,881	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	1,867	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4	1,856	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1,851	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV	1,851	OA
0124a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	1,832	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1,789	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1,779	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1,771	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1,761	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1,748	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1,720	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1,700	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1,694	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1,672	OA
91307		Procedure	C4		AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1,649	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	1,626	OA
0011a	Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1,624	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	1,596	OA
0001a	Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	1,576	AV
208	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	CV		OA
0001a	Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1,540	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	1,528	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1,505	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1,486	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1,463	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4	1,446	AV
80777027399		Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	C4	1,439	AV
80777027399		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1,439	OA
59267100002		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1,426	OA
91301		Procedure	C4		AV
80777027399		Procedure	ND		AV
0011a		Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1,426	OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	1,335	AV
208	Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0004a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1,326	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	1,312	OA
207	Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1,262	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	1,247	OA
208	Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1,243	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1,242	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1,220	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1,219	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1,203	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1,187	AV
91307		Procedure	C4		OA
218		Procedure	CV		OA
0071a		Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1,161	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1,143	AV
208		Procedure	CV		OA
0004a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1,140	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV	1,120	OA
0124a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4	1,054	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	CV	1,023	OA
0064a	Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1,013	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	CV	992	OA
0001a	Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	958	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	938	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	925	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	917	OA
59267100002		Procedure	ND		OA
0001a		Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	915	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	914	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	903	OA
0011a		Procedure	C4		AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	900	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	894	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	893	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	868	OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	862	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV	857	OA
0124a		Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	852	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	851	AV
80777027310		Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	841	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	830	AV
80777027399		Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	827	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	812	OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	811	OA
0001a	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	C4		AV
	Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-				
	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	809	OA
80777027310	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	ND		OA
0011a	Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For	Procedure	C4		OA
	Intramuscular Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50				
	Mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-				
	2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike				
	Protein, Preservative Fr				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	805	OA
208	Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary				
	Series And Ic Dose Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-				
	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	799	AV
207	Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	799	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	798	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml	Procedure	CV	791	OA
0124a	Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	790	OA
0064a	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml	Procedure	CV	789	OA
0124a	Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	788	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	784	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	778	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;	Procedure	CV		OA
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	767	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	760	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	CV	759	OA
0064a	Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	758	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	758	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV	753	OA
0124a		Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	753	AV
208		Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	744	AV
208		Procedure	CV		OA
0004a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	735	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	732	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	724	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	724	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	714	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	707	IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	702	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	CV	697	OA
0064a	Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	692	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	691	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	691	AV
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
59267100002	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	664	OA
0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
59267100001	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	659	OA
208	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV	656	OA
0124a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	653	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	634	OA
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	632	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	630	OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	629	OA
59267100002		Procedure	ND		AV
0004a		Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	627	OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	614	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	613	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	601	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	584	AV
207		Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
Sarscov2covid19vaccinevectorno	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Prescription	N/A	581	N/A
212	Sarscov2covid19vaccinevectorno	Procedure	CV	581	OA
0031a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	567	AV
208	Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	551	OA
208	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	CV		OA
0001a	Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	550	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	549	AV
0064a		Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	549	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	545	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	538	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	534	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV	531	OA
0124a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4	528	AV
59267100002		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	525	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	517	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	511	AV
91301		Procedure	C4		OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4	505	AV
59267100002		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	504	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	504	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	502	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
212	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV	500	OA
208	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	497	OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	494	OA
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV	483	OA
0124a		Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	478	OA
0031a		Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	473	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	471	IS
0001a	Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	468	OA
0064a	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	C4		AV
	Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	468	AV
80777027399	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	ND		AV
207	Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For	Procedure	CV		OA
0011a	Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	466	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	464	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	463	N/A
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	462	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	460	OA
59267100002		Procedure	ND		AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	458	IS
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	454	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	453	OA
59267100001		Procedure	ND		AV
0004a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4	451	AV
59267100002		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	449	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	448	IS
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	447	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	442	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	441	OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	430	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	424	OA
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	417	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;	Procedure	CV		OA
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	410	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	408	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	407	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	403	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	402	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	392	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	390	IS
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	384	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	383	AV
0011a	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	381	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	CV	376	OA
0011a	Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	372	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary	Procedure	C4		AV
0001a	Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	CV	371	OA
0064a	Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	365	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	362	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	361	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	359	OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	356	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	356	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	352	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	338	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	337	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	337	OA
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	336	OA
0011a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	332	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	331	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	331	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	329	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	329	IS
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
91300	Severe Acute Respiratory Syndrome	Procedure	C4	325	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	323	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	323	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	318	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	311	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	310	IP
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	310	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	305	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	304	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	302	AV
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	301	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	300	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	299	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	293	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	292	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	292	OA
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	291	OA
91300		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	289	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	288	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	287	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	287	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	286	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	282	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	279	OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	278	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	277	AV
0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	276	IS
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
91300	Severe Acute Respiratory Syndrome	Procedure	C4	275	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	274	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	274	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	272	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	271	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	270	OA
59267100001	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	ND		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	268	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	268	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	267	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	264	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	264	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	262	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	260	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	260	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	259	OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	259	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	258	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	257	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	255	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	253	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	251	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	248	OA
218		Procedure	CV		OA
0001a		Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	248	OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	245	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	244	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	243	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	243	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	242	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscu				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	240	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	239	AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	239	N/A OA
91301 207	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure Procedure	C4 CV	239	AV OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	238	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	238	OA
207		Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	238	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	236	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	235	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	235	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	234	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	233	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	233	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	233	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	232	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	231	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	231	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	231	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV	226	OA
0124a	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	226	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	225	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	224	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	221	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	220	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	218	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 207	Sarscov2covid19vaccinevectorno Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	217	N/A OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	217	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	216	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	213	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	212	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	212	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	211	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	210	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	209	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	209	N/A
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	209	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	209	ED
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	209	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	208	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	207	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	206	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
207		Procedure	CV	205	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	205	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	203	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	202	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	202	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	201	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	200	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	200	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	200	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	199	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	199	OA
207		Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	197	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	196	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	196	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	195	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	195	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	195	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	195	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	193	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	193	OA
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	191	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	189	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	189	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	188	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	188	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	188	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	187	OA
0071a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	187	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	187	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	185	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	184	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	184	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	184	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	183	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	182	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	CV		OA
0064a	Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	182	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	180	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
80777027310	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	ND		AV
207	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
0011a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
91301	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4	180	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	179	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	179	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	179	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
Sarscov2covid19vaccinemrn	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription	N/A	178	N/A
aspik	Sarscov2covid19vaccinemrnaspik	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4	178	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	177	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	177	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	176	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	176	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	176	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
59267100002	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	175	AV
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	173	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	172	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	172	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	171	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	170	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	169	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	169	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	167	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	166	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	166	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	166	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	164	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	162	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	162	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos 208	Covid19mrnalnpspf100mcg05mldos Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	162	N/A OA
218 0071a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	CV C4	161	OA AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	161	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	161	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	160	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	160	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	160	AV
207	Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By	Procedure	C4	158	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	156	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	156	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	155	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	153	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	153	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	152	IP
91307	Severe Acute Respiratory Syndrome	Procedure	C4	151	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	150	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	149	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	149	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	149	OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn aspik 218	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	147	N/A OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	147	OA
208 0004a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	CV C4	147	OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	146	OA
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	145	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	145	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	144	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	143	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	143	IS
0124a		Procedure	C4	141	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	140	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	140	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	139	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscul	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	139	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399 207	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure Procedure	ND CV	138	AV OA
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	137	N/A OA
Sarscov2covid19vaccinemrnaspik 212	Sarscov2covid19vaccinemrnaspik Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	136	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	136	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	136	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	136	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	136	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	134	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	133	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	133	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0004a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	132	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	132	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	131	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	131	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	130	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	128	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	127	N/A
aspik	Immunization Administration By	Procedure	C4		OA
0004a	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	127	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	126	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	125	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	125	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	124	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	124	OA
0001a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	123	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	123	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	123	AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	123	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	123	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	122	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	122	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	122	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	121	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	121	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	121	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	121	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	120	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	120	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	120	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	119	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	118	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	117	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	117	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	117	ED
91300	Severe Acute Respiratory Syndrome	Procedure	C4	116	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	116	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	116	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	116	AV
0001a		Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	115	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	115	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	115	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	115	OA
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	114	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	114	OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	113	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	113	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	113	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	111	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	111	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	111	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	111	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	111	AV
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	110	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	110	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	110	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	109	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	108	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	108	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	108	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	107	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	107	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	106	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	105	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	105	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	104	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	104	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		OA
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	104	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs),	Procedure	C4		OA
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	104	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	104	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	103	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	103	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	103	IP
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	102	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	102	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	101	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	101	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	101	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	101	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	100	OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	100	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	100	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	100	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	100	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	100	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	100	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	100	ED
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	99	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	99	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	99	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208 0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	98	OA
		Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	98	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	97	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	97	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	97	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	97	OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	95	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	95	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	95	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	95	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	95	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
212	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	95	OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	94	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	94	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	93	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	93	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	93	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	93	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	92	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	92	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
59267100001	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND	92	OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	91	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	91	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	90	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	90	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	90	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	90	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	89	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	88	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
91301	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	88	OA
80777027399	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	ND		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	87	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	87	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	87	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	87	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	86	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	86	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	85	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	85	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	85	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	84	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	84	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	84	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	83	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	83	N/A
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	83	IS
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	82	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	82	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	82	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	82	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	81	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	81	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	81	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	81	OA
208	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND	80	AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	79	OA
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	79	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	79	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	79	N/A
05mldos	Immunization Administration By	Procedure	C4		OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	79	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	78	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	78	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	77	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	77	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	77	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	76	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	76	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	76	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	76	N/A
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	76	N/A OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	76	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	75	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	75	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	75	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	75	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	75	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		OA
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	75	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	75	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
	Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	74	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	74	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	74	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	73	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	73	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	73	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	73	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	73	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	73	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	72	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	72	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	72	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	71	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	71	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	71	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	71	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	71	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	71	OA
0011a		Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	70	AV
59267100001		Procedure	ND		AV
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	70	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	70	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	70	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	70	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	70	OA
0004a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	69	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	69	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By				
	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	69	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	69	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	69	OA
0031a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0001a		Procedure	C4		AV
59267100001		Procedure	ND	69	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	68	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	68	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	68	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	68	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	68	OA
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	67	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	67	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	67	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Covid19mrnalnpspf100mcg 05mldos 207	Covid19mrnalnpspf100mcg05mldos Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	67	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	66	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a		Procedure	C4	66	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	66	OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	66	IS
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	66	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	65	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	65	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	65	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	65	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	64	OA
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	64	OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	63	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	63	AV
207	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	63	OA
0011a		Procedure	C4		AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	62	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	62	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	62	OA
207		Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	62	IS
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	61	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	61	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	61	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	61	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	61	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	61	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	60	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	60	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	60	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	60	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	59	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	59	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	59	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	59	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	58	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	58	N/A
orno	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	58	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				
Covid19mrnalnpsbivalentbo oster 207	Covid19mrnalnpsbivalentbooster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	58	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose 208	Covid19mrnalnpspf30mcg03mldose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	58	N/A OA
Sarscov2covid19vaccinemrnaspik 0064a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Prescription Procedure	N/A C4	57	N/A OA
208 0071a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	CV C4	57	OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	57	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	57	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	56	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	56	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	56	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	56	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	56	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	56	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	56	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	55	N/A
orno	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	55	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	55	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	55	OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	55	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
0031a	Immunization Administration By	Procedure	C4	55	AV
0011a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	54	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	54	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	54	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	54	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	54	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	54	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	54	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	54	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	54	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	54	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	53	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	53	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	53	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	53	OA
0004a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	53	OA
207	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	53	OA
0001a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	53	OA
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	53	OA
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	52	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	52	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinevectorno 207	Sarscov2covid19vaccinevectorno Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	52	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	52	AV
80777027399		Procedure	ND		AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	52	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	52	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	52	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	52	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	51	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
218	Immunization Administration	Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	51	OA
0071a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	51	OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	51	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	51	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	51	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	50	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	50	AV
0071a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	50	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	50	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	49	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	49	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		OA
0011a	Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	49	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	49	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	49	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	49	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	48	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	48	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	48	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	48	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	48	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	48	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	48	OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	48	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0031a	Immunization Administration By	Procedure	C4	48	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	48	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	47	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	47	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	47	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	47	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	47	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	47	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	47	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	47	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	47	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	47	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	47	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	47	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	47	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	46	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	46	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	46	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	46	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0004a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	46	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	46	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	46	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	46	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	46	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	46	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	46	OA
208	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	46	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	46	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	45	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	45	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0071a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	45	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	45	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	45	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	45	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	45	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	45	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	45	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	45	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	45	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	44	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	44	IP
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	44	IP
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	44	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	44	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	44	AV
0004a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	44	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	44	AV
207	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	44	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	43	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	43	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	43	OA
0001a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	43	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	43	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	43	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	43	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	42	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	42	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	42	IS
91300	Severe Acute Respiratory Syndrome	Procedure	C4	42	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	42	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	42	OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	42	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	42	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	42	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND	41	AV
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	41	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	41	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	41	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	41	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	41	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	41	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	41	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	41	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	41	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	41	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	40	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	40	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	40	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	40	OA
0001a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	40	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	40	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	40	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	40	OA
0124a	Immunization Administration By	Procedure	C4	39	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	39	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	39	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	39	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	39	AV
208		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	39	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	39	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	39	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	39	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	39	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	39	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	39	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	38	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	38	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	38	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	38	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	38	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	38	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	38	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	38	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	38	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	37	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose 0071a	Covid19mrnalnpspf10mcg02mldose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	37	N/A OA
Sarscov2covid19vaccinemrnaspik 0004a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	37	N/A AV
91300 59267100001 208	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure Procedure Procedure	C4 ND CV	37	AV AV OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	37	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	37	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	37	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	37	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	37	AV
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	37	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	37	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	37	OA
0004a		Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	37	OA
0031a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	37	OA
0004a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	36	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	36	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
80777027310	80777027310	Procedure	C4		AV
0011a	0011a				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	36	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	36	AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	36	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	36	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	36	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	36	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	36	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	35	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	35	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	35	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	35	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	35	IP
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	35	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	35	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscul				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	35	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	35	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	35	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	35	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	35	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	35	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	35	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	35	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	35	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	35	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	34	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a		Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	34	OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	34	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	34	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	34	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	34	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	34	OA
0011a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	34	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	34	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	34	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	33	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	33	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	33	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	33	AV
0071a		Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV	33	OA
0124a		Procedure	C4		AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription	N/A	33	N/A
0031a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	33	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	33	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	33	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	33	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	33	AV
218		Procedure	CV		OA
0001a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	33	AV
218		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	33	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	33	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	32	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	32	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	32	AV
300	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0124a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	32	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	32	N/A
orno	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	32	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	32	OA
208		Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	32	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	32	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	32	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	32	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	31	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	31	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	31	AV
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	31	N/A OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	31	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	31	N/A
orno	Immunization Administration By	Procedure	C4		AV
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	31	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	31	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	31	AV
59267100002		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	31	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	CV		OA
0011a	Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	31	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	31	OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	31	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	31	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	30	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	30	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	30	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	30	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	30	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	30	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	30	OA
59267100002		Procedure	ND		AV
0001a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	30	AV
80777027399		Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	30	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	30	AV
0001a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	30	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	30	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	30	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	30	IS
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	29	OA
0124a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	29	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	29	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	29	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	29	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	29	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	29	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	29	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	29	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	29	OA
0011a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	29	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	29	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	29	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	28	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	28	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	28	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV	28	OA
0124a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	28	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	28	AV
59267100001		Procedure	ND		AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4	28	OA
80777027399		Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	28	OA
0001a		Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	28	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	28	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	28	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	28	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	28	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	28	IP
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	27	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	27	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	27	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	27	OA
0124a	eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	27	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	27	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	27	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	27	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	27	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	27	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	27	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	ND		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	27	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	27	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	27	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	27	IP
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	26	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	26	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	26	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	26	OA
0071a		Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	26	OA
0071a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	26	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	26	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	26	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		OA
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	26	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0001a	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	26	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	26	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	26	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	26	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	26	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	26	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	26	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	26	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	26	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	26	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	26	OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	26	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	26	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	26	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos 212	Covid19mrnalnpspf100mcg05mldos Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	26	N/A OA
80777027399 207 0064a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure Procedure Procedure	ND CV C4	25	AV OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	25	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	25	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	25	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	25	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	25	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	25	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	25	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	25	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	25	N/A
orno	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
208	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	25	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	25	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	25	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	25	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	25	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	25	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		ED
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	25	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	25	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	25	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	25	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	25	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	25	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	25	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	25	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	25	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	24	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	24	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	24	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	24	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	24	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	24	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	24	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	24	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	24	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	24	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	24	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	24	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	24	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	24	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	24	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	24	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	24	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	24	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	24	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	24	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	24	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	24	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	24	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	24	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	24	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	24	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	24	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	24	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	23	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	23	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	23	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	23	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	23	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	23	N/A
aspik	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV		OA
300	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
208	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	23	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	23	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	23	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4	23	OA
59267100002		Procedure	ND		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	23	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	23	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	23	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	23	OA
207		Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	23	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	23	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	23	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	23	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	23	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	23	OA
208	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	23	OA
208	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	23	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	C4		AV
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	23	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	23	OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	23	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	22	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	22	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	22	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	22	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	22	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	22	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	22	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	22	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	22	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	22	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	22	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	22	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	22	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	22	OA
208		Procedure	CV		OA
0001a	eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	22	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	22	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	22	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	22	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	22	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	22	OA
207	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	22	OA
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	22	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	22	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	22	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	22	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	21	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	21	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	21	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV		OA
208	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	21	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	21	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	21	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	21	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	21	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	21	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	21	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	21	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	21	N/A
91300	Severe Acute Respiratory Syndrome	Procedure	C4		OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	21	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	21	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	21	ED
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	21	OA
0001a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	21	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	21	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	21	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	21	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	21	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	21	OA
0031a		Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	21	OA
0004a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	20	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	20	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	20	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	20	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	20	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		OA
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	20	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		OA
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	20	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 208	Sarscov2covid19vaccinevectorno Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	20	N/A OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	20	IP
59267100002 0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	ND C4	20	IP IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	20	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	20	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	20	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	20	AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	20	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	20	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	20	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	20	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	20	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	20	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	20	OA
80777027310		Procedure	ND		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	20	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	ND		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	20	AV
207	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	20	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	20	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	20	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	20	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	20	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	20	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	20	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	20	AV
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0004a	Mcg/0.3ml Dose	Procedure	C4		OA
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	19	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	19	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	19	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	19	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	19	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	19	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	19	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	19	AV
0071a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	19	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	19	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik212	Sarscov2covid19vaccinemrnaspik Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	19	N/A OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	19	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	19	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	19	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	19	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	19	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	19	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	19	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	19	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	19	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	19	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	19	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	19	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	19	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	19	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	19	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	19	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	19	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	19	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	18	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	18	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	18	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	18	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	18	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	18	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	18	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	18	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	18	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	18	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	18	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	18	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	18	N/A
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	18	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	18	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	18	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	18	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndro				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	18	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	18	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	18	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	18	AV
208		Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	18	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	18	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	18	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	18	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	18	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	18	OA
0004a	Dose;	Procedure	C4		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	18	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	18	OA
0031a	0.5 Ml;	Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	18	IP
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	17	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0064a	fda Eua	Procedure	C4		AV
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	17	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	17	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	17	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	17	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	17	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	17	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		AV
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	17	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	17	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	17	AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	17	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	17	OA
0001a		Procedure	C4		IP
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4	17	AV
59267100001		Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	17	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	17	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0001a	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	17	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	17	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	17	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	17	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	17	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	17	N/A
Covid19mrnalnpspf10mcg02mldose	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	17	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	17	AV
80777027310		Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	17	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	17	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	17	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	17	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	17	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	17	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0011a	Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	17	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	17	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	17	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	17	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	17	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	17	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	17	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	17	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	17	IS
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	16	OA
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	16	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	16	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	16	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	16	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	16	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	16	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	16	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	16	IS
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV	16	OA
0124a	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	16	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	16	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	16	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	16	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	16	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0011a	Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By I				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	16	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	16	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	16	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	16	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	16	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	16	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	16	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	16	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	16	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	16	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	16	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	16	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	16	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	16	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	16	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	16	OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	16	OA
208		Procedure	CV		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND	16	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	16	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	16	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	16	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	16	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	16	OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	15	OA
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	15	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	15	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	15	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	15	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	15	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	15	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect orno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	15	N/A OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
208		Procedure	CV		OA
0001a		Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	15	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	15	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	IP
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	15	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	CV		OA
0011a	Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	15	OA
80777027310		Procedure	ND		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
208		Procedure	CV		OA
0001a		Procedure	C4		ED
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	15	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	15	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	15	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	15	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	15	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91307	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	15	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	15	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	15	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	15	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	15	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	15	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	15	OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	15	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	15	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	15	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster 208	Covid19mrnalnpsbivalentbooster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	15	N/A OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	15	OA
Covid19mrnalnpsbivalentbooster 218	Covid19mrnalnpsbivalentbooster Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	15	N/A OA
218 0011a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	15	OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	15	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	15	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	15	IS
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	14	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	14	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	14	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	14	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	14	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	14	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	14	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	14	AV
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	14	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	14	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	14	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0071a	Immunization Administration By	Procedure	C4	14	OA
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	14	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	14	N/A
aspik	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND		AV
59267100001	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	14	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
208		Procedure	C4		OA
0001a					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	14	N/A
aspik	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND		AV
80777027399	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	14	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	14	N/A
orno	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
208	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	14	N/A
orno					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	14	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	14	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	14	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	14	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	14	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	14	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	14	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immuni				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	14	N/A
oster	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	14	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	14	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	14	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	14	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	14	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	14	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	14	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	14	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	14	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	14	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	14	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	14	N/A
91305	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91307	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91309	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	14	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	14	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	14	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	14	OA
0004a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	14	OA
0004a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		OA
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	14	OA
0011a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	14	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	14	IS
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	13	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	13	AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	13	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	13	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	13	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	13	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	13	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	13	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	13	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	13	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	13	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	13	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	13	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	13	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	13	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	13	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 0031a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	13	N/A AV
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	13	N/A OA AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	13	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	13	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo	Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	13	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	13	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	13	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	13	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	13	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	13	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	13	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	13	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	13	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	13	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	13	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	13	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	13	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	13	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	13	OA
0001a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	13	OA
0001a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	13	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	13	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	13	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	13	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	13	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	13	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	13	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose 207	Covid19mrnalnpspf30mcg03mldose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	13	N/A OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	13	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	13	OA
Covid19mrnalnpspf10mcg02mldose 208	Covid19mrnalnpspf10mcg02mldose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	13	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	13	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	13	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	13	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	13	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	13	IS
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	13	IP
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	13	IP
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	12	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	12	OA
0064a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	12	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	12	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	12	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91300 208 0001a	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure Procedure	N/A C4 CV C4	12	N/A AV OA AV
Sarscov2covid19vaccinemrnaspik 91307	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Prescription Procedure	N/A C4	12	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By	Procedure	C4	12	IS
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IS
300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	12	OA
208	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	12	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	12	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	12	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	12	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		OA
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	12	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		OA
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	12	N/A OA AV
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	12	N/A OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo	Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein,	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	12	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	12	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	12	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	12	OA
208		Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	12	OA
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	12	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	12	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	12	OA
0004a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	12	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	11	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	11	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	11	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	11	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	11	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	11	N/A
0124a	Immunization Administration By	Procedure	C4	11	IS
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	11	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	11	AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	11	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	11	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	11	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	11	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	AV
91300	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	11	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	11	OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	11	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	11	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	11	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	11	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	11	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	11	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	11	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	11	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	11	OA
0011a		Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	11	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	11	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	11	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	11	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	11	OA
208 0031a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure Procedure	CV C4	11	OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	11	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	11	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	11	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	11	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	11	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	11	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	11	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	11	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	10	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	10	OA
0064a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	10	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	10	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	10	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	10	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	10	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	10	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A		N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	10	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	10	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	10	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	10	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	10	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	10	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	10	AV
300	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0124a	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	10	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-C	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	10	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	10	OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	10	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91301	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respira				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	10	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	10	OA
207		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	AV
218		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	10	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	10	AV
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	10	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	10	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	10	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	10	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	10	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	10	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	10	OA
218		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	10	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Covid19mrnalnpspf100mcg 05mldos	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	10	N/A
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4		OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	10	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	10	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	10	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	10	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	10	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	10	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	10	OA
208	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	10	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	10	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	10	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	10	OA
0004a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	10	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	10	IS
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	10	AV
0011a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	10	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	10	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	10	IS
91301	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	9	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	9	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	9	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	9	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	9	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	9	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	9	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	9	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	9	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	9	OA
0071a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	9	N/A
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	9	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	9	N/A
59267100002	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	9	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	9	N/A OA
Sarscov2covid19vaccinemrnaspik Covid19mrnalnpspf30mcg03mldose	Sarscov2covid19vaccinemrnaspik Covid19mrnalnpspf30mcg03mldose	Prescription Prescription	N/A N/A	9	N/A N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	9	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	9	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	9	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	9	N/A
orno	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	IS
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	9	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	9	IS
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IS
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		IS
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	9	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By I	Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By I	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	9	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	9	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	9	AV
0001a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	9	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	9	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	9	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	9	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	9	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos 207	Covid19mrnalnpspf100mcg05mldos Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	9	N/A OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	9	OA
Covid19mrnalnpspf100mcg 05mldos 207	Covid19mrnalnpspf100mcg05mldos Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	9	N/A OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	9	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	9	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	9	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	9	OA
207	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	9	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	9	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	9	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	9	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	9	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	9	OA
208		Procedure	CV		OA
208 0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	9	OA
		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose 208	Covid19mrnalnpspf30mcg03mldose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	9	N/A OA
Covid19mrnalnpspf30mcg03mldose 208	Covid19mrnalnpspf30mcg03mldose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	9	N/A OA
Covid19mrnalnpspf30mcg03mldose 208	Covid19mrnalnpspf30mcg03mldose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	9	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	9	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	9	N/A
oster	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	9	OA
0031a	0.5 Ml;	Procedure	C4		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	9	OA
0004a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	9	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	9	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	9	OA
0064a	Immunization Administration By	Procedure	C4	9	IS
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	9	IP
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP
91301	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	8	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	8	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	8	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	8	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	8	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	8	OA
0064a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV
0001a		Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	8	AV
0071a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	8	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	8	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	8	N/A
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	8	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	8	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	8	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	8	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	8	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	8	IS
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	8	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	8	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	8	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	8	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	8	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	8	OA
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure Procedure	N/A CV C4	8	N/A OA AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	8	N/A OA AV
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	8	N/A OA
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	8	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	IP
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		IP
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IP
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	8	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Ad	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserva	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	8	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	AV
80777027310 0031a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	8	OA
0001a	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	8	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	8	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	8	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	8	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	8	AV
0001a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	8	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	8	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
91307	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	8	OA
207	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	8	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	8	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	8	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	8	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	8	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	8	OA
208	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	8	AV
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	8	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	8	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	8	OA
208		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	8	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	8	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	8	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	8	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	8	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	8	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	8	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	8	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	8	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	8	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	8	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose 300	Covid19mrnalnpspf10mcg02mldose Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Prescription Procedure	N/A CV	8	N/A OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	8	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	8	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	7	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	7	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	7	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	7	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	7	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	7	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	7	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
0071a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	7	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	7	OA
0071a		Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	7	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	7	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91301 80777027399 80777027310 0011a	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure Procedure Procedure	N/A C4 ND ND C4	7	N/A AV AV AV AV
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	7	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	7	N/A OA
Sarscov2covid19vaccinemrnaspik 0124a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Prescription Procedure	N/A C4	7	N/A AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	7	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	7	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	7	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	7	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	7	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	7	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	7	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	7	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	7	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		OA
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	7	IS
0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfiz	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Do	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	7	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	7	N/A
91300	Severe Acute Respiratory Syndrome	Procedure	C4		OA
300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		OA
0004a		Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		ED
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscu	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Prese	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		OA
0011a	Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	7	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	7	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	7	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	7	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	7	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	7	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	7	OA
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	7	OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	7	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	7	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	7	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	7	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	7	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	7	OA
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	7	OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	7	OA
207	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	7	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	7	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	7	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	7	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	7	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	7	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	7	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	7	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	7	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IS
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	7	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	7	N/A
oster 300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	7	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	7	IS
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	6	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	6	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	6	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	6	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscul	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	6	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	6	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	6	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	6	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	6	OA
0071a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	6	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	6	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	6	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	6	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	6	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0071a	Immunization Administration By	Procedure	C4	6	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	6	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91301 80777027310 207 0011a	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure Procedure Procedure	N/A C4 ND CV C4	6	N/A AV AV OA AV
Sarscov2covid19vaccinemrnaspik 212	Sarscov2covid19vaccinemrnaspik Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	6	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	6	N/A OA
Sarscov2covid19vaccinemrnaspik 208 Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	6	N/A OA OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	6	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	6	N/A OA
Sarscov2covid19vaccinemrnaspik 80777027399 207 0011a	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure Procedure	N/A ND CV C4	6	N/A OA OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	6	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
Sarscov2covid19vaccinemrnaspik 218	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	6	N/A OA
Sarscov2covid19vaccinemrnaspik 80777027399 0011a	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure	N/A ND C4	6	N/A AV AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	6	IS
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
0124a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	6	OA
0124a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	6	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	6	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	6	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	6	AV
0124a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	6	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	6	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	6	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	6	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	6	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	6	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		OA
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	6	N/A
orno	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	6	N/A OA
91300 208 0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure Procedure	C4 CV C4	6	IP OA IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	6	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster	Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscul	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	6	AV
300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Mode	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	6	OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	6	OA
208		Procedure	CV		OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	6	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	6	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	IP
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Prese	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	6	AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	ED
59267100001		Procedure	ND		ED
0001a		Procedure	C4		ED
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	6	OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	6	AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	6	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	6	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	6	OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	6	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	6	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	6	OA
0001a		Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	6	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	6	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	6	AV
208		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	6	AV
218		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	6	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	6	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	6	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	6	N/A
oster	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	6	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	6	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	6	OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	6	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	6	OA
207 0004a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	CV C4	6	OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	6	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	6	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	6	AV
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	6	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	6	N/A
300 208	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure Procedure	CV CV		OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	6	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	6	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV
0004a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	6	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	6	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	6	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	6	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	6	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	6	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	6	OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	6	AV
0011a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	6	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	6	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	5	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	5	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By	Procedure	C4	5	AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	5	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	5	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	5	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	5	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	5	OA
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	OA
91307		Procedure	C4		AV
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	5	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	5	OA
0071a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	5	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	5	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
aspik	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND		AV
59267100001	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	5	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	5	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	5	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	ED
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	5	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		ED
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
0124a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By	Procedure	C4	5	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	5	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	5	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	5	N/A
oster	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV		OA
300	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		OA
0124a	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	5	N/A
orno	Immunization Administration By	Procedure	C4		AV
0031a	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	5	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	5	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	IP
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		IP
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	5	OA
0001a		Procedure	C4		IP
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	IP
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	IS
0004a		Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	5	IS
59267100001	Spike Protein, Lnp, Preservative Free,	Procedure	ND		IS
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		IS
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0001a	Dose;	Procedure	C4		IS
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	ED
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
59267100001	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	ND		AV
0011a	Use	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, M				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	5	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Do	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV		OA
0001a	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	5	AV
80777027310		Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	5	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	5	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208					
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		OA
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	5	OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0004a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	5	OA
208		Procedure	CV		OA
0031a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	5	OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	IP
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		IP
0011a		Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	5	ED
207		Procedure	CV		OA
0011a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Ad Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	ND		AV
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	5	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	5	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	5	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	5	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	5	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	5	AV
208		Procedure	CV		OA
0001a		Procedure	C4		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	5	AV
0001a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	5	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	5	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs),	Procedure	C4		OA
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	5	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	5	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	5	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	5	OA
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	5	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	5	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	5	OA
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	5	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	5	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	5	OA
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	5	N/A
91305	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91307	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	5	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	5	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	5	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	5	OA
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0004a	Dose;	Procedure	C4		AV
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	5	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	5	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	5	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	5	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	5	OA
218	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	5	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV	5	OA
0011a	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	5	IP
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	5	AV
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	5	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND	4	OA
207		Procedure	CV		OA
0064a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
207	Dose;	Procedure	CV		OA
0064a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	ED
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	4	OA
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0001a	Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dos	Procedure	ND		AV
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	4	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91300	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Prescription Procedure	N/A C4	4	N/A OA
Sarscov2covid19vaccinemrnaspik 91300	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Prescription Procedure	N/A C4	4	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	4	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	4	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
207	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND		AV
80777027310	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
0011a	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	4	N/A OA
Sarscov2covid19vaccinemrnaspik 212	Sarscov2covid19vaccinemrnaspik Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	4	N/A OA
Sarscov2covid19vaccinemrnaspik 300	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Prescription Procedure	N/A CV	4	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
Sarscov2covid19vaccinemrnaspik Covid19mrnalnpspf100mcg05mldos	Sarscov2covid19vaccinemrnaspik Covid19mrnalnpspf100mcg05mldos	Prescription Prescription	N/A N/A	4	N/A N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	IS
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	4	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	4	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	4	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	4	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	4	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
0124a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	4	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	4	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		OA
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	4	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 91301	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Prescription Procedure	N/A C4	4	N/A OA
Sarscov2covid19vaccinevectorno 0031a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	4	N/A AV
Sarscov2covid19vaccinevectorno 0031a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	4	N/A AV
Sarscov2covid19vaccinevectorno 208	Sarscov2covid19vaccinevectorno Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	4	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	4	N/A
orno	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	IS
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IS
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		IS
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome C	Procedure	C4	4	AV
208		Procedure	CV		OA
0031a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV		OA
0001a	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-C				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4	4	AV
59267100002		Procedure	ND		OA
59267100002		Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4	4	AV
80777027399		Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
207		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	4	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	4	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	4	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	C4	4	AV
300		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0004a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Mode	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	4	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original For	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	4	N/A
91300	Severe Acute Respiratory Syndrome	Procedure	C4		OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	IP
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	ED
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		ED
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscu				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Ad	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	4	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0004a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	4	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		OA
0011a	Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		OA
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By I				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	4	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	ED
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscul	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
300	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	4	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
0011a	Immunization Administration By	Procedure	C4	4	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	4	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	4	AV
218		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	4	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	4	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	4	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	4	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
212	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	4	OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	4	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	4	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	4	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free,	Procedure	ND	4	AV
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	4	OA
208	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0004a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	4	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	4	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	4	N/A
05mldos	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
212					
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	4	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	4	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	4	OA
0031a	0.5 Ml;	Procedure	C4		IP
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	4	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	4	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	4	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	4	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0004a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	4	N/A
2mldose					
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	4	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
0004a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	4	IP
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	4	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
0031a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	ED
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		ED
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
0064a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
0064a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0064a		Procedure	C4		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0064a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0064a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0064a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0064a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND	3	OA
207		Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	OA
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
59267100001	Spike Protein, Preservative Free, 10	Procedure	ND		AV
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dos				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
208	Mcg/0.2 Ml Dosage, Diluent	Procedure	CV		OA
0071a	Reconstituted, Tris-Suc	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	D				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	3	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	3	OA
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
0071a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	3	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0071a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0071a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	3	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	3	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Se				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND		OA
59267100002	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
aspik	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 300 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	3	N/A OA OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	3	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 212 208	Sarscov2covid19vaccinemrnaspik Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	3	N/A OA OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	3	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	3	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 80777027399208	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A ND CV	3	N/A AV OA
Sarscov2covid19vaccinemrnaspik 0031a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	3	N/A AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	IS
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	3	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		ED
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	3	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	3	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	3	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	3	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	3	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	3	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	3	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	3	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	3	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	3	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 91301 207	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A C4 CV	3	N/A OA OA
Sarscov2covid19vaccinevectorno 80777027399	Sarscov2covid19vaccinevectorno Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Prescription Procedure	N/A ND	3	N/A AV
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	3	N/A OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 0031a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	3	N/A AV
91300 0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	C4 C4	3	OA IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	IP
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0001a	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Covid-	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immuni	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	3	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
212	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
300	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Orig				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	3	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
300		Procedure	CV		OA
0004a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	3	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	3	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	3	AV
218		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	3	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	3	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By I				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster D	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	3	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	3	OA
208		Procedure	CV		OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	3	OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	3	OA
300		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	OA
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
91300	Severe Acute Respiratory Syndrome	Procedure	C4		OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	ED
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	ED
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
91301		Procedure	C4		OA
80777027310		Procedure	ND		OA
80777027310		Procedure	ND		AV
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use

Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose

Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose

Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coro				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4	3	AV
212		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Corona	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	3	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		ED
0011a	Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	3	AV
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4	3	AV
80777027399		Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	AV
80777027310		Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-L	Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	3	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	3	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	3	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91307	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91307	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	3	OA
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91301		Procedure	C4	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
91301 0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	ED
91300 0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	ED
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	ED
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	ED
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		ED
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	3	OA
207		Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0011a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
212	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
300	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	3	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	3	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	eua Authorized	Procedure	C4		OA
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	3	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	eua Authorized	Procedure	C4		OA
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	3	AV
218		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0004a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	3	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	3	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	3	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0004a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	OA
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	3	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	3	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	3	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3	OA
207		Procedure	CV		OA
0011a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	3	OA OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	3	OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	3	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0031a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	3	OA
0004a		Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	3	OA
208		Procedure	CV		OA
0004a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
0004a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	3	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	3	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	3	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	3	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	OA
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	3	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	3	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	3	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	3	OA
0004a		Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	3	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	3	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	3	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	3	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	3	OA
0004a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	3	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	3	OA
0011a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	3	OA
	Pf, 30 Mcg/0.3 Ml Dose;				
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	3	OA
0031a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	3	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	3	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	3	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	3	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	3	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		ED
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
0064a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0064a	Dose;	Procedure	C4		AV
0064a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	ND		AV
0064a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
80777027310	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		AV
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0064a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose;	Procedure	CV		OA
0064a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
0064a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND		AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	2	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	2	OA
207		Procedure	CV		OA
0064a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	IP
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	ED
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	2	OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscul				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscul				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscul	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	2	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0071a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0071a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0071a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original For				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0071a	Original For	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	2	AV
218		Procedure	CV		OA
207		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	2	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a					
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
91307		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose;	Procedure	CV		OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	2	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	2	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0071a	Immunization Administration By	Procedure	C4	2	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By	Procedure	C4	2	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		OA
0071a	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
0071a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208		Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a					
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		OA
59267100002		Procedure	C4		OA
0001a					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 300	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Prescription Procedure	N/A CV	2	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
Sarscov2covid19vaccinemrnaspik 208 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	2	N/A OA OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207 0011a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure	N/A CV C4	2	N/A OA AV
Sarscov2covid19vaccinemrnaspik 80777027399 207 0011a	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure Procedure	N/A ND CV C4	2	N/A AV OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207 0011a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure	N/A CV C4	2	N/A OA OA
Sarscov2covid19vaccinemrnaspik 212 207	Sarscov2covid19vaccinemrnaspik Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	2	N/A OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	2	N/A OA
Sarscov2covid19vaccinemrnaspik 218 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	2	N/A OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 212 208	Sarscov2covid19vaccinemrnaspik Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	2	N/A OA OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	2	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV		OA
208	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A		N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
aspik	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND		OA
80777027399	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A		N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		IP
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	IP
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	IS
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	IS
0124a	Immunization Administration By	Procedure	C4	2	AV
0124a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	ED
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	ED
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0124a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Bivalent Booster,				
	Pf, 30 Mcg/0.3 Ml Dose;				
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0124a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
0124a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0124a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
oster	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV		OA
300	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
0124a	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By	Procedure	C4	2	AV
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	2	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		OA
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 91300	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Prescription Procedure	N/A C4	2	N/A OA
Sarscov2covid19vaccinevectorno 91301 212 207	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure Procedure	N/A C4 CV CV	2	N/A OA OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 207 0031a	Sarscov2covid19vaccinevectorno Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	2	N/A OA AV
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	2	N/A OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	2	N/A OA AV
Sarscov2covid19vaccinevectorno 207	Sarscov2covid19vaccinevectorno Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect orno 212 207	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	2	N/A OA OA
Sarscov2covid19vaccinevect orno 218 212	Sarscov2covid19vaccinevectorno Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure Procedure	N/A CV CV	2	N/A OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	IP
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	IP
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IP
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	2	IP
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	IP
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		IP
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	IP
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		IP
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	IP
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	IP
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IP
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	IS
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		IS
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	IS
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		IS
0001a		Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	2	OA
59267100001		Procedure	ND		IS
208		Procedure	CV		OA
0001a		Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	2	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	IS
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		IS
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	IS
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		IS
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	IS
59267100001	Spike Protein, Lnp, Preservative Free,	Procedure	ND		IS
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		IS
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	IS
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	ED
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	ED
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	ED
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		ED
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndro				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immuni	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfiz	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coro				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By I				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respirato	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immuni	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	2	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original For				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Do	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	2	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4	2	AV
212		Procedure	CV		OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
212	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
212	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunizati	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used				
	Immunization Administration				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administrati	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	2	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	2	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
300	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Orig				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV		OA
0001a	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dos	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4	2	AV
59267100001		Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4	2	AV
59267100002		Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
207		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein,				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4	2	AV
59267100001		Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0011a	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immuni	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	2	OA
0031a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Do				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0001a		Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
59267100001		Procedure	ND		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
208	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	OA
212		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		OA
208		Procedure	CV		OA
0004a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV		OA
0004a	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	IP
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	IP
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		IP
0011a		Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	IS
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		IS
0011a		Procedure	C4		IS
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	IS
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91301		Procedure	C4		ED
80777027310		Procedure	ND		ED
80777027310		Procedure	ND		AV
0011a		Procedure	C4		AV
0011a		Procedure	C4		ED

Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use

Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose

Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose

Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4	2	AV
80777027399		Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
80777027399	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301		Procedure	C4		AV
80777027310		Procedure	ND		AV
80777027310		Procedure	ND		OA
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use

Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose

Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose

Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
80777027310	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	2	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	2	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	2	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	2	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[c	Procedure	C4	2	AV
300		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	2	AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserva	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	AV
208		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
80777027399		Procedure	ND		AV
0011a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	2	AV
80777027310		Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4	2	AV
80777027399		Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	2	OA
80777027310		Procedure	ND		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	2	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	2	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	2	OA
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0011a	Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	2	OA
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV		OA
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-L	Procedure	C4		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	2	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		ED
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0001a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0001a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
207	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	2	OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
59267100001	Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	CV		OA
0011a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	2	OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0004a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	2	OA
207		Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose 91307 208	Covid19mrnalnpspf10mcg02mldose Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A C4 CV	2	N/A OA OA
Covid19mrnalnpspf10mcg02mldose 91307 218	Covid19mrnalnpspf10mcg02mldose Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure Procedure	N/A C4 CV	2	N/A OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	2	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	2	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	2	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
0011a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
207	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0011a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
207	eua Authorized	Procedure	CV		OA
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	2	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	2	AV
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
oster	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV		OA
300	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
207	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	IP
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
207	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	2	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0004a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
oster	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV		OA
208	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208 0004a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
208	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
oster	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV		OA
300	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
208	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
208	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
208	eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
oster	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0004a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	2	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0011a	0.5 Ml;	Procedure	C4		OA
0011a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	OA
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0031a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	ND	2	AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0004a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0011a	0.5 Ml;	Procedure	C4		AV
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	C4		AV
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml;	Procedure	C4		AV
0011a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0031a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0031a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	2	OA
0011a		Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV		OA
218	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	2	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	IP
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	IP
0004a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	2	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	2	OA
0004a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	2	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose 300	Covid19mrnalnpspf30mcg03mldose Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Prescription Procedure	N/A CV	2	N/A OA
Covid19mrnalnpsbivalentbooster 300 0004a	Covid19mrnalnpsbivalentbooster Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A CV C4	2	N/A OA AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	2	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	IS
0004a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	IS
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By	Procedure	C4	2	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	2	ED
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
0031a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A		N/A
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	2	IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
0031a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	OA
0031a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	IP
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	IS
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
Covid19mrnalnpspf30mcg0 3mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	2	N/A
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A		N/A
Covid19mrnalnpspf30mcg0 3mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	2	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		ED
0064a		Procedure	C4		ED
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND	1	ED
207		Procedure	CV		OA
0064a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	ED
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		ED
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	1	OA
0064a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	ED
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0064a	fda Eua	Procedure	C4		AV
0064a	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0064a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0064a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0064a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
80777027310	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		AV
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0064a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND		AV
80777027310	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Immunization Administration By	Procedure	C4		AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND		AV
80777027399	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0124a	Immunization Administration By	Procedure	C4	1	IS
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By	Procedure	C4	1	AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
0064a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA
0064a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscu	Procedure	ND		AV
0064a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscu				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscu	Procedure	ND		AV
0064a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0011a	Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0004a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0011a	Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	ND		AV
0064a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	CV		OA
0064a	Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0011a	Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0064a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	1	OA
0064a		Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0064a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0064a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0064a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0064a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0064a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0064a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
300	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
59267100001	Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0064a	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	C4		AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IS
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND	1	OA
207		Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0064a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		OA
0064a		Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0064a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND	1	OA
207		Procedure	CV		OA
0064a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
0064a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	Immunization Administration By	Procedure	C4		OA
0064a	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
0064a	Immunization Administration By	Procedure	C4	1	OA
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By	Procedure	C4	1	IP
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0071a		Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	IP
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IP
218		Procedure	CV		OA
0071a		Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	IP
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		ED
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		ED
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0071a	Immunization Administration By	Procedure	C4	1	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a		Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0071a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0071a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
59267100001	Spike Protein, Preservative Free, 10	Procedure	ND		AV
208	Mcg/0.2 Ml Dosage, Diluent	Procedure	CV		OA
0071a	Reconstituted, Tris-Suc	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dos				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
59267100001	Spike Protein, Preservative Free, 10	Procedure	ND		AV
218	Mcg/0.2 Ml Dosage, Diluent	Procedure	CV		OA
0071a	Reconstituted, Tris-Suc	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dos				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original For				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscul				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscul				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
0071a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscul	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0071a	Original For	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
208	Mcg/0.2 Ml Dosage, Diluent	Procedure	CV		OA
0071a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
208	Mcg/0.2 Ml Dosage, Diluent	Procedure	CV		OA
0071a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original For				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	OA
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome	Procedure	C4		OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0071a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs	Procedure	C4		AV
0001a	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs	Procedure	C4		AV
0001a	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs	Procedure	C4		AV
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0071a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscul				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91307	Severe Acute Respiratory Syndrome	Procedure	C4		AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
218		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a		Procedure	C4		AV
0004a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
218		Procedure	CV		OA
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91307	Severe Acute Respiratory Syndrome	Procedure	C4		OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0071a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0071a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
218	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
208	eua Authorized	Procedure	CV		OA
0071a	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0071a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
218	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0071a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
218	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0071a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
218	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0071a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0071a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By	Procedure	C4	1	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Immunization Administration By	Procedure	C4		AV
0071a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0071a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscul	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0071a		Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0071a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0071a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
218	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0071a	eua Authorized	Procedure	C4		OA
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		OA
0071a	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0071a	Immunization Administration By	Procedure	C4	1	OA
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
	Sarscov2covid19vaccinemrnaspik	Prescription	N/A		N/A
Sarscov2covid19vaccinemrnaspik212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
	Sarscov2covid19vaccinemrnaspik	Prescription	N/A		N/A
Sarscov2covid19vaccinemrnaspik212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
207	Reconstituted, For Intr	Procedure	C4		AV
0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-L	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91300 59267100001 208 0001a	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-L	Prescription Procedure Procedure Procedure Procedure	N/A C4 ND CV C4	1	N/A AV AV OA AV
Sarscov2covid19vaccinemrnaspik 91300	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Prescription Procedure	N/A C4	1	N/A AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acu				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
208	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91300 208	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A C4 CV	1	N/A OA OA
Sarscov2covid19vaccinemrnaspik 91300 207	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A C4 CV	1	N/A OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91300 0011a	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure	N/A C4 C4	1	N/A OA AV
Sarscov2covid19vaccinemrnaspik 91301	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Prescription Procedure	N/A C4	1	N/A AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91301	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respira				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027399	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp,	Procedure	C4		AV
0011a					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine,	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine,	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91301 80777027310 207	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure Procedure	N/A C4 ND CV	1	N/A AV AV OA
Sarscov2covid19vaccinemrnaspik 91301 80777027310 0011a	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure Procedure	N/A C4 ND C4	1	N/A AV AV AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91301 208	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A C4 CV	1	N/A OA OA
Sarscov2covid19vaccinemrnaspik 91301	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinemrnaspik 91301	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Prescription Procedure	N/A C4	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91301	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinemrnaspik 91301 80777027399	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Prescription Procedure Procedure	N/A C4 ND	1	N/A OA AV
Sarscov2covid19vaccinemrnaspik 91301 80777027399	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Prescription Procedure Procedure	N/A C4 ND	1	N/A OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 0001a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A AV
Sarscov2covid19vaccinemrnaspik 207 0001a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207 0001a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV
Sarscov2covid19vaccinemrnaspik 59267100001 207 0001a	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure Procedure	N/A ND CV C4	1	N/A AV OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208		Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik208207 0001a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure Procedure	N/A CV CV C4	1	N/A OA OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs	Procedure	C4		OA
0001a	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs	Procedure	C4		OA
0001a	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208 0001a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A CV C4	1	N/A OA OA
Sarscov2covid19vaccinemrnaspik 212 0001a	Sarscov2covid19vaccinemrnaspik Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A CV C4	1	N/A OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 59267100001 0001a	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A ND C4	1	N/A OA OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND		AV
80777027399	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A		N/A
Covid19mrnalnpspf100mcg05mldos 207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Covid19mrnalnpspf100mcg05mldos	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
207	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV		OA
300	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
207	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND		AV
80777027310	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
0011a	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207 0011a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure	N/A CV C4	1	N/A OA OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 218 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	1	N/A OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 218 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	1	N/A OA OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn aspik 208 0004a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV
Sarscov2covid19vaccinemrn aspik 208 0004a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A CV C4	1	N/A OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND		AV
80777027310	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	C4		AV
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 212 0031a	Sarscov2covid19vaccinemrnaspik Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA OA
Sarscov2covid19vaccinemrnaspik 212 0031a	Sarscov2covid19vaccinemrnaspik Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	C4		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV		OA
300	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Immunization Administration By	Procedure	C4		OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 300	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 0004a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A AV
Sarscov2covid19vaccinemrnaspik Covid19mrnalnpspf30mcg03mldose	Sarscov2covid19vaccinemrnaspik Covid19mrnalnpspf30mcg03mldose	Prescription Prescription	N/A N/A	1	N/A N/A
Sarscov2covid19vaccinemrnaspik 218	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik Covid19mrnalnpspf10mcg02mldose 218	Sarscov2covid19vaccinemrnaspik Covid19mrnalnpspf10mcg02mldose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Prescription Procedure	N/A N/A CV	1	N/A N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 59267100001	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Prescription Procedure	N/A ND	1	N/A AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik 80777027310 0011a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure	N/A ND C4	1	N/A AV AV
Sarscov2covid19vaccinemrnaspik 0011a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure	N/A C4	1	N/A AV
Sarscov2covid19vaccinemrnaspik 0011a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure	N/A C4	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 80777027310	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Prescription Procedure	N/A ND	1	N/A AV
Sarscov2covid19vaccinemrnaspik 80777027399	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Prescription Procedure	N/A ND	1	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik 80777027399	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Prescription Procedure	N/A ND	1	N/A OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IP
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IP
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IP
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	ED
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By	Procedure	C4	1	IS
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0124a	Immunization Administration By	Procedure	C4	1	IS
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IS
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IS
0124a	Immunization Administration By	Procedure	C4	1	IS
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IS
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IS
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IS
0124a	Immunization Administration By	Procedure	C4	1	IS
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IS
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	IS
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		ED
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		ED
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	ED
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
0124a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
0124a	eua Authorized	Procedure	C4		OA
0124a	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0124a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0124a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0124a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0004a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0124a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0124a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4	1	OA
300		Procedure	CV		OA
208		Procedure	CV		OA
0124a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208		Procedure	CV		OA
0124a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0124a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0124a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV		OA
0124a	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV	1	OA
0124a	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV		OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0124a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0124a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0124a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV	1	OA
0124a		Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV	1	OA
208		Procedure	CV		OA
0124a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0124a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
0004a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
300	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0124a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Bivalent Booster,				
	Pf, 30 Mcg/0.3 Ml Dose;				
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
0124a	Immunization Administration By	Procedure	C4	1	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
0124a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV		OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0124a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0124a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0124a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
207	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0124a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0124a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
0004a	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
0004a	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV		OA
0124a		Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV	1	OA
0124a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0124a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0124a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0124a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0124a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV	1	OA
0124a		Procedure	C4		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV	1	OA
208		Procedure	CV		OA
0124a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		OA
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV		OA
300	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
208	eua Authorized	Procedure	C4		OA
0124a	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		OA
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0124a	eua Authorized	Procedure	C4		OA
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV		OA
0124a		Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	CV	1	OA
0124a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	1	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0124a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		OA
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV		OA
300	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		OA
0124a	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				
0124a	Immunization Administration By	Procedure	C4	1	OA
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Bivalent				
	Spike Protein, Prese				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
212	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 91301	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinevectorno 2120031a	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV
Sarscov2covid19vaccinevectorno 0001a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 91307	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinevectorno 212 207	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	1	N/A OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
0031a	Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212 208	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	1	N/A OA OA
Sarscov2covid19vaccinevectorno 212 208	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	1	N/A OA OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
208	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
0031a	Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 300 208	Sarscov2covid19vaccinevectorno Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	1	N/A OA OA
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV
Sarscov2covid19vaccinevectorno Covid19mrnalnpspf100mcg05mldos 212	Sarscov2covid19vaccinevectorno Covid19mrnalnpspf100mcg05mldos Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Prescription Procedure	N/A N/A CV	1	N/A N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 218	Sarscov2covid19vaccinevectorno Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
Sarscov2covid19vaccinevectorno 0004a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
Sarscov2covid19vaccinevectorno 0031a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinevectorno Covid19mrnalnpspf100mcg05mldos	Sarscov2covid19vaccinevectorno Covid19mrnalnpspf100mcg05mldos	Prescription Prescription	N/A N/A	1	N/A N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A		N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IP
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IP
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		IP
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IP
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IP
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IP
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		IP
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IP
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		IP
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IP
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IP
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		IP
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		IP
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	IP
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		IP
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	IP
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		IP
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IP
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		IP
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IS
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IS
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IS
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		IS
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4	1	IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IS
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	IS
59267100002	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		IS
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		IS
0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IS
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		ED
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	ED
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	ED
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	ED
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		ED
208		Procedure	CV		OA
0004a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	ED
59267100001		Procedure	ND		ED
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	ED
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4	1	ED
59267100002		Procedure	ND		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	ED
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	ED
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
91300		Procedure	C4	1	AV
91300		Procedure	C4		OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
0001a		Procedure	C4		OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301		Procedure	C4		AV
91300		Procedure	C4		AV
91300		Procedure	C4		OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Pri	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immuni	Procedure	ND		AV
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Pri	Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0001a	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0031a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
59267100001	Spike Protein, Preservative Free, 10	Procedure	ND		AV
218	Mcg/0.2 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dos				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dos	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Y	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Rec	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Do	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfiz	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo	Procedure	ND		AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfiz	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo	Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
59267100001	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	ND		AV
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spi				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose.				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Seri	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Ser	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
59267100001	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	ND		AV
208	Use	Procedure	CV		OA
0011a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
59267100002	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	ND		AV
59267100001	Use	Procedure	ND		AV
208	Severe Acute Respiratory Syndrome	Procedure	CV		OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
208	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Do				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Ser	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), M				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By I				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	ND		AV
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein,	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0031a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
208	Mcg/0.2 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf,				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
300		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S,				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
59267100002		Procedure	ND		AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-C	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-C				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-C				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4	1	AV
212		Procedure	CV		OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
212	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
212	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
212	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4	1	AV
212		Procedure	CV		OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscul				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscul				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscul				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV		OA
208	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intram	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Bivalent Booster,				
	Pf, 30 Mcg/0.3 Ml Dose;				
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Adminis				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome C	Procedure	C4	1	AV
208		Procedure	CV		OA
0031a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg0	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
3mldose	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Di				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Di				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
300	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Bivalent Booster,				
	Pf, 30 Mcg/0.3 Ml Dose;				
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Synd				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100002	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	AV
212		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
208		Procedure	CV		OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
207		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Ade	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0004a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0031a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Ade				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4	1	AV
212		Procedure	CV		OA
208		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
208		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	AV
212		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	AV
212		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	AV
212		Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0004a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	C4	1	AV
300		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
300		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome	Procedure	C4		AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV		OA
0004a	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV		OA
91300	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
300		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
300		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
59267100001		Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	OA
59267100001		Procedure	ND		OA
212		Procedure	CV		OA
0031a		Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4	1	OA
59267100001		Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	OA
0031a	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
Covid19mrnalnpspf30mcg03mldose	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300					

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscu	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
207	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Mode	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dos	Procedure	ND		AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 M	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		OA
80777027310		Procedure	ND		OA
59267100001		Procedure	ND		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4	1	OA
212		Procedure	CV		OA
208		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	OA
0031a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
59267100002		Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose	Procedure	CV		OA
0001a	Original For	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208		Procedure	CV		OA
0004a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208		Procedure	CV		OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome C	Procedure	C4	1	OA
208		Procedure	CV		OA
0031a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV		OA
0001a	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
59267100002		Procedure	ND		AV
208		Procedure	CV		OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
207		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
212	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Bivalent Booster,				
	Pf, 30 Mcg/0.3 Ml Dose;				
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By Intram				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		IS
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
59267100001		Procedure	ND		OA
207		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
218		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administra	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
218		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome	Procedure	C4		OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
59267100002		Procedure	ND		OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome C	Procedure	C4	1	OA
208		Procedure	CV		OA
0031a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4	1	OA
59267100002		Procedure	ND		OA
59267100001		Procedure	ND		OA
0004a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	IP
80777027310		Procedure	ND		IP
207		Procedure	CV		OA
0011a		Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IP
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		IP
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IP
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IP
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IS
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IS
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		IS
0064a		Procedure	C4		IS
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IS
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	ND		IS
0031a		Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IS
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or	Procedure	ND		ED
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0011a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscu	Procedure	ND		ED
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		ED
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0011a	Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscu	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscu	Procedure	ND		ED
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
0011a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	ED
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	ED
80777027399		Procedure	ND		ED
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		ED
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		ED
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	1	ED
80777027310		Procedure	ND		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301		Procedure	C4		AV
80777027399		Procedure	ND		OA
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
80777027310		Procedure	ND		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose

Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose

Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose

Covid-19, Mrna, Lnp

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0031a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301		Procedure	C4		AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
80777027399	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		OA
0011a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscu	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscu	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301		Procedure	C4		AV
80777027399		Procedure	ND		OA
80777027399		Procedure	ND		AV
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use

Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose

Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose

Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndr

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administ	Procedure	ND		AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0031a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0031a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4	1	AV
212		Procedure	CV		OA
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus D	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0031a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
0031a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0001a	Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0001a	Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0001a	Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0001a	Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
208	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Prese	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
59267100001		Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Mono				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0011a	Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By I				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
212	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use	Procedure	C4		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4	1	AV
212		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Corona	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine,				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome	Procedure	C4		AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA

Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco

Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Corona	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
208		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4	1	AV
212		Procedure	CV		OA
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	1	AV
80777027310		Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
218		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0011a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
218		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	ND		AV
218		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV		OA
0011a	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0031a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome	Procedure	C4		AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
59267100001		Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4	1	AV
59267100002		Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	1	AV
80777027310		Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		OA
0011a	Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos Severe Acute Respiratory Syndrome	Prescription Procedure	N/A C4	1	N/A OA
91301 207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
208		Procedure	CV		OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022	Procedure	C4		AV
0011a	Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By I				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
80777027399		Procedure	ND		OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respirat	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4	1	OA
212		Procedure	CV		OA
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
212		Procedure	CV		OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	OA
212		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By I				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0001a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/3	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-L				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
80777027310		Procedure	ND		OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		OA
208	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4	1	OA
212		Procedure	CV		OA
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		IP
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		IP
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		IP
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		IS
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		IS
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserva	Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	OA
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
80777027310		Procedure	ND		OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
208		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
80777027310		Procedure	ND		OA
208		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	1	OA
80777027310		Procedure	ND		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		ED
0011a		Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	ED
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		ED
208		Procedure	CV		OA
0001a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		ED
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0001a		Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	ED
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		ED
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	ED
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
0031a	Immunization Administration By	Procedure	C4	1	ED
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0001a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0001a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
0001a	Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs	Procedure	C4		OA
0001a	Through 11 Yrs), Pfizer Tris-Sucrose	Procedure	C4		AV
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscul	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0001a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0001a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0031a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
300	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208 0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	CV C4	1	OA AV
208 0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	CV C4	1	OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
0031a		Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208 0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	CV C4	1	OA AV
208 0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	CV C4	1	OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0031a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
0031a		Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0001a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0011a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	1	IS
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
300	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0011a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0011a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
59267100002	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0011a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0011a	Immunization Administration By	Procedure	C4	1	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
59267100001	Spike Protein, Lnp, Preservative Free,	Procedure	ND		AV
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND		AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	1	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		OA
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0001a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
59267100001	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	C4		OA
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Synd				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs	Procedure	C4		OA
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0001a		Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0004a	Immunization Administration By	Procedure	C4	1	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0001a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
218		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	1	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	1	AV
218		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	1	OA
300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	CV		OA
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208					
218					
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	1	OA
218		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0004a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	1	OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207 0031a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	1	OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
218	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
207	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos 207	Covid19mrnalnpspf100mcg05mldos Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
Covid19mrnalnpspf100mcg 05mldos 207	Covid19mrnalnpspf100mcg05mldos Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV		OA
207	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV		OA
207	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
300	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV		OA
0011a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
207	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0011a	eua Authorized	Procedure	C4		OA
207	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0031a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
207	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207		Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV		OA
208		Procedure	CV		OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0004a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0004a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207		Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
0011a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
207	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0011a	eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	IP
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	IS
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		IS
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
80777027310	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0031a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
	Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	IS
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207 0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure Procedure	CV C4	1	OA IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	1	OA
0064a		Procedure	C4		IS
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0011a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos 208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	1	OA
208		Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208		Procedure	CV		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND	1	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0004a	fda Eua (5 Yrs	Procedure	C4		AV
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0011a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0004a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0004a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0004a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208		Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208		Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV		OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
	eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
300	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0004a	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	eua Authorized	Procedure	C4		AV
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	eua Authorized	Procedure	C4		OA
	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
	eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0004a		Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0011a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	1	OA
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		AV
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		OA
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0004a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0031a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		IP
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		IP
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		ED
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
Covid19mrnalnpspf30mcg0	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
3mldose	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
Covid19mrnalnpspf30mcg0	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
3mldose	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
212	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
212	Dose, Tris-Sucrose;	Procedure	CV		OA
0031a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
212	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
212	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
oster	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		IP
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		IP
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
212	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0031a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	1	OA
0031a		Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
Covid19mrnalnpspf10mcg02mldose		Prescription	N/A	1	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose 218	Covid19mrnalnpspf10mcg02mldose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	1	N/A OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
Covid19mrnalnpspf10mcg02mldose 218	Covid19mrnalnpspf10mcg02mldose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	1	N/A OA
Covid19mrnalnpspf10mcg02mldose 218	Covid19mrnalnpspf10mcg02mldose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0011a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0011a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
218	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0004a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0011a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose 218	Covid19mrnalnpspf10mcg02mldose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	1	N/A OA
Covid19mrnalnpsbivalentbooster 218	Covid19mrnalnpsbivalentbooster Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	1	N/A OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV		OA
218	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV	1	OA
218	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0004a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Covid19mrnalnpsbivalentbooster	Prescription	N/A		N/A
Covid19mrnalnpsbivalentbo	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
oster	Dose, Tris-Sucrose;				
218	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	IP
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	1	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	1	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	1	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	1	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0031a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV		OA
300	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	1	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0004a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	1	OA
0004a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	1	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
300	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	1	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	1	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	1	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	1	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	1	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By	Procedure	C4	1	IS
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0011a	Immunization Administration By	Procedure	C4	1	IS
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	1	IS
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IS
0004a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0004a	Immunization Administration By	Procedure	C4	1	OA
0004a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	1	AV
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	IP
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	IS
80777027310	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		IS
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		IS
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
0064a	Immunization Administration By	Procedure	C4	1	IS
0011a	Intramuscular Injection Of Severe Acute	Procedure	C4		IS
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0011a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0011a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0031a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A		N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	IS
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscul	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
208		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
218		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
218		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
218		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
59267100001		Procedure	ND		AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
59267100002		Procedure	ND		AV
218		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218					
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV	0	OA
0004a	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
208		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
208		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	AV
218		Procedure	CV		OA
207		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	OA
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	OA
218		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	OA
208		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	OA
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	OA
218		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose 218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4	0	AV
80777027399		Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	IS
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	C4	0	AV
80777027310		Procedure	ND		AV
300		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
207		Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	0	OA
208	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IP
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IP
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IS
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IS
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		ED
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		ED
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
0011a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0031a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
212	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0031a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0031a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	C4		AV
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV C4	0	OA AV
207 0031a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV C4	0	OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
208	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
59267100001	Spike Protein, Lnp, Preservative Free,	Procedure	ND		AV
212	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0031a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
59267100001	Spike Protein, Lnp, Preservative Free,	Procedure	ND		AV
212	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0031a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
80777027310	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		AV
212	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0031a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	0	OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	0	OA
212		Procedure	CV		OA
0031a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	0	OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
0011a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
59267100001	Spike Protein, Lnp, Preservative Free,	Procedure	ND		AV
212	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0031a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0031a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
212		Procedure	CV		OA
0031a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
212	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0031a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	0	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0031a	Immunization Administration By	Procedure	C4	0	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0031a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0031a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By	Procedure	C4	0	OA
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0031a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0031a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By	Procedure	C4	0	OA
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	0	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
91307	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	0	OA
0031a		Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
208	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
212		Procedure	CV		OA
0011a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		IS
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		ED
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
212		Procedure	CV		OA
0031a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	0	OA
0031a		Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
212	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0031a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	0	OA
0031a		Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0031a	Immunization Administration By	Procedure	C4	0	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IS
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	ED
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV	0	OA
59267100001	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	0	OA
208	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	0	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	0	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	0	OA
208	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0004a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV	0	OA
59267100001	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	0	OA
0004a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	0	OA
	Pf, 30 Mcg/0.3 Ml Dose;				
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	0	OA
	Pf, 30 Mcg/0.3 Ml Dose;				
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	0	OA
	Pf, 30 Mcg/0.3 Ml Dose;				
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	0	OA
	Pf, 30 Mcg/0.3 Ml Dose;				
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By	Procedure	C4	0	OA
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	ED
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV	0	OA
59267100002	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	0	OA AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	0	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	IP
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IP
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IP
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	IS
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	0	OA
0004a		Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
80777027310	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027310	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	0	AV
80777027399	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
80777027310	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	0	OA AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	0	OA
207	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	0	OA
207	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
oster	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND	0	AV
207		Procedure	CV		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND	0	AV
207		Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
80777027310	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IP
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	0	IS
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0064a	Immunization Administration By	Procedure	C4	0	IS
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	IS
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	0	OA
208	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	0	OA
0004a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	0	OA
0004a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	0	OA
0004a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	0	OA
0004a	Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpsbivalentbo	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
oster	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV		OA
300	Pf, 30 Mcg/0.3 Ml Dose;				
	eua Authorized				
	Pfizer Adult Bivalent Booster Ages 12+ Yrs,				
	Original Strain + Omicron Ba.4/Ba.5				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	ED

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	ED
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
	Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
	Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	OA
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	OA
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
208	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	IP
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	IP
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	IP

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	IS
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	IS
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose 218	Covid19mrnalnpspf10mcg02mldose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	0	N/A OA
Covid19mrnalnpspf10mcg02mldose 218	Covid19mrnalnpspf10mcg02mldose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	0	N/A OA
Covid19mrnalnpsbivalentbooster 0011a	Covid19mrnalnpsbivalentbooster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure	N/A C4	0 0	N/A AV
80777027310 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	ND C4	0	AV AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg0 3mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster,	Procedure	CV	0	OA
0011a	Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	OA
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpsbivalentbooster 300	Covid19mrnalnpsbivalentbooster Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Prescription Procedure	N/A CV	0	N/A OA
Covid19mrnalnpspf30mcg03mldose 300	Covid19mrnalnpspf30mcg03mldose Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Prescription Procedure	N/A CV	0	N/A OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	OA
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster 300	Covid19mrnalnpsbivalentbooster Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Prescription Procedure	N/A CV	0	N/A OA
Covid19mrnalnpsbivalentbooster 300	Covid19mrnalnpsbivalentbooster Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Prescription Procedure	N/A CV	0	N/A OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	ED
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV		OA
0004a	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
300	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
59267100001	Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0004a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster 300	Covid19mrnalnpsbivalentbooster Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Prescription Procedure	N/A CV	0	N/A OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized	Procedure	CV	0	OA
59267100001	Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5 Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	OA
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	OA
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		OA
	Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster 300	Covid19mrnalnpsbivalentbooster Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Prescription Procedure	N/A CV	0	N/A OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	0	OA
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster 300	Covid19mrnalnpsbivalentbooster Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Prescription Procedure	N/A CV	0	N/A OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001 0004a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	ND C4	0	AV AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV		OA
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Covid19mrnalnpsbivalentbo oster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	0	N/A

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	OA
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp,	Procedure	C4		OA
0031a	Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	IP
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	IS
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	IS
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0031a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IS
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	IS
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	IS
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IS
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS

Table 5a r01. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]The code category is defined as PX or RX: PX stands for "Procedure," and RX stands for "Dispensing."

[3]Code type is defined as C4, ND, or CV: C4 refers to Current Procedural Terminology, Fourth Edition (CPT-4); ND stands for National Drug Codes (NDCs); and CV represents the immunization information systems (IIS) Vaccine Administered Code Set (CVX) codes.

[4]Encounter Care Setting is defined as AV, OA, ED, IP, or IS: AV stands for Ambulatory Visit; OA refers to Other Ambulatory Visit; ED means Emergency Department; IP denotes Inpatient Hospital Stay; and IS represents Non-Acute Institutional Stay.
N/A stands for Not Applicable.

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1,978,908	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	996,548	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	754,279	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	546,965	AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	524,891	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	457,847	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	339,087	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	320,337	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	252,708	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	247,829	AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	228,614	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	199,490	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	166,150	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	CV	154,790	OA
0011a	Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	147,524	AV
0001a	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	135,109	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	122,346	AV
0011a	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	116,225	OA
208	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	115,052	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
Covid19mrnalnpspf10mcg02mldose	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription	N/A	113,754	N/A
Sarscov2covid19vaccinemrnaspik	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	108,099	N/A
207	Sarscov2covid19vaccinemrnaspik	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;	Procedure	CV	98,915	OA
0001a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	91,107	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	84,002	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	83,108	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	77,452	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	75,748	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	72,057	AV
0011a	Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	69,370	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	69,322	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	CV	69,179	OA
0011a	Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	68,719	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	67,693	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	65,084	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	60,213	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	59,830	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	55,328	OA
207	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	55,041	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	53,464	AV
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	53,234	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	52,377	OA
208	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	CV		OA
0001a	Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	51,836	OA
0001a	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	C4		AV
	Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-				
	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	CV	48,546	OA
0011a	Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And				
	Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By Intramuscular Injection Of				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-				
	2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike				
	Protein, Preservative Fr				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	47,582	AV
	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	CV	46,422	OA
0011a	Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And				
	Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By Intramuscular Injection Of				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-				
	2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike				
	Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	45,943	AV
0001a	Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	44,362	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	39,727	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	39,524	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	39,070	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	37,951	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	37,563	AV
208	Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	36,875	AV
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	36,778	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	35,431	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	33,835	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	32,515	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	30,836	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	30,285	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	27,630	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	27,033	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	26,662	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	26,610	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	26,503	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	25,294	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	24,992	AV
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	24,012	AV
59267100002		Procedure	ND		AV
0001a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	22,241	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	20,399	AV
80777027399		Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	20,134	AV
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	20,094	OA
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	20,054	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	19,883	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	19,010	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	18,839	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	17,991	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	17,874	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	17,285	AV
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	16,971	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	16,878	AV
208		Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	16,337	OA
0071a		Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	16,009	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	15,604	OA
91300		Procedure	C4		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	15,084	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	14,498	AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	13,711	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	13,101	AV
208	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	CV		OA
0001a	Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	12,679	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	12,371	OA
80777027399	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	ND		AV
0011a	Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	11,912	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	11,181	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	11,005	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	10,876	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10,844	OA
91300		Procedure	C4		AV
59267100002		Procedure	ND		AV
0001a		Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10,637	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	10,361	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	10,094	AV
91300		Procedure	C4		OA
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	10,049	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4	10,040	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	9,917	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	9,636	AV
0004a	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	C4		AV
	Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-				
	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0004a	Immunization Administration By Intramuscular Injection Of	Procedure	C4	9,504	OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-				
	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	9,345	AV
208	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	CV		OA
0001a	Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary				
	Series And Ic Dose Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-				
	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8,999	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8,867	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8,730	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	8,330	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	8,201	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8,143	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	8,084	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	8,024	AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	7,897	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7,857	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	7,768	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4		OA
218		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7,765	OA
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	7,331	OA
212		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	7,122	AV
0004a	Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	7,116	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6,865	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND		AV
0001a	Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6,813	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	CV	6,686	OA
0011a	Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	6,637	AV
208	Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	6,475	AV
218	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	CV		OA
0071a	Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	6,339	OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6,313	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	6,300	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4	6,056	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	6,014	OA
80777027310		Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	5,999	OA
218	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	5,802	AV
0031a	2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	5,712	AV
207	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	CV		OA
0011a	Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5,635	OA
91300		Procedure	C4		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	5,538	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	5,522	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	5,455	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	5,436	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And	Procedure	C4	5,372	OA
91301		Procedure	C4		AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4	5,175	AV
59267100002		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	5,151	N/A
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5,063	OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	4,823	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;	Procedure	CV	4,781	OA
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4,744	OA
91301		Procedure	C4		AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4,645	OA
91301		Procedure	C4		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
212	Immunization Administration By Intramuscu Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	4,625	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4,585	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4,498	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	4,398	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4,228	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	4,121	AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
0011a		Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	4,050	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3,770	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
208		Procedure	CV	3,723	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3,638	OA
0011a		Procedure	C4		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3,615	AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3,523	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	3,483	N/A
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	3,362	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	3,358	AV
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3,356	AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	3,313	OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3,263	AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3,243	OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3,192	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3,135	OA
91301		Procedure	C4		AV
0011a		Procedure	C4		AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3,117	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	3,028	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3,015	OA
91301		Procedure	C4		AV
80777027310		Procedure	ND		AV
0011a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	2,949	OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	2,927	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2,923	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2,913	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2,904	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	2,863	AV
0064a	Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2,856	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2,817	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	2,689	AV
207	Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2,670	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	2,588	OA
208	Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	CV	2,550	OA
0011a	Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2,451	OA
218		Procedure	CV		OA
0071a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2,424	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2,404	AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	2,375	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	2,360	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4	2,345	OA
91301		Procedure	C4		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2,320	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	2,308	OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	2,289	AV
0001a	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	C4		AV
	Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-				
	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	2,270	AV
	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	2,266	AV
0031a	2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike	Procedure	C4		AV
	Protein, Adenovirus Type 26 (Ad26) Vector, Preservative				
	Free, 5x1010 Viral Particles/0				
	Immunization Administration By Intramuscular Injection Of				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-				
	2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike				
	Protein, Adenovirus Type 26				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	2,263	OA
59267100001	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	ND		OA
0001a	Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,				
	Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-				
	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2,249	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4	2,241	AV
59267100002		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2,194	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	2,166	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;	Procedure	CV	2,090	OA
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2,081	OA
91300		Procedure	C4		AV
59267100002		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	2,014	OA
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1,994	AV
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1,969	OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1,962	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1,959	OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1,946	OA
0071a		Procedure	C4	1,936	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1,917	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1,905	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1,858	OA
91307		Procedure	C4		AV
0071a		Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1,854	OA
91307		Procedure	C4		AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4	1,847	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1,843	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1,830	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1,820	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1,806	OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,774	AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1,766	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1,749	OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1,743	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1,724	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	1,718	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1,716	OA
0031a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1,702	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,698	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,674	OA
91307		Procedure	C4		AV
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,652	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1,584	OA
0081a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1,573	OA
91307		Procedure	C4		AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1,558	OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,556	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1,538	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1,525	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1,474	OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	1,459	OA
0001a	Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1,436	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1,431	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	1,428	OA
0064a		Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1,425	OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1,421	AV
80777027399		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
207	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV	1,408	OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1,407	OA
91301		Procedure	C4		AV
80777027399		Procedure	ND		AV
0011a		Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1,363	OA
0001a		Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1,354	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1,318	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1,300	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1,288	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1,280	OA
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1,237	OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	1,217	OA
208	Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	1,216	AV
212	2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1,206	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1,205	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1,200	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1,194	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1,180	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1,170	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1,139	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1,111	OA
91307		Procedure	C4		AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1,069	AV
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4	1,041	AV
59267100002		Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4	1,012	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	964	OA
0001a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	951	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	950	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	930	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;	Procedure	CV	923	OA
0064a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	916	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	913	OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	900	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	897	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	893	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	865	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	858	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	853	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	849	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	847	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	840	OA
212		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	840	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	821	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	820	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	819	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	810	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	805	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	792	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	785	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	780	AV
208		Procedure	CV		OA
0004a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	779	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	778	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	769	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	769	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	757	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	756	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	742	AV
0001a		Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	742	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	738	OA
0071a	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	C4		AV
	Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-				
	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	724	OA
207	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	CV		OA
0011a	Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-				
	2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	716	AV
59267100001	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	ND		AV
0004a	Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-				
	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	704	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	692	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	682	AV
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
80777027399	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	673	OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	655	OA
0011a	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	C4		AV
	Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	653	AV
59267100001	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	ND		AV
	Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	649	OA
80777027310	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	ND		OA
0011a	Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	647	AV
59267100001		Procedure	ND		AV
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	641	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	641	OA
0031a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	633	AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	624	OA
0031a		Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	621	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	CV	620	OA
0064a	Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	619	OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	616	OA
0001a	Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	608	OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	602	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	578	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	570	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	570	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	568	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	563	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	549	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	548	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	535	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	533	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	531	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	530	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	525	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	520	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	518	IS
0001a	Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	518	OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	516	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	506	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	506	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	505	OA
91301		Procedure	C4		AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	505	AV
91303		Procedure	C4		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4	504	AV
59267100002		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	497	OA
212		Procedure	CV		OA
0031a		Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	490	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	489	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	488	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	487	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	482	OA
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	481	AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	473	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4	472	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	469	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	465	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	460	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	451	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	450	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	450	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	449	OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	438	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	438	OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	433	OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	431	AV
59267100002		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	430	OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	430	AV
91303		Procedure	C4		OA
212		Procedure	CV		OA
0031a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	429	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	423	N/A
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	421	AV
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	413	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50	Procedure	CV	410	OA
0064a	Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	C4	398	AV
207	Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	393	OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	388	OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp,	Procedure	ND	383	IS
0001a	Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	375	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;	Procedure	CV	372	OA
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	367	AV
0011a	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	C4		AV
	Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	367	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary	Procedure	C4		AV
0001a	Series And Ic Dose Original Formulation. Eua 8/31/2022	Procedure	C4		OA
	Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	361	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-	Procedure	C4	360	OA
0064a	2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike	Procedure	C4		AV
	Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	359	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	354	OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	353	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	348	OA
59267100002		Procedure	ND		AV
0004a		Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	343	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	341	OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	337	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	336	OA
0004a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	335	OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	333	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	328	OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	327	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4	326	OA
91303		Procedure	C4		AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	324	OA
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	321	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	320	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	320	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	320	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	319	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	317	OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	316	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	316	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	313	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	312	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	309	OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	306	AV
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	302	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	299	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	298	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	297	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	290	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	288	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	288	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	287	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	286	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	286	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	284	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	279	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	277	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	273	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0004a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	271	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	270	OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	270	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	269	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	269	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	268	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	268	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	266	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	266	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
91300	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	264	OA
207	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV	264	OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	260	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	260	OA
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	258	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	256	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	255	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	254	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	251	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	251	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	251	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	251	IS
0011a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		IS
	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	250	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	249	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	248	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	246	AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	245	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	243	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs	Procedure	C4		AV
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	243	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	242	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscu				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	242	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	241	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	240	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	240	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	239	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	238	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		OA
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	237	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	236	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	235	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	234	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	231	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	230	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	230	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0004a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	227	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose	Procedure	CV		OA
0071a	Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	227	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	224	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	223	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	222	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	222	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	221	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	219	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	218	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	216	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	214	OA
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	213	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	212	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	210	OA
0011a	Immunization Administration By	Procedure	C4	208	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	206	OA
80777027310		Procedure	ND		OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	204	OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	203	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	200	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	200	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	200	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	198	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	198	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	198	AV
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	197	OA
207		Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	194	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	194	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	193	AV
0001a		Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	193	IS
0011a		Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	192	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	192	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	189	OA
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	189	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	189	N/A
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	188	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	188	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	187	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	187	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	186	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	186	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	184	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	183	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	183	OA
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	183	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	182	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	182	AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	179	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	178	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	177	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002 208	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure Procedure	ND CV	177	AV OA
Covid19mrnalnpspf10mcg02mldose 219	Covid19mrnalnpspf10mcg02mldose Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Prescription Procedure	N/A CV	177	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	176	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	174	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	173	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	173	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	172	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	172	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	171	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91307	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	171	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	171	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	171	OA
0001a		Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	171	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose 218 208	Covid19mrnalnpspf10mcg02mldose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	169	N/A OA OA
Covid19mrnalnpspf100mcg05mldos 207	Covid19mrnalnpspf100mcg05mldos Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	168	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	164	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	164	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	164	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	163	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	162	OA
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	161	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	161	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	161	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	160	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	158	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	157	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	157	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	156	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	154	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	152	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	152	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	151	IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	150	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	150	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	149	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	149	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	149	IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	148	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	148	OA
218	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	147	AV
219	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0081a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	144	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	144	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	144	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	143	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	143	OA
208	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	139	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	139	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	138	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscul				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	137	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 0011a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure	N/A C4	137	N/A OA
Covid19mrnalnpspf100mcg05mldos 208	Covid19mrnalnpspf100mcg05mldos Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	137	N/A OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	136	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	136	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	135	OA
0081a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	135	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	135	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	133	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	132	N/A
orno	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	132	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	130	OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	130	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	130	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	129	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	128	OA
0001a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	128	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	127	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	127	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	126	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	126	OA
Sarscov2covid19vaccinemrnaspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription	N/A	124	N/A
208	Sarscov2covid19vaccinemrnaspik	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	122	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	122	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	122	AV
0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	122	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	121	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	121	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	120	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	120	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	120	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	119	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	119	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	119	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	119	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	118	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	116	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	116	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	115	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	114	OA
0081a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	114	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	112	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	112	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	112	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	112	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	111	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	111	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	110	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	109	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4	108	AV
91300		Procedure	C4		OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	108	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	107	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	106	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	106	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	105	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	104	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	104	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 207	Sarscov2covid19vaccinevectorno Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	103	N/A OA
91300 208	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure Procedure	C4 CV	103	AV OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	103	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	103	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	102	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	102	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	102	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	101	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	101	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	101	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	101	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	101	AV
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	100	OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	99	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	97	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	97	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	97	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	97	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	96	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	96	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	96	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	96	OA
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	96	OA
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	96	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	96	OA
208		Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	95	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	95	OA
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	95	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	95	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	94	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	94	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	94	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208 0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	94	OA AV
208 0081a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	CV C4	93	OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	93	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	92	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	90	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	90	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0004a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	90	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	90	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By	Procedure	C4	89	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	89	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
Sarscov2covid19vaccinemrn aspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	88	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	88	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	88	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	87	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	87	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	86	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	86	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	86	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	86	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	85	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	85	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	85	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	84	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	84	OA
0031a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	84	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	83	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	83	OA
0071a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	83	AV
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	82	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	82	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	82	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	82	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	82	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	81	N/A OA
212 0011a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	81	OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	80	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	80	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	79	AV
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND	79	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	78	OA
208		Procedure	CV		OA
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	78	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	78	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	77	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	77	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	76	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	76	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	76	N/A
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	76	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	76	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	76	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	76	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik208	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	75	N/A
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100001208 0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	75	OA
		Procedure	CV		OA
		Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	74	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	74	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	74	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	74	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	74	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	74	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		OA
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	74	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	73	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	73	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	73	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	73	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	73	OA
0004a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	72	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	72	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	72	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	71	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By				
	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	71	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	71	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	70	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	70	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	70	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	70	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	70	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	69	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preserv				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	69	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
0064a	Immunization Administration By	Procedure	C4	69	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	69	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	69	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	69	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	69	OA
0031a		Procedure	C4		AV
0001a		Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	69	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	68	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	68	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	68	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	68	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	67	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	67	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	66	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	66	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 0004a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	66	N/A OA
Covid19mrnalnpspf100mcg05mldos 207	Covid19mrnalnpspf100mcg05mldos Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	66	N/A OA
218 0071a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	CV C4	65	OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	65	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	65	OA
208		Procedure	CV		OA
0004a		Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	65	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	65	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	64	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	64	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	64	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	64	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	63	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	63	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	62	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	62	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	62	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	62	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	62	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV	62	OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	61	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	61	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	61	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	61	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	60	AV
218		Procedure	CV		OA
0071a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	60	OA
0081a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	60	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	60	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	60	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	60	OA
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	60	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	59	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	59	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	59	OA
207		Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	59	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	59	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	59	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV		OA
219	Dose, Tris-Sucrose;	Procedure	CV		OA
218	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series				
0031a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	59	IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	58	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	58	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	58	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	58	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	58	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	57	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	57	N/A
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	57	AV
207	Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	57	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	57	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	57	IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	57	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	56	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	56	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	56	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	56	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	56	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	55	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	55	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	55	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	55	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	55	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	55	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	55	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	54	N/A OA
91300 208 0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure Procedure	C4 CV C4	54	AV OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	54	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	54	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	54	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	53	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	53	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	53	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		OA
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	53	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	53	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	52	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	52	OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	51	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	51	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By				
	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	51	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	51	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	51	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	51	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	50	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	50	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	50	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	50	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	50	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	50	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	50	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	50	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	49	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	49	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	49	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	49	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	49	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	49	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	48	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	48	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	48	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	48	OA
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	48	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	48	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	47	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	47	OA
0071a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	47	AV
59267100001		Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4	47	AV
80777027399		Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	47	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	47	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	47	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	47	OA
0031a	Immunization Administration By	Procedure	C4	47	AV
0031a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	46	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	46	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	46	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	46	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	46	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	46	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	46	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	46	AV
207	Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	46	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	45	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	45	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	45	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0071a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	45	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0004a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	45	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	45	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	45	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	45	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	45	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	45	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	44	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	44	OA
80777027310	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	44	AV
207		Procedure	CV		OA
0064a		Procedure	C4		AV
59267100001		Procedure	ND	44	AV
0071a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	44	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	44	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	44	AV
207	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	44	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	44	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	43	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	43	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	43	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	43	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	43	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	43	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	43	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	43	OA
208	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	43	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	43	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	43	ED
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	42	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	42	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	42	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	42	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	42	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	42	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	42	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	41	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	41	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	41	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	41	ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	41	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	41	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	41	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome	Procedure	C4	41	OA
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	41	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	40	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	40	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	40	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	40	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	40	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	40	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	40	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	40	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	40	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	40	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	40	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	40	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	39	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	39	OA
0071a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	39	N/A
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	39	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	39	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	39	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	39	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome	Procedure	C4	39	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	39	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	39	AV
208		Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	39	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	39	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	39	OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	38	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	38	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	38	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	38	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	38	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	38	OA
207	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
0064a	Immunization Administration By	Procedure	C4	37	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	37	IS
0001a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		IS
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	37	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	37	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	37	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	37	OA
59267100002		Procedure	ND		AV
208		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	37	OA
91301		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	37	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	37	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	37	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	37	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	37	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	36	AV
Sarscov2covid19vaccinemrnaspik	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription	N/A	36	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 208	Sarscov2covid19vaccinevectorno Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	36	N/A OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	36	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	36	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	36	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	36	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND	36	AV
208		Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	36	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	36	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	35	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	35	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	35	N/A
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	35	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	35	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	35	N/A
orno	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	35	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	35	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	35	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	35	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	35	AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	35	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	35	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	34	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	34	AV
80777027399		Procedure	ND		AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	34	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	34	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	34	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	34	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	34	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	34	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	34	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	34	OA
208	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	33	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	33	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	33	N/A OA
91300 80777027310 0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure Procedure	C4 ND C4	33	AV AV AV
91300 59267100002	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure Procedure	C4 ND	33	OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	33	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	33	OA
0011a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	33	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	33	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	33	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	33	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	33	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	33	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	32	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	32	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	32	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	32	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	32	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	32	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	32	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	32	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	32	OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001 208	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure Procedure	ND CV	32	AV OA
59267100001 208	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure Procedure	ND CV	32	OA OA
Covid19mrnalnpspf30mcg03mldose 208	Covid19mrnalnpspf30mcg03mldose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	32	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	31	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preserv				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	31	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	31	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	31	OA
0071a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	31	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	31	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	31	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	31	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	31	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	31	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	31	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	31	OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	31	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	31	OA
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	30	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	30	AV
219	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0081a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	30	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	30	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	30	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	30	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	30	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	30	AV
0064a	Immunization Administration By	Procedure	C4	29	OA
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	29	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	29	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	29	AV
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	29	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	29	N/A
59267100001 0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	ND C4	29	IS IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	29	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	29	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	29	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	29	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	29	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	29	OA
0011a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	29	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	29	AV
0001a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	29	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	29	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	28	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	28	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	28	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	28	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	28	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	28	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	28	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	28	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	28	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	27	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	27	OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	27	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	27	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	27	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	27	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	27	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	27	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	27	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	27	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	27	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	27	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	27	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	26	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	26	OA
208		Procedure	CV		OA
0071a		Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	26	OA
0071a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	26	AV
0081a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	26	OA
0081a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	26	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	26	N/A
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	26	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	26	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	26	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	26	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	26	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
91303	Severe Acute Respiratory Syndrome	Procedure	C4	26	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	26	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	26	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	26	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	26	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	26	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	26	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	25	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	25	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	25	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	25	AV
0081a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	25	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	25	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 218 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	25	N/A OA OA
Sarscov2covid19vaccinemrnaspik 219 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	25	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	25	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	25	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	25	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	25	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	25	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	25	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	25	ED
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	25	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	25	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	25	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	25	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	25	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	25	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	25	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	25	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	24	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preserv				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND	24	AV
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	24	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	24	OA
0071a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	24	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	24	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	24	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	24	N/A
orno	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	24	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	24	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	24	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	24	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	24	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	24	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	24	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	24	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	24	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	24	OA
207	Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	24	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	24	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	24	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	23	ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	23	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	23	OA
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	23	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	23	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	23	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	23	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		ED
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	23	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	23	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	23	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	23	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	23	OA
0001a		Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	23	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	23	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	23	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	23	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	23	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	23	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	22	AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	22	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	22	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	22	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	22	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	22	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	22	OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	22	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	22	OA
0081a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	22	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	22	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	22	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
212	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0001a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
	Vector, Preservative Free, 5x1010 Viral Particles/0				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	22	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	22	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	22	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	22	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	22	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	22	OA
207	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	22	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	22	OA
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	22	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	22	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	22	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	22	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	21	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		OA
0071a	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	21	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	21	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo	Procedure	C4		AV
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 212 208	Sarscov2covid19vaccinemrnaspik Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	21	N/A OA OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	21	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	21	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	21	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	21	N/A
91300	Severe Acute Respiratory Syndrome	Procedure	C4		OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	21	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	21	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	21	AV
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	21	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	21	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	21	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	21	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	21	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	21	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	21	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	21	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	21	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	21	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	21	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV		OA
219	Dose, Tris-Sucrose;	Procedure	CV		OA
218	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	20	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	20	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (6 Mo	Procedure	CV		OA
0071a	Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	20	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	20	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	20	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	20	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	20	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	20	IP
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	20	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	20	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	20	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	20	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
91303	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	20	OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	20	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	20	AV
0001a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	20	OA
0001a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	20	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	20	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	20	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	20	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	19	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	19	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	19	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	19	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	19	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (6 Mo	Procedure	C4		AV
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	19	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	19	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	19	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	19	OA
208		Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	19	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	19	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	ND		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	19	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	19	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	19	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	19	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	19	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	19	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	19	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	19	N/A
91301	Severe Acute Respiratory Syndrome	Procedure	C4		OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	19	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	19	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
91303		Procedure	C4	19	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	19	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	19	AV
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	19	OA
0001a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	19	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	19	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	19	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		ED
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	19	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	19	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	19	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	19	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	18	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	18	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	18	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	18	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	18	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	18	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	18	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	18	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	18	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	18	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	18	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	18	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	18	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	18	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	18	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	18	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	18	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	18	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	18	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	18	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	18	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	18	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	18	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	18	OA
208		Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
91307	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	18	AV
218	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	18	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	18	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	18	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	18	N/A
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	18	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	17	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	17	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	17	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	17	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	17	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	17	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208 0011a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure	N/A CV C4	17	N/A OA AV
Sarscov2covid19vaccinemrnaspik 0004a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	17	N/A AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect orno 212 207	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	17	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	17	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	17	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	17	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	17	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
218		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	17	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	17	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	17	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	17	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	17	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	17	AV
207		Procedure	CV		OA
0011a		Procedure	C4		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	17	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	17	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	17	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	17	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	17	OA
91303	Severe Acute Respiratory Syndrome	Procedure	C4	17	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	17	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	17	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	17	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	17	OA
207		Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	17	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	17	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	17	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	17	IS
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	16	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	16	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	16	AV
0071a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	16	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		AV
0001a		Procedure	C4		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	16	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	16	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	16	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	16	N/A OA
Sarscov2covid19vaccinemrnaspik 218	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	16	N/A OA
59267100001 0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	ND C4	16	IP IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	16	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	16	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	16	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	16	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	16	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	16	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		OA
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By I				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	16	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	16	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	16	OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	16	OA
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
91303	Severe Acute Respiratory Syndrome	Procedure	C4	16	OA
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	16	OA
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	16	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	16	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	16	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	16	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	16	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	16	OA
208 0004a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	CV C4	16	OA OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	16	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	15	AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	15	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	15	AV
0081a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn aspik 208 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	15	N/A OA OA
Sarscov2covid19vaccinevect orno 212 208	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	15	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	15	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
91300	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	15	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	15	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	15	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	15	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	15	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	15	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	15	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	15	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	15	OA
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	15	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	15	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	15	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	15	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	15	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	15	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
91307	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	15	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	15	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	15	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	15	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	15	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	15	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	15	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	15	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	15	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	15	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	15	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	15	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	15	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	15	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	15	OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	14	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	14	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
0081a	Immunization Administration By	Procedure	C4	14	AV
0071a	Intramuscular Injection Of Severe Acute	Procedure	C4		AV
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	14	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	14	OA
0071a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	14	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	14	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	14	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91301 80777027310 0011a	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure Procedure	N/A C4 ND C4	14	N/A AV AV AV
Sarscov2covid19vaccinemrnaspik 208 0001a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A CV C4	14	N/A OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose 59267100001 208 0001a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure Procedure	N/A ND CV C4	14	N/A AV OA AV
Sarscov2covid19vaccinemrnaspik 208 0001a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A CV C4	14	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik212	Sarscov2covid19vaccinemrnaspik Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	14	N/A OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	14	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	14	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	14	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	14	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	14	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	14	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	14	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immuni	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	14	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	14	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	14	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	14	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	14	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	14	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	14	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	14	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	14	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	14	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	14	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	14	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	14	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	14	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	14	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	14	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	14	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	14	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	14	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	14	OA
208		Procedure	CV		OA
208 0004a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	14	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	14	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	14	ED
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	14	IP
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	13	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	13	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	13	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	13	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	13	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	13	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	13	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	13	OA
0081a		Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	13	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription	N/A	13	N/A
0031a		Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	IP
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	13	AV
91300		Procedure	C4		OA
59267100002	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	13	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0004a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	13	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	13	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	13	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	13	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	13	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	13	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	13	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		ED
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	13	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	13	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	13	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	13	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	13	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	13	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	13	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	13	OA
0031a	0.5 Ml;	Procedure	C4		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	13	OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	12	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	12	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	12	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	12	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	12	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	12	OA
0081a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	12	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn aspik 219 218	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure Procedure	N/A CV CV	12	N/A OA OA
Sarscov2covid19vaccinevect orno 212 0031a	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	12	N/A OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	12	N/A
orno	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	C4		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	12	IP
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	ND		AV
0031a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
0001a	Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Ade				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	12	AV
59267100002		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	12	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	12	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	12	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	12	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	12	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	12	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	12	OA
0001a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	12	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	12	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	12	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	12	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	12	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	12	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	12	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	12	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	12	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	12	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	12	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (6 Mo	Procedure	CV		OA
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	12	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV		OA
219	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	12	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	12	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	11	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0064a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	11	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	11	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	11	OA
0064a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	11	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	11	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	11	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	11	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	11	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	11	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	11	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	11	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	11	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	11	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	11	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	11	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	11	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	11	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	11	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	11	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	11	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	11	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	11	OA
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	11	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	11	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	11	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	11	AV
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	11	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	11	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	11	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	11	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	11	N/A
3mldose	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207					
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	11	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	11	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	11	OA
0011a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	11	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	11	OA
0031a	0.5 Ml;	Procedure	C4		ED
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	11	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	10	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	10	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	10	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	10	OA
0071a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	10	OA
0071a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	10	OA
0081a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	10	AV
219	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0081a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	10	OA
0081a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	10	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	10	N/A
Sarscov2covid19vaccinemrnaspik 80777027399	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Prescription Procedure	N/A ND	10	N/A AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-C				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	10	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	10	AV
80777027399		Procedure	ND		AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		OA
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	10	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	10	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	10	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	C4		AV
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respira				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	10	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	10	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	10	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	10	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	10	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	10	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	10	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	10	OA
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	C4		AV
	Protein, Adenovirus Type 26 (Ad26)				
	Vector, Preservative Free, 5x1010 Viral				
	Particles/0				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	10	AV
0001a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	10	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	10	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	10	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0004a	Immunization Administration By	Procedure	C4	10	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	10	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	10	OA
207		Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	10	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	10	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	10	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	10	AV
207	Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	10	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	10	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	10	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	10	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	10	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	10	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	10	OA
208	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	10	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	10	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	10	IS
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	10	IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	9	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	9	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	9	OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	9	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	9	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	9	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND	9	AV
208		Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	9	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	9	OA
208		Procedure	CV		OA
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose 59267100001 208 0001a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure Procedure	N/A ND CV C4	9	N/A AV OA AV
Sarscov2covid19vaccinemrnaspik 208 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	9	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	9	N/A OA
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	9	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo	Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4	9	OA
91300		Procedure	C4		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	9	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	9	IP
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		IP
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	9	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And	Procedure	ND		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By I	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By I				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	9	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	9	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91303	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	9	AV
212		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	9	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	9	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	9	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	9	AV
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	9	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	9	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	9	OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	9	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	9	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	9	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Covid19mrnalnpspf100mcg 05mldos 207	Covid19mrnalnpspf100mcg05mldos Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	9	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	9	OA
207		Procedure	CV		OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	9	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	9	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		OA
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	9	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	9	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	9	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	9	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	9	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	9	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	9	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	9	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	9	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	9	OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	9	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	9	IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	9	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	8	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	8	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	8	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	8	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	8	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	8	N/A
2mldose	Immunization Administration By	Procedure	C4		AV
0071a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	8	OA
0081a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
0081a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	8	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	8	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91301 0011a	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure	N/A C4 C4	8	N/A OA AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	8	N/A
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	8	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	8	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 219	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Prescription Procedure	N/A CV	8	N/A OA
Sarscov2covid19vaccinemrnaspik 219	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Prescription Procedure	N/A CV	8	N/A OA
Sarscov2covid19vaccinevectorno 91300	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Prescription Procedure	N/A C4	8	N/A OA
Sarscov2covid19vaccinevectorno 208	Sarscov2covid19vaccinevectorno Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	8	N/A OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	8	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	AV
91300	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		OA
59267100001	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	8	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome C	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
219	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	8	AV
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	8	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Ad				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preserva				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	8	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	8	N/A
91301	Severe Acute Respiratory Syndrome	Procedure	C4		AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	8	N/A
	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	8	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	8	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	8	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	8	ED
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91303	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	8	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	8	OA
0001a		Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	8	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	8	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	8	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	8	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	8	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	8	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	8	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	8	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	8	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	8	OA
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	8	OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	8	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	8	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	8	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	8	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	8	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	8	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	8	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	8	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	8	OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	8	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	8	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose 208	Covid19mrnalnpspf10mcg02mldose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	8	N/A OA
Covid19mrnalnpspf30mcg03mldose 208	Covid19mrnalnpspf30mcg03mldose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	8	N/A OA
80777027310 208 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure Procedure	ND CV C4	8	OA OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	8	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	8	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	8	OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	8	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	8	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	8	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	8	IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0064a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	7	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	7	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	7	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	7	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	7	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	7	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	7	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	7	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	7	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	7	OA
0071a		Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	7	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	7	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
0081a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	7	OA
0081a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	7	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	7	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	7	OA
208		Procedure	CV		OA
0081a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	7	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	7	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	7	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 212 207	Sarscov2covid19vaccinemrnaspik Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	7	N/A OA OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	7	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 219 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	7	N/A OA OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	7	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	7	N/A
Sarscov2covid19vaccinevectorno 212 208	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	7	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	7	N/A OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	ND		AV
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfiz				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo	Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Do				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0004a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	AV
91303	Severe Acute Respiratory Syndrome	Procedure	C4	7	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	7	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		ED
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		ED
	Immunization Administration By Intramuscu				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	OA
91301		Procedure	C4		AV
80777027399		Procedure	ND		AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	7	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Prese	Procedure	ND		AV
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	7	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	7	OA
80777027310		Procedure	ND		OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	7	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	7	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	7	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	7	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	7	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	7	AV
219	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	7	OA
207		Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	7	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	7	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	7	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	7	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	7	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	7	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	7	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	7	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	7	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	7	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	7	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	7	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	7	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	7	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV	7	OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	7	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	7	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	7	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	7	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	7	IP
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	7	IS
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	7	AV
0011a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	7	ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	6	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	6	AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	6	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0064a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	6	OA
0071a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
0071a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	6	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	6	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	6	OA
0071a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	6	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	6	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	6	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	6	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	6	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	6	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0071a	Immunization Administration By	Procedure	C4	6	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	6	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	OA
0081a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	6	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	6	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	6	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	6	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	6	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
aspik	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND		OA
80777027399	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
208	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	6	N/A
aspik					

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 91303 212 0031a	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure Procedure	N/A C4 CV C4	6	N/A AV OA AV
Sarscov2covid19vaccinevectorno 91303 0031a	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A C4 C4	6	N/A AV AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 91303	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Prescription Procedure	N/A C4	6	N/A OA
Sarscov2covid19vaccinevectorno 91303 212	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure Procedure	N/A C4 CV	6	N/A OA OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	6	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	6	N/A OA AV
Sarscov2covid19vaccinevectorno 0031a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	6	N/A AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	6	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Mode	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	6	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	6	OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	6	OA
208		Procedure	CV		OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	6	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	6	IP
207		Procedure	CV		OA
0011a		Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	IS
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IS
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Prese	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	6	OA
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	6	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	6	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	6	AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	6	AV
208		Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	6	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	6	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (6 Mo	Procedure	CV		OA
0001a	Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	6	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	6	AV
0001a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	6	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	6	OA
208	0.5 Ml;	Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		OA
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	6	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	6	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	6	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	6	OA
207	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	6	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	6	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	6	AV
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	6	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND	6	AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV	6	OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	6	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	6	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	6	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	6	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	6	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	6	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	6	AV
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	6	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	6	OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	6	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	6	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	6	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	6	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	6	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	6	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	6	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	6	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	6	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	6	AV
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	6	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	6	AV
0011a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preserv				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	5	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	5	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	5	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	5	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	5	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	5	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vacci	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	5	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	5	OA
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	OA
91307		Procedure	C4		AV
0071a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	5	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	5	OA
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	OA
218		Procedure	CV		OA
0071a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
0071a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs	Procedure	C4		OA
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	5	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	5	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0081a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	5	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	5	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	5	OA
208		Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	5	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo	Procedure	C4		AV
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	5	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	5	OA
208	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0081a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91301 207	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A C4 CV	5	N/A OA OA
Sarscov2covid19vaccinemrnaspik 91303 212	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure Procedure	N/A C4 CV	5	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	5	N/A OA
Sarscov2covid19vaccinemrnaspik 208 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	5	N/A OA OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	5	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	5	N/A OA OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	5	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
Sarscov2covid19vaccinemrnaspik 218	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	5	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	5	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A		N/A
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	IP
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		IP
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	IP
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		IP
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IP
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	IS
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
59267100001	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	ND		AV
0011a	Use	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, M				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4	5	OA
91300		Procedure	C4		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Do				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
219	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/3				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	5	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	5	OA
208		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	5	AV
80777027310		Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Ad				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	5	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	5	AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	5	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	5	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
91301	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	5	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
91303	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	ND		AV
212	Protein, Adenovirus Type 26 (Ad26)	Procedure	CV		OA
0031a	Vector, Preservative Free, 5x1010 Viral	Procedure	C4		AV
	Particles/0				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Dna, Spike				
	Protein, Adenovirus Type 26 (Ad26)				
	Vector, Preservative Free, 5x1010 Viral				
	Particles/0				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	5	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
91303	Severe Acute Respiratory Syndrome	Procedure	C4	5	OA
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	5	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	5	OA
91303	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	5	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	5	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	5	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	5	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	5	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	5	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	5	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	5	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs),	Procedure	C4		OA
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	5	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	5	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	5	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	5	OA
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	5	AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	5	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	5	OA
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	5	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		OA
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	5	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	5	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	5	OA
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	5	OA
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	5	OA IP
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	5	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	5	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	5	OA
208		Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	5	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		OA
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	5	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	5	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	5	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	5	OA
0031a	0.5 Ml;	Procedure	C4		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	5	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	5	OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	5	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	5	IP
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	5	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	5	IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	5	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	5	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	5	IP
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	4	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	4	OA
0064a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	4	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	4	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	4	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	4	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dos	Procedure	ND		AV
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	4	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	4	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	4	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
0081a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	4	OA
0081a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	4	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	4	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	4	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	4	OA
0081a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
219	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0081a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	4	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	4	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo	Procedure	C4		AV
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	4	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	4	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	4	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik Sarscov2covid19vaccinemrnaspik 59267100001 208 0001a	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure Procedure	N/A ND CV C4	4	N/A OA OA OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4	N/A
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	4	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 218 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	4	N/A OA OA
Sarscov2covid19vaccinemrnaspik 80777027310 207 0011a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure Procedure	N/A ND CV C4	4	N/A AV OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	4	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	4	N/A OA
Sarscov2covid19vaccinemrnaspik 800777027399 0011a	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure	N/A ND C4	4	N/A AV AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	4	N/A
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	4	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	IP
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IP
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	4	OA
0001a		Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
208	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
0001a	Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-C	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
212	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	4	AV
80777027310		Procedure	ND		AV
59267100001		Procedure	ND		AV
0011a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4	4	AV
80777027399		Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Mode	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original For	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	4	OA
59267100002		Procedure	ND		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	4	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	IP
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	IS
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscu				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Ad				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	4	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By I				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
207	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0011a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
	Vector, Preservative Free, 5x1010 Viral Particles/0				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	4	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	4	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	4	AV
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	4	OA
91303	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0001a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
	Vector, Preservative Free, 5x1010 Viral Particles/0				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0001a	Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	4	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	4	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By	Procedure	C4	4	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91307	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	4	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	4	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4	4	AV
59267100001		Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	4	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	4	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	4	OA AV
207 0031a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure Procedure	CV C4	4	OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	4	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	4	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	4	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	4	OA
207	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	4	OA
207	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
212	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	4	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
207	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	4	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	4	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	4	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	4	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	4	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	4	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	4	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0011a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	4	OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	4	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	4	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	4	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	4	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	4	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	4	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	4	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	4	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	4	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	4	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	4	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	4	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	4	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	4	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	4	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	4	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0064a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
0064a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
207	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	3	AV
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	3	OA
0064a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND	3	OA
207		Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
207	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	3	OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
207	Dose;	Procedure	CV		OA
0064a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
59267100001	Spike Protein, Preservative Free, 10	Procedure	ND		AV
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dos				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
208	Mcg/0.2 Ml Dosage, Diluent	Procedure	CV		OA
0071a	Reconstituted, Tris-Suc	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	D				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
219	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vacci				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	3	OA
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
0071a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
219	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3	OA
207		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0071a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (6 Mo	Procedure	CV		OA
0071a	Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0071a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (6 Mo	Procedure	CV		OA
0071a	Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (6 Mo	Procedure	CV		OA
0071a	Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	3	OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	3	OA
0071a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
0071a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	3	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0081a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vacci	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0081a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
219	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0081a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0081a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0081a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0081a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0081a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0081a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0081a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0081a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
0081a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo	Procedure	C4		OA
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	3	N/A
orno	Sarscov2covid19vaccinemrnaspik	Prescription	N/A		N/A
Sarscov2covid19vaccinemrn					
aspik					

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91300 208 0001a	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Se	Prescription Procedure Procedure Procedure Procedure	N/A C4 C4 CV C4	3	N/A OA AV OA AV
Sarscov2covid19vaccinemrnaspik 91300	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Prescription Procedure	N/A C4	3	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91300	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Prescription Procedure	N/A C4	3	N/A OA
Sarscov2covid19vaccinemrnaspik 91300 208	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A C4 CV	3	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91300 208	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A C4 CV	3	N/A OA OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	3	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	3	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218		Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	3	N/A OA
Sarscov2covid19vaccinemrnaspik 208 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	3	N/A OA OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	3	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 212 208	Sarscov2covid19vaccinemrnaspik Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	3	N/A OA OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	3	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	3	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik Sarscov2covid19vaccinemrnaspik 80777027399208	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A ND CV	3	N/A AV OA
Sarscov2covid19vaccinemrnaspik 212	Sarscov2covid19vaccinemrnaspik Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	3	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3	N/A
Sarscov2covid19vaccinemrnaspik Covid19mrnalnpspf100mcg05mldos	Sarscov2covid19vaccinemrnaspik Covid19mrnalnpspf100mcg05mldos	Prescription Prescription	N/A N/A	3	N/A N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 91303 212 0031a	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure Procedure	N/A C4 CV C4	3	N/A AV OA AV
Sarscov2covid19vaccinevectorno 91303 80777027399	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Prescription Procedure Procedure	N/A C4 ND	3	N/A OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	3	N/A
orno	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immuni				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
212	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
219	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/3				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By I				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	3	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	3	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		OA
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4	3	OA
59267100002		Procedure	ND		OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	3	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		OA
0004a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	ED
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	ED
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use	Procedure	C4		OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Corona	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	3	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	AV
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	3	AV
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	3	AV
80777027399		Procedure	ND		AV
80777027310		Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-L	Procedure	C4		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	3	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	3	OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	3	OA
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	3	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	3	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	3	ED
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	3	AV
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	3	AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	3	OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
91303	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	ND		AV
212	Protein, Adenovirus Type 26 (Ad26)	Procedure	CV		OA
0031a	Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	3	AV
0031a		Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	3	OA
212		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	3	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
0001a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	3	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	3	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
219	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0011a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs	Procedure	C4		AV
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
219	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	3	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
219	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
219	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	3	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (6 Mo	Procedure	C4		OA
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	3	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	3	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	3	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	3	OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	3	AV
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos 208 207	Covid19mrnalnpspf100mcg05mldos Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	3	N/A OA OA
Covid19mrnalnpspf100mcg05mldos 207	Covid19mrnalnpspf100mcg05mldos Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	3	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	3	AV
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	3	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	3	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	3	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	3	OA
207		Procedure	CV		OA
0011a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
207	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	3	OA OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0004a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	3	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	3	OA
0031a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	3	OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	3	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
208	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	3	OA
208		Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
208	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	3	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV		OA
219	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	3	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV
0004a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	OA
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	3	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	3	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	3	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV		OA
219	Dose, Tris-Sucrose;	Procedure	CV		OA
218	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0004a	fda Eua (6 Mo	Procedure	C4		OA
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	3	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	3	OA
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	3	N/A
3mldose	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
219					
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	3	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	3	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	3	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	3	IS
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	3	N/A
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	ND	3	AV
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
0064a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0071a	Immunization Administration By	Procedure	C4	2	AV
0064a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0064a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0064a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose;	Procedure	CV		OA
0064a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	2	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0081a		Procedure	C4		AV
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0081a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By	Procedure	C4	2	AV
0071a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vacci				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0071a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0071a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	2	OA
0071a		Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original For				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original For				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0071a	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
59267100001		Procedure	ND		AV
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose;	Procedure	CV		OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	2	OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	2	OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (6 Mo	Procedure	C4		AV
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (6 Mo	Procedure	C4		AV
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
219	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
218	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0071a	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (6 Mo	Procedure	C4		AV
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	2	OA
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		OA
0071a	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
0071a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		OA
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0081a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0081a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0081a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0081a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0081a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
0081a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0081a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0081a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	2	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 59267100002 208 0001a	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure Procedure	N/A ND CV C4	2	N/A AV OA AV
Sarscov2covid19vaccinemrnaspik 0001a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	2	N/A AV
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208 0001a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A CV C4	2	N/A OA OA
Sarscov2covid19vaccinemrnaspik 0001a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	2	N/A OA
Sarscov2covid19vaccinemrnaspik 59267100002 0001a	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A ND C4	2	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA
Sarscov2covid19vaccinemrnaspik 208 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	2	N/A OA OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 212 207	Sarscov2covid19vaccinemrnaspik Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	2	N/A OA OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207 0011a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure	N/A CV C4	2	N/A OA AV
Sarscov2covid19vaccinemrnaspik 80777027399 207 0011a	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure Procedure	N/A ND CV C4	2	N/A AV OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207 0011a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure	N/A CV C4	2	N/A OA OA
Sarscov2covid19vaccinemrnaspik 212 207	Sarscov2covid19vaccinemrnaspik Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	2	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	2	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	2	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 218 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	2	N/A OA OA
Sarscov2covid19vaccinemrnaspik 212 208	Sarscov2covid19vaccinemrnaspik Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	2	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 219 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	2	N/A OA OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	2	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
80777027399 0011a		Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	2	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A		N/A
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		OA
91303		Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect orno 91301	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Prescription Procedure	N/A C4	2	N/A OA
Sarscov2covid19vaccinevect orno 91303 91301 212 207	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Mod	Prescription Procedure Procedure Procedure Procedure	N/A C4 C4 CV CV	2	N/A OA OA OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect orno 212 207	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	2	N/A OA OA
Sarscov2covid19vaccinevect orno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	2	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	2	N/A
orno	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
212	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	IP
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IP
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		IP
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	IP
0001a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		IP
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	IP
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		IP
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	IP
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		IP
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	IP
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	IS
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	IS
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	IS
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		IS
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IS
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		IS
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		IS
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IS
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		IS
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	IS
59267100001	Spike Protein, Lnp, Preservative Free,	Procedure	ND		IS
0001a	Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose;	Procedure	C4		IS
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	IS
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		IS
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	IS
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		IS
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	ED
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immuni	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	ND		AV
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfiz				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By I				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immuni				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91303	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	C4		AV
59267100001	Protein, Adenovirus Type 26 (Ad26)	Procedure	ND		AV
212	Vector, Preservative Free, 5x1010 Viral	Procedure	CV		OA
0031a	Particles/0	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Dna, Spike				
	Protein, Adenovirus Type 26 (Ad26)				
	Vector, Preservative Free, 5x1010 Viral				
	Particles/0				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dos				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	ND		AV
0001a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
	Vector, Preservative Free, 5x1010 Viral Particles/0				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	2	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original For				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Do				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vacci	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
219	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/3				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
212	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
212	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunizati				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administrati				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
219	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Seve				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0004a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
212	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
219	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Va				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
219	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dos	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein,				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4	2	AV
59267100001		Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immuni				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster D				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
207	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	2	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	2	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	2	OA
208		Procedure	CV		OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Do				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
208	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	OA
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	2	OA
219		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	IP
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		IP
0011a		Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		ED
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		ED
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use	Procedure	C4		ED
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	ED
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		ED
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301		Procedure	C4		AV
80777027310		Procedure	ND		OA
80777027310		Procedure	ND		AV
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use

Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose

Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose

Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91303	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91301	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	C4		AV
80777027310	Protein, Adenovirus Type 26 (Ad26)	Procedure	ND		AV
0031a	Vector, Preservative Free, 5x1010 Viral	Procedure	C4		AV
0011a	Particles/0	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By I				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
212	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
	Vector, Preservative Free, 5x1010 Viral Particles/0				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	2	AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	2	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	2	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	2	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0004a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserva				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	2	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	2	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	2	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	2	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	2	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	2	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	2	OA
207		Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-L				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	2	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	2	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	2	IP
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IP
91303	Severe Acute Respiratory Syndrome	Procedure	C4	2	IS
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	2	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		ED
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	ED
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		ED
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
91300	Severe Acute Respiratory Syndrome	Procedure	C4	2	ED
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		ED
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
91303	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91303	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	2	ED
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
91303	Severe Acute Respiratory Syndrome	Procedure	C4	2	ED
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	2	OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
91303	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
212	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
0011a	Vector, Preservative Free, 5x1010 Viral	Procedure	C4		AV
	Particles/0				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Dna, Spike				
	Protein, Adenovirus Type 26 (Ad26)				
	Vector, Preservative Free, 5x1010 Viral				
	Particles/0				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Cor				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	2	OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	2	OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome C	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	2	AV
208		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	2	AV
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	ND		AV
212	Protein, Adenovirus Type 26 (Ad26)	Procedure	CV		OA
0031a	Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [cov				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
212	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
	Vector, Preservative Free, 5x1010 Viral Particles/0				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
91303	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Dna, Spike				
	Protein, Adenovirus Type 26 (Ad26)				
	Vector, Preservative Free, 5x1010 Viral Particles/0				
	Immunization Administration By Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	2	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	2	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	ND		AV
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	CV		OA
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	2	OA
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	2	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	2	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	2	AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0001a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0001a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	2	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
207	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	2	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs),	Procedure	C4		AV
0001a	Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
59267100001	Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	CV		OA
0011a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	2	OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	2	OA
208		Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	2	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	2	OA
208		Procedure	CV		OA
0001a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
219	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
219	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
218	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	C4		AV
	Dose, Tris-Sucrose;				
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos 0001a	Covid19mrnalnpspf100mcg05mldos Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	2	N/A AV
Covid19mrnalnpspf10mcg02mldose 0001a	Covid19mrnalnpspf10mcg02mldose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	2	N/A AV
207 0001a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	CV C4	2	OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	2	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	2	OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
219	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	2	OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	2	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	2	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	2	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
207	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	2	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	2	OA
207		Procedure	CV		OA
0011a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	2	OA AV
207 0004a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	CV C4	2	OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	2	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	2	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
207	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	2	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
0011a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	2	OA
0004a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	IP
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		IP
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	2	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	2	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0031a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
218		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0004a	Dose;	Procedure	C4		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
	Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	AV
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208 0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	2	OA AV
208 0004a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure Procedure	CV C4	2	OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV		OA
219	Dose, Tris-Sucrose;	Procedure	CV		OA
218	fda Eua (6 Mo	Procedure	CV		OA
208	Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	2	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	OA
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	2	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	2	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0011a	0.5 Ml;	Procedure	C4		OA
0011a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	2	N/A
2mldose	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0011a	0.5 Ml;	Procedure	C4		OA
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	2	AV
212	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml;	Procedure	C4		AV
0011a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	2	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0031a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0004a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	2	OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	2	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	2	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	2	IS
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	IP
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	2	AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	2	N/A
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	2	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	2	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	ED
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		ED
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
0064a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0064a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0064a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0064a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0064a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0064a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Sarscov2covid19vaccinemrnaspik	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Prescription	N/A	1	N/A
0064a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027399	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a					
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0064a		Procedure	C4		AV
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0064a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscu				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0064a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscu				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0004a	Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
207		Procedure	CV		OA
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND		AV
0064a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0064a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207 0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	1	OA
		Procedure	C4		AV
207 0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	1	OA
		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0064a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0064a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0064a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND		AV
80777027310	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0064a	fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0064a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0064a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0064a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	AV
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0064a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fre				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0064a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preserv				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND	1	OA
207		Procedure	CV		OA
0064a		Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND	1	OA
207		Procedure	CV		OA
0064a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	ND	1	OA
207		Procedure	CV		OA
0064a		Procedure	C4		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	CV		OA
0064a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		OA
207	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	CV		OA
0064a		Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0064a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0064a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	IP
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	IP
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		ED
	Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0071a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0081a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
219	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0081a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0071a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0081a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vacci	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vacci	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208		Procedure	CV		OA
0081a		Procedure	C4		AV
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0081a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0081a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0081a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vacci	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By	Procedure	C4	1	AV
0071a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0081a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By	Procedure	C4	1	AV
0071a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By	Procedure	C4	1	AV
0071a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0071a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
59267100001	Spike Protein, Preservative Free, 10	Procedure	ND		AV
208	Mcg/0.2 Ml Dosage, Diluent	Procedure	CV		OA
0071a	Reconstituted, Tris-Suc	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dos				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo	Procedure	ND		AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
59267100001	Spike Protein, Preservative Free, 10	Procedure	ND		AV
218	Mcg/0.2 Ml Dosage, Diluent	Procedure	CV		OA
0071a	Reconstituted, Tris-Suc	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dos				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original For				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
219	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vacci				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
0071a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vacci				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0071a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original For				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
208	Mcg/0.2 Ml Dosage, Diluent	Procedure	CV		OA
0071a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
208	Mcg/0.2 Ml Dosage, Diluent	Procedure	CV		OA
0071a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original For				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	OA
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome	Procedure	C4		OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vacci	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
0071a		Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (6 Mo	Procedure	C4		AV
0001a	Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0071a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91307	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
218	Spike Protein, Preservative Free, 10	Procedure	C4		AV
0071a	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0071a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vacci	Procedure	C4	1	AV
219		Procedure	CV		OA
208		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91307	Severe Acute Respiratory Syndrome	Procedure	C4		AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0071a	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
219	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a		Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a		Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91307	Severe Acute Respiratory Syndrome	Procedure	C4		OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0071a	Immunization Administration By	Procedure	C4	1	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0071a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (6 Mo	Procedure	CV		OA
0071a	Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (6 Mo	Procedure	C4		AV
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (6 Mo	Procedure	CV		OA
0071a	Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0071a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0071a		Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (6 Mo	Procedure	C4		AV
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		AV
0071a	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0071a		Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
218		Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (6 Mo	Procedure	C4		AV
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0071a		Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0071a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0071a	Immunization Administration By	Procedure	C4	1	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
218		Procedure	CV		OA
0071a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0071a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0071a		Procedure	C4		OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0071a	Spike Protein, Preservative Free, 30	Procedure	C4		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0071a	Mcg/0.3ml Dose	Procedure	C4		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0071a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0071a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0071a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (6 Mo	Procedure	C4		OA
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0071a	fda Eua (6 Mo	Procedure	C4		OA
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0071a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	C4		OA
0071a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IP
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By	Procedure	C4	1	AV
0081a	Intramuscular Injection Of Severe Acute	Procedure	C4		OA
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
0081a	fda Eua (6 Mo	Procedure	C4		OA
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
219	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0081a	Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0081a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0081a	Immunization Administration By	Procedure	C4	1	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0081a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0081a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vacci				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
219	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0081a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0081a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0081a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
219	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0081a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0081a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0081a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0081a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0081a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0081a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0081a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0081a	Immunization Administration By	Procedure	C4	1	AV
	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	1	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0081a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0081a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0081a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0081a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0081a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0081a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0081a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0081a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	1	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0081a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0081a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0081a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
219	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
208	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0081a	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0081a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo	Procedure	C4		AV
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0081a	Immunization Administration By	Procedure	C4	1	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0081a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo	Procedure	C4		AV
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0081a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0081a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	1	OA
0081a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
212	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo	Procedure	C4		AV
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo	Procedure	C4		AV
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
219	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0081a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0081a	Immunization Administration By	Procedure	C4	1	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
208		Procedure	CV		OA
0081a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0081a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0081a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0081a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A		N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
207	Reconstituted, For Intr	Procedure	C4		AV
0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-L				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91300 59267100001 208 0001a	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-L	Prescription Procedure Procedure Procedure Procedure	N/A C4 ND CV C4	1	N/A AV AV OA AV
Sarscov2covid19vaccinemrnaspik 91300	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Prescription Procedure	N/A C4	1	N/A AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91300 208	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A C4 CV	1	N/A AV OA
Sarscov2covid19vaccinemrnaspik 91300 59267100001 208	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure Procedure	N/A C4 ND CV	1	N/A AV AV OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91300	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Prescription Procedure	N/A C4	1	N/A AV
Sarscov2covid19vaccinemrnaspik 91300 0004a	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A C4 C4	1	N/A AV AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acu				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
212	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer	Procedure	CV		OA
208	Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91300 208	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A C4 CV	1	N/A OA OA
Sarscov2covid19vaccinemrnaspik 91300 207	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A C4 CV	1	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208		Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91301	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Prescription Procedure	N/A C4	1	N/A AV
Sarscov2covid19vaccinemrnaspik 91301 91301 207 0011a	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respira	Prescription Procedure Procedure Procedure Procedure	N/A C4 C4 CV C4	1	N/A OA AV OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp,	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	C4		AV
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine,				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	C4		AV
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine,				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91301 80777027310207	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure Procedure	N/A C4 ND CV	1	N/A AV AV OA
Sarscov2covid19vaccinemrnaspik 91301 807770273990011a	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure Procedure	N/A C4 ND C4	1	N/A AV AV AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91301 80777027399	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Prescription Procedure Procedure	N/A C4 ND	1	N/A OA OA
Sarscov2covid19vaccinemrnaspik 91301 207	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A C4 CV	1	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91301 207	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A C4 CV	1	N/A OA OA
Sarscov2covid19vaccinemrnaspik 91301 207	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A C4 CV	1	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91301 208	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A C4 CV	1	N/A OA OA
Sarscov2covid19vaccinemrnaspik 91301	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinemrnaspik 91301	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Prescription Procedure	N/A C4	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91301	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinemrnaspik 91301 80777027399	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Prescription Procedure Procedure	N/A C4 ND	1	N/A OA AV
Sarscov2covid19vaccinemrnaspik 91301 80777027399	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Prescription Procedure Procedure	N/A C4 ND	1	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 91303	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinemrnaspik 91303 208	Sarscov2covid19vaccinemrnaspik Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A C4 CV	1	N/A OA OA
Sarscov2covid19vaccinemrnaspik 0001a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207 0001a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV
Sarscov2covid19vaccinemrnaspik 207 0001a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207		Procedure	CV		OA
0001a		Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 59267100001 208 0001a	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure Procedure	N/A ND CV C4	1	N/A AV OA AV
Sarscov2covid19vaccinemrnaspik 0001a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs	Procedure	C4		OA
0001a	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
aspik	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs	Procedure	C4		OA
0001a	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 219 208 0001a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure Procedure	N/A CV CV C4	1	N/A OA OA OA
Sarscov2covid19vaccinemrnaspik 212 0001a	Sarscov2covid19vaccinemrnaspik Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A CV C4	1	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	1	N/A OA OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrn aspik 80777027399 207 0011a	Sarscov2covid19vaccinemrnaspik Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure Procedure	N/A ND CV C4	1	N/A AV OA AV
Sarscov2covid19vaccinemrn aspik 208 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	1	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207 0011a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure	N/A CV C4	1	N/A OA OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A		N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	1	N/A OA OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 80777027310 207 0011a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure Procedure	N/A ND CV C4	1	N/A AV OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 207 0011a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure	N/A CV C4	1	N/A OA OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 219 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	1	N/A OA OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 208 0011a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure	N/A CV C4	1	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 218 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	1	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 219 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	1	N/A OA OA
Sarscov2covid19vaccinemrnaspik 218 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	1	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik 208	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 208 0004a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV
Sarscov2covid19vaccinemrnaspik 80777027310 208 0011a	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure Procedure Procedure	N/A ND CV C4	1	N/A AV OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 212 0031a	Sarscov2covid19vaccinemrnaspik Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik 0011a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik 0004a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A		N/A
Sarscov2covid19vaccinemrnaspik 218	Sarscov2covid19vaccinemrnaspik Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A		N/A
Sarscov2covid19vaccinemrnaspik 218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		OA
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinemrnaspik 0031a	Sarscov2covid19vaccinemrnaspik Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	1	N/A AV
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	1	N/A
Sarscov2covid19vaccinevectorno 91300 0001a	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A C4 C4	1	N/A AV AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect orno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
212	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer	Procedure	CV		OA
208	Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure Procedure	N/A C4 C4	1	N/A OA OA
Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A C4 CV	1	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91303	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	C4		AV
0031a	Protein, Adenovirus Type 26 (Ad26)				
	Vector, Preservative Free, 5x1010 Viral				
	Particles/0				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91303	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
212	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	C4		AV
0031a	Protein, Adenovirus Type 26 (Ad26)				
	Vector, Preservative Free, 5x1010 Viral				
	Particles/0				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Severe Acute Respiratory Syndrome	Procedure	C4		AV
91303	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
212	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	C4		AV
0031a	Protein, Adenovirus Type 26 (Ad26)				
	Vector, Preservative Free, 5x1010 Viral				
	Particles/0				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect orno 91303 212 0031a	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure Procedure	N/A C4 CV C4	1	N/A AV OA AV
Sarscov2covid19vaccinevect orno 91303 0031a	Sarscov2covid19vaccinevectorno Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A C4 C4	1	N/A OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 0001a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A OA
Sarscov2covid19vaccinevectorno 212 207	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure Procedure	N/A CV CV	1	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevect	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
orno	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212 207 0031a	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure Procedure	N/A CV CV C4	1	N/A OA OA AV
Sarscov2covid19vaccinevectorno 208	Sarscov2covid19vaccinevectorno Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212 208	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	1	N/A OA OA
Sarscov2covid19vaccinevectorno 212 208	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Prescription Procedure Procedure	N/A CV CV	1	N/A OA OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212 208 0031a	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure Procedure	N/A CV CV C4	1	N/A OA OA AV
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA AV
Sarscov2covid19vaccinevectorno Covid19mrnalnpspf100mcg05mldos 212	Sarscov2covid19vaccinevectorno Covid19mrnalnpspf100mcg05mldos Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Prescription Procedure	N/A N/A CV	1	N/A N/A OA
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 212	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinevectorno 212 0031a	Sarscov2covid19vaccinevectorno Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure Procedure	N/A CV C4	1	N/A OA OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A
Sarscov2covid19vaccinevectorno 218	Sarscov2covid19vaccinevectorno Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	1	N/A OA
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Sarscov2covid19vaccinevectorno 0004a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Prescription Procedure	N/A C4	1	N/A AV
Sarscov2covid19vaccinevectorno 0031a	Sarscov2covid19vaccinevectorno Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Prescription Procedure	N/A C4	1	N/A AV
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	1	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	IP
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	IP
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IP
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		IP
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	IP
59267100001		Procedure	ND		IP
208		Procedure	CV		OA
0001a		Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	IP
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IP
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		IP
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	IP
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		IP
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		IP
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4	1	IP
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	IP
0001a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		IP
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	IP
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		IP
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	IP
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	IS
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	IS
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IS
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	IS
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IS
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	IS
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IS
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		IS
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
0004a	Immunization Administration By	Procedure	C4	1	IS
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	IS
59267100002	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		IS
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		IS
0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	IS
59267100001	Spike Protein, Lnp, Preservative Free,	Procedure	ND		IS
0001a	Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		ED
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	ED
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		ED
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	ED
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		ED
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
91300	Spike Protein, Preservative Free, 100	Procedure	C4		AV
208	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
207	Use	Procedure	CV		OA
0011a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Ln				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Pri	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immuni				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Pri				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dos	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dos	Procedure	ND		AV
208		Procedure	CV		OA
0031a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	ND		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
59267100001	Spike Protein, Preservative Free, 10	Procedure	ND		AV
218	Mcg/0.2 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dos				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dos	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Y				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Do				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30	Procedure	ND		AV
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfiz				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent	Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfiz	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Use				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Bo	Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
59267100001	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	ND		AV
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spi				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose.				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Seri				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Ser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
208	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
59267100001	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	ND		AV
208	Use	Procedure	CV		OA
0011a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
59267100002	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	ND		AV
59267100001	Use	Procedure	ND		AV
208	Severe Acute Respiratory Syndrome	Procedure	CV		OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
208	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
0001a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Do				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
208	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100002	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respirato				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), M				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By I				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
212	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
0001a	Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Ade	Procedure	ND		AV
0031a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Rec	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Do	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-C	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vacci	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
219	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/3				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-C	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
212	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
219	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/3				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
219	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/3				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
219	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Seve				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
212	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
219	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/3				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used Immunization Administration By				
	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vacci	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vacci	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
219	Spike Protein, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/3				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0004a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Prote	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndro	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome C	Procedure	C4	1	AV
208		Procedure	CV		OA
0031a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By				
	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
219	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Di				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
219	Spike Protein, Preservative Free, 30	Procedure	CV		OA
218	Mcg/0.3 Ml Dosage, Diluent	Procedure	CV		OA
0001a	Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booste				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By				
	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
219	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
219	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Va				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
219	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
219	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Synd	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome	Procedure	C4		AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (1	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
219	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0004a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
208		Procedure	CV		OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0031a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Ade				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0031a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Ade				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0031a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
59267100001		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0004a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4	1	AV
59267100002		Procedure	ND		AV
59267100001		Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
59267100001		Procedure	ND		AV
0004a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
3mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
91300	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		OA
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscu				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5 Ml Dosage, For Intramuscular Use Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Mode	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
59267100002	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0001a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dos				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 M				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Tris-Sucrose Formulation	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
212	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
208	Protein, Adenovirus Type 26 (Ad26)	Procedure	CV		OA
0031a	Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Do				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0031a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
219	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Seve				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0004a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome C	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Prote				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
59267100001		Procedure	ND		AV
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Rec				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		OA
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
212	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3 Ml Dosage, Diluent	Procedure	C4		OA
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vacci	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30	Procedure	C4		OA
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
0001a	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		IS
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administra	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0004a	Spike Protein, Preservative Free, 30	Procedure	C4		OA
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
212		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
208	Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
59267100001		Procedure	ND		OA
208		Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0004a	Spike Protein, Preservative Free, 30	Procedure	C4		OA
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome C	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IP
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		IP
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IP
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		IP
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		IP
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IS
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		IS
0011a		Procedure	C4		IS
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	IS
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
91301	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		ED
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		ED
80777027310	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	ND		AV
207	Use	Procedure	CV		OA
0011a	Severe Acute Respiratory Syndrome	Procedure	C4		ED
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscu	Procedure	ND		ED
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		ED
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		ED
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		ED
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		ED
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		ED
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscu				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		ED
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		ED
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		ED
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		ED
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		ED
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		ED
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	ED
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
80777027310		Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4	1	AV
80777027399		Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
80777027399	Spike Protein, Preservative Free, 100	Procedure	ND		AV
80777027310	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	ND		AV
80777027310	Use	Procedure	ND		OA
207	Severe Acute Respiratory Syndrome	Procedure	CV		OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult	Procedure	CV		OA
0031a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
80777027399	Spike Protein, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		OA
0011a	Severe Acute Respiratory Syndrome	Procedure	C4		AV
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (1				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sar				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscu				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscu				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sar	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
80777027399	Spike Protein, Preservative Free, 100	Procedure	ND		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
0011a	Use	Procedure	C4		OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
80777027310	Spike Protein, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		OA
	Use				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
91303		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.	Procedure	ND		AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
207	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
0011a	Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
207	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
0011a	Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
212	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
207	Protein, Adenovirus Type 26 (Ad26)	Procedure	CV		OA
0031a	Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
207	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
	Vector, Preservative Free, 5x1010 Viral Particles/0				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
212	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
	Vector, Preservative Free, 5x1010 Viral Particles/0				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus	Procedure	ND		AV
0031a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
80777027310	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	ND		AV
212	Protein, Adenovirus Type 26 (Ad26)	Procedure	CV		OA
0031a	Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Seve				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
212	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
	Vector, Preservative Free, 5x1010 Viral Particles/0				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
80777027310		Procedure	ND		AV
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
59267100001	Spike Protein, Preservative Free, 100	Procedure	ND		AV
208	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Prese	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Mono				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		OA
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By I				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	ND		AV
207	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
212	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND		AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	CV		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Ser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		ED
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Corona	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	C4		AV
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine,				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Corona	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4	1	AV
212		Procedure	CV		OA
208		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND		AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preser	Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
80777027310		Procedure	ND		AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV		OA
0011a	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	C4	1	AV
59267100001		Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 100				
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND		AV
0004a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		ED
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
59267100002		Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preserv	Procedure	ND		AV
0031a		Procedure	C4		AV
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome	Procedure	C4		AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	AV
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
80777027310	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	ND		OA
0011a	Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
208		Procedure	CV		OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By I				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		OA
0011a	Use	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
80777027399		Procedure	ND		OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027399	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respirat				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
91303		Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record	Procedure	CV		OA
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91301	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
212	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
	Vector, Preservative Free, 5x1010 Viral Particles/0				
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
0001a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		AV
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By I				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
80777027399		Procedure	ND		AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	OA
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/3	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular	Procedure	C4		OA
0011a	Use	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-L				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
80777027310		Procedure	ND		OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavir	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Us	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4	1	OA
212		Procedure	CV		OA
207		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua	Procedure	CV		OA
0011a	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		OA
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IP
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		IP
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IS
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		IS
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IS
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		IS
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 100				
	Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preser				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free,				
	Reconstituted, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preserva				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
207	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
80777027310		Procedure	ND		OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	1	OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome	Procedure	C4		OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
208		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
208	Spike Protein, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Co	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0011a	Spike Protein, Preservative Free, 100	Procedure	C4		AV
	Mcg/0.5 Ml Dosage, For Intramuscular				
	Use				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	OA
208		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
80777027310		Procedure	ND		OA
208		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4	1	OA
80777027310		Procedure	ND		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0004a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		IS
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		AV
0011a		Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		OA
80777027310	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		OA
0011a	Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
91301	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	1	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IP
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IP
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	IS
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	IS
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		ED
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4	1	ED
59267100001		Procedure	ND		ED
208		Procedure	CV		OA
0001a		Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
0001a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
0001a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	ED
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		ED
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	ED
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	ED
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		ED
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	ED
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		ED
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	ED
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91303	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		ED
0031a	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	C4		ED
	Protein, Adenovirus Type 26 (Ad26)				
	Vector, Preservative Free, 5x1010 Viral				
	Particles/0				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Dna, Spike				
	Protein, Adenovirus Type 26 (Ad26)				
	Vector, Preservative Free, 5x1010 Viral				
	Particles/0				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
	Disease [covid-19]) Vaccine, Dna, Spike				
	Protein, Adenovirus Type 26 (Ad26)				
	Vector, Preservative Free, 5x1010 Viral				
	Particles/0				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,				
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	ED
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	ED
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	AV
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
207	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
207	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	CV		OA
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0011a	Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	AV
208	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	AV
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	AV
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	AV
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	AV
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	AV
212		Procedure	CV		OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	AV
212		Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	C4		OA
0031a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
	Vector, Preservative Free, 5x1010 Viral Particles/0				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	AV
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
212	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0031a	Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Sp	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	AV
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
80777027310	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	ND		AV
212	Protein, Adenovirus Type 26 (Ad26)	Procedure	CV		OA
0031a	Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [cov				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
80777027399		Procedure	ND		AV
212		Procedure	CV		OA
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	C4		OA
0031a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
	Vector, Preservative Free, 5x1010 Viral Particles/0				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coro				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	OA
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	OA
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
212	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91303	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
212	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
207	Protein, Adenovirus Type 26 (Ad26)	Procedure	CV		OA
0011a	Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0031a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
212		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	OA
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	OA
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027310	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
212	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0011a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
	Vector, Preservative Free, 5x1010 Viral Particles/0				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
212	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0011a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
	Vector, Preservative Free, 5x1010 Viral Particles/0				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose				
	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	OA
212		Procedure	CV		OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	OA
212		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	OA
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	OA
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	CV		OA
0031a		Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose	Procedure	CV		OA
0031a	Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91303	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
212	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	ND		AV
0031a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0001a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
	Vector, Preservative Free, 5x1010 Viral Particles/0				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0 Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4	1	AV
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Dna, Spike	Procedure	CV		OA
0001a	Protein, Adenovirus Type 26 (Ad26)	Procedure	C4		AV
	Vector, Preservative Free, 5x1010 Viral Particles/0				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0001a		Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	1	AV
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND	1	AV
208		Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		OA
0001a	fda Eua (5 Yrs	Procedure	C4		AV
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
0001a	Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Cor				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vacci	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (6 Mo	Procedure	C4		OA
0001a	Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vacci				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (6 Mo	Procedure	CV		OA
0001a	Through 4 Yrs), Pfizer Tris-Sucrose	Procedure	C4		OA
0001a	Pediatric Primary Series	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;				
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	C4		AV
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4	1	OA
218		Procedure	CV		OA
208		Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
208	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disea	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	CV		OA
0001a	Spike Protein, Preservative Free, 10	Procedure	C4		AV
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0031a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0001a		Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
212	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (6 Mo	Procedure	CV		OA
0001a	Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
219	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0011a	Mcg/0.3ml Dose	Procedure	C4		AV
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0031a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
212	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
218		Procedure	CV		OA
208		Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
219	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
219	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
219	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
218	Mcg/0.3ml Dose	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV		OA
0001a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
219	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
208	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208		Procedure	CV		OA
0031a		Procedure	C4		AV
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0031a	Dose;	Procedure	C4		AV
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	1	AV
212		Procedure	CV		OA
0001a		Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	1	AV
0001a		Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	1	AV
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
219	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By	Procedure	C4	1	IS
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0001a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
	Reconstituted, 30 Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0011a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0001a	Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0011a	Spike Protein, Lnp, Preservative Free,	Procedure	C4		AV
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
59267100002	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		AV
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0001a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0011a	Immunization Administration By	Procedure	C4	1	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	1	OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		OA
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		OA
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0001a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
59267100001	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	C4		OA
0001a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		OA
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Synd				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0001a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
207	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0001a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0001a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0001a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		OA
212	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0001a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	OA
208		Procedure	CV		OA
0001a		Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	OA
212		Procedure	CV		OA
208		Procedure	CV		OA
0001a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0001a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0001a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	C4		OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0001a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0001a	Dose, Tris-Sucrose;	Procedure	C4		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0001a	fda Eua (6 Mo	Procedure	C4		OA
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
0004a	Immunization Administration By	Procedure	C4	1	OA
0001a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
0001a	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
218	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0001a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	1	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	1	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	1	AV
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	C4	1	AV
219		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	1	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0011a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	AV
0031a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	1	OA
219		Procedure	CV		OA
218		Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose					
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	1	OA
218		Procedure	CV		OA
208					
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	1	OA
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	1	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0004a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
207	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	1	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	1	OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	1	OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0031a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207		Procedure	CV		OA
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	1	OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	OA
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
207	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
218	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207					
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos 207	Covid19mrnalnpspf100mcg05mldos Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
Covid19mrnalnpspf100mcg 05mldos 207	Covid19mrnalnpspf100mcg05mldos Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	1	OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		ED

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
0011a	fda Eua	Procedure	C4		AV
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0031a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207					

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
207		Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
207	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV		OA
208	Dose;	Procedure	CV		OA
207	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
0011a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
208		Procedure	CV		OA
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208		Procedure	CV		OA
207		Procedure	CV		OA
0004a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
207	Mcg/0.3ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose;	Procedure	CV		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
207	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		OA
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
0011a	fda Eua 02/27/2021, 1-Dose	Procedure	C4		AV
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
207	0.5 Ml;	Procedure	CV		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml				
	Dose Or 50 Mcg/0.25ml Dose;				
	fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary				
	Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;	Procedure	CV		OA
207	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose;	Procedure	C4		AV
0011a	fda Eua	Procedure	C4		OA
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	1	OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
0011a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
207	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
207	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207					
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	OA
207		Procedure	CV		OA
0011a		Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV		OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos 207	Covid19mrnalnpspf100mcg05mldos Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
Covid19mrnalnpspf100mcg05mldos 207	Covid19mrnalnpspf100mcg05mldos Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	1	N/A OA
80777027399 207 0011a	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure Procedure	ND CV C4	1	AV OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	IP
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IS
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
207		Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
80777027310	Spike Protein, Lnp, Preservative Free, 100	Procedure	ND		AV
207	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua				
	And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0031a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND	1	OA
207		Procedure	CV		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND	1	OA
207		Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	1	OA
0064a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4		IS
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
208	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	1	OA
208		Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
0004a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protei				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose;	Procedure	C4		OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	1	OA
208		Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	1	OA
208		Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	1	OA
208		Procedure	CV		OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208		Procedure	CV		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	1	OA
0004a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (6 Mo	Procedure	CV		OA
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml				
	Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs),				
	Pfizer Adult Primary Series And Ic Dose				
	Original Formulation. Eua 8/31/2022				
	Rescinded Monovalent Booster Dose.				
	Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0011a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (6 Mo	Procedure	CV		OA
0004a	Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	1	OA
208		Procedure	CV		OA
0004a	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
0004a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose;	Procedure	CV		OA
0004a	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0004a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	1	OA
0004a		Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	ND	1	AV
208		Procedure	CV		OA
0004a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0004a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
208	Spike Protein, Lnp, Preservative Free, 30	Procedure	CV		OA
0004a	Mcg/0.3ml Dose	Procedure	C4		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0011a	Dose;	Procedure	C4		ED
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protei	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
0011a	Reconstituted, 30 Mcg/0.3ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0011a	Dose;	Procedure	C4		AV
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml	Procedure	CV	1	OA
0031a	Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
208	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	1	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0011a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml;	Procedure	CV	1	OA
0031a	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
212		Procedure	CV		OA
0031a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0031a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0011a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		OA
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
Covid19mrnalnpspf30mcg0	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
3mldose	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV		OA
212	0.5 Ml;				
	fda Eua 02/27/2021, 1-Dose				
	Vaccine. Used To Record Janssen/J&j				
	Vaccines Administered In The Us And In				
	Non-Us Locations				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		AV
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
212	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
212	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0011a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		IP
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	1	OA
0031a	0.5 Ml;	Procedure	C4		IP
	fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
212	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0031a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV		OA
219	Dose, Tris-Sucrose;	Procedure	CV		OA
218	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	1	OA
0011a		Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	1	OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
218	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	1	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
0004a	fda Eua (6 Mo	Procedure	C4		AV
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0011a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus				
	Disease[covid-19]) Vaccine, Mrn-Lnp,				
	Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218					
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218					
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
0031a	Dose, Tris-Sucrose;	Procedure	C4		AV
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Dna, Spike Protein,				
	Adenovirus Type 26				
Covid19mrnalnpspf100mcg	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
05mldos	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	1	OA
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
Covid19mrnalnpspf10mcg0	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	1	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV		OA
219	Dose, Tris-Sucrose;				
	fda Eua (6 Mo				
	Through 4 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	1	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	1	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	1	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	1	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	1	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	1	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	1	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	1	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	1	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By	Procedure	C4	1	IP
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IP
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	IS
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
	Mcg/0.3ml Dose				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
0004a	Immunization Administration By	Procedure	C4	1	AV
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	OA
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0004a	Mcg/0.3ml Dose	Procedure	C4		OA
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				
	Immunization Administration By				
	Intramuscular Injection Of Severe Acute				
	Respiratory Syndrome Coronavirus 2				
	(Sars-Cov-2) (Coronavirus Disease				
	[covid-19]) Vaccine, Mrna-Lnp, Spike				
	Protein, Preservative F				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	IP
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		IP
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	IS
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	IS
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND		IS
0011a		Procedure	C4		IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By	Procedure	C4	1	AV
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	1	AV
0011a	Spike Protein, Lnp, Preservative Free, 100	Procedure	C4		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	1	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	ED
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	1	IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	AV
0031a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	1	OA
0031a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	1	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	1	AV
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A		N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	1	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
0001a	Mcg/0.2 Ml Dosage, Diluent	Procedure	C4		AV
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 30				
	Mcg/0.3 Ml Dosage, Diluent				
	Reconstituted, For Intr				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				
	Immunization Administration By				
	Intramuscul				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
91300	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	CV		OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr				
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;				
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0001a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
0001a	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	CV		OA
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	ND		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
208		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
218		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
218		Procedure	CV		OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
208	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
59267100002	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	ND		AV
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
59267100001		Procedure	ND		AV
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
219	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
59267100001	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208		Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	0	OA
218	Dose, Tris-Sucrose;	Procedure	CV		OA
208	fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free,	Procedure	CV		OA
208	Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	C4		AV
59267100001	Disease [covid-19]) Vaccine, Mrna-Lnp,	Procedure	ND		AV
218	Spike Protein, Preservative Free, 10	Procedure	CV		OA
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Severe Acute Respiratory Syndrome				
	Coronavirus 2 (Sars-Cov-2) (Coronavirus				
	Disease [covid-19]) Vaccine, Mrna-Lnp,				
	Spike Protein, Preservative Free, 10				
	Mcg/0.2 Ml Dosage, Diluent				
	Reconstituted, Tris-Suc				
	Sars-Cov-2 (Covid-19) Vaccine, Mrna,				
	Spike Protein, Lnp, Preservative Free, 30				
	Mcg/0.3ml Dose				
	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml				
	Dose, Tris-Sucrose;				
	fda Eua (5 Yrs				
	Through 11 Yrs), Pfizer Tris-Sucrose				
	Pediatric Primary Series, Ic, And Booster				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
59267100001		Procedure	ND		AV
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
59267100001		Procedure	ND		AV
218		Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	C4	0	AV
218		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND		AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	ED
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
207		Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4	0	OA
80777027310		Procedure	ND		AV
207		Procedure	CV		OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	AV
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	0	OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
91300	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
208	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4		AV
	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	C4		AV
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	C4	0	AV
208		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	0	OA
0001a	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose;	Procedure	CV	0	OA
59267100001	fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose;	Procedure	CV	0	OA
	fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	IS
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
207	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
0011a	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
91301	Severe Acute Respiratory Syndrome	Procedure	C4	0	AV
80777027399	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	AV
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND	0	AV
208		Procedure	CV		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	ND	0	AV
208		Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
91307	Severe Acute Respiratory Syndrome	Procedure	C4	0	OA
218	Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	Severe Acute Respiratory Syndrome	Procedure	C4		OA
91307	Coronavirus 2 (Sars-Cov-2) (Coronavirus	Procedure	CV		OA
218	Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	0	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose 218	Covid19mrnalnpspf10mcg02mldose Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Prescription Procedure	N/A CV	0	N/A OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IP
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	0	OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	0	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV	0	OA
0011a		Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	CV C4	0	OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100	Procedure	CV		OA
0011a	Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	C4		AV
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	C4		AV
	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	ND	0	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	CV		OA
0011a		Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
207	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
207	Dose Or 50 Mcg/0.25ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco				
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399 207	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure Procedure	ND CV	0	AV OA
Covid19mrnalnpspf100mcg05mldos 207	Covid19mrnalnpspf100mcg05mldos Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Prescription Procedure	N/A CV	0	N/A OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
219	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	IP
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
80777027310 0011a	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure Procedure	ND C4	0	AV AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	CV	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
0011a	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0064a	Immunization Administration By	Procedure	C4	0	IS
0004a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		IS
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	IS
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	IS
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	ED
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND	0	AV
207		Procedure	CV		OA
0011a		Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	ND	0	AV
207		Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV	0	OA
208	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
218	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	CV		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
219	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	OA
208	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV		OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	OA
208	Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
208	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV		OA
	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used				
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	IP

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	0	OA
212 0031a	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure Procedure	CV C4	0	OA AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf,	Procedure	CV	0	OA
0031a	0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	IS
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	IS
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg0 3mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml	Procedure	CV		OA
218	Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster				
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218					

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218					
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
2mldose	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
218					
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By	Procedure	C4	0	OA
0011a	Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	AV
0011a	Dose Or 50 Mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
3mldose 219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
3mldose 0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	CV	0	OA
0004a	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV		OA
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV		OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0004a	Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4		AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg0 2mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	OA
0004a	Spike Protein, Lnp, Preservative Free, 30	Procedure	C4		AV
0004a	Mcg/0.3ml Dose	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F				
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	AV
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml	Procedure	ND	0	OA
0011a	Dose Or 50 Mcg/0.25ml Dose	Procedure	C4		AV
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr				

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	OA
0011a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4		OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	IS
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	IS
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna,	Procedure	ND	0	AV
0031a	Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4		AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IS
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	IS
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
Covid19mrnalnpspf30mcg0 3mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	0	N/A
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IP
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	IS
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	OA
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND		AV
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	0	AV
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	0	OA

Table 5a r02. Full Code Distribution of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts	Encounter Care Setting[4]
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	0	AV
Covid19mrnalnpspf100mcg 05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	0	N/A
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	0	IS

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2]The code category is defined as PX or RX: PX stands for "Procedure," and RX stands for "Dispensing."

[3]Code type is defined as C4, ND, or CV: C4 refers to Current Procedural Terminology, Fourth Edition (CPT-4); ND stands for National Drug Codes (NDCs); and CV represents the immunization information systems (IIS) Vaccine Administered Code Set (CVX) codes.

[4]Encounter Care Setting is defined as AV, OA, ED, IP, or IS: AV stands for Ambulatory Visit; OA refers to Other Ambulatory Visit; ED means Emergency Department; IP denotes Inpatient Hospital Stay; and IS represents Non-Acute Institutional Stay.
N/A stands for Not Applicable.

Table 5b r01. Total Code Counts of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	4,089,031
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3,822,657
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2,414,289
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2,327,881
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1,307,421
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1,300,301
Covid19mrnalnpsbivalentbooster	Covid19mrnalnpsbivalentbooster	Prescription	N/A	798,022
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	683,637
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	485,090
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	434,616
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	418,332
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	365,931
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	364,720
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	270,274

Table 5b r01. Total Code Counts of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	266,893
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	265,303
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	249,090
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	222,870
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	199,060
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	191,088
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	190,680
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	181,022
0124a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Bivalent Spike Protein, Prese	Procedure	C4	180,085
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	165,102
300	Covid-19, Mrna, Lnp-S, Bivalent Booster, Pf, 30 Mcg/0.3 Ml Dose; eua Authorized Pfizer Adult Bivalent Booster Ages 12+ Yrs, Original Strain + Omicron Ba.4/Ba.5	Procedure	CV	155,284

Table 5b r01. Total Code Counts of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least One COVID-19 Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]The code category is defined as PX or RX: PX stands for "Procedure," and RX stands for "Dispensing."

[3]Code type is defined as C4, ND, or CV: C4 refers to Current Procedural Terminology, Fourth Edition (CPT-4); ND stands for National Drug Codes (NDCs); and CV represents the immunization information systems (IIS) Vaccine Administered Code Set (CVX) codes.
N/A stands for Not Applicable.

Table 5b r02. Total Code Counts of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts
208	Covid-19, Mrna, Lnp-S, Pf, 30 Mcg/0.3 Ml Dose; fda Eua (12+ Yrs) And Bla (16+ Yrs), Pfizer Adult Primary Series And Ic Dose Original Formulation. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used	Procedure	CV	3,624,287
Sarscov2covid19vaccinemrnaspik	Sarscov2covid19vaccinemrnaspik	Prescription	N/A	3,289,766
207	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose; fda Eua And Bla (18+ Yrs), Moderna Adult Primary Series And Ic Dose. Eua 8/31/2022 Rescinded Monovalent Booster Dose. Used To Reco	Procedure	CV	2,253,654
0001a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	2,230,907
0011a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fr	Procedure	C4	1,240,636
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 30 Mcg/0.3 Ml Dosage, Diluent Reconstituted, For Intr	Procedure	C4	1,207,643
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 100 Mcg/0.5 Ml Dosage, For Intramuscular Use	Procedure	C4	635,360
59267100001	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 30 Mcg/0.3ml Dose	Procedure	ND	373,727
Covid19mrnalnpspf100mcg05mldos	Covid19mrnalnpspf100mcg05mldos	Prescription	N/A	371,262
218	Covid-19, Mrna, Lnp-S, Pf, 10 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (5 Yrs Through 11 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series, Ic, And Booster	Procedure	CV	338,811
Covid19mrnalnpspf10mcg02mldose	Covid19mrnalnpspf10mcg02mldose	Prescription	N/A	236,443
212	Covid-19 Vaccine, Vector-Nr, Rs-Ad26, Pf, 0.5 Ml; fda Eua 02/27/2021, 1-Dose Vaccine. Used To Record Janssen/J&j Vaccines Administered In The Us And In Non-Us Locations	Procedure	CV	233,488

Table 5b r02. Total Code Counts of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts
0071a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	228,806
59267100002	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, Reconstituted, 30 Mcg/0.3ml Dose	Procedure	ND	228,427
80777027399	Sars-Cov-2 (Covid-19) Vaccine, Mrna, Spike Protein, Lnp, Preservative Free, 100 Mcg/0.5ml Or 50mcg/0.25ml Dose	Procedure	ND	227,671
80777027310	Covid-19, Mrna, Lnp-S, Pf, 100 Mcg/0.5ml Dose Or 50 Mcg/0.25ml Dose	Procedure	ND	162,919
91307	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative Free, 10 Mcg/0.2 Ml Dosage, Diluent Reconstituted, Tris-Suc	Procedure	C4	145,981
Sarscov2covid19vaccinevectorno	Sarscov2covid19vaccinevectorno	Prescription	N/A	129,777
0031a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26	Procedure	C4	98,442
0064a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease[covid-19]) Vaccine, Mrn-Lnp, Spike Protein, Preservative Fre	Procedure	C4	84,282
Covid19mrnalnpspf30mcg03mldose	Covid19mrnalnpspf30mcg03mldose	Prescription	N/A	81,702
0081a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	78,027
0004a	Immunization Administration By Intramuscular Injection Of Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Mrna-Lnp, Spike Protein, Preservative F	Procedure	C4	67,190
91303	Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) (Coronavirus Disease [covid-19]) Vaccine, Dna, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Preservative Free, 5x1010 Viral Particles/0	Procedure	C4	64,410

Table 5b r02. Total Code Counts of Coronavirus Disease 2019 (COVID-19) Vaccination (At Least Two COVID-19 Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

Code	Code Description	Code Category[2]	Code Type[3]	Overall Counts
219	Covid-19, Mrna, Lnp-S, Pf, 3 Mcg/0.2 Ml Dose, Tris-Sucrose; fda Eua (6 Mo Through 4 Yrs), Pfizer Tris-Sucrose Pediatric Primary Series	Procedure	CV	56,163

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2]The code category is defined as PX or RX: PX stands for "Procedure," and RX stands for "Dispensing."

[3]Code type is defined as C4, ND, or CV: C4 refers to Current Procedural Terminology, Fourth Edition (CPT-4); ND stands for National Drug Codes (NDCs); and CV represents the immunization information systems (IIS) Vaccine Administered Code Set (CVX) codes.

N/A stands for Not Applicable.

Table 6 r01. Summary of Patient-Level Cohort Attrition (At Least One Coronavirus Disease 2019 [COVID-19] Vaccine)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	Vaccine	
	Remaining	**Excluded**
Members Meeting Enrollment and Demographic Requirements		
Enrolled at any point during the query period	93,815,800	N/A
Had required coverage type (medical and/or drug coverage)	59,770,225	34,045,575
Enrolled during specified age range	59,769,730	495
Had requestable medical charts	59,769,730	0
Met demographic requirements (sex, race, and Hispanic origin)	59,734,101	35,629
Members with a Valid Index Event		
Had any cohort-defining claim during the query period	19,806,226	39,927,875
Claim recorded during specified age range	19,806,111	115
Episode defining index claim recorded during the query period	19,806,111	0
Members with Required Pre-Index History		
Had sufficient pre-index continuous enrollment	17,278,500	2,527,611
Met inclusion and exclusion criteria[2]	15,530,103	1,748,397
Evidence of any prior COVID-19 vaccination	N/A	1,748,397
Met event incidence criteria	15,530,103	0
Had sufficient post-index continuous enrollment	15,530,103	0
Had index episode of at least required length	15,530,103	0
Had index episode longer than blackout period	15,530,103	0
Did not have an event during blackout period	15,530,103	0
Final Cohort		
Number of members	15,530,103	N/A
Number of episodes	15,530,103	N/A

[1]The cohort includes patients who received at least one COVID-19 vaccine. The index date is defined as the date of the first COVID-19 vaccination, which is identified as the first instance with no prior COVID-19 vaccination records.

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum o f all patients in each criterion.

N/A: Not Applicable

Table 6 r02. Summary of Patient-Level Cohort Attrition (At Least Two Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	(COVID-19) Vaccines	
	Remaining	**Excluded**
Members Meeting Enrollment and Demographic Requirements		
Enrolled at any point during the query period	93,815,800	N/A
Had required coverage type (medical and/or drug coverage)	59,770,225	34,045,575
Enrolled during specified age range	59,769,730	495
Had requestable medical charts	59,769,730	0
Met demographic requirements (sex, race, and Hispanic origin)	59,734,101	35,629
Members with a Valid Index Event		
Had any cohort-defining claim during the query period	19,806,226	39,927,875
Claim recorded during specified age range	19,806,111	115
Episode defining index claim recorded during the query period	19,806,111	0
Members with Required Pre-Index History		
Had sufficient pre-index continuous enrollment	17,278,500	2,527,611
Met inclusion and exclusion criteria[2]	11,915,048	5,363,452
Evidence of COVID-19 vaccine 1-4 days after the index (duplicated)	N/A	205,378
Evidence of any prior COVID-19 vaccination	N/A	1,921,050
No evidence of second COVID-19 vaccination	N/A	5,358,488
Met event incidence criteria	11,915,048	0
Members with Required Post-Index Follow-Up		
Had sufficient post-index continuous enrollment	11,915,048	0
Had index episode of at least required length	11,915,048	0
Had index episode longer than blackout period	11,915,048	0
Did not have an event during blackout period	11,915,048	0
Final Cohort		
Number of members	11,915,048	N/A
Number of episodes	11,915,048	N/A

[1]The cohort includes patients who received at least two COVID-19 vaccines. The index date is defined as the date of the first COVID-19 vaccination, identified as the first instance with no prior COVID-19 vaccination records. Additionally, individuals were required to have received a second dose at least four days after the index date. Patients with a duplicate vaccine code within 1-4 days after the index were excluded from the analysis.

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal th e sum of all patients in each criterion.

N/A: Not Applicable

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first Pfizer Coronavirus Disease 2019 (COVID-19) vaccine followed by a second Pfizer Coronavirus disease 2019 (COVID-19) vaccine (Pfizer-Pfizer combination)		With a first Moderna COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Moderna-Moderna combination)	
	Remaining	Excluded	Remaining	Excluded
Members Meeting Enrollment and Demographic Requirements				
Enrolled at any point during the query period	93,815,800	N/A	93,815,800	N/A
Had required coverage type (medical and/or drug coverage)	59,770,225	34,045,575	59,770,225	34,045,575
Enrolled during specified age range	59,769,730	495	59,769,730	495
Had requestable medical charts	59,769,730	0	59,769,730	0
Met demographic requirements (sex, race, and Hispanic origin)	59,734,101	35,629	59,734,101	35,629
Members with a Valid Index Event				
Had any cohort-defining claim during the query period	12,695,776	47,038,325	8,076,105	51,657,996
Claim recorded during specified age range	12,695,685	91	8,076,076	29
Episode defining index claim recorded during the query period	12,695,685	0	8,076,076	0
Members with Required Pre-Index History				
Had sufficient pre-index continuous enrollment	11,062,704	1,632,981	7,074,221	1,001,855
Met inclusion andexclusion criteria[2]	9,114,170	1,948,534	5,584,660	1,489,561
Evidence of Claims codes	N/A	N/A	N/A	N/A
Evidence of any prior COVID-19 vaccination for the type of vaccine cohorts	N/A	N/A	N/A	N/A
Evidence of IIS codes	N/A	N/A	N/A	N/A
Evidence of any prior COVID-19 vaccination for vaccine brand cohorts	N/A	1,948,534	N/A	1,489,561
No evidence of IIS codes on index	N/A	N/A	N/A	N/A
Met event incidence criteria	9,114,170	0	5,584,660	0
Members with Required Post-Index Follow-Up				
Had sufficient post-index continuous enrollment	9,114,170	0	5,584,660	0
Had index episode of at least required length	9,114,170	0	5,584,660	0
Had index episode longer than blackout period	9,114,170	0	5,584,660	0
Did not have an event during blackout period	9,114,170	0	5,584,660	0

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first Pfizer Coronavirus Disease 2019 (COVID-19) vaccine followed by a second Pfizer Coronavirus disease 2019 (COVID-19) vaccine (Pfizer-Pfizer combination)		With a first Moderna COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Moderna-Moderna combination)	
	Remaining	Excluded	Remaining	Excluded
Final Cohort				
Number of members	9,114,170	N/A	5,584,660	N/A
Number of episodes	9,114,170	N/A	5,584,660	N/A

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first Janssen COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Janssen-Janssen combination)		With a first Novavax or Unspecified COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Novavax or Unspecified-Novavax or Unspecified combination)	
	Remaining	Excluded	Remaining	Excluded
Members Meeting Enrollment and Demographic Requirements				
Enrolled at any point during the query period	93,815,800	N/A	93,815,800	N/A
Had required coverage type (medical and/or drug coverage)	59,770,225	34,045,575	59,770,225	34,045,575
Enrolled during specified age range	59,769,730	495	59,769,730	495
Had requestable medical charts	59,769,730	0	59,769,730	0
Met demographic requirements (sex, race, and Hispanic origin)	59,734,101	35,629	59,734,101	35,629
Members with a Valid Index Event				
Had any cohort-defining claim during the query period	*****	58,736,448	122,064	59,612,037
Claim recorded during specified age range	*****	*****	122,064	0
Episode defining index claim recorded during the query period	997,648	0	122,064	0
Members with Required Pre-Index History				
Had sufficient pre-index continuous enrollment	849,397	148,251	105,072	16,992
Met inclusion andexclusion criteria[2]	818,691	30,706	67,284	37,788
Evidence of Claims codes	N/A	N/A	N/A	N/A
Evidence of any prior COVID-19 vaccination for the type of vaccine cohorts	N/A	N/A	N/A	N/A
Evidence of IIS codes	N/A	N/A	N/A	N/A
Evidence of any prior COVID-19 vaccination for vaccine brand cohorts	N/A	30,706	N/A	37,788
No evidence of IIS codes on index	N/A	N/A	N/A	N/A
Met event incidence criteria	818,691	0	67,284	0
Members with Required Post-Index Follow-Up				
Had sufficient post-index continuous enrollment	818,691	0	67,284	0
Had index episode of at least required length	818,691	0	67,284	0
Had index episode longer than blackout period	818,691	0	67,284	0
Did not have an event during blackout period	818,691	0	67,284	0

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first Janssen COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Janssen-Janssen combination)		With a first Novavax or Unspecified COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Novavax or Unspecified-Novavax or Unspecified combination)	
	Remaining	Excluded	Remaining	Excluded
Final Cohort				
Number of members	818,691	N/A	67,284	N/A
Number of episodes	818,691	N/A	67,284	N/A

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first Pfizer COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Pfizer-Moderna combination)		With a first Moderna COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Moderna-Pfizer combination)	
	Remaining	**Excluded**	**Remaining**	**Excluded**
Members Meeting Enrollment and Demographic Requirements				
Enrolled at any point during the query period	93,815,800	N/A	93,815,800	N/A
Had required coverage type (medical and/or drug coverage)	59,770,225	34,045,575	59,770,225	34,045,575
Enrolled during specified age range	59,769,730	495	59,769,730	495
Had requestable medical charts	59,769,730	0	59,769,730	0
Met demographic requirements (sex, race, and Hispanic origin)	59,734,101	35,629	59,734,101	35,629
Members with a Valid Index Event				
Had any cohort-defining claim during the query period	12,695,776	47,038,325	8,076,105	51,657,996
Claim recorded during specified age range	12,695,685	91	8,076,076	29
Episode defining index claim recorded during the query period	12,695,685	0	8,076,076	0
Members with Required Pre-Index History				
Had sufficient pre-index continuous enrollment	11,062,704	1,632,981	7,074,221	1,001,855
Met inclusion andexclusion criteria[2]	9,114,170	1,948,534	5,584,660	1,489,561
Evidence of Claims codes	N/A	N/A	N/A	N/A
Evidence of any prior COVID-19 vaccination for the type of vaccine cohorts	N/A	N/A	N/A	N/A
Evidence of IIS codes	N/A	N/A	N/A	N/A
Evidence of any prior COVID-19 vaccination for vaccine brand cohorts	N/A	1,948,534	N/A	1,489,561
No evidence of IIS codes on index	N/A	N/A	N/A	N/A
Met event incidence criteria	9,114,170	0	5,584,660	0
Members with Required Post-Index Follow-Up				
Had sufficient post-index continuous enrollment	9,114,170	0	5,584,660	0
Had index episode of at least required length	9,114,170	0	5,584,660	0
Had index episode longer than blackout period	9,114,170	0	5,584,660	0
Did not have an event during blackout period	9,114,170	0	5,584,660	0
Final Cohort				

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first Pfizer COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Pfizer-Moderna combination)		With a first Moderna COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Moderna-Pfizer combination)	
	Remaining	Excluded	Remaining	Excluded
Number of members	9,114,170	N/A	5,584,660	N/A
Number of episodes	9,114,170	N/A	5,584,660	N/A

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first Pfizer COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Pfizer-Novavax or Unspecified combination)		With a first Pfizer COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Pfizer-Janssen combination)	
	Remaining	Excluded	Remaining	Excluded
Members Meeting Enrollment and Demographic Requirements				
Enrolled at any point during the query period	93,815,800	N/A	93,815,800	N/A
Had required coverage type (medical and/or drug coverage)	59,770,225	34,045,575	59,770,225	34,045,575
Enrolled during specified age range	59,769,730	495	59,769,730	495
Had requestable medical charts	59,769,730	0	59,769,730	0
Met demographic requirements (sex, race, and Hispanic origin)	59,734,101	35,629	59,734,101	35,629
Members with a Valid Index Event				
Had any cohort-defining claim during the query period	12,695,776	47,038,325	12,695,776	47,038,325
Claim recorded during specified age range	12,695,685	91	12,695,685	91
Episode defining index claim recorded during the query period	12,695,685	0	12,695,685	0
Members with Required Pre-Index History				
Had sufficient pre-index continuous enrollment	11,062,704	1,632,981	11,062,704	1,632,981
Met inclusion andexclusion criteria[2]	9,114,170	1,948,534	9,114,170	1,948,534
Evidence of Claims codes	N/A	N/A	N/A	N/A
Evidence of any prior COVID-19 vaccination for the type of vaccine cohorts	N/A	N/A	N/A	N/A
Evidence of IIS codes	N/A	N/A	N/A	N/A
Evidence of any prior COVID-19 vaccination for vaccine brand cohorts	N/A	1,948,534	N/A	1,948,534
No evidence of IIS codes on index	N/A	N/A	N/A	N/A
Met event incidence criteria	9,114,170	0	9,114,170	0
Members with Required Post-Index Follow-Up				
Had sufficient post-index continuous enrollment	9,114,170	0	9,114,170	0
Had index episode of at least required length	9,114,170	0	9,114,170	0
Had index episode longer than blackout period	9,114,170	0	9,114,170	0
Did not have an event during blackout period	9,114,170	0	9,114,170	0
Final Cohort				

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first Pfizer COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Pfizer-Novavax or Unspecified combination)		With a first Pfizer COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Pfizer-Janssen combination)	
	Remaining	Excluded	Remaining	Excluded
Number of members	9,114,170	N/A	9,114,170	N/A
Number of episodes	9,114,170	N/A	9,114,170	N/A

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first Moderna COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Moderna-Janssen combination)		With a first Moderna COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Moderna-Novavax or Unspecified combination)	
	Remaining	Excluded	Remaining	Excluded
Members Meeting Enrollment and Demographic Requirements				
Enrolled at any point during the query period	93,815,800	N/A	93,815,800	N/A
Had required coverage type (medical and/or drug coverage)	59,770,225	34,045,575	59,770,225	34,045,575
Enrolled during specified age range	59,769,730	495	59,769,730	495
Had requestable medical charts	59,769,730	0	59,769,730	0
Met demographic requirements (sex, race, and Hispanic origin)	59,734,101	35,629	59,734,101	35,629
Members with a Valid Index Event				
Had any cohort-defining claim during the query period	8,076,105	51,657,996	8,076,105	51,657,996
Claim recorded during specified age range	8,076,076	29	8,076,076	29
Episode defining index claim recorded during the query period	8,076,076	0	8,076,076	0
Members with Required Pre-Index History				
Had sufficient pre-index continuous enrollment	7,074,221	1,001,855	7,074,221	1,001,855
Met inclusion andexclusion criteria[2]	5,584,660	1,489,561	5,584,660	1,489,561
Evidence of Claims codes	N/A	N/A	N/A	N/A
Evidence of any prior COVID-19 vaccination for the type of vaccine cohorts	N/A	N/A	N/A	N/A
Evidence of IIS codes	N/A	N/A	N/A	N/A
Evidence of any prior COVID-19 vaccination for vaccine brand cohorts	N/A	1,489,561	N/A	1,489,561
No evidence of IIS codes on index	N/A	N/A	N/A	N/A
Met event incidence criteria	5,584,660	0	5,584,660	0
Members with Required Post-Index Follow-Up				
Had sufficient post-index continuous enrollment	5,584,660	0	5,584,660	0
Had index episode of at least required length	5,584,660	0	5,584,660	0
Had index episode longer than blackout period	5,584,660	0	5,584,660	0
Did not have an event during blackout period	5,584,660	0	5,584,660	0
Final Cohort				

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first Moderna COVID-19 vaccine followed by a second Janssen COVID-19 vaccine (Moderna-Janssen combination)		With a first Moderna COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Moderna-Novavax or Unspecified combination)	
	Remaining	Excluded	Remaining	Excluded
Number of members	5,584,660	N/A	5,584,660	N/A
Number of episodes	5,584,660	N/A	5,584,660	N/A

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first Janssen COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Janssen-Moderna combination)		With a first Janssen COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Janssen-Pfizer combination)	
	Remaining	Excluded	Remaining	Excluded
Members Meeting Enrollment and Demographic Requirements				
Enrolled at any point during the query period	93,815,800	N/A	93,815,800	N/A
Had required coverage type (medical and/or drug coverage)	59,770,225	34,045,575	59,770,225	34,045,575
Enrolled during specified age range	59,769,730	495	59,769,730	495
Had requestable medical charts	59,769,730	0	59,769,730	0
Met demographic requirements (sex, race, and Hispanic origin)	59,734,101	35,629	59,734,101	35,629
Members with a Valid Index Event				
Had any cohort-defining claim during the query period	*****	58,736,448	*****	58,736,448
Claim recorded during specified age range	*****	*****	*****	*****
Episode defining index claim recorded during the query period	997,648	0	997,648	0
Members with Required Pre-Index History				
Had sufficient pre-index continuous enrollment	849,397	148,251	849,397	148,251
Met inclusion andexclusion criteria[2]	818,691	30,706	818,691	30,706
Evidence of Claims codes	N/A	N/A	N/A	N/A
Evidence of any prior COVID-19 vaccination for the type of vaccine cohorts	N/A	N/A	N/A	N/A
Evidence of IIS codes	N/A	N/A	N/A	N/A
Evidence of any prior COVID-19 vaccination for vaccine brand cohorts	N/A	30,706	N/A	30,706
No evidence of IIS codes on index	N/A	N/A	N/A	N/A
Met event incidence criteria	818,691	0	818,691	0
Members with Required Post-Index Follow-Up				
Had sufficient post-index continuous enrollment	818,691	0	818,691	0
Had index episode of at least required length	818,691	0	818,691	0
Had index episode longer than blackout period	818,691	0	818,691	0
Did not have an event during blackout period	818,691	0	818,691	0
Final Cohort				

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first Janssen COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Janssen-Moderna combination)		With a first Janssen COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Janssen-Pfizer combination)	
	Remaining	Excluded	Remaining	Excluded
Number of members	818,691	N/A	818,691	N/A
Number of episodes	818,691	N/A	818,691	N/A

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first Janssen COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Janssen-Novavax or Unspecified combination)		With a first Novavax or Unspecified COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Novavax or Unspecified-Moderna combination)	
	Remaining	Excluded	Remaining	Excluded
Members Meeting Enrollment and Demographic Requirements				
Enrolled at any point during the query period	93,815,800	N/A	93,815,800	N/A
Had required coverage type (medical and/or drug coverage)	59,770,225	34,045,575	59,770,225	34,045,575
Enrolled during specified age range	59,769,730	495	59,769,730	495
Had requestable medical charts	59,769,730	0	59,769,730	0
Met demographic requirements (sex, race, and Hispanic origin)	59,734,101	35,629	59,734,101	35,629
Members with a Valid Index Event				
Had any cohort-defining claim during the query period	*****	58,736,448	122,064	59,612,037
Claim recorded during specified age range	*****	*****	122,064	0
Episode defining index claim recorded during the query period	997,648	0	122,064	0
Members with Required Pre-Index History				
Had sufficient pre-index continuous enrollment	849,397	148,251	105,072	16,992
Met inclusion andexclusion criteria[2]	818,691	30,706	67,284	37,788
Evidence of Claims codes	N/A	N/A	N/A	N/A
Evidence of any prior COVID-19 vaccination for the type of vaccine cohorts	N/A	N/A	N/A	N/A
Evidence of IIS codes	N/A	N/A	N/A	N/A
Evidence of any prior COVID-19 vaccination for vaccine brand cohorts	N/A	30,706	N/A	37,788
No evidence of IIS codes on index	N/A	N/A	N/A	N/A
Met event incidence criteria	818,691	0	67,284	0
Members with Required Post-Index Follow-Up				
Had sufficient post-index continuous enrollment	818,691	0	67,284	0
Had index episode of at least required length	818,691	0	67,284	0
Had index episode longer than blackout period	818,691	0	67,284	0
Did not have an event during blackout period	818,691	0	67,284	0
Final Cohort				

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first Janssen COVID-19 vaccine followed by a second Novavax or Unspecified COVID-19 vaccine (Janssen-Novavax or Unspecified combination)		With a first Novavax or Unspecified COVID-19 vaccine followed by a second Moderna COVID-19 vaccine (Novavax or Unspecified-Moderna combination)	
	Remaining	Excluded	Remaining	Excluded
Number of members	818,691	N/A	67,284	N/A
Number of episodes	818,691	N/A	67,284	N/A

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first Novavax or Unspecified COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Novavax or Unspecified-Pfizer combination)		With a first Novavax or Unspecified COVID-19 vaccine followed by a second Janssen or Unspecified COVID-19 vaccine (Novavax or Unspecified-Janssen combination)	
	Remaining	Excluded	Remaining	Excluded
Members Meeting Enrollment and Demographic Requirements				
Enrolled at any point during the query period	93,815,800	N/A	93,815,800	N/A
Had required coverage type (medical and/or drug coverage)	59,770,225	34,045,575	59,770,225	34,045,575
Enrolled during specified age range	59,769,730	495	59,769,730	495
Had requestable medical charts	59,769,730	0	59,769,730	0
Met demographic requirements (sex, race, and Hispanic origin)	59,734,101	35,629	59,734,101	35,629
Members with a Valid Index Event				
Had any cohort-defining claim during the query period	122,064	59,612,037	122,064	59,612,037
Claim recorded during specified age range	122,064	0	122,064	0
Episode defining index claim recorded during the query period	122,064	0	122,064	0
Members with Required Pre-Index History				
Had sufficient pre-index continuous enrollment	105,072	16,992	105,072	16,992
Met inclusion andexclusion criteria[2]	67,284	37,788	67,284	37,788
Evidence of Claims codes	N/A	N/A	N/A	N/A
Evidence of any prior COVID-19 vaccination for the type of vaccine cohorts	N/A	N/A	N/A	N/A
Evidence of IIS codes	N/A	N/A	N/A	N/A
Evidence of any prior COVID-19 vaccination for vaccine brand cohorts	N/A	37,788	N/A	37,788
No evidence of IIS codes on index	N/A	N/A	N/A	N/A
Met event incidence criteria	67,284	0	67,284	0
Members with Required Post-Index Follow-Up				
Had sufficient post-index continuous enrollment	67,284	0	67,284	0
Had index episode of at least required length	67,284	0	67,284	0
Had index episode longer than blackout period	67,284	0	67,284	0
Did not have an event during blackout period	67,284	0	67,284	0
Final Cohort				

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first Novavax or Unspecified COVID-19 vaccine followed by a second Pfizer COVID-19 vaccine (Novavax or Unspecified-Pfizer combination)		With a first Novavax or Unspecified COVID-19 vaccine followed by a second Janssen or Unspecified COVID-19 vaccine (Novavax or Unspecified-Janssen combination)	
	Remaining	Excluded	Remaining	Excluded
Number of members	67,284	N/A	67,284	N/A
Number of episodes	67,284	N/A	67,284	N/A

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD)

	With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only Claims-OnlyClaims combination)		With a first COVID-19 vaccine identified only by immunization information systems (IIS) codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only IIS-Only IIS combination)	
	Remaining	Excluded	Remaining	Excluded
Members Meeting Enrollment and Demographic Requirements				
Enrolled at any point during the query period	93,815,800	N/A	93,815,800	N/A
Had required coverage type (medical and/or drug coverage)	59,770,225	34,045,575	59,770,225	34,045,575
Enrolled during specified age range	59,769,730	495	59,769,730	495
Had requestable medical charts	59,769,730	0	59,769,730	0
Met demographic requirements (sex, race, and Hispanic origin)	59,734,101	35,629	59,734,101	35,629
Members with a Valid Index Event				
Had any cohort-defining claim during the query period	17,535,855	42,198,246	10,170,581	49,563,520
Claim recorded during specified age range	17,535,743	112	10,170,519	62
Episode defining index claim recorded during the query period	17,535,743	0	10,170,519	0
Members with Required Pre-Index History				
Had sufficient pre-index continuous enrollment	15,388,791	2,146,952	8,859,724	1,310,795
Met inclusion andexclusion criteria[2]	7,701,405	7,687,386	1,677,891	7,181,833
Evidence of Claims codes	N/A	N/A	N/A	7,039,892
Evidence of any prior COVID-19 vaccination for the type of vaccine cohorts	N/A	7,064,621	N/A	6,562,709
Evidence of IIS codes	N/A	7,066,125	N/A	N/A
Evidence of any prior COVID-19 vaccination for vaccine brand cohorts	N/A	N/A	N/A	N/A
No evidence of IIS codes on index	N/A	N/A	N/A	N/A
Met event incidence criteria	7,701,405	0	1,677,891	0
Members with Required Post-Index Follow-Up				
Had sufficient post-index continuous enrollment	7,701,405	0	1,677,891	0
Had index episode of at least required length	7,701,405	0	1,677,891	0
Had index episode longer than blackout period	7,701,405	0	1,677,891	0
Did not have an event during blackout period	7,701,405	0	1,677,891	0
Final Cohort				

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD)

	With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only Claims-OnlyClaims combination)		With a first COVID-19 vaccine identified only by immunization information systems (IIS) codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only IIS-Only IIS combination)	
	Remaining	Excluded	Remaining	Excluded
Number of members	7,701,405	N/A	1,677,891	N/A
Number of episodes	7,701,405	N/A	1,677,891	N/A

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only Claims-Only IIS combination)		With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only IIS-Only claims combination)	
	Remaining	Excluded	Remaining	Excluded
Members Meeting Enrollment and Demographic Requirements				
Enrolled at any point during the query period	93,815,800	N/A	93,815,800	N/A
Had required coverage type (medical and/or drug coverage)	59,770,225	34,045,575	59,770,225	34,045,575
Enrolled during specified age range	59,769,730	495	59,769,730	495
Had requestable medical charts	59,769,730	0	59,769,730	0
Met demographic requirements (sex, race, and Hispanic origin)	59,734,101	35,629	59,734,101	35,629
Members with a Valid Index Event				
Had any cohort-defining claim during the query period	17,535,855	42,198,246	10,170,581	49,563,520
Claim recorded during specified age range	17,535,743	112	10,170,519	62
Episode defining index claim recorded during the query period	17,535,743	0	10,170,519	0
Members with Required Pre-Index History				
Had sufficient pre-index continuous enrollment	15,388,791	2,146,952	8,859,724	1,310,795
Met inclusion andexclusion criteria[2]	8,002,553	7,386,238	3,301,529	5,558,195
Evidence of Claims codes	N/A	N/A	N/A	5,239,050
Evidence of any prior COVID-19 vaccination for the type of vaccine cohorts	N/A	6,786,619	N/A	4,982,089
Evidence of IIS codes	N/A	6,410,471	N/A	N/A
Evidence of any prior COVID-19 vaccination for vaccine brand cohorts	N/A	N/A	N/A	N/A
No evidence of IIS codes on index	N/A	N/A	N/A	N/A
Met event incidence criteria	8,002,553	0	3,301,529	0
Members with Required Post-Index Follow-Up				
Had sufficient post-index continuous enrollment	8,002,553	0	3,301,529	0
Had index episode of at least required length	8,002,553	0	3,301,529	0
Had index episode longer than blackout period	8,002,553	0	3,301,529	0
Did not have an event during blackout period	8,002,553	0	3,301,529	0

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Only Claims-Only IIS combination)		With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (Only IIS-Only claims combination)	
	Remaining	Excluded	Remaining	Excluded
Final Cohort				
Number of members	8,002,553	N/A	3,301,529	N/A
Number of episodes	8,002,553	N/A	3,301,529	N/A

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only Claims-Claims and IIS combination)		With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only IIS-IIS and Claims combination)	
	Remaining	**Excluded**	**Remaining**	**Excluded**
Members Meeting Enrollment and Demographic Requirements				
Enrolled at any point during the query period	93,815,800	N/A	93,815,800	N/A
Had required coverage type (medical and/or drug coverage)	59,770,225	34,045,575	59,770,225	34,045,575
Enrolled during specified age range	59,769,730	495	59,769,730	495
Had requestable medical charts	59,769,730	0	59,769,730	0
Met demographic requirements (sex, race, and Hispanic origin)	59,734,101	35,629	59,734,101	35,629
Members with a Valid Index Event				
Had any cohort-defining claim during the query period	17,535,855	42,198,246	10,170,581	49,563,520
Claim recorded during specified age range	17,535,743	112	10,170,519	62
Episode defining index claim recorded during the query period	17,535,743	0	10,170,519	0
Members with Required Pre-Index History				
Had sufficient pre-index continuous enrollment	15,388,791	2,146,952	8,859,724	1,310,795
Met inclusion andexclusion criteria[2]	8,002,553	7,386,238	3,301,529	5,558,195
Evidence of Claims codes	N/A	N/A	N/A	5,239,050
Evidence of any prior COVID-19 vaccination for the type of vaccine cohorts	N/A	6,786,619	N/A	4,982,089
Evidence of IIS codes	N/A	6,410,471	N/A	N/A
Evidence of any prior COVID-19 vaccination for vaccine brand cohorts	N/A	N/A	N/A	N/A
No evidence of IIS codes on index	N/A	N/A	N/A	N/A
Met event incidence criteria	8,002,553	0	3,301,529	0
Members with Required Post-Index Follow-Up				
Had sufficient post-index continuous enrollment	8,002,553	0	3,301,529	0
Had index episode of at least required length	8,002,553	0	3,301,529	0
Had index episode longer than blackout period	8,002,553	0	3,301,529	0
Did not have an event during blackout period	8,002,553	0	3,301,529	0
Final Cohort				
Number of members	8,002,553	N/A	3,301,529	N/A

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first COVID-19 vaccine identified only by claims codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only Claims-Claims and IIS combination)		With a first COVID-19 vaccine identified only by IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (Only IIS-IIS and Claims combination)	
	Remaining	**Excluded**	**Remaining**	**Excluded**
Number of episodes	8,002,553	N/A	3,301,529	N/A

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Claims and IIS-Only IIS combination)		With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (IIS and Claims-Only Claims combination)	
	Remaining	Excluded	Remaining	Excluded
Members Meeting Enrollment and Demographic Requirements				
Enrolled at any point during the query period	93,815,800	N/A	93,815,800	N/A
Had required coverage type (medical and/or drug coverage)	59,770,225	34,045,575	59,770,225	34,045,575
Enrolled during specified age range	59,769,730	495	59,769,730	495
Had requestable medical charts	59,769,730	0	59,769,730	0
Met demographic requirements (sex, race, and Hispanic origin)	59,734,101	35,629	59,734,101	35,629
Members with a Valid Index Event				
Had any cohort-defining claim during the query period	17,535,855	42,198,246	17,535,855	42,198,246
Claim recorded during specified age range	17,535,743	112	17,535,743	112
Episode defining index claim recorded during the query period	17,535,743	0	17,535,743	0
Members with Required Pre-Index History				
Had sufficient pre-index continuous enrollment	15,388,791	2,146,952	15,388,791	2,146,952
Met inclusion andexclusion criteria[2]	4,226,021	11,162,770	4,226,021	11,162,770
Evidence of Claims codes	N/A	N/A	N/A	N/A
Evidence of any prior COVID-19 vaccination for the type of vaccine cohorts	N/A	8,511,113	N/A	8,511,113
Evidence of IIS codes	N/A	N/A	N/A	N/A
Evidence of any prior COVID-19 vaccination for vaccine brand cohorts	N/A	N/A	N/A	N/A
No evidence of IIS codes on index	N/A	9,218,316	N/A	9,218,316
Met event incidence criteria	4,226,021	0	4,226,021	0
Members with Required Post-Index Follow-Up				
Had sufficient post-index continuous enrollment	4,226,021	0	4,226,021	0
Had index episode of at least required length	4,226,021	0	4,226,021	0
Had index episode longer than blackout period	4,226,021	0	4,226,021	0
Did not have an event during blackout period	4,226,021	0	4,226,021	0

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by IIS codes (Claims and IIS-Only IIS combination)		With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified only by claims codes (IIS and Claims-Only Claims combination)	
	Remaining	Excluded	Remaining	Excluded
Final Cohort				
Number of members	4,226,021	N/A	4,226,021	N/A
Number of episodes	4,226,021	N/A	4,226,021	N/A

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (IIS and Claims-IIS and Claims combination)	
	Remaining	Excluded
Members Meeting Enrollment and Demographic Requirements		
Enrolled at any point during the query period	93,815,800	N/A
Had required coverage type (medical and/or drug coverage)	59,770,225	34,045,575
Enrolled during specified age range	59,769,730	495
Had requestable medical charts	59,769,730	0
Met demographic requirements (sex, race, and Hispanic origin)	59,734,101	35,629
Members with a Valid Index Event		
Had any cohort-defining claim during the query period	17,535,855	42,198,246
Claim recorded during specified age range	17,535,743	112
Episode defining index claim recorded during the query period	17,535,743	0
Members with Required Pre-Index History		
Had sufficient pre-index continuous enrollment	15,388,791	2,146,952
Met inclusion andexclusion criteria[2]	4,226,021	11,162,770
Evidence of Claims codes	N/A	N/A
Evidence of any prior COVID-19 vaccination for the type of vaccine cohorts	N/A	8,511,113
Evidence of IIS codes	N/A	N/A
Evidence of any prior COVID-19 vaccination for vaccine brand cohorts	N/A	N/A
No evidence of IIS codes on index	N/A	9,218,316
Met event incidence criteria	4,226,021	0
Members with Required Post-Index Follow-Up		
Had sufficient post-index continuous enrollment	4,226,021	0
Had index episode of at least required length	4,226,021	0
Had index episode longer than blackout period	4,226,021	0
Did not have an event during blackout period	4,226,021	0
Final Cohort		
Number of members	4,226,021	N/A
Number of episodes	4,226,021	N/A

Table 6 r03. Summary of Patient-Level Cohort Attrition (Combinations of Brand or Code Type for the First and Second Coronavirus Disease 2019 [COVID-19] Vaccine Records) Among Patients with At Least One COVID-19 Vaccine[1] in the Rapid Sentinel Distributed Database (SDD) from November 1, 2020 to February 29, 2024

	With a first COVID-19 vaccine identified by claims and IIS codes, followed by a second COVID-19 vaccine also identified by claims and IIS codes (IIS and Claims-IIS and Claims combination)	
	Remaining	Excluded

[1]The cohorts include patients who received at least one COVID-19 vaccine. Cohorts were defined based on vaccine brand (Pfizer-BioNTech, Moderna, Janssen, Other [including Novavax or unspecified]) and data source (immunization information systems [IIS] only, claims data only, or both IIS and claims data). The index date is the date of the first COVID-19 vaccination, identified as the first record with no prior COVID-19 vaccination records. We included 16 cohorts based on brand combinations for the first and second doses (Pfizer-Pfizer, Moderna-Moderna, Janssen-Janssen, Other-Other, Pfizer-Moderna, Pfizer-Janssen, Pfizer-Other, Moderna-Pfizer, Moderna-Janssen, Moderna-Other, Janssen-Pfizer, Janssen-Moderna, Janssen-Other, Other-Pfizer, Other-Moderna, and Other-Janssen) and 9 cohorts based on data source combinations for the first and second doses (Only IIS-Only IIS, Only IIS-IIS & Claims, Only IIS-Only Claims, Only Claims-Only Claims, Only Claims-IIS & Claims, Only Claims-Only IIS, IIS & Claims-Only IIS, IIS & Claims-Only Claims, and IIS & Claims-IIS & Claims).

[2]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 6 r04. Summary of Patient-Level Cohort Attrition (Booster Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024

	With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[2]		With Booster COVID-19 Vaccine (Including Individuals Ever Immunocompromised)[3,4]		With Booster COVID-19 Vaccine (Excluding Individuals Ever Immunocompromised)[3,5]		With Booster COVID-19 Vaccine (Booster Specific Code)[6]	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members Meeting Enrollment and Demographic Requirements								
Enrolled at any point during the query period	84,081,410	N/A	84,081,410	N/A	84,081,410	N/A	84,081,410	N/A
Had required coverage type (medical and/or drug coverage)	53,193,164	30,888,246	53,193,164	30,888,246	53,193,164	30,888,246	53,193,164	30,888,246
Enrolled during specified age range	53,192,716	448	53,192,716	448	53,192,716	448	53,192,716	448
Had requestable medical charts	53,192,716	0	53,192,716	0	53,192,716	0	53,192,716	0
Met demographic requirements (sex, race, and Hispanic origin)	53,159,451	33,265	53,159,451	33,265	53,159,451	33,265	53,159,451	33,265
Members with a Valid Index Event								
Had any cohort-defining claim during the query period	14,817,477	38,341,974	14,817,477	38,341,974	14,817,477	38,341,974	8,030,066	45,129,385
Claim recorded during specified age range	14,817,398	79	14,817,398	79	14,817,398	79	8,030,032	34
Episode defining index claim recorded during the query period	14,817,398	0	14,817,398	0	14,817,398	0	8,030,032	0
Members with Required Pre-Index History								
Had sufficient pre-index continuous enrollment	13,061,687	1,755,711	13,061,687	1,755,711	13,061,687	1,755,711	7,210,340	819,692
Met inclusion and exclusion criteria[7]	7,730,120	5,331,567	1,752,336	11,309,351	4,418,268	8,643,419	7,210,340	0
Evidence of immunocompromised ***(excludes individuals meeting this criterion from non-immunocompromised cohort)***	N/A	N/A	N/A	N/A	N/A	5,278,578	N/A	N/A
No evidence of two previous COVID-19 vaccine codes ***(excludes individuals meeting this criterion from non-immunocompromised cohort)***	N/A	N/A	N/A	N/A	N/A	5,668,469	N/A	N/A

Table 6 r04. Summary of Patient-Level Cohort Attrition (Booster Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024

	With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[2]		With Booster COVID-19 Vaccine (Including Individuals Ever Immunocompromised)[3,4]		With Booster COVID-19 Vaccine (Excluding Individuals Ever Immunocompromised)[3,5]		With Booster COVID-19 Vaccine (Booster Specific Code)[6]	
	Remaining	**Excluded**	**Remaining**	**Excluded**	**Remaining**	**Excluded**	**Remaining**	**Excluded**
No evidence of three previous COVID-19 vaccine codes and immunocompromised ***(excludes individuals meeting this criterion from immunocompromised cohort)***	N/A	N/A	N/A	11,309,351	N/A	N/A	N/A	N/A
No evidence of two previous COVID-19 vaccine codes ***(excludes individuals meeting this criterion from the overall booster cohort)***	N/A	5,331,567	N/A	N/A	N/A	N/A	N/A	N/A
Met event incidence criteria	7,730,120	0	1,752,336	0	4,418,268	0	7,210,340	0
Members with Required Post-Index Follow-Up								
Had sufficient post-index continuous enrollment	7,730,120	0	1,752,336	0	4,418,268	0	7,210,340	0
Had index episode of at least required length	7,730,120	0	1,752,336	0	4,418,268	0	7,210,340	0
Had index episode longer than blackout period	7,730,120	0	1,752,336	0	4,418,268	0	7,210,340	0
Did not have an event during blackout period	7,730,120	0	1,752,336	0	4,418,268	0	7,210,340	0
Final Cohort								
Number of members	7,730,120	N/A	1,752,336	N/A	4,418,268	N/A	7,210,340	N/A
Number of episodes	7,730,120	N/A	1,752,336	N/A	4,418,268	N/A	7,210,340	N/A

Table 6 r04. Summary of Patient-Level Cohort Attrition (Booster Coronavirus Disease 2019 [COVID-19] Vaccines)[1] in the Rapid Sentinel Distributed Database (SDD) from September 1, 2021 to February 29, 2024

	With Booster Coronavirus Disease 2019 (COVID-19) Vaccine[2]		With Booster COVID-19 Vaccine (Including Individuals Ever Immunocompromised)[3,4]		With Booster COVID-19 Vaccine (Excluding Individuals Ever Immunocompromised)[3,5]		With Booster COVID-19 Vaccine (Booster Specific Code)[6]	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded

[1]The cohorts include patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. We defined boosters using four different cohorts:

- Cohort 1: Individuals with evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 2: Individuals with a history of an immunocompromising condition and evidence of at least three vaccine codes more than four days apart prior to their booster dose.
- Cohort 3: Individuals without a history of an immunocompromising condition and evidence of at least two vaccine codes more than four days apart prior to their booster dose.
- Cohort 4: Individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine.

[2]The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who have evidence of receiving at least two vaccine doses more than four days apart prior to their booster dose.

[3]Including any evidence of HIV/AIDS, Hematological Malignancy, Treatment-Independent Immune Deficiencies, Dialysis, Chemo Therapeutic Agents/ Diagnoses and Procedures, Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures, Steroid Diagnoses and Procedures, Organ Transplant Diagnoses and Procedures, or Solid Malignancies any time before index.

[4]The cohort includes patients with evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals with a history of an immunocompromising condition and evidence of at least three vaccine doses more than four days apart prior to their booster dose.

[5]The cohort includes patients without evidence of an immunocompromising condition in their enrollment history who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date set as the date of the booster. Recipients of boosters are defined as individuals without a history of an immunocompromising condition and evidence of at least two vaccine doses more than four days apart prior to their booster dose.

[6]The cohort includes patients who received a Pfizer-BioNTech or Moderna COVID-19 vaccine booster after September 1, 2021, with the index date defined as the date of the booster. Recipients of boosters are defined as individuals who received a vaccine where the code description specified that it was for a booster or bivalent COVID-19 vaccine. No prior evidence of having COVID-19 vaccination inclusion criteria was required for this cohort.

[7]Patients can meet multiple inclusion and/or exclusion criteria; therefore, the total number of patients excluded overall may not equal the sum of all patients in each criterion.

N/A: Not Applicable

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (May 17, 2024)

Masked DP ID	DP Start Date	DP End Date[1]
DP01	07/01/2017	01/31/2024
DP02	07/01/2017	01/31/2024
DP03	07/01/2017	02/29/2024
DP04	01/01/2017	12/31/2023
DP05	01/01/2017	11/30/2023
DP06	07/01/2017	02/29/2024

[1]End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Non-proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request

Non-proprietary Name	Proprietary Name
Pfizer	
30 mcg/0.3 mL for adult 16+ (original formula)	Comirnaty
COVID-19 vac mRNA,tris(Pfizer)/PF	Pfizer-BioNTech Covid-19 Vaccine
COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose	Pfizer-BioNTech Covid-19 Vaccine
COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose	Pfizer-BioNTech Covid-19 Vaccine
COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose	Pfizer-BioNTech Covid-19 Vaccine
COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL	Pfizer-BioNTech Covid-19 Vaccine, Bivalent
COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL	Pfizer-BioNTech Covid-19 Vaccine, Bivalent
COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose	Pfizer-BioNTech Covid-19 Vaccine, Bivalent
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose	Pfizer-BioNTech Covid-19 Vaccine
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation	Comirnaty
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, reconstituted, 30 mcg/0.3mL dose	Pfizer-BioNTech Covid-19 Vaccine
Moderna	
0.5 mL dose (same as original EUA formula)	Spikevax
0.5 mL dose of Original and Omicron COVID-19 strains	Moderna COVID-19 Vaccine, Bivalent
COVID-19 vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose	Moderna COVID-19 Vaccine
COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose	Moderna COVID-19 Vaccine
COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose	Spikevax
COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose	Moderna COVID-19 Vaccine
COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose	Moderna COVID-19 Vaccine, Pediatric Vaccine
COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose, 6mo-<6yr	Moderna COVID-19 Vaccine, Pediatric Vaccine
COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose	Moderna COVID-19 Vaccine, Pediatric Vaccine
COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose, 6yr-<12yr	Moderna COVID-19 Vaccine, Pediatric Vaccine
COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL	Moderna COVID-19 Vaccine, Bivalent
COVID-19, mRNA, LNP-S, bivalent booster, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose	Moderna COVID-19 Vaccine, Bivalent
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose	Moderna COVID-19 Vaccine
SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL or 50mcg/0.25mL dose	Moderna COVID-19 Vaccine
Novavax	
SARS-COV-2 (COVID-19) vaccine, Subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL per dose	NOVAVAX COVID-19 Vaccine, Adjuvanted
Jannsen	
SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL	Janssen COVID-19 Vaccine

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

Code	Code Description	Code Category	Code Type
	Pfizer		
0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, first dose	Procedure	CPT-4
0002A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, second dose	Procedure	CPT-4
0003A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, third dose	Procedure	CPT-4
0004A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, booster dose	Procedure	CPT-4
00069100001	30 mcg/0.3 mL for adult 16+ (original formula)	Procedure	NDC
00069100002	30 mcg/0.3 mL for adult 16+ (original formula)	Procedure	NDC
00069100003	30 mcg/0.3 mL for adult 16+ (original formula)	Procedure	NDC
00069202501	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation	Procedure	NDC
00069202510	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation	Procedure	NDC
00069202525	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose, tris-sucrose formulation	Procedure	NDC
0051A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, tris-sucrose formulation, first dose	Procedure	CPT-4
0052A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, tris-sucrose formulation, second dose	Procedure	CPT-4
0053A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, tris-sucrose formulation, third dose	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

0054A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose	Procedure	CPT-4
0071A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation, first dose	Procedure	CPT-4
0072A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation, second dose	Procedure	CPT-4
0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation, third dose	Procedure	CPT-4
0074A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose	Procedure	CPT-4
0081A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation, first dose	Procedure	CPT-4
0082A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation, second dose	Procedure	CPT-4
0083A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation, third dose	Procedure	CPT-4
0124A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, tris-sucrose formulation booster dose	Procedure	CPT-4
0154A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation booster dose	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

	COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose; FDA EUA (12+ yrs) and BLA (16+ yrs), Pfizer adult primary series and IC dose original formulation. EUA 8/31/2022 rescinded monovalent booster dose. Used to record Pfizer vaccines administered in the US and in non-US locations		
208	(includes tradename Comirnaty)	Procedure	CV
	COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose; FDA EUA (12+ yrs) and BLA (16+ yrs), Pfizer adult primary series and IC dose tris-sucrose formulation. EUA 8/31/2022		
217	rescinded monovalent booster dose	Procedure	CV
	COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose;		
218	FDA EUA (5 yrs through 11 yrs), Pfizer tris-sucrose pediatric primary series, IC, and booster	Procedure	CV
	COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose;		
219	FDA EUA (6 mo through 4 yrs), Pfizer tris-sucrose pediatric primary series	Procedure	CV
	COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose;		
300	EUA authorized Pfizer adult bivalent booster ages 12+ yrs, original strain + omicron BA.4/BA.5	Procedure	CV
	COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL dose;		
301	EUA authorized (5 yrs through 11 yrs) Pfizer bivalent booster, original strain + omicron BA.4/BA.5	Procedure	CV
	COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose;		
302	Pre-EUA Pfizer bivalent (ages 6 mo through 4 yrs), original strain + omicron BA.4/BA.5	Procedure	CV
59267007801	COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose	Procedure	NDC
59267007802	COVID-19 vac mRNA,tris(Pfizer)/PF	Procedure	NDC
59267007804	COVID-19, mRNA, LNP-S, PF, 3 mcg/0.2 mL dose, tris-sucrose	Procedure	NDC
59267030401	COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose	Procedure	NDC
59267030402	COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose	Procedure	NDC
59267056501	COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL dose	Procedure	NDC
59267056502	COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL dose	Procedure	NDC
59267060901	COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose	Procedure	NDC
59267060902	COVID-19, mRNA, LNP-S, bivalent, PF, 3 mcg/0.2 mL dose	Procedure	NDC
59267100001	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 30 mcg/0.3mL dose	Procedure	NDC
59267100002	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, reconstituted, 30 mcg/0.3mL dose	Procedure	NDC
59267100003	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, reconstituted, 30 mcg/0.3mL dose	Procedure	NDC
59267102501	COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose	Procedure	NDC
59267102502	COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose	Procedure	NDC
59267102503	COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose	Procedure	NDC
59267102504	COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris-sucrose	Procedure	NDC

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

59267105501	COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose	Procedure	NDC
59267105502	COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose	Procedure	NDC
59267105504	COVID-19, mRNA, LNP-S, PF, 10 mcg/0.2 mL dose, tris-sucrose	Procedure	NDC
59267140401	COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose	Procedure	NDC
59267140402	COVID-19, mRNA, LNP-S, bivalent booster, PF, 30 mcg/0.3 mL dose	Procedure	NDC
91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use	Procedure	CPT-4
91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	Procedure	CPT-4
91307	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	Procedure	CPT-4
91308	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	Procedure	CPT-4
91312	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	Procedure	CPT-4
91315	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	Procedure	CPT-4
91317	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	Procedure	CPT-4
	Moderna		
0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRN-LNP, spike protein, preservative free, 100mcg/0.5mL dosage, first dose	Procedure	CPT-4
0012A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRN-LNP, spike protein, preservative free, 100mcg/0.5mL dosage, second dose	Procedure	CPT-4
0013A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRN-LNP, spike protein, preservative free, 100mcg/0.5mL dosage, third dose	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

0064A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRN-LNP, spike protein, preservative free, 50mcg/0.25mL dosage, booster dose	Procedure	CPT-4
0091A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50mcg/0.5mL dosage, for intramuscular use, first dose	Procedure	CPT-4
0092A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50mcg/0.5mL dosage, for intramuscular use, second dose	Procedure	CPT-4
0093A	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50mcg/0.5mL dosage, for intramuscular use, third dose	Procedure	CPT-4
0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50mcg/0.5mL dosage, for intramuscular use, booster dose	Procedure	CPT-4
0111A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25mcg/0.25mL dosage, for intramuscular use, first dose	Procedure	CPT-4
0112A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25mcg/0.25mL dosage, for intramuscular use, second dose	Procedure	CPT-4
0113A	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25mcg/0.25mL dosage, for intramuscular use, third dose	Procedure	CPT-4
0134A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRN-LNP, spike protein, bivalent, preservative free, 50mcg/0.5mL dosage, booster dose	Procedure	CPT-4
0144A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease[COVID-19]) vaccine, mRN-LNP, spike protein, bivalent, preservative free, 25mcg/0.25mL dosage, booster dose	Procedure	CPT-4
0164A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2mL dosage, booster dose	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

	COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose;		
207	FDA EUA and BLA (18+ yrs), Moderna adult primary series and IC dose. EUA 8/31/2022 rescinded monovalent booster dose. Used to record Moderna vaccines administered in the US and in non-US locations (includes tradename Spikevax)	Procedure	CV
	COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose;		
221	FDA EUA Moderna, EUA 8/31/2022 rescinded use of this product for adult monovalent booster dose. Vaccine now only authorized for 6 yrs through 11 primary series and IC doses	Procedure	CV
	COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose;		
227	Temporarily inactivated - Use CVX code 221 for EUA Moderna Pediatric 6yr to<12 yr vaccine 2.5 mL vial, 50 mcg/0.5 mL dose	Procedure	CV
	COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose;		
228	FDA EUA Authorized (6 mo through 5 yrs), Moderna pediatric primary series and IC dose	Procedure	CV
	COVID-19, mRNA, LNP-S, bivalent booster, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose;		
229	EUA authorized Moderna bivalent booster 2 dose levels: ages 6 yrs thru 11 yrs 0.25mL dose; 12 years and older 0.5mL dose	Procedure	CV
	COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL;		
230	Pre-EUA Moderna bivalent booster (ages 6 mo through 5 yrs), original strain + omicron BA.4/BA.5	Procedure	CV
80777010011	COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose	Procedure	NDC
80777010015	0.5 mL dose (same as original EUA formula)	Procedure	NDC
80777010098	0.5 mL dose (same as original EUA formula)	Procedure	NDC
80777010099	COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose	Procedure	NDC
80777027310	COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose	Procedure	NDC
80777027315	COVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose	Procedure	NDC
80777027398	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose	Procedure	NDC
80777027399	SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL or 50mcg/0.25mL dose	Procedure	NDC
80777027505	COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose	Procedure	NDC
80777027599	COVID-19 vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose	Procedure	NDC
80777027705	COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose	Procedure	NDC
80777027799	COVID-19, mRNA, LNP-S, PF, pediatric 50 mcg/0.5 mL dose, 6yr-<12yr	Procedure	NDC
80777027905	COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose	Procedure	NDC
80777027999	COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose, 6mo-<6yr	Procedure	NDC
80777028005	0.5 mL dose of Original and Omicron COVID-19 strains	Procedure	NDC
80777028099	0.5 mL dose of Original and Omicron COVID-19 strains	Procedure	NDC
80777028205	COVID-19, mRNA, LNP-S, bivalent booster, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose	Procedure	NDC

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

80777028299	COVID-19, mRNA, LNP-S, bivalent booster, PF, 50 mcg/0.5 mL or 25mcg/0.25 mL dose	Procedure	NDC
80777028302	COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL	Procedure	NDC
80777028399	COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL	Procedure	NDC
91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use	Procedure	CPT-4
91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	Procedure	CPT-4
91309	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	Procedure	CPT-4
91311	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	Procedure	CPT-4
91313	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	Procedure	CPT-4
91314	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	Procedure	CPT-4
91316	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2mL dosage, for intramuscular use	Procedure	CPT-4
	Novavax		
0041A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5mcg/0.5mL dosage; first dose	Procedure	CPT-4
0042A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5mcg/0.5mL dosage; seconod dose	Procedure	CPT-4
0044A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5mcg/0.5mL dosage; booster	Procedure	CPT-4
211	COVID-19, subunit, rS-nanoparticle+Matrix-M1 Adjuvant, PF, 0.5 mL; FDA EUA Authorized, Novavax primary series adult dose	Procedure	CV
80631010001	SARS-COV-2 (COVID-19) vaccine, Subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL per dose	Procedure	NDC
80631010010	SARS-COV-2 (COVID-19) vaccine, Subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL per dose	Procedure	NDC

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Healthcare Common Procedure Coding System, Level II (HCPCS), National Drug Code (NDC), and Codes Used to Define Outcomes in this Request

80631010201	SARS-COV-2 (COVID-19) vaccine, Subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL per dose	Procedure	NDC
80631010210	SARS-COV-2 (COVID-19) vaccine, Subunit, recombinant spike protein-nanoparticle+Matrix-M1 Adjuvant, preservative free, 0.5mL per dose	Procedure	NDC
91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use	Procedure	CPT-4
	Jannsen		
0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage; single dose	Procedure	CPT-4
0034A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage; booster	Procedure	CPT-4
212	COVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL; FDA EUA 02/27/2021, 1-dose vaccine. Used to record Janssen/J&J vaccines administered in the US and in non-US locations	Procedure	CV
59676058005	SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL	Procedure	NDC
59676058015	SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mL	Procedure	NDC
91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5 mL dosage, for intramuscular use	Procedure	CPT-4
	Unknown Vaccination Brand		
213	SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED; Unspecified code for COVID-19 not to be used to record patient US administration. May be used to record historic US administration if product not known. CVX code 500 should be used to record Non-US vaccine where product is not known.	Procedure	CV
M0201	COVID-19 vaccine home admin	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
	Reactive Airway and Lung Diseases		
J66.0	Byssinosis	Diagnosis	ICD-10-CM
J66.1	Flax-dressers' disease	Diagnosis	ICD-10-CM
J66.2	Cannabinosis	Diagnosis	ICD-10-CM
J66.8	Airway disease due to other specific organic dusts	Diagnosis	ICD-10-CM
J67.0	Farmer's lung	Diagnosis	ICD-10-CM
J67.1	Bagassosis	Diagnosis	ICD-10-CM
J67.2	Bird fancier's lung	Diagnosis	ICD-10-CM
J67.3	Suberosis	Diagnosis	ICD-10-CM
J67.4	Maltworker's lung	Diagnosis	ICD-10-CM
J67.5	Mushroom-worker's lung	Diagnosis	ICD-10-CM
J67.6	Maple-bark-stripper's lung	Diagnosis	ICD-10-CM
J67.7	Air conditioner and humidifier lung	Diagnosis	ICD-10-CM
J67.8	Hypersensitivity pneumonitis due to other organic dusts	Diagnosis	ICD-10-CM
J67.9	Hypersensitivity pneumonitis due to unspecified organic dust	Diagnosis	ICD-10-CM
J68.0	Bronchitis and pneumonitis due to chemicals, gases, fumes and vapors	Diagnosis	ICD-10-CM
J68.4	Chronic respiratory conditions due to chemicals, gases, fumes and vapors	Diagnosis	ICD-10-CM
J68.8	Other respiratory conditions due to chemicals, gases, fumes and vapors	Diagnosis	ICD-10-CM
J68.9	Unspecified respiratory condition due to chemicals, gases, fumes and vapors	Diagnosis	ICD-10-CM
	Other Chronic Respiratory Diseases (Pneumonia and Bronchitis)		
B44.81	Allergic bronchopulmonary aspergillosis	Diagnosis	ICD-10-CM
G47.34	Idiopathic sleep related nonobstructive alveolar hypoventilation	Diagnosis	ICD-10-CM
G47.36	Sleep related hypoventilation in conditions classified elsewhere	Diagnosis	ICD-10-CM
G47.39	Other sleep apnea	Diagnosis	ICD-10-CM
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43	Emphysema	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44	Other chronic obstructive pulmonary disease	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
J61	Pneumoconiosis due to asbestos and other mineral fibers	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

J62	Pneumoconiosis due to dust containing silica	Diagnosis	ICD-10-CM
J62.8	Pneumoconiosis due to other dust containing silica	Diagnosis	ICD-10-CM
J63	Pneumoconiosis due to other inorganic dusts	Diagnosis	ICD-10-CM
J63.6	Pneumoconiosis due to other specified inorganic dusts	Diagnosis	ICD-10-CM
J65	Pneumoconiosis associated with tuberculosis	Diagnosis	ICD-10-CM
J70	Respiratory conditions due to other external agents	Diagnosis	ICD-10-CM
J70.1	Chronic and other pulmonary manifestations due to radiation	Diagnosis	ICD-10-CM
J70.3	Chronic drug-induced interstitial lung disorders	Diagnosis	ICD-10-CM
J70.4	Drug-induced interstitial lung disorders, unspecified	Diagnosis	ICD-10-CM
J70.5	Respiratory conditions due to smoke inhalation	Diagnosis	ICD-10-CM
J70.8	Respiratory conditions due to other specified external agents	Diagnosis	ICD-10-CM
J70.9	Respiratory conditions due to unspecified external agent	Diagnosis	ICD-10-CM
J82	Pulmonary eosinophilia, not elsewhere classified	Diagnosis	ICD-10-CM
J82.8	Pulmonary eosinophilia, not elsewhere classified	Diagnosis	ICD-10-CM
J82.89	Other pulmonary eosinophilia, not elsewhere classified	Diagnosis	ICD-10-CM
J84	Other interstitial pulmonary diseases	Diagnosis	ICD-10-CM
J84.0	Alveolar and parieto-alveolar conditions	Diagnosis	ICD-10-CM
J84.09	Other alveolar and parieto-alveolar conditions	Diagnosis	ICD-10-CM
J84.1	Other interstitial pulmonary diseases with fibrosis	Diagnosis	ICD-10-CM
J84.10	Pulmonary fibrosis, unspecified	Diagnosis	ICD-10-CM
J84.111	Idiopathic interstitial pneumonia, not otherwise specified	Diagnosis	ICD-10-CM
J84.113	Idiopathic non-specific interstitial pneumonitis	Diagnosis	ICD-10-CM
J84.115	Respiratory bronchiolitis interstitial lung disease	Diagnosis	ICD-10-CM
J84.117	Desquamative interstitial pneumonia	Diagnosis	ICD-10-CM
J84.17	Other interstitial pulmonary diseases with fibrosis in diseases classified elsewhere	Diagnosis	ICD-10-CM
J84.170	Interstitial lung disease with progressive fibrotic phenotype in diseases classified elsewhere	Diagnosis	ICD-10-CM
J84.178	Other interstitial pulmonary diseases with fibrosis in diseases classified elsewhere	Diagnosis	ICD-10-CM
J84.8	Other specified interstitial pulmonary diseases	Diagnosis	ICD-10-CM
J84.82	Adult pulmonary Langerhans cell histiocytosis	Diagnosis	ICD-10-CM
J84.84	Other interstitial lung diseases of childhood	Diagnosis	ICD-10-CM
J84.841	Neuroendocrine cell hyperplasia of infancy	Diagnosis	ICD-10-CM
J84.842	Pulmonary interstitial glycogenosis	Diagnosis	ICD-10-CM
J84.843	Alveolar capillary dysplasia with vein misalignment	Diagnosis	ICD-10-CM
J84.848	Other interstitial lung diseases of childhood	Diagnosis	ICD-10-CM
J84.89	Other specified interstitial pulmonary diseases	Diagnosis	ICD-10-CM
J84.9	Interstitial pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J91	Pleural effusion in conditions classified elsewhere	Diagnosis	ICD-10-CM
J92.0	Pleural plaque with presence of asbestos	Diagnosis	ICD-10-CM
J96.1	Chronic respiratory failure	Diagnosis	ICD-10-CM
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM
J98.4	Other disorders of lung	Diagnosis	ICD-10-CM
J98.9	Respiratory disorder, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

P27	Chronic respiratory disease originating in the perinatal period	Diagnosis	ICD-10-CM
P27.0	Wilson-Mikity syndrome	Diagnosis	ICD-10-CM
P27.1	Bronchopulmonary dysplasia originating in the perinatal period	Diagnosis	ICD-10-CM
P27.8	Other chronic respiratory diseases originating in the perinatal period	Diagnosis	ICD-10-CM
P27.9	Unspecified chronic respiratory disease originating in the perinatal period	Diagnosis	ICD-10-CM
	Sickle Cell Disease		
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia, unspecified, with acute chest syndrome	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia, unspecified, with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.419	Sickle-cell thalassemia, unspecified, with crisis	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis	ICD-10-CM
D57.44	Sickle-cell thalassemia beta plus without crisis	Diagnosis	ICD-10-CM
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome	Diagnosis	ICD-10-CM
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration	Diagnosis	ICD-10-CM
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
	Liver Disease (Severe/Moderate)		
B18	Chronic viral hepatitis	Diagnosis	ICD-10-CM
B18.0	Chronic viral hepatitis B with delta-agent	Diagnosis	ICD-10-CM
B18.1	Chronic viral hepatitis B without delta-agent	Diagnosis	ICD-10-CM
B18.2	Chronic viral hepatitis C	Diagnosis	ICD-10-CM
B18.8	Other chronic viral hepatitis	Diagnosis	ICD-10-CM
B18.9	Chronic viral hepatitis, unspecified	Diagnosis	ICD-10-CM
E83.01	Wilson's disease	Diagnosis	ICD-10-CM
E83.110	Hereditary hemochromatosis	Diagnosis	ICD-10-CM
E88.01	Alpha-1-antitrypsin deficiency	Diagnosis	ICD-10-CM
I85	Esophageal varices	Diagnosis	ICD-10-CM
I85.0	Esophageal varices	Diagnosis	ICD-10-CM
I85.00	Esophageal varices without bleeding	Diagnosis	ICD-10-CM
I85.01	Esophageal varices with bleeding	Diagnosis	ICD-10-CM
I85.1	Secondary esophageal varices	Diagnosis	ICD-10-CM
I85.10	Secondary esophageal varices without bleeding	Diagnosis	ICD-10-CM
I85.11	Secondary esophageal varices with bleeding	Diagnosis	ICD-10-CM
I86.4	Gastric varices	Diagnosis	ICD-10-CM
K65.2	Spontaneous bacterial peritonitis	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.1	Alcoholic hepatitis	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.3	Alcoholic cirrhosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.4	Alcoholic hepatic failure	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
K71.0	Toxic liver disease with cholestasis	Diagnosis	ICD-10-CM
K71.1	Toxic liver disease with hepatic necrosis	Diagnosis	ICD-10-CM
K71.10	Toxic liver disease with hepatic necrosis, without coma	Diagnosis	ICD-10-CM
K71.11	Toxic liver disease with hepatic necrosis, with coma	Diagnosis	ICD-10-CM
K71.2	Toxic liver disease with acute hepatitis	Diagnosis	ICD-10-CM
K71.3	Toxic liver disease with chronic persistent hepatitis	Diagnosis	ICD-10-CM
K71.4	Toxic liver disease with chronic lobular hepatitis	Diagnosis	ICD-10-CM
K71.5	Toxic liver disease with chronic active hepatitis	Diagnosis	ICD-10-CM
K71.50	Toxic liver disease with chronic active hepatitis without ascites	Diagnosis	ICD-10-CM
K71.51	Toxic liver disease with chronic active hepatitis with ascites	Diagnosis	ICD-10-CM
K71.6	Toxic liver disease with hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K71.7	Toxic liver disease with fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

K71.8	Toxic liver disease with other disorders of liver	Diagnosis	ICD-10-CM
K71.9	Toxic liver disease, unspecified	Diagnosis	ICD-10-CM
K72.01	Acute and subacute hepatic failure with coma	Diagnosis	ICD-10-CM
K72.1	Chronic hepatic failure	Diagnosis	ICD-10-CM
K72.10	Chronic hepatic failure without coma	Diagnosis	ICD-10-CM
K72.11	Chronic hepatic failure with coma	Diagnosis	ICD-10-CM
K72.9	Hepatic failure, unspecified	Diagnosis	ICD-10-CM
K72.90	Hepatic failure, unspecified without coma	Diagnosis	ICD-10-CM
K72.91	Hepatic failure, unspecified with coma	Diagnosis	ICD-10-CM
K73	Chronic hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.0	Chronic persistent hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.1	Chronic lobular hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.2	Chronic active hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.8	Other chronic hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.9	Chronic hepatitis, unspecified	Diagnosis	ICD-10-CM
K74	Fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K74.0	Hepatic fibrosis	Diagnosis	ICD-10-CM
K74.1	Hepatic sclerosis	Diagnosis	ICD-10-CM
K74.2	Hepatic fibrosis with hepatic sclerosis	Diagnosis	ICD-10-CM
K74.3	Primary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.4	Secondary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.5	Biliary cirrhosis, unspecified	Diagnosis	ICD-10-CM
K74.6	Other and unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.60	Unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.69	Other cirrhosis of liver	Diagnosis	ICD-10-CM
K75.0	Abscess of liver	Diagnosis	ICD-10-CM
K75.1	Phlebitis of portal vein	Diagnosis	ICD-10-CM
K75.2	Nonspecific reactive hepatitis	Diagnosis	ICD-10-CM
K75.3	Granulomatous hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K75.4	Autoimmune hepatitis	Diagnosis	ICD-10-CM
K75.8	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.81	Nonalcoholic steatohepatitis (NASH)	Diagnosis	ICD-10-CM
K75.89	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.9	Inflammatory liver disease, unspecified	Diagnosis	ICD-10-CM
K76.0	Fatty (change of) liver, not elsewhere classified	Diagnosis	ICD-10-CM
K76.1	Chronic passive congestion of liver	Diagnosis	ICD-10-CM
K76.2	Central hemorrhagic necrosis of liver	Diagnosis	ICD-10-CM
K76.3	Infarction of liver	Diagnosis	ICD-10-CM
K76.4	Peliosis hepatis	Diagnosis	ICD-10-CM
K76.5	Hepatic veno-occlusive disease	Diagnosis	ICD-10-CM
K76.6	Portal hypertension	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
K76.8	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.81	Hepatopulmonary syndrome	Diagnosis	ICD-10-CM
K76.89	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.9	Liver disease, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

K83.01	Primary sclerosing cholangitis	Diagnosis	ICD-10-CM
K91.83	Postprocedural hepatorenal syndrome	Diagnosis	ICD-10-CM
R18	Ascites	Diagnosis	ICD-10-CM
R18.8	Other ascites	Diagnosis	ICD-10-CM
Z94.4	Liver transplant status	Diagnosis	ICD-10-CM
	Tuberculosis		
A15	Respiratory tuberculosis	Diagnosis	ICD-10-CM
A15.5	Tuberculosis of larynx, trachea and bronchus	Diagnosis	ICD-10-CM
A15.6	Tuberculous pleurisy	Diagnosis	ICD-10-CM
A15.7	Primary respiratory tuberculosis	Diagnosis	ICD-10-CM
A15.8	Other respiratory tuberculosis	Diagnosis	ICD-10-CM
A15.9	Respiratory tuberculosis unspecified	Diagnosis	ICD-10-CM
A19	Miliary tuberculosis	Diagnosis	ICD-10-CM
A19.0	Acute miliary tuberculosis of a single specified site	Diagnosis	ICD-10-CM
A19.1	Acute miliary tuberculosis of multiple sites	Diagnosis	ICD-10-CM
A19.2	Acute miliary tuberculosis, unspecified	Diagnosis	ICD-10-CM
A19.8	Other miliary tuberculosis	Diagnosis	ICD-10-CM
A19.9	Miliary tuberculosis, unspecified	Diagnosis	ICD-10-CM
B90	Sequelae of tuberculosis	Diagnosis	ICD-10-CM
B90.9	Sequelae of respiratory and unspecified tuberculosis	Diagnosis	ICD-10-CM
J65	Pneumoconiosis associated with tuberculosis	Diagnosis	ICD-10-CM
Z22.7	Latent tuberculosis	Diagnosis	ICD-10-CM
Z86.11	Personal history of tuberculosis	Diagnosis	ICD-10-CM
Z86.15	Personal history of latent tuberculosis infection	Diagnosis	ICD-10-CM
	Cystic fibrosis		
E84	Cystic fibrosis	Diagnosis	ICD-10-CM
E84.0	Cystic fibrosis with pulmonary manifestations	Diagnosis	ICD-10-CM
E84.1	Cystic fibrosis with intestinal manifestations	Diagnosis	ICD-10-CM
E84.11	Meconium ileus in cystic fibrosis	Diagnosis	ICD-10-CM
E84.19	Cystic fibrosis with other intestinal manifestations	Diagnosis	ICD-10-CM
E84.8	Cystic fibrosis with other manifestations	Diagnosis	ICD-10-CM
E84.9	Cystic fibrosis, unspecified	Diagnosis	ICD-10-CM
P09.4	Abnormal findings on neonatal screening for cystic fibrosis	Diagnosis	ICD-10-CM
Z14.1	Cystic fibrosis carrier	Diagnosis	ICD-10-CM
	Congenital or Acquired Heart Disease		
02Q50ZZ	Repair Atrial Septum, Open Approach	Procedure	ICD-10-PCS
02QM0ZZ	Repair Ventricular Septum, Open Approach	Procedure	ICD-10-PCS
02U507Z	Supplement Atrial Septum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02U50JZ	Supplement Atrial Septum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
02U53JZ	Supplement Atrial Septum with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
02UM07Z	Supplement Ventricular Septum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
02UM0JZ	Supplement Ventricular Septum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

02UM3JZ	Supplement Ventricular Septum with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
33647	Repair of atrial septal defect and ventricular septal defect, with direct or patch closure	Procedure	CPT-4
33720	Repair sinus of Valsalva aneurysm, with cardiopulmonary bypass	Procedure	CPT-4
33741	Transcatheter atrial septostomy (TAS) for congenital cardiac anomalies to create effective atrial flow, including all imaging guidance by the proceduralist, when performed, any method (eg, Rashkind, Sang-Park, balloon, cutting balloon, blade)	Procedure	CPT-4
33745	Transcatheter intracardiac shunt (TIS) creation by stent placement for congenital cardiac anomalies to establish effective intracardiac flow, including all imaging guidance by the proceduralist, when performed, left and right heart diagnostic cardiac catheterization for congenital cardiac anomalies, and target zone angioplasty, when performed (eg, atrial septum, Fontan fenestration, right ventricular outflow tract, Mustard/Senning/Warden baffles); initial intracardiac shunt	Procedure	CPT-4
33746	Transcatheter intracardiac shunt (TIS) creation by stent placement for congenital cardiac anomalies to establish effective intracardiac flow, including all imaging guidance by the proceduralist, when performed, left and right heart diagnostic cardiac catheterization for congenital cardiac anomalies, and target zone angioplasty, when performed (eg, atrial septum, Fontan fenestration, right ventricular outflow tract, Mustard/Senning/Warden baffles); each additional intracardiac shunt location (List separately in addition to code for primary procedure)	Procedure	CPT-4
33924	Ligation and takedown of a systemic-to-pulmonary artery shunt, performed in conjunction with a congenital heart procedure (List separately in addition to code for primary procedure)	Procedure	CPT-4
75572	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed)	Procedure	CPT-4
75573	Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology in the setting of congenital heart disease (including 3D image postprocessing, assessment of LV cardiac function, RV structure and function and evaluation of venous structures, if performed)	Procedure	CPT-4
93303	Transthoracic echocardiography for congenital cardiac anomalies; complete	Procedure	CPT-4
93304	Transthoracic echocardiography for congenital cardiac anomalies; follow-up or limited study	Procedure	CPT-4
93315	Transesophageal echocardiography for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

93316	Transesophageal echocardiography for congenital cardiac anomalies; placement of transesophageal probe only	Procedure	CPT-4
93317	Transesophageal echocardiography for congenital cardiac anomalies; image acquisition, interpretation and report only	Procedure	CPT-4
93530	Right heart catheterization, for congenital cardiac anomalies	Procedure	CPT-4
93531	Combined right heart catheterization and retrograde left heart catheterization, for congenital cardiac anomalies	Procedure	CPT-4
93532	Combined right heart catheterization and transseptal left heart catheterization through intact septum with or without retrograde left heart catheterization, for congenital cardiac anomalies	Procedure	CPT-4
93533	Combined right heart catheterization and transseptal left heart catheterization through existing septal opening, with or without retrograde left heart catheterization, for congenital cardiac anomalies	Procedure	CPT-4
93563	Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective coronary angiography during congenital heart catheterization (List separately in addition to code for primary procedure)	Procedure	CPT-4
93564	Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective opacification of aortocoronary venous or arterial bypass graft(s) (eg, aortocoronary saphenous vein, free radial artery, or free mammary artery graft) to one or more coronary arteries and in situ arterial conduits (eg, internal mammary), whether native or used for bypass to one or more coronary arteries during congenital heart catheterization, when performed (List separately in addition to code for primary procedure)	Procedure	CPT-4
93580	Percutaneous transcatheter closure of congenital interatrial communication (ie, Fontan fenestration, atrial septal defect) with implant	Procedure	CPT-4
93581	Percutaneous transcatheter closure of a congenital ventricular septal defect with implant	Procedure	CPT-4
P29.38	Other persistent fetal circulation	Diagnosis	ICD-10-CM
Q20.0	Common arterial trunk	Diagnosis	ICD-10-CM
Q20.1	Double outlet right ventricle	Diagnosis	ICD-10-CM
Q20.2	Double outlet left ventricle	Diagnosis	ICD-10-CM
Q20.3	Discordant ventriculoarterial connection	Diagnosis	ICD-10-CM
Q20.4	Double inlet ventricle	Diagnosis	ICD-10-CM
Q20.5	Discordant atrioventricular connection	Diagnosis	ICD-10-CM
Q20.6	Isomerism of atrial appendages	Diagnosis	ICD-10-CM
Q20.8	Other congenital malformations of cardiac chambers and connections	Diagnosis	ICD-10-CM
Q20.9	Congenital malformation of cardiac chambers and connections, unspecified	Diagnosis	ICD-10-CM
Q21.0	Ventricular septal defect	Diagnosis	ICD-10-CM
Q21.1	Atrial septal defect	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Q21.2	Atrioventricular septal defect	Diagnosis	ICD-10-CM
Q21.3	Tetralogy of Fallot	Diagnosis	ICD-10-CM
Q21.4	Aortopulmonary septal defect	Diagnosis	ICD-10-CM
Q21.8	Other congenital malformations of cardiac septa	Diagnosis	ICD-10-CM
Q21.9	Congenital malformation of cardiac septum, unspecified	Diagnosis	ICD-10-CM
Q22.0	Pulmonary valve atresia	Diagnosis	ICD-10-CM
Q22.1	Congenital pulmonary valve stenosis	Diagnosis	ICD-10-CM
Q22.2	Congenital pulmonary valve insufficiency	Diagnosis	ICD-10-CM
Q22.3	Other congenital malformations of pulmonary valve	Diagnosis	ICD-10-CM
Q22.4	Congenital tricuspid stenosis	Diagnosis	ICD-10-CM
Q22.5	Ebstein's anomaly	Diagnosis	ICD-10-CM
Q22.6	Hypoplastic right heart syndrome	Diagnosis	ICD-10-CM
Q22.8	Other congenital malformations of tricuspid valve	Diagnosis	ICD-10-CM
Q22.9	Congenital malformation of tricuspid valve, unspecified	Diagnosis	ICD-10-CM
Q23.0	Congenital stenosis of aortic valve	Diagnosis	ICD-10-CM
Q23.1	Congenital insufficiency of aortic valve	Diagnosis	ICD-10-CM
Q23.2	Congenital mitral stenosis	Diagnosis	ICD-10-CM
Q23.3	Congenital mitral insufficiency	Diagnosis	ICD-10-CM
Q23.4	Hypoplastic left heart syndrome	Diagnosis	ICD-10-CM
Q23.8	Other congenital malformations of aortic and mitral valves	Diagnosis	ICD-10-CM
Q23.9	Congenital malformation of aortic and mitral valves, unspecified	Diagnosis	ICD-10-CM
Q24.0	Dextrocardia	Diagnosis	ICD-10-CM
Q24.1	Levocardia	Diagnosis	ICD-10-CM
Q24.2	Cor triatriatum	Diagnosis	ICD-10-CM
Q24.3	Pulmonary infundibular stenosis	Diagnosis	ICD-10-CM
Q24.4	Congenital subaortic stenosis	Diagnosis	ICD-10-CM
Q24.5	Malformation of coronary vessels	Diagnosis	ICD-10-CM
Q24.6	Congenital heart block	Diagnosis	ICD-10-CM
Q24.8	Other specified congenital malformations of heart	Diagnosis	ICD-10-CM
Q24.9	Congenital malformation of heart, unspecified	Diagnosis	ICD-10-CM
Q25.0	Patent ductus arteriosus	Diagnosis	ICD-10-CM
Q25.1	Coarctation of aorta	Diagnosis	ICD-10-CM
Q25.21	Interruption of aortic arch	Diagnosis	ICD-10-CM
Q25.29	Other atresia of aorta	Diagnosis	ICD-10-CM
Q25.3	Supravalvular aortic stenosis	Diagnosis	ICD-10-CM
Q25.40	Congenital malformation of aorta unspecified	Diagnosis	ICD-10-CM
Q25.41	Absence and aplasia of aorta	Diagnosis	ICD-10-CM
Q25.42	Hypoplasia of aorta	Diagnosis	ICD-10-CM
Q25.43	Congenital aneurysm of aorta	Diagnosis	ICD-10-CM
Q25.44	Congenital dilation of aorta	Diagnosis	ICD-10-CM
Q25.45	Double aortic arch	Diagnosis	ICD-10-CM
Q25.46	Tortuous aortic arch	Diagnosis	ICD-10-CM
Q25.47	Right aortic arch	Diagnosis	ICD-10-CM
Q25.48	Anomalous origin of subclavian artery	Diagnosis	ICD-10-CM
Q25.49	Other congenital malformations of aorta	Diagnosis	ICD-10-CM
Q25.5	Atresia of pulmonary artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Q25.6	Stenosis of pulmonary artery	Diagnosis	ICD-10-CM
Q25.71	Coarctation of pulmonary artery	Diagnosis	ICD-10-CM
Q25.72	Congenital pulmonary arteriovenous malformation	Diagnosis	ICD-10-CM
Q25.79	Other congenital malformations of pulmonary artery	Diagnosis	ICD-10-CM
Q25.8	Other congenital malformations of other great arteries	Diagnosis	ICD-10-CM
Q25.9	Congenital malformation of great arteries, unspecified	Diagnosis	ICD-10-CM
Q26.0	Congenital stenosis of vena cava	Diagnosis	ICD-10-CM
Q26.1	Persistent left superior vena cava	Diagnosis	ICD-10-CM
Q26.2	Total anomalous pulmonary venous connection	Diagnosis	ICD-10-CM
Q26.3	Partial anomalous pulmonary venous connection	Diagnosis	ICD-10-CM
Q26.4	Anomalous pulmonary venous connection, unspecified	Diagnosis	ICD-10-CM
Q87.40	Marfan's syndrome, unspecified	Diagnosis	ICD-10-CM
Q87.410	Marfan's syndrome with aortic dilation	Diagnosis	ICD-10-CM
Q87.418	Marfan's syndrome with other cardiovascular manifestations	Diagnosis	ICD-10-CM
Q87.82	Arterial tortuosity syndrome	Diagnosis	ICD-10-CM
Q90.0	Trisomy 21, nonmosaicism (meiotic nondisjunction)	Diagnosis	ICD-10-CM
Q90.1	Trisomy 21, mosaicism (mitotic nondisjunction)	Diagnosis	ICD-10-CM
Q90.2	Trisomy 21, translocation	Diagnosis	ICD-10-CM
Q90.9	Down syndrome, unspecified	Diagnosis	ICD-10-CM
Q91.0	Trisomy 18, nonmosaicism (meiotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.1	Trisomy 18, mosaicism (mitotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.2	Trisomy 18, translocation	Diagnosis	ICD-10-CM
Q91.3	Trisomy 18, unspecified	Diagnosis	ICD-10-CM
Q91.4	Trisomy 13, nonmosaicism (meiotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.5	Trisomy 13, mosaicism (mitotic nondisjunction)	Diagnosis	ICD-10-CM
Q91.6	Trisomy 13, translocation	Diagnosis	ICD-10-CM
Q91.7	Trisomy 13, unspecified	Diagnosis	ICD-10-CM
Q93.81	Velo-cardio-facial syndrome	Diagnosis	ICD-10-CM
Q93.82	Williams syndrome	Diagnosis	ICD-10-CM
	Lung Cancer		
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
	Breast Cancer		
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
Z17.0	Estrogen receptor positive status [ER+]	Diagnosis	ICD-10-CM
Z17.1	Estrogen receptor negative status [ER-]	Diagnosis	ICD-10-CM
Z19.1	Hormone sensitive malignancy status	Diagnosis	ICD-10-CM
Z19.2	Hormone resistant malignancy status	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z86.000	Personal history of in-situ neoplasm of breast	Diagnosis	ICD-10-CM
	Colorectal Cancer		
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
	Prostate Cancer		
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
	Endometrial Cancer		
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
	Other Cancer		
C00.0	Malignant neoplasm of external upper lip	Diagnosis	ICD-10-CM
C00.1	Malignant neoplasm of external lower lip	Diagnosis	ICD-10-CM
C00.2	Malignant neoplasm of external lip, unspecified	Diagnosis	ICD-10-CM
C00.3	Malignant neoplasm of upper lip, inner aspect	Diagnosis	ICD-10-CM
C00.4	Malignant neoplasm of lower lip, inner aspect	Diagnosis	ICD-10-CM
C00.5	Malignant neoplasm of lip, unspecified, inner aspect	Diagnosis	ICD-10-CM
C00.6	Malignant neoplasm of commissure of lip, unspecified	Diagnosis	ICD-10-CM
C00.8	Malignant neoplasm of overlapping sites of lip	Diagnosis	ICD-10-CM
C00.9	Malignant neoplasm of lip, unspecified	Diagnosis	ICD-10-CM
C01	Malignant neoplasm of base of tongue	Diagnosis	ICD-10-CM
C02.0	Malignant neoplasm of dorsal surface of tongue	Diagnosis	ICD-10-CM
C02.1	Malignant neoplasm of border of tongue	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C02.2	Malignant neoplasm of ventral surface of tongue	Diagnosis	ICD-10-CM
C02.3	Malignant neoplasm of anterior two-thirds of tongue, part unspecified	Diagnosis	ICD-10-CM
C02.4	Malignant neoplasm of lingual tonsil	Diagnosis	ICD-10-CM
C02.8	Malignant neoplasm of overlapping sites of tongue	Diagnosis	ICD-10-CM
C02.9	Malignant neoplasm of tongue, unspecified	Diagnosis	ICD-10-CM
C03.0	Malignant neoplasm of upper gum	Diagnosis	ICD-10-CM
C03.1	Malignant neoplasm of lower gum	Diagnosis	ICD-10-CM
C03.9	Malignant neoplasm of gum, unspecified	Diagnosis	ICD-10-CM
C04.0	Malignant neoplasm of anterior floor of mouth	Diagnosis	ICD-10-CM
C04.1	Malignant neoplasm of lateral floor of mouth	Diagnosis	ICD-10-CM
C04.8	Malignant neoplasm of overlapping sites of floor of mouth	Diagnosis	ICD-10-CM
C04.9	Malignant neoplasm of floor of mouth, unspecified	Diagnosis	ICD-10-CM
C05.0	Malignant neoplasm of hard palate	Diagnosis	ICD-10-CM
C05.1	Malignant neoplasm of soft palate	Diagnosis	ICD-10-CM
C05.2	Malignant neoplasm of uvula	Diagnosis	ICD-10-CM
C05.8	Malignant neoplasm of overlapping sites of palate	Diagnosis	ICD-10-CM
C05.9	Malignant neoplasm of palate, unspecified	Diagnosis	ICD-10-CM
C06.0	Malignant neoplasm of cheek mucosa	Diagnosis	ICD-10-CM
C06.1	Malignant neoplasm of vestibule of mouth	Diagnosis	ICD-10-CM
C06.2	Malignant neoplasm of retromolar area	Diagnosis	ICD-10-CM
C06.80	Malignant neoplasm of overlapping sites of unspecified parts of mouth	Diagnosis	ICD-10-CM
C06.89	Malignant neoplasm of overlapping sites of other parts of mouth	Diagnosis	ICD-10-CM
C06.9	Malignant neoplasm of mouth, unspecified	Diagnosis	ICD-10-CM
C07	Malignant neoplasm of parotid gland	Diagnosis	ICD-10-CM
C08.0	Malignant neoplasm of submandibular gland	Diagnosis	ICD-10-CM
C08.1	Malignant neoplasm of sublingual gland	Diagnosis	ICD-10-CM
C08.9	Malignant neoplasm of major salivary gland, unspecified	Diagnosis	ICD-10-CM
C09.0	Malignant neoplasm of tonsillar fossa	Diagnosis	ICD-10-CM
C09.1	Malignant neoplasm of tonsillar pillar (anterior) (posterior)	Diagnosis	ICD-10-CM
C09.8	Malignant neoplasm of overlapping sites of tonsil	Diagnosis	ICD-10-CM
C09.9	Malignant neoplasm of tonsil, unspecified	Diagnosis	ICD-10-CM
C10.0	Malignant neoplasm of vallecula	Diagnosis	ICD-10-CM
C10.1	Malignant neoplasm of anterior surface of epiglottis	Diagnosis	ICD-10-CM
C10.2	Malignant neoplasm of lateral wall of oropharynx	Diagnosis	ICD-10-CM
C10.3	Malignant neoplasm of posterior wall of oropharynx	Diagnosis	ICD-10-CM
C10.4	Malignant neoplasm of branchial cleft	Diagnosis	ICD-10-CM
C10.8	Malignant neoplasm of overlapping sites of oropharynx	Diagnosis	ICD-10-CM
C10.9	Malignant neoplasm of oropharynx, unspecified	Diagnosis	ICD-10-CM
C11.0	Malignant neoplasm of superior wall of nasopharynx	Diagnosis	ICD-10-CM
C11.1	Malignant neoplasm of posterior wall of nasopharynx	Diagnosis	ICD-10-CM
C11.2	Malignant neoplasm of lateral wall of nasopharynx	Diagnosis	ICD-10-CM
C11.3	Malignant neoplasm of anterior wall of nasopharynx	Diagnosis	ICD-10-CM
C11.8	Malignant neoplasm of overlapping sites of nasopharynx	Diagnosis	ICD-10-CM
C11.9	Malignant neoplasm of nasopharynx, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C12	Malignant neoplasm of pyriform sinus	Diagnosis	ICD-10-CM
C13.0	Malignant neoplasm of postcricoid region	Diagnosis	ICD-10-CM
C13.1	Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect	Diagnosis	ICD-10-CM
C13.2	Malignant neoplasm of posterior wall of hypopharynx	Diagnosis	ICD-10-CM
C13.8	Malignant neoplasm of overlapping sites of hypopharynx	Diagnosis	ICD-10-CM
C13.9	Malignant neoplasm of hypopharynx, unspecified	Diagnosis	ICD-10-CM
C14.0	Malignant neoplasm of pharynx, unspecified	Diagnosis	ICD-10-CM
C14.2	Malignant neoplasm of Waldeyer's ring	Diagnosis	ICD-10-CM
C14.8	Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx	Diagnosis	ICD-10-CM
C15.3	Malignant neoplasm of upper third of esophagus	Diagnosis	ICD-10-CM
C15.4	Malignant neoplasm of middle third of esophagus	Diagnosis	ICD-10-CM
C15.5	Malignant neoplasm of lower third of esophagus	Diagnosis	ICD-10-CM
C15.8	Malignant neoplasm of overlapping sites of esophagus	Diagnosis	ICD-10-CM
C15.9	Malignant neoplasm of esophagus, unspecified	Diagnosis	ICD-10-CM
C16.0	Malignant neoplasm of cardia	Diagnosis	ICD-10-CM
C16.1	Malignant neoplasm of fundus of stomach	Diagnosis	ICD-10-CM
C16.2	Malignant neoplasm of body of stomach	Diagnosis	ICD-10-CM
C16.3	Malignant neoplasm of pyloric antrum	Diagnosis	ICD-10-CM
C16.4	Malignant neoplasm of pylorus	Diagnosis	ICD-10-CM
C16.5	Malignant neoplasm of lesser curvature of stomach, unspecified	Diagnosis	ICD-10-CM
C16.6	Malignant neoplasm of greater curvature of stomach, unspecified	Diagnosis	ICD-10-CM
C16.8	Malignant neoplasm of overlapping sites of stomach	Diagnosis	ICD-10-CM
C16.9	Malignant neoplasm of stomach, unspecified	Diagnosis	ICD-10-CM
C17.0	Malignant neoplasm of duodenum	Diagnosis	ICD-10-CM
C17.1	Malignant neoplasm of jejunum	Diagnosis	ICD-10-CM
C17.2	Malignant neoplasm of ileum	Diagnosis	ICD-10-CM
C17.3	Meckel's diverticulum, malignant	Diagnosis	ICD-10-CM
C17.8	Malignant neoplasm of overlapping sites of small intestine	Diagnosis	ICD-10-CM
C17.9	Malignant neoplasm of small intestine, unspecified	Diagnosis	ICD-10-CM
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C21.0	Malignant neoplasm of anus, unspecified	Diagnosis	ICD-10-CM
C21.1	Malignant neoplasm of anal canal	Diagnosis	ICD-10-CM
C21.2	Malignant neoplasm of cloacogenic zone	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal	Diagnosis	ICD-10-CM
C22.0	Liver cell carcinoma	Diagnosis	ICD-10-CM
C22.1	Intrahepatic bile duct carcinoma	Diagnosis	ICD-10-CM
C22.2	Hepatoblastoma	Diagnosis	ICD-10-CM
C22.3	Angiosarcoma of liver	Diagnosis	ICD-10-CM
C22.4	Other sarcomas of liver	Diagnosis	ICD-10-CM
C22.7	Other specified carcinomas of liver	Diagnosis	ICD-10-CM
C22.8	Malignant neoplasm of liver, primary, unspecified as to type	Diagnosis	ICD-10-CM
C22.9	Malignant neoplasm of liver, not specified as primary or secondary	Diagnosis	ICD-10-CM
C23	Malignant neoplasm of gallbladder	Diagnosis	ICD-10-CM
C24.0	Malignant neoplasm of extrahepatic bile duct	Diagnosis	ICD-10-CM
C24.1	Malignant neoplasm of ampulla of Vater	Diagnosis	ICD-10-CM
C24.8	Malignant neoplasm of overlapping sites of biliary tract	Diagnosis	ICD-10-CM
C24.9	Malignant neoplasm of biliary tract, unspecified	Diagnosis	ICD-10-CM
C25.0	Malignant neoplasm of head of pancreas	Diagnosis	ICD-10-CM
C25.1	Malignant neoplasm of body of pancreas	Diagnosis	ICD-10-CM
C25.2	Malignant neoplasm of tail of pancreas	Diagnosis	ICD-10-CM
C25.3	Malignant neoplasm of pancreatic duct	Diagnosis	ICD-10-CM
C25.4	Malignant neoplasm of endocrine pancreas	Diagnosis	ICD-10-CM
C25.7	Malignant neoplasm of other parts of pancreas	Diagnosis	ICD-10-CM
C25.8	Malignant neoplasm of overlapping sites of pancreas	Diagnosis	ICD-10-CM
C25.9	Malignant neoplasm of pancreas, unspecified	Diagnosis	ICD-10-CM
C26.0	Malignant neoplasm of intestinal tract, part unspecified	Diagnosis	ICD-10-CM
C26.1	Malignant neoplasm of spleen	Diagnosis	ICD-10-CM
C26.9	Malignant neoplasm of ill-defined sites within the digestive system	Diagnosis	ICD-10-CM
C30.0	Malignant neoplasm of nasal cavity	Diagnosis	ICD-10-CM
C30.1	Malignant neoplasm of middle ear	Diagnosis	ICD-10-CM
C31.0	Malignant neoplasm of maxillary sinus	Diagnosis	ICD-10-CM
C31.1	Malignant neoplasm of ethmoidal sinus	Diagnosis	ICD-10-CM
C31.2	Malignant neoplasm of frontal sinus	Diagnosis	ICD-10-CM
C31.3	Malignant neoplasm of sphenoid sinus	Diagnosis	ICD-10-CM
C31.8	Malignant neoplasm of overlapping sites of accessory sinuses	Diagnosis	ICD-10-CM
C31.9	Malignant neoplasm of accessory sinus, unspecified	Diagnosis	ICD-10-CM
C32.0	Malignant neoplasm of glottis	Diagnosis	ICD-10-CM
C32.1	Malignant neoplasm of supraglottis	Diagnosis	ICD-10-CM
C32.2	Malignant neoplasm of subglottis	Diagnosis	ICD-10-CM
C32.3	Malignant neoplasm of laryngeal cartilage	Diagnosis	ICD-10-CM
C32.8	Malignant neoplasm of overlapping sites of larynx	Diagnosis	ICD-10-CM
C32.9	Malignant neoplasm of larynx, unspecified	Diagnosis	ICD-10-CM
C33	Malignant neoplasm of trachea	Diagnosis	ICD-10-CM
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
C37	Malignant neoplasm of thymus	Diagnosis	ICD-10-CM
C38.0	Malignant neoplasm of heart	Diagnosis	ICD-10-CM
C38.1	Malignant neoplasm of anterior mediastinum	Diagnosis	ICD-10-CM
C38.2	Malignant neoplasm of posterior mediastinum	Diagnosis	ICD-10-CM
C38.3	Malignant neoplasm of mediastinum, part unspecified	Diagnosis	ICD-10-CM
C38.4	Malignant neoplasm of pleura	Diagnosis	ICD-10-CM
C38.8	Malignant neoplasm of overlapping sites of heart, mediastinum and pleura	Diagnosis	ICD-10-CM
C39.0	Malignant neoplasm of upper respiratory tract, part unspecified	Diagnosis	ICD-10-CM
C39.9	Malignant neoplasm of lower respiratory tract, part unspecified	Diagnosis	ICD-10-CM
C40.00	Malignant neoplasm of scapula and long bones of unspecified upper limb	Diagnosis	ICD-10-CM
C40.01	Malignant neoplasm of scapula and long bones of right upper limb	Diagnosis	ICD-10-CM
C40.02	Malignant neoplasm of scapula and long bones of left upper limb	Diagnosis	ICD-10-CM
C40.10	Malignant neoplasm of short bones of unspecified upper limb	Diagnosis	ICD-10-CM
C40.11	Malignant neoplasm of short bones of right upper limb	Diagnosis	ICD-10-CM
C40.12	Malignant neoplasm of short bones of left upper limb	Diagnosis	ICD-10-CM
C40.20	Malignant neoplasm of long bones of unspecified lower limb	Diagnosis	ICD-10-CM
C40.21	Malignant neoplasm of long bones of right lower limb	Diagnosis	ICD-10-CM
C40.22	Malignant neoplasm of long bones of left lower limb	Diagnosis	ICD-10-CM
C40.30	Malignant neoplasm of short bones of unspecified lower limb	Diagnosis	ICD-10-CM
C40.31	Malignant neoplasm of short bones of right lower limb	Diagnosis	ICD-10-CM
C40.32	Malignant neoplasm of short bones of left lower limb	Diagnosis	ICD-10-CM
C40.80	Malignant neoplasm of overlapping sites of bone and articular cartilage of unspecified limb	Diagnosis	ICD-10-CM
C40.81	Malignant neoplasm of overlapping sites of bone and articular cartilage of right limb	Diagnosis	ICD-10-CM
C40.82	Malignant neoplasm of overlapping sites of bone and articular cartilage of left limb	Diagnosis	ICD-10-CM
C40.90	Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb	Diagnosis	ICD-10-CM
C40.91	Malignant neoplasm of unspecified bones and articular cartilage of right limb	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C40.92	Malignant neoplasm of unspecified bones and articular cartilage of left limb	Diagnosis	ICD-10-CM
C41.0	Malignant neoplasm of bones of skull and face	Diagnosis	ICD-10-CM
C41.1	Malignant neoplasm of mandible	Diagnosis	ICD-10-CM
C41.2	Malignant neoplasm of vertebral column	Diagnosis	ICD-10-CM
C41.3	Malignant neoplasm of ribs, sternum and clavicle	Diagnosis	ICD-10-CM
C41.4	Malignant neoplasm of pelvic bones, sacrum and coccyx	Diagnosis	ICD-10-CM
C41.9	Malignant neoplasm of bone and articular cartilage, unspecified	Diagnosis	ICD-10-CM
C43.0	Malignant melanoma of lip	Diagnosis	ICD-10-CM
C43.10	Malignant melanoma of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C43.11	Malignant melanoma of right eyelid, including canthus	Diagnosis	ICD-10-CM
C43.111	Malignant melanoma of right upper eyelid, including canthus	Diagnosis	ICD-10-CM
C43.112	Malignant melanoma of right lower eyelid, including canthus	Diagnosis	ICD-10-CM
C43.12	Malignant melanoma of left eyelid, including canthus	Diagnosis	ICD-10-CM
C43.121	Malignant melanoma of left upper eyelid, including canthus	Diagnosis	ICD-10-CM
C43.122	Malignant melanoma of left lower eyelid, including canthus	Diagnosis	ICD-10-CM
C43.20	Malignant melanoma of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C43.21	Malignant melanoma of right ear and external auricular canal	Diagnosis	ICD-10-CM
C43.22	Malignant melanoma of left ear and external auricular canal	Diagnosis	ICD-10-CM
C43.30	Malignant melanoma of unspecified part of face	Diagnosis	ICD-10-CM
C43.31	Malignant melanoma of nose	Diagnosis	ICD-10-CM
C43.39	Malignant melanoma of other parts of face	Diagnosis	ICD-10-CM
C43.4	Malignant melanoma of scalp and neck	Diagnosis	ICD-10-CM
C43.51	Malignant melanoma of anal skin	Diagnosis	ICD-10-CM
C43.52	Malignant melanoma of skin of breast	Diagnosis	ICD-10-CM
C43.59	Malignant melanoma of other part of trunk	Diagnosis	ICD-10-CM
C43.60	Malignant melanoma of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.61	Malignant melanoma of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.62	Malignant melanoma of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.70	Malignant melanoma of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C43.71	Malignant melanoma of right lower limb, including hip	Diagnosis	ICD-10-CM
C43.72	Malignant melanoma of left lower limb, including hip	Diagnosis	ICD-10-CM
C43.8	Malignant melanoma of overlapping sites of skin	Diagnosis	ICD-10-CM
C43.9	Malignant melanoma of skin, unspecified	Diagnosis	ICD-10-CM
C45.0	Mesothelioma of pleura	Diagnosis	ICD-10-CM
C45.1	Mesothelioma of peritoneum	Diagnosis	ICD-10-CM
C45.2	Mesothelioma of pericardium	Diagnosis	ICD-10-CM
C45.7	Mesothelioma of other sites	Diagnosis	ICD-10-CM
C45.9	Mesothelioma, unspecified	Diagnosis	ICD-10-CM
C46.0	Kaposi's sarcoma of skin	Diagnosis	ICD-10-CM
C46.1	Kaposi's sarcoma of soft tissue	Diagnosis	ICD-10-CM
C46.2	Kaposi's sarcoma of palate	Diagnosis	ICD-10-CM
C46.3	Kaposi's sarcoma of lymph nodes	Diagnosis	ICD-10-CM
C46.4	Kaposi's sarcoma of gastrointestinal sites	Diagnosis	ICD-10-CM
C46.50	Kaposi's sarcoma of unspecified lung	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C46.51	Kaposi's sarcoma of right lung	Diagnosis	ICD-10-CM
C46.52	Kaposi's sarcoma of left lung	Diagnosis	ICD-10-CM
C46.7	Kaposi's sarcoma of other sites	Diagnosis	ICD-10-CM
C46.9	Kaposi's sarcoma, unspecified	Diagnosis	ICD-10-CM
C47.0	Malignant neoplasm of peripheral nerves of head, face and neck	Diagnosis	ICD-10-CM
C47.10	Malignant neoplasm of peripheral nerves of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.11	Malignant neoplasm of peripheral nerves of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.12	Malignant neoplasm of peripheral nerves of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.20	Malignant neoplasm of peripheral nerves of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C47.21	Malignant neoplasm of peripheral nerves of right lower limb, including hip	Diagnosis	ICD-10-CM
C47.22	Malignant neoplasm of peripheral nerves of left lower limb, including hip	Diagnosis	ICD-10-CM
C47.3	Malignant neoplasm of peripheral nerves of thorax	Diagnosis	ICD-10-CM
C47.4	Malignant neoplasm of peripheral nerves of abdomen	Diagnosis	ICD-10-CM
C47.5	Malignant neoplasm of peripheral nerves of pelvis	Diagnosis	ICD-10-CM
C47.6	Malignant neoplasm of peripheral nerves of trunk, unspecified	Diagnosis	ICD-10-CM
C47.8	Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system	Diagnosis	ICD-10-CM
C47.9	Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified	Diagnosis	ICD-10-CM
C48.0	Malignant neoplasm of retroperitoneum	Diagnosis	ICD-10-CM
C48.1	Malignant neoplasm of specified parts of peritoneum	Diagnosis	ICD-10-CM
C48.2	Malignant neoplasm of peritoneum, unspecified	Diagnosis	ICD-10-CM
C48.8	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum	Diagnosis	ICD-10-CM
C49.0	Malignant neoplasm of connective and soft tissue of head, face and neck	Diagnosis	ICD-10-CM
C49.10	Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C49.11	Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C49.12	Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C49.20	Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C49.21	Malignant neoplasm of connective and soft tissue of right lower limb, including hip	Diagnosis	ICD-10-CM
C49.22	Malignant neoplasm of connective and soft tissue of left lower limb, including hip	Diagnosis	ICD-10-CM
C49.3	Malignant neoplasm of connective and soft tissue of thorax	Diagnosis	ICD-10-CM
C49.4	Malignant neoplasm of connective and soft tissue of abdomen	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C49.5	Malignant neoplasm of connective and soft tissue of pelvis	Diagnosis	ICD-10-CM
C49.6	Malignant neoplasm of connective and soft tissue of trunk, unspecified	Diagnosis	ICD-10-CM
C49.8	Malignant neoplasm of overlapping sites of connective and soft tissue	Diagnosis	ICD-10-CM
C49.9	Malignant neoplasm of connective and soft tissue, unspecified	Diagnosis	ICD-10-CM
C49.A0	Gastrointestinal stromal tumor, unspecified site	Diagnosis	ICD-10-CM
C49.A1	Gastrointestinal stromal tumor of esophagus	Diagnosis	ICD-10-CM
C49.A2	Gastrointestinal stromal tumor of stomach	Diagnosis	ICD-10-CM
C49.A3	Gastrointestinal stromal tumor of small intestine	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
C49.A9	Gastrointestinal stromal tumor of other sites	Diagnosis	ICD-10-CM
C4A.0	Merkel cell carcinoma of lip	Diagnosis	ICD-10-CM
C4A.10	Merkel cell carcinoma of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.11	Merkel cell carcinoma of right eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.111	Merkel cell carcinoma of right upper eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.112	Merkel cell carcinoma of right lower eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.12	Merkel cell carcinoma of left eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.121	Merkel cell carcinoma of left upper eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.122	Merkel cell carcinoma of left lower eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.20	Merkel cell carcinoma of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C4A.21	Merkel cell carcinoma of right ear and external auricular canal	Diagnosis	ICD-10-CM
C4A.22	Merkel cell carcinoma of left ear and external auricular canal	Diagnosis	ICD-10-CM
C4A.30	Merkel cell carcinoma of unspecified part of face	Diagnosis	ICD-10-CM
C4A.31	Merkel cell carcinoma of nose	Diagnosis	ICD-10-CM
C4A.39	Merkel cell carcinoma of other parts of face	Diagnosis	ICD-10-CM
C4A.4	Merkel cell carcinoma of scalp and neck	Diagnosis	ICD-10-CM
C4A.51	Merkel cell carcinoma of anal skin	Diagnosis	ICD-10-CM
C4A.52	Merkel cell carcinoma of skin of breast	Diagnosis	ICD-10-CM
C4A.59	Merkel cell carcinoma of other part of trunk	Diagnosis	ICD-10-CM
C4A.60	Merkel cell carcinoma of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.61	Merkel cell carcinoma of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.62	Merkel cell carcinoma of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.70	Merkel cell carcinoma of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C4A.71	Merkel cell carcinoma of right lower limb, including hip	Diagnosis	ICD-10-CM
C4A.72	Merkel cell carcinoma of left lower limb, including hip	Diagnosis	ICD-10-CM
C4A.8	Merkel cell carcinoma of overlapping sites	Diagnosis	ICD-10-CM
C4A.9	Merkel cell carcinoma, unspecified	Diagnosis	ICD-10-CM
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
C51.0	Malignant neoplasm of labium majus	Diagnosis	ICD-10-CM
C51.1	Malignant neoplasm of labium minus	Diagnosis	ICD-10-CM
C51.2	Malignant neoplasm of clitoris	Diagnosis	ICD-10-CM
C51.8	Malignant neoplasm of overlapping sites of vulva	Diagnosis	ICD-10-CM
C51.9	Malignant neoplasm of vulva, unspecified	Diagnosis	ICD-10-CM
C52	Malignant neoplasm of vagina	Diagnosis	ICD-10-CM
C53.0	Malignant neoplasm of endocervix	Diagnosis	ICD-10-CM
C53.1	Malignant neoplasm of exocervix	Diagnosis	ICD-10-CM
C53.8	Malignant neoplasm of overlapping sites of cervix uteri	Diagnosis	ICD-10-CM
C53.9	Malignant neoplasm of cervix uteri, unspecified	Diagnosis	ICD-10-CM
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
C55	Malignant neoplasm of uterus, part unspecified	Diagnosis	ICD-10-CM
C56.1	Malignant neoplasm of right ovary	Diagnosis	ICD-10-CM
C56.2	Malignant neoplasm of left ovary	Diagnosis	ICD-10-CM
C56.9	Malignant neoplasm of unspecified ovary	Diagnosis	ICD-10-CM
C57.00	Malignant neoplasm of unspecified fallopian tube	Diagnosis	ICD-10-CM
C57.01	Malignant neoplasm of right fallopian tube	Diagnosis	ICD-10-CM
C57.02	Malignant neoplasm of left fallopian tube	Diagnosis	ICD-10-CM
C57.10	Malignant neoplasm of unspecified broad ligament	Diagnosis	ICD-10-CM
C57.11	Malignant neoplasm of right broad ligament	Diagnosis	ICD-10-CM
C57.12	Malignant neoplasm of left broad ligament	Diagnosis	ICD-10-CM
C57.20	Malignant neoplasm of unspecified round ligament	Diagnosis	ICD-10-CM
C57.21	Malignant neoplasm of right round ligament	Diagnosis	ICD-10-CM
C57.22	Malignant neoplasm of left round ligament	Diagnosis	ICD-10-CM
C57.3	Malignant neoplasm of parametrium	Diagnosis	ICD-10-CM
C57.4	Malignant neoplasm of uterine adnexa, unspecified	Diagnosis	ICD-10-CM
C57.7	Malignant neoplasm of other specified female genital organs	Diagnosis	ICD-10-CM
C57.8	Malignant neoplasm of overlapping sites of female genital organs	Diagnosis	ICD-10-CM
C57.9	Malignant neoplasm of female genital organ, unspecified	Diagnosis	ICD-10-CM
C58	Malignant neoplasm of placenta	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C60.0	Malignant neoplasm of prepuce	Diagnosis	ICD-10-CM
C60.1	Malignant neoplasm of glans penis	Diagnosis	ICD-10-CM
C60.2	Malignant neoplasm of body of penis	Diagnosis	ICD-10-CM
C60.8	Malignant neoplasm of overlapping sites of penis	Diagnosis	ICD-10-CM
C60.9	Malignant neoplasm of penis, unspecified	Diagnosis	ICD-10-CM
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
C62.00	Malignant neoplasm of unspecified undescended testis	Diagnosis	ICD-10-CM
C62.01	Malignant neoplasm of undescended right testis	Diagnosis	ICD-10-CM
C62.02	Malignant neoplasm of undescended left testis	Diagnosis	ICD-10-CM
C62.10	Malignant neoplasm of unspecified descended testis	Diagnosis	ICD-10-CM
C62.11	Malignant neoplasm of descended right testis	Diagnosis	ICD-10-CM
C62.12	Malignant neoplasm of descended left testis	Diagnosis	ICD-10-CM
C62.90	Malignant neoplasm of unspecified testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C62.91	Malignant neoplasm of right testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C62.92	Malignant neoplasm of left testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C63.00	Malignant neoplasm of unspecified epididymis	Diagnosis	ICD-10-CM
C63.01	Malignant neoplasm of right epididymis	Diagnosis	ICD-10-CM
C63.02	Malignant neoplasm of left epididymis	Diagnosis	ICD-10-CM
C63.10	Malignant neoplasm of unspecified spermatic cord	Diagnosis	ICD-10-CM
C63.11	Malignant neoplasm of right spermatic cord	Diagnosis	ICD-10-CM
C63.12	Malignant neoplasm of left spermatic cord	Diagnosis	ICD-10-CM
C63.2	Malignant neoplasm of scrotum	Diagnosis	ICD-10-CM
C63.7	Malignant neoplasm of other specified male genital organs	Diagnosis	ICD-10-CM
C63.8	Malignant neoplasm of overlapping sites of male genital organs	Diagnosis	ICD-10-CM
C63.9	Malignant neoplasm of male genital organ, unspecified	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C65.1	Malignant neoplasm of right renal pelvis	Diagnosis	ICD-10-CM
C65.2	Malignant neoplasm of left renal pelvis	Diagnosis	ICD-10-CM
C65.9	Malignant neoplasm of unspecified renal pelvis	Diagnosis	ICD-10-CM
C66.1	Malignant neoplasm of right ureter	Diagnosis	ICD-10-CM
C66.2	Malignant neoplasm of left ureter	Diagnosis	ICD-10-CM
C66.9	Malignant neoplasm of unspecified ureter	Diagnosis	ICD-10-CM
C67.0	Malignant neoplasm of trigone of bladder	Diagnosis	ICD-10-CM
C67.1	Malignant neoplasm of dome of bladder	Diagnosis	ICD-10-CM
C67.2	Malignant neoplasm of lateral wall of bladder	Diagnosis	ICD-10-CM
C67.3	Malignant neoplasm of anterior wall of bladder	Diagnosis	ICD-10-CM
C67.4	Malignant neoplasm of posterior wall of bladder	Diagnosis	ICD-10-CM
C67.5	Malignant neoplasm of bladder neck	Diagnosis	ICD-10-CM
C67.6	Malignant neoplasm of ureteric orifice	Diagnosis	ICD-10-CM
C67.7	Malignant neoplasm of urachus	Diagnosis	ICD-10-CM
C67.8	Malignant neoplasm of overlapping sites of bladder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C67.9	Malignant neoplasm of bladder, unspecified	Diagnosis	ICD-10-CM
C68.0	Malignant neoplasm of urethra	Diagnosis	ICD-10-CM
C68.1	Malignant neoplasm of paraurethral glands	Diagnosis	ICD-10-CM
C68.8	Malignant neoplasm of overlapping sites of urinary organs	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
C69.00	Malignant neoplasm of unspecified conjunctiva	Diagnosis	ICD-10-CM
C69.01	Malignant neoplasm of right conjunctiva	Diagnosis	ICD-10-CM
C69.02	Malignant neoplasm of left conjunctiva	Diagnosis	ICD-10-CM
C69.10	Malignant neoplasm of unspecified cornea	Diagnosis	ICD-10-CM
C69.11	Malignant neoplasm of right cornea	Diagnosis	ICD-10-CM
C69.12	Malignant neoplasm of left cornea	Diagnosis	ICD-10-CM
C69.20	Malignant neoplasm of unspecified retina	Diagnosis	ICD-10-CM
C69.21	Malignant neoplasm of right retina	Diagnosis	ICD-10-CM
C69.22	Malignant neoplasm of left retina	Diagnosis	ICD-10-CM
C69.30	Malignant neoplasm of unspecified choroid	Diagnosis	ICD-10-CM
C69.31	Malignant neoplasm of right choroid	Diagnosis	ICD-10-CM
C69.32	Malignant neoplasm of left choroid	Diagnosis	ICD-10-CM
C69.40	Malignant neoplasm of unspecified ciliary body	Diagnosis	ICD-10-CM
C69.41	Malignant neoplasm of right ciliary body	Diagnosis	ICD-10-CM
C69.42	Malignant neoplasm of left ciliary body	Diagnosis	ICD-10-CM
C69.50	Malignant neoplasm of unspecified lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.51	Malignant neoplasm of right lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.52	Malignant neoplasm of left lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.60	Malignant neoplasm of unspecified orbit	Diagnosis	ICD-10-CM
C69.61	Malignant neoplasm of right orbit	Diagnosis	ICD-10-CM
C69.62	Malignant neoplasm of left orbit	Diagnosis	ICD-10-CM
C69.80	Malignant neoplasm of overlapping sites of unspecified eye and adnexa	Diagnosis	ICD-10-CM
C69.81	Malignant neoplasm of overlapping sites of right eye and adnexa	Diagnosis	ICD-10-CM
C69.82	Malignant neoplasm of overlapping sites of left eye and adnexa	Diagnosis	ICD-10-CM
C69.90	Malignant neoplasm of unspecified site of unspecified eye	Diagnosis	ICD-10-CM
C69.91	Malignant neoplasm of unspecified site of right eye	Diagnosis	ICD-10-CM
C69.92	Malignant neoplasm of unspecified site of left eye	Diagnosis	ICD-10-CM
C70.0	Malignant neoplasm of cerebral meninges	Diagnosis	ICD-10-CM
C70.1	Malignant neoplasm of spinal meninges	Diagnosis	ICD-10-CM
C70.9	Malignant neoplasm of meninges, unspecified	Diagnosis	ICD-10-CM
C71.0	Malignant neoplasm of cerebrum, except lobes and ventricles	Diagnosis	ICD-10-CM
C71.1	Malignant neoplasm of frontal lobe	Diagnosis	ICD-10-CM
C71.2	Malignant neoplasm of temporal lobe	Diagnosis	ICD-10-CM
C71.3	Malignant neoplasm of parietal lobe	Diagnosis	ICD-10-CM
C71.4	Malignant neoplasm of occipital lobe	Diagnosis	ICD-10-CM
C71.5	Malignant neoplasm of cerebral ventricle	Diagnosis	ICD-10-CM
C71.6	Malignant neoplasm of cerebellum	Diagnosis	ICD-10-CM
C71.7	Malignant neoplasm of brain stem	Diagnosis	ICD-10-CM
C71.8	Malignant neoplasm of overlapping sites of brain	Diagnosis	ICD-10-CM
C71.9	Malignant neoplasm of brain, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C72.0	Malignant neoplasm of spinal cord	Diagnosis	ICD-10-CM
C72.1	Malignant neoplasm of cauda equina	Diagnosis	ICD-10-CM
C72.20	Malignant neoplasm of unspecified olfactory nerve	Diagnosis	ICD-10-CM
C72.21	Malignant neoplasm of right olfactory nerve	Diagnosis	ICD-10-CM
C72.22	Malignant neoplasm of left olfactory nerve	Diagnosis	ICD-10-CM
C72.30	Malignant neoplasm of unspecified optic nerve	Diagnosis	ICD-10-CM
C72.31	Malignant neoplasm of right optic nerve	Diagnosis	ICD-10-CM
C72.32	Malignant neoplasm of left optic nerve	Diagnosis	ICD-10-CM
C72.40	Malignant neoplasm of unspecified acoustic nerve	Diagnosis	ICD-10-CM
C72.41	Malignant neoplasm of right acoustic nerve	Diagnosis	ICD-10-CM
C72.42	Malignant neoplasm of left acoustic nerve	Diagnosis	ICD-10-CM
C72.50	Malignant neoplasm of unspecified cranial nerve	Diagnosis	ICD-10-CM
C72.59	Malignant neoplasm of other cranial nerves	Diagnosis	ICD-10-CM
C72.9	Malignant neoplasm of central nervous system, unspecified	Diagnosis	ICD-10-CM
C73	Malignant neoplasm of thyroid gland	Diagnosis	ICD-10-CM
C74.00	Malignant neoplasm of cortex of unspecified adrenal gland	Diagnosis	ICD-10-CM
C74.01	Malignant neoplasm of cortex of right adrenal gland	Diagnosis	ICD-10-CM
C74.02	Malignant neoplasm of cortex of left adrenal gland	Diagnosis	ICD-10-CM
C74.10	Malignant neoplasm of medulla of unspecified adrenal gland	Diagnosis	ICD-10-CM
C74.11	Malignant neoplasm of medulla of right adrenal gland	Diagnosis	ICD-10-CM
C74.12	Malignant neoplasm of medulla of left adrenal gland	Diagnosis	ICD-10-CM
C74.90	Malignant neoplasm of unspecified part of unspecified adrenal gland	Diagnosis	ICD-10-CM
C74.91	Malignant neoplasm of unspecified part of right adrenal gland	Diagnosis	ICD-10-CM
C74.92	Malignant neoplasm of unspecified part of left adrenal gland	Diagnosis	ICD-10-CM
C75.0	Malignant neoplasm of parathyroid gland	Diagnosis	ICD-10-CM
C75.1	Malignant neoplasm of pituitary gland	Diagnosis	ICD-10-CM
C75.2	Malignant neoplasm of craniopharyngeal duct	Diagnosis	ICD-10-CM
C75.3	Malignant neoplasm of pineal gland	Diagnosis	ICD-10-CM
C75.4	Malignant neoplasm of carotid body	Diagnosis	ICD-10-CM
C75.5	Malignant neoplasm of aortic body and other paraganglia	Diagnosis	ICD-10-CM
C75.8	Malignant neoplasm with pluriglandular involvement, unspecified	Diagnosis	ICD-10-CM
C75.9	Malignant neoplasm of endocrine gland, unspecified	Diagnosis	ICD-10-CM
C76.0	Malignant neoplasm of head, face and neck	Diagnosis	ICD-10-CM
C76.1	Malignant neoplasm of thorax	Diagnosis	ICD-10-CM
C76.2	Malignant neoplasm of abdomen	Diagnosis	ICD-10-CM
C76.3	Malignant neoplasm of pelvis	Diagnosis	ICD-10-CM
C76.40	Malignant neoplasm of unspecified upper limb	Diagnosis	ICD-10-CM
C76.41	Malignant neoplasm of right upper limb	Diagnosis	ICD-10-CM
C76.42	Malignant neoplasm of left upper limb	Diagnosis	ICD-10-CM
C76.50	Malignant neoplasm of unspecified lower limb	Diagnosis	ICD-10-CM
C76.51	Malignant neoplasm of right lower limb	Diagnosis	ICD-10-CM
C76.52	Malignant neoplasm of left lower limb	Diagnosis	ICD-10-CM
C76.8	Malignant neoplasm of other specified ill-defined sites	Diagnosis	ICD-10-CM
C77.0	Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C77.1	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C77.2	Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C77.3	Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes	Diagnosis	ICD-10-CM
C77.4	Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes	Diagnosis	ICD-10-CM
C77.5	Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C77.8	Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions	Diagnosis	ICD-10-CM
C77.9	Secondary and unspecified malignant neoplasm of lymph node, unspecified	Diagnosis	ICD-10-CM
C78.00	Secondary malignant neoplasm of unspecified lung	Diagnosis	ICD-10-CM
C78.01	Secondary malignant neoplasm of right lung	Diagnosis	ICD-10-CM
C78.02	Secondary malignant neoplasm of left lung	Diagnosis	ICD-10-CM
C78.1	Secondary malignant neoplasm of mediastinum	Diagnosis	ICD-10-CM
C78.2	Secondary malignant neoplasm of pleura	Diagnosis	ICD-10-CM
C78.30	Secondary malignant neoplasm of unspecified respiratory organ	Diagnosis	ICD-10-CM
C78.39	Secondary malignant neoplasm of other respiratory organs	Diagnosis	ICD-10-CM
C78.4	Secondary malignant neoplasm of small intestine	Diagnosis	ICD-10-CM
C78.5	Secondary malignant neoplasm of large intestine and rectum	Diagnosis	ICD-10-CM
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum	Diagnosis	ICD-10-CM
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct	Diagnosis	ICD-10-CM
C78.80	Secondary malignant neoplasm of unspecified digestive organ	Diagnosis	ICD-10-CM
C78.89	Secondary malignant neoplasm of other digestive organs	Diagnosis	ICD-10-CM
C79.00	Secondary malignant neoplasm of unspecified kidney and renal pelvis	Diagnosis	ICD-10-CM
C79.01	Secondary malignant neoplasm of right kidney and renal pelvis	Diagnosis	ICD-10-CM
C79.02	Secondary malignant neoplasm of left kidney and renal pelvis	Diagnosis	ICD-10-CM
C79.10	Secondary malignant neoplasm of unspecified urinary organs	Diagnosis	ICD-10-CM
C79.11	Secondary malignant neoplasm of bladder	Diagnosis	ICD-10-CM
C79.19	Secondary malignant neoplasm of other urinary organs	Diagnosis	ICD-10-CM
C79.2	Secondary malignant neoplasm of skin	Diagnosis	ICD-10-CM
C79.31	Secondary malignant neoplasm of brain	Diagnosis	ICD-10-CM
C79.32	Secondary malignant neoplasm of cerebral meninges	Diagnosis	ICD-10-CM
C79.40	Secondary malignant neoplasm of unspecified part of nervous system	Diagnosis	ICD-10-CM
C79.49	Secondary malignant neoplasm of other parts of nervous system	Diagnosis	ICD-10-CM
C79.51	Secondary malignant neoplasm of bone	Diagnosis	ICD-10-CM
C79.52	Secondary malignant neoplasm of bone marrow	Diagnosis	ICD-10-CM
C79.60	Secondary malignant neoplasm of unspecified ovary	Diagnosis	ICD-10-CM
C79.61	Secondary malignant neoplasm of right ovary	Diagnosis	ICD-10-CM
C79.62	Secondary malignant neoplasm of left ovary	Diagnosis	ICD-10-CM
C79.70	Secondary malignant neoplasm of unspecified adrenal gland	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C79.71	Secondary malignant neoplasm of right adrenal gland	Diagnosis	ICD-10-CM
C79.72	Secondary malignant neoplasm of left adrenal gland	Diagnosis	ICD-10-CM
C79.81	Secondary malignant neoplasm of breast	Diagnosis	ICD-10-CM
C79.82	Secondary malignant neoplasm of genital organs	Diagnosis	ICD-10-CM
C79.89	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-10-CM
C79.9	Secondary malignant neoplasm of unspecified site	Diagnosis	ICD-10-CM
C7A.00	Malignant carcinoid tumor of unspecified site	Diagnosis	ICD-10-CM
C7A.010	Malignant carcinoid tumor of the duodenum	Diagnosis	ICD-10-CM
C7A.011	Malignant carcinoid tumor of the jejunum	Diagnosis	ICD-10-CM
C7A.012	Malignant carcinoid tumor of the ileum	Diagnosis	ICD-10-CM
C7A.019	Malignant carcinoid tumor of the small intestine, unspecified portion	Diagnosis	ICD-10-CM
C7A.020	Malignant carcinoid tumor of the appendix	Diagnosis	ICD-10-CM
C7A.021	Malignant carcinoid tumor of the cecum	Diagnosis	ICD-10-CM
C7A.022	Malignant carcinoid tumor of the ascending colon	Diagnosis	ICD-10-CM
C7A.023	Malignant carcinoid tumor of the transverse colon	Diagnosis	ICD-10-CM
C7A.024	Malignant carcinoid tumor of the descending colon	Diagnosis	ICD-10-CM
C7A.025	Malignant carcinoid tumor of the sigmoid colon	Diagnosis	ICD-10-CM
C7A.026	Malignant carcinoid tumor of the rectum	Diagnosis	ICD-10-CM
C7A.029	Malignant carcinoid tumor of the large intestine, unspecified portion	Diagnosis	ICD-10-CM
C7A.090	Malignant carcinoid tumor of the bronchus and lung	Diagnosis	ICD-10-CM
C7A.091	Malignant carcinoid tumor of the thymus	Diagnosis	ICD-10-CM
C7A.092	Malignant carcinoid tumor of the stomach	Diagnosis	ICD-10-CM
C7A.093	Malignant carcinoid tumor of the kidney	Diagnosis	ICD-10-CM
C7A.094	Malignant carcinoid tumor of the foregut, unspecified	Diagnosis	ICD-10-CM
C7A.095	Malignant carcinoid tumor of the midgut, unspecified	Diagnosis	ICD-10-CM
C7A.096	Malignant carcinoid tumor of the hindgut, unspecified	Diagnosis	ICD-10-CM
C7A.098	Malignant carcinoid tumors of other sites	Diagnosis	ICD-10-CM
C7A.1	Malignant poorly differentiated neuroendocrine tumors	Diagnosis	ICD-10-CM
C7A.8	Other malignant neuroendocrine tumors	Diagnosis	ICD-10-CM
C7B.00	Secondary carcinoid tumors, unspecified site	Diagnosis	ICD-10-CM
C7B.01	Secondary carcinoid tumors of distant lymph nodes	Diagnosis	ICD-10-CM
C7B.02	Secondary carcinoid tumors of liver	Diagnosis	ICD-10-CM
C7B.03	Secondary carcinoid tumors of bone	Diagnosis	ICD-10-CM
C7B.04	Secondary carcinoid tumors of peritoneum	Diagnosis	ICD-10-CM
C7B.09	Secondary carcinoid tumors of other sites	Diagnosis	ICD-10-CM
C7B.1	Secondary Merkel cell carcinoma	Diagnosis	ICD-10-CM
C7B.8	Other secondary neuroendocrine tumors	Diagnosis	ICD-10-CM
C80.0	Disseminated malignant neoplasm, unspecified	Diagnosis	ICD-10-CM
C80.1	Malignant (primary) neoplasm, unspecified	Diagnosis	ICD-10-CM
C80.2	Malignant neoplasm associated with transplanted organ	Diagnosis	ICD-10-CM
D37.01	Neoplasm of uncertain behavior of lip	Diagnosis	ICD-10-CM
D37.02	Neoplasm of uncertain behavior of tongue	Diagnosis	ICD-10-CM
D37.030	Neoplasm of uncertain behavior of the parotid salivary glands	Diagnosis	ICD-10-CM
D37.031	Neoplasm of uncertain behavior of the sublingual salivary glands	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

D37.032	Neoplasm of uncertain behavior of the submandibular salivary glands	Diagnosis	ICD-10-CM
D37.039	Neoplasm of uncertain behavior of the major salivary glands, unspecified	Diagnosis	ICD-10-CM
D37.04	Neoplasm of uncertain behavior of the minor salivary glands	Diagnosis	ICD-10-CM
D37.05	Neoplasm of uncertain behavior of pharynx	Diagnosis	ICD-10-CM
D37.09	Neoplasm of uncertain behavior of other specified sites of the oral cavity	Diagnosis	ICD-10-CM
D37.5	Neoplasm of uncertain behavior of rectum	Diagnosis	ICD-10-CM
D37.6	Neoplasm of uncertain behavior of liver, gallbladder and bile ducts	Diagnosis	ICD-10-CM
D37.8	Neoplasm of uncertain behavior of other specified digestive organs	Diagnosis	ICD-10-CM
D37.9	Neoplasm of uncertain behavior of digestive organ, unspecified	Diagnosis	ICD-10-CM
D38.0	Neoplasm of uncertain behavior of larynx	Diagnosis	ICD-10-CM
D38.1	Neoplasm of uncertain behavior of trachea, bronchus and lung	Diagnosis	ICD-10-CM
D38.2	Neoplasm of uncertain behavior of pleura	Diagnosis	ICD-10-CM
D38.3	Neoplasm of uncertain behavior of mediastinum	Diagnosis	ICD-10-CM
D38.4	Neoplasm of uncertain behavior of thymus	Diagnosis	ICD-10-CM
D38.5	Neoplasm of uncertain behavior of other respiratory organs	Diagnosis	ICD-10-CM
D38.6	Neoplasm of uncertain behavior of respiratory organ, unspecified	Diagnosis	ICD-10-CM
D39.0	Neoplasm of uncertain behavior of uterus	Diagnosis	ICD-10-CM
D39.10	Neoplasm of uncertain behavior of unspecified ovary	Diagnosis	ICD-10-CM
D39.11	Neoplasm of uncertain behavior of right ovary	Diagnosis	ICD-10-CM
D39.12	Neoplasm of uncertain behavior of left ovary	Diagnosis	ICD-10-CM
D39.2	Neoplasm of uncertain behavior of placenta	Diagnosis	ICD-10-CM
D39.8	Neoplasm of uncertain behavior of other specified female genital organs	Diagnosis	ICD-10-CM
D39.9	Neoplasm of uncertain behavior of female genital organ, unspecified	Diagnosis	ICD-10-CM
D40.0	Neoplasm of uncertain behavior of prostate	Diagnosis	ICD-10-CM
D40.10	Neoplasm of uncertain behavior of unspecified testis	Diagnosis	ICD-10-CM
D40.11	Neoplasm of uncertain behavior of right testis	Diagnosis	ICD-10-CM
D40.12	Neoplasm of uncertain behavior of left testis	Diagnosis	ICD-10-CM
D40.8	Neoplasm of uncertain behavior of other specified male genital organs	Diagnosis	ICD-10-CM
D40.9	Neoplasm of uncertain behavior of male genital organ, unspecified	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D41.3	Neoplasm of uncertain behavior of urethra	Diagnosis	ICD-10-CM
D41.4	Neoplasm of uncertain behavior of bladder	Diagnosis	ICD-10-CM
D41.8	Neoplasm of uncertain behavior of other specified urinary organs	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

D41.9	Neoplasm of uncertain behavior of unspecified urinary organ	Diagnosis	ICD-10-CM
D42.0	Neoplasm of uncertain behavior of cerebral meninges	Diagnosis	ICD-10-CM
D42.1	Neoplasm of uncertain behavior of spinal meninges	Diagnosis	ICD-10-CM
D42.9	Neoplasm of uncertain behavior of meninges, unspecified	Diagnosis	ICD-10-CM
D43.0	Neoplasm of uncertain behavior of brain, supratentorial	Diagnosis	ICD-10-CM
D43.1	Neoplasm of uncertain behavior of brain, infratentorial	Diagnosis	ICD-10-CM
D43.2	Neoplasm of uncertain behavior of brain, unspecified	Diagnosis	ICD-10-CM
D43.3	Neoplasm of uncertain behavior of cranial nerves	Diagnosis	ICD-10-CM
D43.4	Neoplasm of uncertain behavior of spinal cord	Diagnosis	ICD-10-CM
D43.8	Neoplasm of uncertain behavior of other specified parts of central nervous system	Diagnosis	ICD-10-CM
D43.9	Neoplasm of uncertain behavior of central nervous system, unspecified	Diagnosis	ICD-10-CM
D44.0	Neoplasm of uncertain behavior of thyroid gland	Diagnosis	ICD-10-CM
D44.10	Neoplasm of uncertain behavior of unspecified adrenal gland	Diagnosis	ICD-10-CM
D44.11	Neoplasm of uncertain behavior of right adrenal gland	Diagnosis	ICD-10-CM
D44.12	Neoplasm of uncertain behavior of left adrenal gland	Diagnosis	ICD-10-CM
D44.2	Neoplasm of uncertain behavior of parathyroid gland	Diagnosis	ICD-10-CM
D44.3	Neoplasm of uncertain behavior of pituitary gland	Diagnosis	ICD-10-CM
D44.4	Neoplasm of uncertain behavior of craniopharyngeal duct	Diagnosis	ICD-10-CM
D44.5	Neoplasm of uncertain behavior of pineal gland	Diagnosis	ICD-10-CM
D44.6	Neoplasm of uncertain behavior of carotid body	Diagnosis	ICD-10-CM
D44.7	Neoplasm of uncertain behavior of aortic body and other paraganglia	Diagnosis	ICD-10-CM
D44.9	Neoplasm of uncertain behavior of unspecified endocrine gland	Diagnosis	ICD-10-CM
D47.01	Cutaneous mastocytosis	Diagnosis	ICD-10-CM
D47.02	Systemic mastocytosis	Diagnosis	ICD-10-CM
D47.09	Other mast cell neoplasms of uncertain behavior	Diagnosis	ICD-10-CM
D47.Z9	Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue	Diagnosis	ICD-10-CM
D48.0	Neoplasm of uncertain behavior of bone and articular cartilage	Diagnosis	ICD-10-CM
D48.1	Neoplasm of uncertain behavior of connective and other soft tissue	Diagnosis	ICD-10-CM
D48.2	Neoplasm of uncertain behavior of peripheral nerves and autonomic nervous system	Diagnosis	ICD-10-CM
D48.3	Neoplasm of uncertain behavior of retroperitoneum	Diagnosis	ICD-10-CM
D48.4	Neoplasm of uncertain behavior of peritoneum	Diagnosis	ICD-10-CM
D48.5	Neoplasm of uncertain behavior of skin	Diagnosis	ICD-10-CM
D48.60	Neoplasm of uncertain behavior of unspecified breast	Diagnosis	ICD-10-CM
D48.61	Neoplasm of uncertain behavior of right breast	Diagnosis	ICD-10-CM
D48.62	Neoplasm of uncertain behavior of left breast	Diagnosis	ICD-10-CM
D48.7	Neoplasm of uncertain behavior of other specified sites	Diagnosis	ICD-10-CM
D48.9	Neoplasm of uncertain behavior, unspecified	Diagnosis	ICD-10-CM
D49.0	Neoplasm of unspecified behavior of digestive system	Diagnosis	ICD-10-CM
D49.1	Neoplasm of unspecified behavior of respiratory system	Diagnosis	ICD-10-CM
D49.2	Neoplasm of unspecified behavior of bone, soft tissue, and skin	Diagnosis	ICD-10-CM
D49.3	Neoplasm of unspecified behavior of breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

D49.4	Neoplasm of unspecified behavior of bladder	Diagnosis	ICD-10-CM
D49.511	Neoplasm of unspecified behavior of right kidney	Diagnosis	ICD-10-CM
D49.512	Neoplasm of unspecified behavior of left kidney	Diagnosis	ICD-10-CM
D49.519	Neoplasm of unspecified behavior of unspecified kidney	Diagnosis	ICD-10-CM
D49.59	Neoplasm of unspecified behavior of other genitourinary organ	Diagnosis	ICD-10-CM
D49.6	Neoplasm of unspecified behavior of brain	Diagnosis	ICD-10-CM
D49.7	Neoplasm of unspecified behavior of endocrine glands and other parts of nervous system	Diagnosis	ICD-10-CM
D49.81	Neoplasm of unspecified behavior of retina and choroid	Diagnosis	ICD-10-CM
D49.89	Neoplasm of unspecified behavior of other specified sites	Diagnosis	ICD-10-CM
D49.9	Neoplasm of unspecified behavior of unspecified site	Diagnosis	ICD-10-CM
Q85.00	Neurofibromatosis, unspecified	Diagnosis	ICD-10-CM
Q85.01	Neurofibromatosis, type 1	Diagnosis	ICD-10-CM
Q85.02	Neurofibromatosis, type 2	Diagnosis	ICD-10-CM
Q85.03	Schwannomatosis	Diagnosis	ICD-10-CM
Q85.09	Other neurofibromatosis	Diagnosis	ICD-10-CM
	Asthma		
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
J82.83	Eosinophilic asthma	Diagnosis	ICD-10-CM
	COPD and Bronchiectasis		
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM
	Diabetes (Type 1 and 2)		
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
Chronic Kidney Disease			
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
D30.00	Benign neoplasm of unspecified kidney	Diagnosis	ICD-10-CM
D30.01	Benign neoplasm of right kidney	Diagnosis	ICD-10-CM
D30.02	Benign neoplasm of left kidney	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E74.8	Other specified disorders of carbohydrate metabolism	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I70.1	Atherosclerosis of renal artery	Diagnosis	ICD-10-CM
I72.2	Aneurysm of renal artery	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sicca syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
M35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
N00.0	Acute nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N00.1	Acute nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N00.2	Acute nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N00.3	Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.4	Acute nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.5	Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N00.6	Acute nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N00.7	Acute nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N00.8	Acute nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N00.9	Acute nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N00.A	Acute nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N13.1	Hydronephrosis with ureteral stricture, not elsewhere classified	Diagnosis	ICD-10-CM
N13.2	Hydronephrosis with renal and ureteral calculous obstruction	Diagnosis	ICD-10-CM
N13.30	Unspecified hydronephrosis	Diagnosis	ICD-10-CM
N13.39	Other hydronephrosis	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N17.0	Acute kidney failure with tubular necrosis	Diagnosis	ICD-10-CM
N17.1	Acute kidney failure with acute cortical necrosis	Diagnosis	ICD-10-CM
N17.2	Acute kidney failure with medullary necrosis	Diagnosis	ICD-10-CM
N17.8	Other acute kidney failure	Diagnosis	ICD-10-CM
N17.9	Acute kidney failure, unspecified	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM
N25.0	Renal osteodystrophy	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.81	Secondary hyperparathyroidism of renal origin	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Q62.0	Congenital hydronephrosis	Diagnosis	ICD-10-CM
Q62.10	Congenital occlusion of ureter, unspecified	Diagnosis	ICD-10-CM
Q62.11	Congenital occlusion of ureteropelvic junction	Diagnosis	ICD-10-CM
Q62.12	Congenital occlusion of ureterovesical orifice	Diagnosis	ICD-10-CM
Q62.2	Congenital megaureter	Diagnosis	ICD-10-CM
Q62.31	Congenital ureterocele, orthotopic	Diagnosis	ICD-10-CM
Q62.32	Cecoureterocele	Diagnosis	ICD-10-CM
Q62.39	Other obstructive defects of renal pelvis and ureter	Diagnosis	ICD-10-CM
R94.4	Abnormal results of kidney function studies	Diagnosis	ICD-10-CM
	Hypertension		
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
	Acute Myocardial Infarction		
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
	Atrial Fibrillation		
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
	Heart Failure		
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
P29.0	Neonatal cardiac failure	Diagnosis	ICD-10-CM
	Ischemic Heart Disease		
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.2	Old myocardial infarction	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
	Stroke/Transient Ischemic Attack(TIA)		
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM
G97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
G97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I66.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I66.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I66.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I66.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I66.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I66.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
I66.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
I66.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM
	History of Cardiac Arrest		
Z86.74	Personal history of sudden cardiac arrest	Diagnosis	ICD-10-CM
	History of Coronary Angioplasty or Bypass		
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
Z98.61	Coronary angioplasty status	Diagnosis	ICD-10-CM
	Alzheimer's Disease and related conditions		
F01.50	Vascular dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F01.51	Vascular dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere without behavioral disturbance	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere with behavioral disturbance	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F04	Amnestic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
F06.1	Catatonic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F06.8	Other specified mental disorders due to known physiological condition	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal dementia	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
R54	Age-related physical debility	Diagnosis	ICD-10-CM
	Depression		
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
	Bipolar or Other Depressive Mood Disorders		
F30.10	Manic episode without psychotic symptoms, unspecified	Diagnosis	ICD-10-CM
F30.11	Manic episode without psychotic symptoms, mild	Diagnosis	ICD-10-CM
F30.12	Manic episode without psychotic symptoms, moderate	Diagnosis	ICD-10-CM
F30.13	Manic episode, severe, without psychotic symptoms	Diagnosis	ICD-10-CM
F30.2	Manic episode, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F30.3	Manic episode in partial remission	Diagnosis	ICD-10-CM
F30.4	Manic episode in full remission	Diagnosis	ICD-10-CM
F30.8	Other manic episodes	Diagnosis	ICD-10-CM
F30.9	Manic episode, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.70	Bipolar disorder, currently in remission, most recent episode unspecified	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.72	Bipolar disorder, in full remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.74	Bipolar disorder, in full remission, most recent episode manic	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F34.81	Disruptive mood dysregulation disorder	Diagnosis	ICD-10-CM
F34.89	Other specified persistent mood disorders	Diagnosis	ICD-10-CM
F34.9	Persistent mood [affective] disorder, unspecified	Diagnosis	ICD-10-CM
F39	Unspecified mood [affective] disorder	Diagnosis	ICD-10-CM
	ADHD		
F63.0	Pathological gambling	Diagnosis	ICD-10-CM
F63.1	Pyromania	Diagnosis	ICD-10-CM
F63.2	Kleptomania	Diagnosis	ICD-10-CM
F63.3	Trichotillomania	Diagnosis	ICD-10-CM
F63.81	Intermittent explosive disorder	Diagnosis	ICD-10-CM
F63.89	Other impulse disorders	Diagnosis	ICD-10-CM
F63.9	Impulse disorder, unspecified	Diagnosis	ICD-10-CM
F90.0	Attention-deficit hyperactivity disorder, predominantly inattentive type	Diagnosis	ICD-10-CM
F90.1	Attention-deficit hyperactivity disorder, predominantly hyperactive type	Diagnosis	ICD-10-CM
F90.2	Attention-deficit hyperactivity disorder, combined type	Diagnosis	ICD-10-CM
F90.8	Attention-deficit hyperactivity disorder, other type	Diagnosis	ICD-10-CM
F90.9	Attention-deficit hyperactivity disorder, unspecified type	Diagnosis	ICD-10-CM
F91	Conduct disorders	Diagnosis	ICD-10-CM
F91.0	Conduct disorder confined to family context	Diagnosis	ICD-10-CM
F91.1	Conduct disorder, childhood-onset type	Diagnosis	ICD-10-CM
F91.2	Conduct disorder, adolescent-onset type	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

F91.3	Oppositional defiant disorder	Diagnosis	ICD-10-CM
F91.8	Other conduct disorders	Diagnosis	ICD-10-CM
F91.9	Conduct disorder, unspecified	Diagnosis	ICD-10-CM
	Cerebral Palsy		
G80	Cerebral palsy	Diagnosis	ICD-10-CM
G80.0	Spastic quadriplegic cerebral palsy	Diagnosis	ICD-10-CM
G80.1	Spastic diplegic cerebral palsy	Diagnosis	ICD-10-CM
G80.2	Spastic hemiplegic cerebral palsy	Diagnosis	ICD-10-CM
G80.3	Athetoid cerebral palsy	Diagnosis	ICD-10-CM
G80.4	Ataxic cerebral palsy	Diagnosis	ICD-10-CM
G80.8	Other cerebral palsy	Diagnosis	ICD-10-CM
G80.9	Cerebral palsy, unspecified	Diagnosis	ICD-10-CM
G81	Hemiplegia and hemiparesis	Diagnosis	ICD-10-CM
G81.0	Flaccid hemiplegia	Diagnosis	ICD-10-CM
G81.00	Flaccid hemiplegia affecting unspecified side	Diagnosis	ICD-10-CM
G81.01	Flaccid hemiplegia affecting right dominant side	Diagnosis	ICD-10-CM
G81.02	Flaccid hemiplegia affecting left dominant side	Diagnosis	ICD-10-CM
G81.03	Flaccid hemiplegia affecting right nondominant side	Diagnosis	ICD-10-CM
G81.04	Flaccid hemiplegia affecting left nondominant side	Diagnosis	ICD-10-CM
G81.1	Spastic hemiplegia	Diagnosis	ICD-10-CM
G81.10	Spastic hemiplegia affecting unspecified side	Diagnosis	ICD-10-CM
G81.11	Spastic hemiplegia affecting right dominant side	Diagnosis	ICD-10-CM
G81.12	Spastic hemiplegia affecting left dominant side	Diagnosis	ICD-10-CM
G81.13	Spastic hemiplegia affecting right nondominant side	Diagnosis	ICD-10-CM
G81.14	Spastic hemiplegia affecting left nondominant side	Diagnosis	ICD-10-CM
G81.9	Hemiplegia, unspecified	Diagnosis	ICD-10-CM
G81.90	Hemiplegia, unspecified affecting unspecified side	Diagnosis	ICD-10-CM
G81.91	Hemiplegia, unspecified affecting right dominant side	Diagnosis	ICD-10-CM
G81.92	Hemiplegia, unspecified affecting left dominant side	Diagnosis	ICD-10-CM
G81.93	Hemiplegia, unspecified affecting right nondominant side	Diagnosis	ICD-10-CM
G81.94	Hemiplegia, unspecified affecting left nondominant side	Diagnosis	ICD-10-CM
G82	Paraplegia (paraparesis) and quadriplegia (quadriparesis)	Diagnosis	ICD-10-CM
G82.2	Paraplegia	Diagnosis	ICD-10-CM
G82.20	Paraplegia, unspecified	Diagnosis	ICD-10-CM
G82.21	Paraplegia, complete	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

G82.22	Paraplegia, incomplete	Diagnosis	ICD-10-CM
G82.5	Quadriplegia	Diagnosis	ICD-10-CM
G82.50	Quadriplegia, unspecified	Diagnosis	ICD-10-CM
G82.51	Quadriplegia, C1-C4 complete	Diagnosis	ICD-10-CM
G82.52	Quadriplegia, C1-C4 incomplete	Diagnosis	ICD-10-CM
G82.53	Quadriplegia, C5-C7 complete	Diagnosis	ICD-10-CM
G82.54	Quadriplegia, C5-C7 incomplete	Diagnosis	ICD-10-CM
G83	Other paralytic syndromes	Diagnosis	ICD-10-CM
G83.0	Diplegia of upper limbs	Diagnosis	ICD-10-CM
G83.1	Monoplegia of lower limb	Diagnosis	ICD-10-CM
G83.10	Monoplegia of lower limb affecting unspecified side	Diagnosis	ICD-10-CM
G83.11	Monoplegia of lower limb affecting right dominant side	Diagnosis	ICD-10-CM
G83.12	Monoplegia of lower limb affecting left dominant side	Diagnosis	ICD-10-CM
G83.13	Monoplegia of lower limb affecting right nondominant side	Diagnosis	ICD-10-CM
G83.14	Monoplegia of lower limb affecting left nondominant side	Diagnosis	ICD-10-CM
G83.2	Monoplegia of upper limb	Diagnosis	ICD-10-CM
G83.20	Monoplegia of upper limb affecting unspecified side	Diagnosis	ICD-10-CM
G83.21	Monoplegia of upper limb affecting right dominant side	Diagnosis	ICD-10-CM
G83.22	Monoplegia of upper limb affecting left dominant side	Diagnosis	ICD-10-CM
G83.23	Monoplegia of upper limb affecting right nondominant side	Diagnosis	ICD-10-CM
G83.24	Monoplegia of upper limb affecting left nondominant side	Diagnosis	ICD-10-CM
G83.3	Monoplegia, unspecified	Diagnosis	ICD-10-CM
G83.30	Monoplegia, unspecified affecting unspecified side	Diagnosis	ICD-10-CM
G83.31	Monoplegia, unspecified affecting right dominant side	Diagnosis	ICD-10-CM
G83.32	Monoplegia, unspecified affecting left dominant side	Diagnosis	ICD-10-CM
G83.33	Monoplegia, unspecified affecting right nondominant side	Diagnosis	ICD-10-CM
G83.34	Monoplegia, unspecified affecting left nondominant side	Diagnosis	ICD-10-CM
G83.4	Cauda equina syndrome	Diagnosis	ICD-10-CM
G83.5	Locked-in state	Diagnosis	ICD-10-CM
G83.8	Other specified paralytic syndromes	Diagnosis	ICD-10-CM
G83.81	Brown-Sequard syndrome	Diagnosis	ICD-10-CM
G83.82	Anterior cord syndrome	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

G83.83	Posterior cord syndrome	Diagnosis	ICD-10-CM
G83.84	Todd's paralysis (postepileptic)	Diagnosis	ICD-10-CM
G83.89	Other specified paralytic syndromes	Diagnosis	ICD-10-CM
G83.9	Paralytic syndrome, unspecified	Diagnosis	ICD-10-CM
	Spinal Cord Injuries		
G96.11	Dural tear	Diagnosis	ICD-10-CM
S12.000A	Unspecified displaced fracture of first cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.000B	Unspecified displaced fracture of first cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.001A	Unspecified nondisplaced fracture of first cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.001B	Unspecified nondisplaced fracture of first cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.100A	Unspecified displaced fracture of second cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.100B	Unspecified displaced fracture of second cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.101A	Unspecified nondisplaced fracture of second cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.101B	Unspecified nondisplaced fracture of second cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.200A	Unspecified displaced fracture of third cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.200B	Unspecified displaced fracture of third cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.201A	Unspecified nondisplaced fracture of third cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.201B	Unspecified nondisplaced fracture of third cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.300A	Unspecified displaced fracture of fourth cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.300B	Unspecified displaced fracture of fourth cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.301A	Unspecified nondisplaced fracture of fourth cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S12.301B	Unspecified nondisplaced fracture of fourth cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.400A	Unspecified displaced fracture of fifth cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.400B	Unspecified displaced fracture of fifth cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.401A	Unspecified nondisplaced fracture of fifth cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.401B	Unspecified nondisplaced fracture of fifth cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.500A	Unspecified displaced fracture of sixth cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.500B	Unspecified displaced fracture of sixth cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.501A	Unspecified nondisplaced fracture of sixth cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.501B	Unspecified nondisplaced fracture of sixth cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.600A	Unspecified displaced fracture of seventh cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.600B	Unspecified displaced fracture of seventh cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.601A	Unspecified nondisplaced fracture of seventh cervical vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S12.601B	Unspecified nondisplaced fracture of seventh cervical vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S12.9XXA	Fracture of neck, unspecified, initial encounter	Diagnosis	ICD-10-CM
S14.0XXA	Concussion and edema of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.0XXS	Concussion and edema of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.101A	Unspecified injury at C1 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.101S	Unspecified injury at C1 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.102A	Unspecified injury at C2 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM

S14.102S	Unspecified injury at C2 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.103A	Unspecified injury at C3 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.103S	Unspecified injury at C3 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.104A	Unspecified injury at C4 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.104S	Unspecified injury at C4 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.105A	Unspecified injury at C5 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.105S	Unspecified injury at C5 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.106A	Unspecified injury at C6 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.106S	Unspecified injury at C6 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.107A	Unspecified injury at C7 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.107S	Unspecified injury at C7 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.108A	Unspecified injury at C8 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.108S	Unspecified injury at C8 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.109A	Unspecified injury at unspecified level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.109S	Unspecified injury at unspecified level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.111A	Complete lesion at C1 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.111S	Complete lesion at C1 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.112A	Complete lesion at C2 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM

S14.112S	Complete lesion at C2 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.113S	Complete lesion at C3 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.114A	Complete lesion at C4 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.114S	Complete lesion at C4 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.115A	Complete lesion at C5 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.115S	Complete lesion at C5 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.116A	Complete lesion at C6 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.116S	Complete lesion at C6 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.117A	Complete lesion at C7 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.117S	Complete lesion at C7 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.118A	Complete lesion at C8 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.118S	Complete lesion at C8 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.119A	Complete lesion at unspecified level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.119S	Complete lesion at unspecified level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.121A	Central cord syndrome at C1 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.121S	Central cord syndrome at C1 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.122A	Central cord syndrome at C2 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.122S	Central cord syndrome at C2 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S14.123A	Central cord syndrome at C3 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.123S	Central cord syndrome at C3 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.124A	Central cord syndrome at C4 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.124S	Central cord syndrome at C4 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.125A	Central cord syndrome at C5 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.125S	Central cord syndrome at C5 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.126A	Central cord syndrome at C6 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.126S	Central cord syndrome at C6 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.127A	Central cord syndrome at C7 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.127S	Central cord syndrome at C7 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.128A	Central cord syndrome at C8 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.128S	Central cord syndrome at C8 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.129A	Central cord syndrome at unspecified level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.129S	Central cord syndrome at unspecified level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.131A	Anterior cord syndrome at C1 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.131S	Anterior cord syndrome at C1 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.132A	Anterior cord syndrome at C2 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.132S	Anterior cord syndrome at C2 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S14.133A	Anterior cord syndrome at C3 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.133S	Anterior cord syndrome at C3 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.134A	Anterior cord syndrome at C4 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.134S	Anterior cord syndrome at C4 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.135A	Anterior cord syndrome at C5 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.135S	Anterior cord syndrome at C5 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.136A	Anterior cord syndrome at C6 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.136S	Anterior cord syndrome at C6 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.137A	Anterior cord syndrome at C7 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.137S	Anterior cord syndrome at C7 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.138A	Anterior cord syndrome at C8 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.138S	Anterior cord syndrome at C8 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.139A	Anterior cord syndrome at unspecified level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.139S	Anterior cord syndrome at unspecified level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.141A	Brown-Sequard syndrome at C1 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.141S	Brown-Sequard syndrome at C1 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.142A	Brown-Sequard syndrome at C2 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.142S	Brown-Sequard syndrome at C2 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S14.143A	Brown-Sequard syndrome at C3 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.143S	Brown-Sequard syndrome at C3 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.144A	Brown-Sequard syndrome at C4 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.144S	Brown-Sequard syndrome at C4 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.145A	Brown-Sequard syndrome at C5 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.145S	Brown-Sequard syndrome at C5 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.146A	Brown-Sequard syndrome at C6 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.146S	Brown-Sequard syndrome at C6 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.147A	Brown-Sequard syndrome at C7 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.147S	Brown-Sequard syndrome at C7 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.148A	Brown-Sequard syndrome at C8 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.148S	Brown-Sequard syndrome at C8 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.149A	Brown-Sequard syndrome at unspecified level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.149S	Brown-Sequard syndrome at unspecified level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.151A	Other incomplete lesion at C1 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.151S	Other incomplete lesion at C1 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.152A	Other incomplete lesion at C2 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.152S	Other incomplete lesion at C2 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S14.153A	Other incomplete lesion at C3 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.153S	Other incomplete lesion at C3 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.154A	Other incomplete lesion at C4 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.154S	Other incomplete lesion at C4 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.155A	Other incomplete lesion at C5 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.155S	Other incomplete lesion at C5 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.156A	Other incomplete lesion at C6 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.156S	Other incomplete lesion at C6 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.157A	Other incomplete lesion at C7 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.157S	Other incomplete lesion at C7 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.158A	Other incomplete lesion at C8 level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.158S	Other incomplete lesion at C8 level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S14.159A	Other incomplete lesion at unspecified level of cervical spinal cord, initial encounter	Diagnosis	ICD-10-CM
S14.159S	Other incomplete lesion at unspecified level of cervical spinal cord, sequela	Diagnosis	ICD-10-CM
S22.009A	Unspecified fracture of unspecified thoracic vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S22.009B	Unspecified fracture of unspecified thoracic vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S22.019A	Unspecified fracture of first thoracic vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S22.019B	Unspecified fracture of first thoracic vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S22.029A	Unspecified fracture of second thoracic vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S22.029B	Unspecified fracture of second thoracic vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S22.039A	Unspecified fracture of third thoracic vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S22.039B	Unspecified fracture of third thoracic vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S22.049A	Unspecified fracture of fourth thoracic vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S22.049B	Unspecified fracture of fourth thoracic vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S22.059A	Unspecified fracture of T5-T6 vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S22.059B	Unspecified fracture of T5-T6 vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S22.069A	Unspecified fracture of T7-T8 vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S22.069B	Unspecified fracture of T7-T8 vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S22.079A	Unspecified fracture of T9-T10 vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S22.079B	Unspecified fracture of T9-T10 vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S22.089A	Unspecified fracture of T11-T12 vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S22.089B	Unspecified fracture of T11-T12 vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S24.0XXA	Concussion and edema of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.0XXS	Concussion and edema of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.101A	Unspecified injury at T1 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.101S	Unspecified injury at T1 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S24.102A	Unspecified injury at T2-T6 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.102S	Unspecified injury at T2-T6 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.103A	Unspecified injury at T7-T10 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.103S	Unspecified injury at T7-T10 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.104A	Unspecified injury at T11-T12 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.104S	Unspecified injury at T11-T12 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.109A	Unspecified injury at unspecified level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.109S	Unspecified injury at unspecified level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.111A	Complete lesion at T1 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.111S	Complete lesion at T1 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.112A	Complete lesion at T2-T6 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.112S	Complete lesion at T2-T6 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.113A	Complete lesion at T7-T10 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.113S	Complete lesion at T7-T10 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.114A	Complete lesion at T11-T12 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.114S	Complete lesion at T11-T12 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.119A	Complete lesion at unspecified level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.119S	Complete lesion at unspecified level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S24.131A	Anterior cord syndrome at T1 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.131S	Anterior cord syndrome at T1 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.132A	Anterior cord syndrome at T2-T6 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.132S	Anterior cord syndrome at T2-T6 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.133A	Anterior cord syndrome at T7-T10 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.133S	Anterior cord syndrome at T7-T10 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.134A	Anterior cord syndrome at T11-T12 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.134S	Anterior cord syndrome at T11-T12 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.139A	Anterior cord syndrome at unspecified level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.139S	Anterior cord syndrome at unspecified level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.141A	Brown-Sequard syndrome at T1 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.141S	Brown-Sequard syndrome at T1 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.142A	Brown-Sequard syndrome at T2-T6 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.142S	Brown-Sequard syndrome at T2-T6 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.143A	Brown-Sequard syndrome at T7-T10 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.143S	Brown-Sequard syndrome at T7-T10 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.144A	Brown-Sequard syndrome at T11-T12 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.144S	Brown-Sequard syndrome at T11-T12 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S24.149A	Brown-Sequard syndrome at unspecified level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.149S	Brown-Sequard syndrome at unspecified level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.151A	Other incomplete lesion at T1 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.151S	Other incomplete lesion at T1 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.152A	Other incomplete lesion at T2-T6 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.152S	Other incomplete lesion at T2-T6 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.153A	Other incomplete lesion at T7-T10 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.153S	Other incomplete lesion at T7-T10 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.154A	Other incomplete lesion at T11-T12 level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.154S	Other incomplete lesion at T11-T12 level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S24.159A	Other incomplete lesion at unspecified level of thoracic spinal cord, initial encounter	Diagnosis	ICD-10-CM
S24.159S	Other incomplete lesion at unspecified level of thoracic spinal cord, sequela	Diagnosis	ICD-10-CM
S32.009A	Unspecified fracture of unspecified lumbar vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.009B	Unspecified fracture of unspecified lumbar vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.019A	Unspecified fracture of first lumbar vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.019B	Unspecified fracture of first lumbar vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.029A	Unspecified fracture of second lumbar vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.029B	Unspecified fracture of second lumbar vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S32.039A	Unspecified fracture of third lumbar vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.039B	Unspecified fracture of third lumbar vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.049A	Unspecified fracture of fourth lumbar vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.049B	Unspecified fracture of fourth lumbar vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.059A	Unspecified fracture of fifth lumbar vertebra, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.059B	Unspecified fracture of fifth lumbar vertebra, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.10XA	Unspecified fracture of sacrum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.10XB	Unspecified fracture of sacrum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.2XXA	Fracture of coccyx, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.2XXB	Fracture of coccyx, initial encounter for open fracture	Diagnosis	ICD-10-CM
S34.01XA	Concussion and edema of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.01XS	Concussion and edema of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.02XA	Concussion and edema of sacral spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.02XS	Concussion and edema of sacral spinal cord, sequela	Diagnosis	ICD-10-CM
S34.101A	Unspecified injury to L1 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.101S	Unspecified injury to L1 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.102A	Unspecified injury to L2 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.102S	Unspecified injury to L2 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.103A	Unspecified injury to L3 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.103S	Unspecified injury to L3 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM

S34.104A	Unspecified injury to L4 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.104S	Unspecified injury to L4 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.105A	Unspecified injury to L5 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.105S	Unspecified injury to L5 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.109A	Unspecified injury to unspecified level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.109S	Unspecified injury to unspecified level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.111A	Complete lesion of L1 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.111S	Complete lesion of L1 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.112A	Complete lesion of L2 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.112S	Complete lesion of L2 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.113A	Complete lesion of L3 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.113S	Complete lesion of L3 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.114A	Complete lesion of L4 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.114S	Complete lesion of L4 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.115A	Complete lesion of L5 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.115S	Complete lesion of L5 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.119A	Complete lesion of unspecified level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.119S	Complete lesion of unspecified level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S34.121A	Incomplete lesion of L1 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.121S	Incomplete lesion of L1 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.122A	Incomplete lesion of L2 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.122S	Incomplete lesion of L2 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.123A	Incomplete lesion of L3 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.123S	Incomplete lesion of L3 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.124A	Incomplete lesion of L4 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.124S	Incomplete lesion of L4 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.125A	Incomplete lesion of L5 level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.125S	Incomplete lesion of L5 level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.129A	Incomplete lesion of unspecified level of lumbar spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.129S	Incomplete lesion of unspecified level of lumbar spinal cord, sequela	Diagnosis	ICD-10-CM
S34.131A	Complete lesion of sacral spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.131S	Complete lesion of sacral spinal cord, sequela	Diagnosis	ICD-10-CM
S34.132A	Incomplete lesion of sacral spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.132S	Incomplete lesion of sacral spinal cord, sequela	Diagnosis	ICD-10-CM
S34.139A	Unspecified injury to sacral spinal cord, initial encounter	Diagnosis	ICD-10-CM
S34.139S	Unspecified injury to sacral spinal cord, sequela	Diagnosis	ICD-10-CM
S34.3XXA	Injury of cauda equina, initial encounter	Diagnosis	ICD-10-CM
	Down Syndrome		
Q90	Down syndrome	Diagnosis	ICD-10-CM
Q90.0	Trisomy 21, nonmosaicism (meiotic nondisjunction)	Diagnosis	ICD-10-CM
Q90.1	Trisomy 21, mosaicism (mitotic nondisjunction)	Diagnosis	ICD-10-CM
Q90.2	Trisomy 21, translocation	Diagnosis	ICD-10-CM
Q90.9	Down syndrome, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Alcohol Abuse or Dependence			
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
Z65.8	Other specified problems related to psychosocial circumstances	Diagnosis	ICD-10-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
Obesity: Diagnosed or Identified by Weight Management Procedure			
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZH	Bypass Jejunum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0D1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
0DB90ZZ	Excision of Duodenum, Open Approach	Procedure	ICD-10-PCS
0DBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DQ64ZZ	Repair Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0TRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
Z68.30	Body mass index (BMI) 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index (BMI) 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index (BMI) 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index (BMI) 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index (BMI) 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index (BMI) 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index (BMI) 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index (BMI) 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index (BMI) 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index (BMI) 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index (BMI) 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index (BMI) 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index (BMI) 50-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index (BMI) 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index (BMI) 70 or greater, adult	Diagnosis	ICD-10-CM
	Overweight		
E66.3	Overweight	Diagnosis	ICD-10-CM
Z68.25	Body mass index (BMI) 25.0-25.9, adult	Diagnosis	ICD-10-CM
Z68.26	Body mass index (BMI) 26.0-26.9, adult	Diagnosis	ICD-10-CM
Z68.27	Body mass index (BMI) 27.0-27.9, adult	Diagnosis	ICD-10-CM
Z68.28	Body mass index (BMI) 28.0-28.9, adult	Diagnosis	ICD-10-CM
Z68.29	Body mass index (BMI) 29.0-29.9, adult	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Smoking: Diagnosed or Identified by Smoking Cessation Procedure			
1034F	Current tobacco smoker (CAD, CAP, COPD, PV) (DM)	Procedure	CPT-2
4001F	Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM) (PV)	Procedure	CPT-2
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD)	Procedure	CPT-2
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Procedure	CPT-4
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	CPT-4
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or referral to external smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco use cessation program) if identified as a tobacco user	Procedure	HCPCS
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Z87.891	Personal history of nicotine dependence	Diagnosis	ICD-10-CM
	HIV/AIDS		
B20	Human immunodeficiency virus [HIV] disease	Diagnosis	ICD-10-CM
B97.35	Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere	Diagnosis	ICD-10-CM
O98.7	Human immunodeficiency virus [HIV] disease complicating pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
O98.71	Human immunodeficiency virus [HIV] disease complicating pregnancy	Diagnosis	ICD-10-CM
O98.711	Human immunodeficiency virus [HIV] disease complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O98.712	Human immunodeficiency virus [HIV] disease complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O98.713	Human immunodeficiency virus [HIV] disease complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O98.719	Human immunodeficiency virus [HIV] disease complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O98.72	Human immunodeficiency virus [HIV] disease complicating childbirth	Diagnosis	ICD-10-CM
O98.73	Human immunodeficiency virus [HIV] disease complicating the puerperium	Diagnosis	ICD-10-CM
Z21	Asymptomatic human immunodeficiency virus [HIV] infection status	Diagnosis	ICD-10-CM
	Hematological Malignancy		

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C81.00	Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.01	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.02	Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.03	Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.04	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.05	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.06	Nodular lymphocyte predominant Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.07	Nodular lymphocyte predominant Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.08	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.09	Nodular lymphocyte predominant Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.10	Nodular sclerosis Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.11	Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.12	Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.13	Nodular sclerosis Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.14	Nodular sclerosis Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.15	Nodular sclerosis Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.16	Nodular sclerosis Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.17	Nodular sclerosis Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.18	Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C81.19	Nodular sclerosis Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.20	Mixed cellularity Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.21	Mixed cellularity Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.22	Mixed cellularity Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.23	Mixed cellularity Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.24	Mixed cellularity Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.25	Mixed cellularity Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.26	Mixed cellularity Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.27	Mixed cellularity Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.28	Mixed cellularity Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.29	Mixed cellularity Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.30	Lymphocyte depleted Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.31	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.32	Lymphocyte depleted Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.33	Lymphocyte depleted Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.34	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.35	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.36	Lymphocyte depleted Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.37	Lymphocyte depleted Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.38	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C81.39	Lymphocyte depleted Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.40	Lymphocyte-rich Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.41	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.42	Lymphocyte-rich Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.43	Lymphocyte-rich Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.44	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.45	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.46	Lymphocyte-rich Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.47	Lymphocyte-rich Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.48	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.49	Lymphocyte-rich Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.70	Other Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.71	Other Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.72	Other Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.73	Other Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.74	Other Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.75	Other Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.76	Other Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.77	Other Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.78	Other Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.79	Other Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.90	Hodgkin lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C81.91	Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C81.92	Hodgkin lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.93	Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.94	Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.95	Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.96	Hodgkin lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.97	Hodgkin lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C81.98	Hodgkin lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.99	Hodgkin lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.00	Follicular lymphoma grade I, unspecified site	Diagnosis	ICD-10-CM
C82.01	Follicular lymphoma grade I, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.02	Follicular lymphoma grade I, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.03	Follicular lymphoma grade I, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.04	Follicular lymphoma grade I, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.05	Follicular lymphoma grade I, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.06	Follicular lymphoma grade I, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.07	Follicular lymphoma grade I, spleen	Diagnosis	ICD-10-CM
C82.08	Follicular lymphoma grade I, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.09	Follicular lymphoma grade I, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.10	Follicular lymphoma grade II, unspecified site	Diagnosis	ICD-10-CM
C82.11	Follicular lymphoma grade II, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.12	Follicular lymphoma grade II, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.13	Follicular lymphoma grade II, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C82.14	Follicular lymphoma grade II, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.15	Follicular lymphoma grade II, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.16	Follicular lymphoma grade II, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.17	Follicular lymphoma grade II, spleen	Diagnosis	ICD-10-CM
C82.18	Follicular lymphoma grade II, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.19	Follicular lymphoma grade II, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.20	Follicular lymphoma grade III, unspecified, unspecified site	Diagnosis	ICD-10-CM
C82.21	Follicular lymphoma grade III, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.22	Follicular lymphoma grade III, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.23	Follicular lymphoma grade III, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.24	Follicular lymphoma grade III, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.25	Follicular lymphoma grade III, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.26	Follicular lymphoma grade III, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.27	Follicular lymphoma grade III, unspecified, spleen	Diagnosis	ICD-10-CM
C82.28	Follicular lymphoma grade III, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.29	Follicular lymphoma grade III, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.30	Follicular lymphoma grade IIIa, unspecified site	Diagnosis	ICD-10-CM
C82.31	Follicular lymphoma grade IIIa, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.32	Follicular lymphoma grade IIIa, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.33	Follicular lymphoma grade IIIa, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM

C82.34	Follicular lymphoma grade IIIa, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.35	Follicular lymphoma grade IIIa, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.36	Follicular lymphoma grade IIIa, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.37	Follicular lymphoma grade IIIa, spleen	Diagnosis	ICD-10-CM
C82.38	Follicular lymphoma grade IIIa, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.39	Follicular lymphoma grade IIIa, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.40	Follicular lymphoma grade IIIb, unspecified site	Diagnosis	ICD-10-CM
C82.41	Follicular lymphoma grade IIIb, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.42	Follicular lymphoma grade IIIb, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.43	Follicular lymphoma grade IIIb, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.44	Follicular lymphoma grade IIIb, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.45	Follicular lymphoma grade IIIb, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.46	Follicular lymphoma grade IIIb, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.47	Follicular lymphoma grade IIIb, spleen	Diagnosis	ICD-10-CM
C82.48	Follicular lymphoma grade IIIb, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.49	Follicular lymphoma grade IIIb, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.50	Diffuse follicle center lymphoma, unspecified site	Diagnosis	ICD-10-CM
C82.51	Diffuse follicle center lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.52	Diffuse follicle center lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.53	Diffuse follicle center lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.54	Diffuse follicle center lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C82.55	Diffuse follicle center lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.56	Diffuse follicle center lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.57	Diffuse follicle center lymphoma, spleen	Diagnosis	ICD-10-CM
C82.58	Diffuse follicle center lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.59	Diffuse follicle center lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.60	Cutaneous follicle center lymphoma, unspecified site	Diagnosis	ICD-10-CM
C82.61	Cutaneous follicle center lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.62	Cutaneous follicle center lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.63	Cutaneous follicle center lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.64	Cutaneous follicle center lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.65	Cutaneous follicle center lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.66	Cutaneous follicle center lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.67	Cutaneous follicle center lymphoma, spleen	Diagnosis	ICD-10-CM
C82.68	Cutaneous follicle center lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.69	Cutaneous follicle center lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.80	Other types of follicular lymphoma, unspecified site	Diagnosis	ICD-10-CM
C82.81	Other types of follicular lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.82	Other types of follicular lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.83	Other types of follicular lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.84	Other types of follicular lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C82.85	Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.86	Other types of follicular lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.87	Other types of follicular lymphoma, spleen	Diagnosis	ICD-10-CM
C82.88	Other types of follicular lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.89	Other types of follicular lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.90	Follicular lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C82.91	Follicular lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.92	Follicular lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.93	Follicular lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.94	Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.95	Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.96	Follicular lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.97	Follicular lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C82.98	Follicular lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.99	Follicular lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.00	Small cell B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.01	Small cell B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.02	Small cell B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.03	Small cell B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.04	Small cell B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.05	Small cell B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C83.06	Small cell B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.07	Small cell B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.08	Small cell B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.09	Small cell B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.10	Mantle cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.11	Mantle cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.12	Mantle cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.13	Mantle cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.14	Mantle cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.15	Mantle cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.16	Mantle cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.17	Mantle cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.18	Mantle cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.19	Mantle cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.30	Diffuse large B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.31	Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.32	Diffuse large B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.33	Diffuse large B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.34	Diffuse large B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.35	Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.36	Diffuse large B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.37	Diffuse large B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.38	Diffuse large B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.39	Diffuse large B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.50	Lymphoblastic (diffuse) lymphoma, unspecified site	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C83.51	Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.52	Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.53	Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.54	Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.55	Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.56	Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.57	Lymphoblastic (diffuse) lymphoma, spleen	Diagnosis	ICD-10-CM
C83.58	Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.59	Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.70	Burkitt lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.71	Burkitt lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.72	Burkitt lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.73	Burkitt lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.74	Burkitt lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.75	Burkitt lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.76	Burkitt lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.77	Burkitt lymphoma, spleen	Diagnosis	ICD-10-CM
C83.78	Burkitt lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.79	Burkitt lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.80	Other non-follicular lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.81	Other non-follicular lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.82	Other non-follicular lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.83	Other non-follicular lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.84	Other non-follicular lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C83.85	Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.86	Other non-follicular lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.87	Other non-follicular lymphoma, spleen	Diagnosis	ICD-10-CM
C83.88	Other non-follicular lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.89	Other non-follicular lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.90	Non-follicular (diffuse) lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C83.91	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.92	Non-follicular (diffuse) lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.93	Non-follicular (diffuse) lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.94	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.95	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.96	Non-follicular (diffuse) lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.97	Non-follicular (diffuse) lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C83.98	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.99	Non-follicular (diffuse) lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.00	Mycosis fungoides, unspecified site	Diagnosis	ICD-10-CM
C84.01	Mycosis fungoides, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.02	Mycosis fungoides, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.03	Mycosis fungoides, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.04	Mycosis fungoides, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.05	Mycosis fungoides, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.06	Mycosis fungoides, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.07	Mycosis fungoides, spleen	Diagnosis	ICD-10-CM
C84.08	Mycosis fungoides, lymph nodes of multiple sites	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C84.09	Mycosis fungoides, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.10	Sezary disease, unspecified site	Diagnosis	ICD-10-CM
C84.11	Sezary disease, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.12	Sezary disease, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.13	Sezary disease, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.14	Sezary disease, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.15	Sezary disease, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.16	Sezary disease, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.17	Sezary disease, spleen	Diagnosis	ICD-10-CM
C84.18	Sezary disease, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.19	Sezary disease, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.40	Peripheral T-cell lymphoma, not classified, unspecified site	Diagnosis	ICD-10-CM
C84.41	Peripheral T-cell lymphoma, not classified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.42	Peripheral T-cell lymphoma, not classified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.43	Peripheral T-cell lymphoma, not classified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.44	Peripheral T-cell lymphoma, not classified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.45	Peripheral T-cell lymphoma, not classified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.46	Peripheral T-cell lymphoma, not classified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.47	Peripheral T-cell lymphoma, not classified, spleen	Diagnosis	ICD-10-CM
C84.48	Peripheral T-cell lymphoma, not classified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.49	Peripheral T-cell lymphoma, not classified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.60	Anaplastic large cell lymphoma, ALK-positive, unspecified site	Diagnosis	ICD-10-CM
C84.61	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.62	Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C84.63	Anaplastic large cell lymphoma, ALK-positive, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.64	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.65	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.66	Anaplastic large cell lymphoma, ALK-positive, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.67	Anaplastic large cell lymphoma, ALK-positive, spleen	Diagnosis	ICD-10-CM
C84.68	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.69	Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.70	Anaplastic large cell lymphoma, ALK-negative, unspecified site	Diagnosis	ICD-10-CM
C84.71	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.72	Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.73	Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.74	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.75	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.76	Anaplastic large cell lymphoma, ALK-negative, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.77	Anaplastic large cell lymphoma, ALK-negative, spleen	Diagnosis	ICD-10-CM
C84.78	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.79	Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.90	Mature T/NK-cell lymphomas, unspecified, unspecified site	Diagnosis	ICD-10-CM
C84.91	Mature T/NK-cell lymphomas, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C84.92	Mature T/NK-cell lymphomas, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.93	Mature T/NK-cell lymphomas, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.94	Mature T/NK-cell lymphomas, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.95	Mature T/NK-cell lymphomas, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.96	Mature T/NK-cell lymphomas, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.97	Mature T/NK-cell lymphomas, unspecified, spleen	Diagnosis	ICD-10-CM
C84.98	Mature T/NK-cell lymphomas, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.99	Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.A0	Cutaneous T-cell lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C84.A1	Cutaneous T-cell lymphoma, unspecified lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.A2	Cutaneous T-cell lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.A3	Cutaneous T-cell lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.A4	Cutaneous T-cell lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.A5	Cutaneous T-cell lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.A6	Cutaneous T-cell lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.A7	Cutaneous T-cell lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C84.A8	Cutaneous T-cell lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.A9	Cutaneous T-cell lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.Z0	Other mature T/NK-cell lymphomas, unspecified site	Diagnosis	ICD-10-CM
C84.Z1	Other mature T/NK-cell lymphomas, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C84.Z2	Other mature T/NK-cell lymphomas, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.Z3	Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.Z4	Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.Z5	Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.Z6	Other mature T/NK-cell lymphomas, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.Z7	Other mature T/NK-cell lymphomas, spleen	Diagnosis	ICD-10-CM
C84.Z8	Other mature T/NK-cell lymphomas, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.Z9	Other mature T/NK-cell lymphomas, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.10	Unspecified B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C85.11	Unspecified B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.12	Unspecified B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.13	Unspecified B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.14	Unspecified B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.15	Unspecified B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.16	Unspecified B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.17	Unspecified B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C85.18	Unspecified B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.19	Unspecified B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.20	Mediastinal (thymic) large B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C85.21	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.22	Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C85.23	Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.24	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.25	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.26	Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.27	Mediastinal (thymic) large B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C85.28	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.29	Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.80	Other specified types of non-Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C85.81	Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.82	Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.83	Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.84	Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.85	Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.86	Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.87	Other specified types of non-Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C85.88	Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.89	Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.90	Non-Hodgkin lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C85.91	Non-Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.92	Non-Hodgkin lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM

C85.93	Non-Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.94	Non-Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.95	Non-Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.96	Non-Hodgkin lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.97	Non-Hodgkin lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C85.98	Non-Hodgkin lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.99	Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C86.0	Extranodal NK/T-cell lymphoma, nasal type	Diagnosis	ICD-10-CM
C86.1	Hepatosplenic T-cell lymphoma	Diagnosis	ICD-10-CM
C86.2	Enteropathy-type (intestinal) T-cell lymphoma	Diagnosis	ICD-10-CM
C86.3	Subcutaneous panniculitis-like T-cell lymphoma	Diagnosis	ICD-10-CM
C86.4	Blastic NK-cell lymphoma	Diagnosis	ICD-10-CM
C86.5	Angioimmunoblastic T-cell lymphoma	Diagnosis	ICD-10-CM
C86.6	Primary cutaneous CD30-positive T-cell proliferations	Diagnosis	ICD-10-CM
C88.0	Waldenstrom macroglobulinemia	Diagnosis	ICD-10-CM
C88.4	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]	Diagnosis	ICD-10-CM
C88.8	Other malignant immunoproliferative diseases	Diagnosis	ICD-10-CM
C90.00	Multiple myeloma not having achieved remission	Diagnosis	ICD-10-CM
C90.01	Multiple myeloma in remission	Diagnosis	ICD-10-CM
C90.02	Multiple myeloma in relapse	Diagnosis	ICD-10-CM
C90.10	Plasma cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C90.12	Plasma cell leukemia in relapse	Diagnosis	ICD-10-CM
C90.20	Extramedullary plasmacytoma not having achieved remission	Diagnosis	ICD-10-CM
C90.22	Extramedullary plasmacytoma in relapse	Diagnosis	ICD-10-CM
C90.30	Solitary plasmacytoma not having achieved remission	Diagnosis	ICD-10-CM
C90.32	Solitary plasmacytoma in relapse	Diagnosis	ICD-10-CM
C91.00	Acute lymphoblastic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C91.02	Acute lymphoblastic leukemia, in relapse	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C91.10	Chronic lymphocytic leukemia of B-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.12	Chronic lymphocytic leukemia of B-cell type in relapse	Diagnosis	ICD-10-CM
C91.30	Prolymphocytic leukemia of B-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.32	Prolymphocytic leukemia of B-cell type, in relapse	Diagnosis	ICD-10-CM
C91.40	Hairy cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C91.42	Hairy cell leukemia, in relapse	Diagnosis	ICD-10-CM
C91.50	Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission	Diagnosis	ICD-10-CM
C91.52	Adult T-cell lymphoma/leukemia (HTLV-1-associated), in relapse	Diagnosis	ICD-10-CM
C91.60	Prolymphocytic leukemia of T-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.62	Prolymphocytic leukemia of T-cell type, in relapse	Diagnosis	ICD-10-CM
C91.90	Lymphoid leukemia, unspecified not having achieved remission	Diagnosis	ICD-10-CM
C91.92	Lymphoid leukemia, unspecified, in relapse	Diagnosis	ICD-10-CM
C91.A0	Mature B-cell leukemia Burkitt-type not having achieved remission	Diagnosis	ICD-10-CM
C91.A2	Mature B-cell leukemia Burkitt-type, in relapse	Diagnosis	ICD-10-CM
C91.Z0	Other lymphoid leukemia not having achieved remission	Diagnosis	ICD-10-CM
C91.Z2	Other lymphoid leukemia, in relapse	Diagnosis	ICD-10-CM
C92.00	Acute myeloblastic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C92.02	Acute myeloblastic leukemia, in relapse	Diagnosis	ICD-10-CM
C92.10	Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission	Diagnosis	ICD-10-CM
C92.12	Chronic myeloid leukemia, BCR/ABL-positive, in relapse	Diagnosis	ICD-10-CM
C92.20	Atypical chronic myeloid leukemia, BCR/ABL-negative, not having achieved remission	Diagnosis	ICD-10-CM
C92.22	Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse	Diagnosis	ICD-10-CM
C92.30	Myeloid sarcoma, not having achieved remission	Diagnosis	ICD-10-CM
C92.32	Myeloid sarcoma, in relapse	Diagnosis	ICD-10-CM
C92.40	Acute promyelocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C92.42	Acute promyelocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C92.50	Acute myelomonocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C92.52	Acute myelomonocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C92.60	Acute myeloid leukemia with 11q23-abnormality not having achieved remission	Diagnosis	ICD-10-CM
C92.62	Acute myeloid leukemia with 11q23-abnormality in relapse	Diagnosis	ICD-10-CM
C92.90	Myeloid leukemia, unspecified, not having achieved remission	Diagnosis	ICD-10-CM
C92.92	Myeloid leukemia, unspecified in relapse	Diagnosis	ICD-10-CM
C92.A0	Acute myeloid leukemia with multilineage dysplasia, not having achieved remission	Diagnosis	ICD-10-CM
C92.A2	Acute myeloid leukemia with multilineage dysplasia, in relapse	Diagnosis	ICD-10-CM
C92.Z0	Other myeloid leukemia not having achieved remission	Diagnosis	ICD-10-CM
C92.Z2	Other myeloid leukemia, in relapse	Diagnosis	ICD-10-CM
C93.00	Acute monoblastic/monocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.02	Acute monoblastic/monocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C93.10	Chronic myelomonocytic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C93.12	Chronic myelomonocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C93.30	Juvenile myelomonocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.32	Juvenile myelomonocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C93.90	Monocytic leukemia, unspecified, not having achieved remission	Diagnosis	ICD-10-CM
C93.92	Monocytic leukemia, unspecified in relapse	Diagnosis	ICD-10-CM
C93.Z0	Other monocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.Z2	Other monocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C94.00	Acute erythroid leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C94.02	Acute erythroid leukemia, in relapse	Diagnosis	ICD-10-CM
C94.20	Acute megakaryoblastic leukemia not having achieved remission	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C94.22	Acute megakaryoblastic leukemia, in relapse	Diagnosis	ICD-10-CM
C94.30	Mast cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C94.32	Mast cell leukemia, in relapse	Diagnosis	ICD-10-CM
C94.40	Acute panmyelosis with myelofibrosis not having achieved remission	Diagnosis	ICD-10-CM
C94.42	Acute panmyelosis with myelofibrosis, in relapse	Diagnosis	ICD-10-CM
C94.6	Myelodysplastic disease, not classified	Diagnosis	ICD-10-CM
C94.80	Other specified leukemias not having achieved remission	Diagnosis	ICD-10-CM
C94.82	Other specified leukemias, in relapse	Diagnosis	ICD-10-CM
C95.00	Acute leukemia of unspecified cell type not having achieved remission	Diagnosis	ICD-10-CM
C95.02	Acute leukemia of unspecified cell type, in relapse	Diagnosis	ICD-10-CM
C95.10	Chronic leukemia of unspecified cell type not having achieved remission	Diagnosis	ICD-10-CM
C95.12	Chronic leukemia of unspecified cell type, in relapse	Diagnosis	ICD-10-CM
C95.90	Leukemia, unspecified not having achieved remission	Diagnosis	ICD-10-CM
C95.92	Leukemia, unspecified, in relapse	Diagnosis	ICD-10-CM
C96.20	Malignant mast cell neoplasm, unspecified	Diagnosis	ICD-10-CM
C96.21	Aggressive systemic mastocytosis	Diagnosis	ICD-10-CM
C96.22	Mast cell sarcoma	Diagnosis	ICD-10-CM
C96.29	Other malignant mast cell neoplasm	Diagnosis	ICD-10-CM
C96.4	Sarcoma of dendritic cells (accessory cells)	Diagnosis	ICD-10-CM
C96.6	Unifocal Langerhans-cell histiocytosis	Diagnosis	ICD-10-CM
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified	Diagnosis	ICD-10-CM
C96.A	Histiocytic sarcoma	Diagnosis	ICD-10-CM
C96.Z	Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue	Diagnosis	ICD-10-CM
D45	Polycythemia vera	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D47.1	Chronic myeloproliferative disease	Diagnosis	ICD-10-CM
D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified	Diagnosis	ICD-10-CM
D47.Z1	Post-transplant lymphoproliferative disorder (PTLD)	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

D47.Z9	Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue	Diagnosis	ICD-10-CM
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM
Treatment-Independent Immune Deficiencies			
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia, unspecified, with splenic sequestration	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D70.0	Congenital agranulocytosis	Diagnosis	ICD-10-CM
D70.4	Cyclic neutropenia	Diagnosis	ICD-10-CM
D71	Functional disorders of polymorphonuclear neutrophils	Diagnosis	ICD-10-CM
D76.1	Hemophagocytic lymphohistiocytosis	Diagnosis	ICD-10-CM
D76.2	Hemophagocytic syndrome, infection-associated	Diagnosis	ICD-10-CM
D76.3	Other histiocytosis syndromes	Diagnosis	ICD-10-CM
D80.0	Hereditary hypogammaglobulinemia	Diagnosis	ICD-10-CM
D80.1	Nonfamilial hypogammaglobulinemia	Diagnosis	ICD-10-CM
D80.2	Selective deficiency of immunoglobulin A [IgA]	Diagnosis	ICD-10-CM
D80.3	Selective deficiency of immunoglobulin G [IgG] subclasses	Diagnosis	ICD-10-CM
D80.4	Selective deficiency of immunoglobulin M [IgM]	Diagnosis	ICD-10-CM
D80.5	Immunodeficiency with increased immunoglobulin M [IgM]	Diagnosis	ICD-10-CM
D80.6	Antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia	Diagnosis	ICD-10-CM
D80.8	Other immunodeficiencies with predominantly antibody defects	Diagnosis	ICD-10-CM
D80.9	Immunodeficiency with predominantly antibody defects, unspecified	Diagnosis	ICD-10-CM
D81.0	Severe combined immunodeficiency [SCID] with reticular dysgenesis	Diagnosis	ICD-10-CM
D81.1	Severe combined immunodeficiency [SCID] with low T- and B-cell numbers	Diagnosis	ICD-10-CM
D81.2	Severe combined immunodeficiency [SCID] with low or normal B-cell numbers	Diagnosis	ICD-10-CM
D81.3	Adenosine deaminase [ADA] deficiency	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

D81.30	Adenosine deaminase deficiency, unspecified	Diagnosis	ICD-10-CM
D81.31	Severe combined immunodeficiency due to adenosine deaminase deficiency	Diagnosis	ICD-10-CM
D81.32	Adenosine deaminase 2 deficiency	Diagnosis	ICD-10-CM
D81.39	Other adenosine deaminase deficiency	Diagnosis	ICD-10-CM
D81.4	Nezelof's syndrome	Diagnosis	ICD-10-CM
D81.5	Purine nucleoside phosphorylase [PNP] deficiency	Diagnosis	ICD-10-CM
D81.6	Major histocompatibility complex class I deficiency	Diagnosis	ICD-10-CM
D81.7	Major histocompatibility complex class II deficiency	Diagnosis	ICD-10-CM
D81.89	Other combined immunodeficiencies	Diagnosis	ICD-10-CM
D81.9	Combined immunodeficiency, unspecified	Diagnosis	ICD-10-CM
D82.0	Wiskott-Aldrich syndrome	Diagnosis	ICD-10-CM
D82.1	Di George's syndrome	Diagnosis	ICD-10-CM
D82.2	Immunodeficiency with short-limbed stature	Diagnosis	ICD-10-CM
D82.3	Immunodeficiency following hereditary defective response to Epstein-Barr virus	Diagnosis	ICD-10-CM
D82.4	Hyperimmunoglobulin E [IgE] syndrome	Diagnosis	ICD-10-CM
D82.8	Immunodeficiency associated with other specified major defects	Diagnosis	ICD-10-CM
D82.9	Immunodeficiency associated with major defect, unspecified	Diagnosis	ICD-10-CM
D83.0	Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function	Diagnosis	ICD-10-CM
D83.1	Common variable immunodeficiency with predominant immunoregulatory T-cell disorders	Diagnosis	ICD-10-CM
D83.2	Common variable immunodeficiency with autoantibodies to B- or T-cells	Diagnosis	ICD-10-CM
D83.8	Other common variable immunodeficiencies	Diagnosis	ICD-10-CM
D83.9	Common variable immunodeficiency, unspecified	Diagnosis	ICD-10-CM
D84.0	Lymphocyte function antigen-1 [LFA-1] defect	Diagnosis	ICD-10-CM
D84.1	Defects in the complement system	Diagnosis	ICD-10-CM
D84.8	Other specified immunodeficiencies	Diagnosis	ICD-10-CM
D84.9	Immunodeficiency, unspecified	Diagnosis	ICD-10-CM
D89.82	Autoimmune lymphoproliferative syndrome [ALPS]	Diagnosis	ICD-10-CM
E40	Kwashiorkor	Diagnosis	ICD-10-CM
E41	Nutritional marasmus	Diagnosis	ICD-10-CM
E42	Marasmic kwashiorkor	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E43	Unspecified severe protein-calorie malnutrition	Diagnosis	ICD-10-CM
E80.3	Defects of catalase and peroxidase	Diagnosis	ICD-10-CM
Q89.01	Asplenia (congenital)	Diagnosis	ICD-10-CM
Q89.09	Congenital malformations of spleen	Diagnosis	ICD-10-CM
	Dialysis		
3E1M39Z	Irrigation of Peritoneal Cavity using Dialysate, Percutaneous Approach	Procedure	ICD-10-PCS
5A1D00Z	Performance of Urinary Filtration, Single	Procedure	ICD-10-PCS
5A1D60Z	Performance of Urinary Filtration, Multiple	Procedure	ICD-10-PCS
5A1D70Z	Performance of Urinary Filtration, Intermittent, Less than 6 Hours Per Day	Procedure	ICD-10-PCS
5A1D80Z	Performance of Urinary Filtration, Prolonged Intermittent, 6-18 hours Per Day	Procedure	ICD-10-PCS
5A1D90Z	Performance of Urinary Filtration, Continuous, Greater than 18 hours Per Day	Procedure	ICD-10-PCS
A4653	Peritoneal dialysis catheter anchoring device, belt, each	Procedure	HCPCS
A4671	Disposable cycler set used with cycler dialysis machine, each	Procedure	HCPCS
A4672	Drainage extension line, sterile, for dialysis, each	Procedure	HCPCS
A4673	Extension line with easy lock connectors, used with dialysis	Procedure	HCPCS
A4674	Chemicals/antiseptics solution used to clean/sterilize dialysis equipment, per 8 oz	Procedure	HCPCS
A4680	Activated carbon filter for hemodialysis, each	Procedure	HCPCS
A4690	Dialyzer (artificial kidneys), all types, all sizes, for hemodialysis, each	Procedure	HCPCS
A4700	Standard dialysate solution, each	Procedure	HCPCS
A4705	Bicarbonate dialysate solution, each	Procedure	HCPCS
A4706	Bicarbonate concentrate, solution, for hemodialysis, per gallon	Procedure	HCPCS
A4707	Bicarbonate concentrate, powder, for hemodialysis, per packet	Procedure	HCPCS
A4708	Acetate concentrate solution, for hemodialysis, per gallon	Procedure	HCPCS
A4709	Acid concentrate, solution, for hemodialysis, per gallon	Procedure	HCPCS
A4712	Water, sterile, for injection, per 10 ml	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

A4714	Treated water (deionized, distilled, or reverse osmosis) for peritoneal dialysis, per gallon	Procedure	HCPCS
A4719	"Y set" tubing for peritoneal dialysis	Procedure	HCPCS
A4720	Dialysate solution, any concentration of dextrose, fluid volume greater than 249 cc, but less than or equal to 999 cc, for peritoneal dialysis	Procedure	HCPCS
A4721	Dialysate solution, any concentration of dextrose, fluid volume greater than 999 cc but less than or equal to 1999 cc, for peritoneal dialysis	Procedure	HCPCS
A4722	Dialysate solution, any concentration of dextrose, fluid volume greater than 1999 cc but less than or equal to 2999 cc, for peritoneal dialysis	Procedure	HCPCS
A4723	Dialysate solution, any concentration of dextrose, fluid volume greater than 2999 cc but less than or equal to 3999 cc, for peritoneal dialysis	Procedure	HCPCS
A4724	Dialysate solution, any concentration of dextrose, fluid volume greater than 3999 cc but less than or equal to 4999 cc, for peritoneal dialysis	Procedure	HCPCS
A4725	Dialysate solution, any concentration of dextrose, fluid volume greater than 4999 cc but less than or equal to 5999 cc, for peritoneal dialysis	Procedure	HCPCS
A4726	Dialysate solution, any concentration of dextrose, fluid volume greater than 5999 cc, for peritoneal dialysis	Procedure	HCPCS
A4728	Dialysate solution, nondextrose containing, 500 ml	Procedure	HCPCS
A4730	Fistula cannulation set for hemodialysis, each	Procedure	HCPCS
A4735	Local/topical anesthetics for dialysis only	Procedure	HCPCS
A4736	Topical anesthetic, for dialysis, per g	Procedure	HCPCS
A4737	Injectable anesthetic, for dialysis, per 10 ml	Procedure	HCPCS
A4740	Shunt accessory, for hemodialysis, any type, each	Procedure	HCPCS
A4750	Blood tubing, arterial or venous, for hemodialysis, each	Procedure	HCPCS
A4755	Blood tubing, arterial and venous combined, for hemodialysis, each	Procedure	HCPCS
A4760	Dialysate solution test kit, for peritoneal dialysis, any type, each	Procedure	HCPCS
A4765	Dialysate concentrate, powder, additive for peritoneal dialysis, per packet	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

A4766	Dialysate concentrate, solution, additive for peritoneal dialysis, per 10 ml	Procedure	HCPCS
A4802	Protamine sulfate, for hemodialysis, per 50 mg	Procedure	HCPCS
A4820	Hemodialysis kit supplies	Procedure	HCPCS
A4850	Hemostats with rubber tips for dialysis	Procedure	HCPCS
A4860	Disposable catheter tips for peritoneal dialysis, per 10	Procedure	HCPCS
A4870	Plumbing and/or electrical work for home hemodialysis equipment	Procedure	HCPCS
A4880	Storage tanks utilized in connection with water purification system, replacement tanks for dialysis	Procedure	HCPCS
A4890	Contracts, repair and maintenance, for hemodialysis equipment	Procedure	HCPCS
A4900	Continuous ambulatory peritoneal dialysis (capd) supply kit	Procedure	HCPCS
A4901	Continuous cycling peritoneal dialysis (ccpd) supply kit	Procedure	HCPCS
A4905	Intermittent peritoneal dialysis (ipd) supply kit	Procedure	HCPCS
A4910	Non-medical supplies for dialysis, (i.e., scale, scissors, stopwatch, etc.)	Procedure	HCPCS
A4911	Drain bag/bottle, for dialysis, each	Procedure	HCPCS
A4912	Gomco drain bottle	Procedure	HCPCS
A4913	Miscellaneous dialysis supplies, not otherwise specified	Procedure	HCPCS
A4914	Preparation kits	Procedure	HCPCS
A4918	Venous pressure clamp, for hemodialysis, each	Procedure	HCPCS
E1500	Centrifuge, for dialysis	Procedure	HCPCS
E1510	Kidney, dialysate delivery system kidney machine, pump recirculating, air removal system, flowrate meter, power off, heater and temperature control with alarm, IV poles, pressure gauge, concentrate container	Procedure	HCPCS
E1520	Heparin infusion pump for hemodialysis	Procedure	HCPCS
E1530	Air bubble detector for hemodialysis, each, replacement	Procedure	HCPCS
E1540	Pressure alarm for hemodialysis, each, replacement	Procedure	HCPCS
E1550	Bath conductivity meter for hemodialysis, each	Procedure	HCPCS
E1560	Blood leak detector for hemodialysis, each, replacement	Procedure	HCPCS
E1570	Adjustable chair, for ESRD patients	Procedure	HCPCS
E1575	Transducer protectors/fluid barriers, for hemodialysis, any size, per 10	Procedure	HCPCS
E1580	Unipuncture control system for hemodialysis	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

E1590	Hemodialysis machine	Procedure	HCPCS
E1592	Automatic intermittent peritoneal dialysis system	Procedure	HCPCS
E1594	Cycler dialysis machine for peritoneal dialysis	Procedure	HCPCS
E1600	Delivery and/or installation charges for hemodialysis equipment	Procedure	HCPCS
E1610	Reverse osmosis water purification system, for hemodialysis	Procedure	HCPCS
E1615	Deionizer water purification system, for hemodialysis	Procedure	HCPCS
E1620	Blood pump for hemodialysis, replacement	Procedure	HCPCS
E1625	Water softening system, for hemodialysis	Procedure	HCPCS
E1630	Reciprocating peritoneal dialysis system	Procedure	HCPCS
E1632	Wearable artificial kidney, each	Procedure	HCPCS
E1634	Peritoneal dialysis clamps, each	Procedure	HCPCS
E1635	Compact (portable) travel hemodialyzer system	Procedure	HCPCS
E1636	Sorbent cartridges, for hemodialysis, per 10	Procedure	HCPCS
Z49	Encounter for care involving renal dialysis	Diagnosis	ICD-10-CM
Z49.01	Encounter for fitting and adjustment of extracorporeal dialysis catheter	Diagnosis	ICD-10-CM
Z49.02	Encounter for fitting and adjustment of peritoneal dialysis catheter	Diagnosis	ICD-10-CM
Z49.31	Encounter for adequacy testing for hemodialysis	Diagnosis	ICD-10-CM
Z49.32	Encounter for adequacy testing for peritoneal dialysis	Diagnosis	ICD-10-CM
Z99.2	Dependence on renal dialysis	Diagnosis	ICD-10-CM
	Chemo Therapeutic Agents/Diagnoses and Procedures		
3E00X05	Introduction of Other Antineoplastic into Skin and Mucous Membranes, External Approach	Procedure	ICD-10-PCS
3E00X0M	Introduction of Antineoplastic, Monoclonal Antibody, into Skin and Mucous Membranes, External Approach	Procedure	ICD-10-PCS
3E01305	Introduction of Other Antineoplastic into Subcutaneous Tissue, Percutaneous Approach	Procedure	ICD-10-PCS
3E0130M	Introduction of Antineoplastic, Monoclonal Antibody, into Subcutaneous Tissue, Percutaneous Approach	Procedure	ICD-10-PCS
3E02305	Introduction of Other Antineoplastic into Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
3E0230M	Introduction of Antineoplastic, Monoclonal Antibody, into Muscle, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

3E03002	Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E03003	Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E03005	Introduction of Other Antineoplastic into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E0300M	Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E0300P	Introduction of Clofarabine into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E03302	Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E03303	Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E03305	Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E0330M	Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E0330P	Introduction of Clofarabine into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E04002	Introduction of High-dose Interleukin-2 into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E04003	Introduction of Low-dose Interleukin-2 into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E04005	Introduction of Other Antineoplastic into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E0400M	Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E0400P	Introduction of Clofarabine into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E04302	Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E04303	Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E04305	Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

3E0430M	Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E0430P	Introduction of Clofarabine into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E05002	Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E05003	Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E05005	Introduction of Other Antineoplastic into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E0500M	Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E0500P	Introduction of Clofarabine into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E05302	Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E05303	Introduction of Low-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E05305	Introduction of Other Antineoplastic into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E0530M	Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E0530P	Introduction of Clofarabine into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E06002	Introduction of High-dose Interleukin-2 into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E06003	Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E06005	Introduction of Other Antineoplastic into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E0600M	Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E0600P	Introduction of Clofarabine into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E06302	Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

3E06303	Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E06305	Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E0630M	Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E0630P	Introduction of Clofarabine into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E09305	Introduction of Other Antineoplastic into Nose, Percutaneous Approach	Procedure	ICD-10-PCS
3E0930M	Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Percutaneous Approach	Procedure	ICD-10-PCS
3E09705	Introduction of Other Antineoplastic into Nose, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0970M	Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E09X05	Introduction of Other Antineoplastic into Nose, External Approach	Procedure	ICD-10-PCS
3E09X0M	Introduction of Antineoplastic, Monoclonal Antibody, into Nose, External Approach	Procedure	ICD-10-PCS
3E0A305	Introduction of Other Antineoplastic into Bone Marrow, Percutaneous Approach	Procedure	ICD-10-PCS
3E0A30M	Introduction of Antineoplastic, Monoclonal Antibody, into Bone Marrow, Percutaneous Approach	Procedure	ICD-10-PCS
3E0B305	Introduction of Other Antineoplastic into Ear, Percutaneous Approach	Procedure	ICD-10-PCS
3E0B30M	Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Percutaneous Approach	Procedure	ICD-10-PCS
3E0B705	Introduction of Other Antineoplastic into Ear, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0B70M	Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0BX05	Introduction of Other Antineoplastic into Ear, External Approach	Procedure	ICD-10-PCS
3E0BX0M	Introduction of Antineoplastic, Monoclonal Antibody, into Ear, External Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

3E0C305	Introduction of Other Antineoplastic into Eye, Percutaneous Approach	Procedure	ICD-10-PCS
3E0C30M	Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Percutaneous Approach	Procedure	ICD-10-PCS
3E0C705	Introduction of Other Antineoplastic into Eye, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0C70M	Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0CX05	Introduction of Other Antineoplastic into Eye, External Approach	Procedure	ICD-10-PCS
3E0CX0M	Introduction of Antineoplastic, Monoclonal Antibody, into Eye, External Approach	Procedure	ICD-10-PCS
3E0D305	Introduction of Other Antineoplastic into Mouth and Pharynx, Percutaneous Approach	Procedure	ICD-10-PCS
3E0D30M	Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Percutaneous Approach	Procedure	ICD-10-PCS
3E0D705	Introduction of Other Antineoplastic into Mouth and Pharynx, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0D70M	Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0DX05	Introduction of Other Antineoplastic into Mouth and Pharynx, External Approach	Procedure	ICD-10-PCS
3E0DX0M	Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, External Approach	Procedure	ICD-10-PCS
3E0E305	Introduction of Other Antineoplastic into Products of Conception, Percutaneous Approach	Procedure	ICD-10-PCS
3E0E30M	Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Percutaneous Approach	Procedure	ICD-10-PCS
3E0E705	Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0E70M	Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0E805	Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

3E0E80M	Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0F305	Introduction of Other Antineoplastic into Respiratory Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0F30M	Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0F705	Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0F70M	Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0F805	Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0F80M	Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0G305	Introduction of Other Antineoplastic into Upper GI, Percutaneous Approach	Procedure	ICD-10-PCS
3E0G30M	Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Percutaneous Approach	Procedure	ICD-10-PCS
3E0G705	Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0G70M	Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0G805	Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0G80M	Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0H305	Introduction of Other Antineoplastic into Lower GI, Percutaneous Approach	Procedure	ICD-10-PCS
3E0H30M	Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Percutaneous Approach	Procedure	ICD-10-PCS
3E0H705	Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0H70M	Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

3E0H805	Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0H80M	Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0J305	Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0J30M	Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0J705	Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0J70M	Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0J805	Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0J80M	Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0K305	Introduction of Other Antineoplastic into Genitourinary Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0K30M	Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0K705	Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0K70M	Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0K805	Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0K80M	Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0L305	Introduction of Other Antineoplastic into Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

3E0L30M	Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0L705	Introduction of Other Antineoplastic into Pleural Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0L70M	Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0M305	Introduction of Other Antineoplastic into Peritoneal Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0M30M	Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0M705	Introduction of Other Antineoplastic into Peritoneal Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0M70M	Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0N305	Introduction of Other Antineoplastic into Male Reproductive, Percutaneous Approach	Procedure	ICD-10-PCS
3E0N30M	Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Percutaneous Approach	Procedure	ICD-10-PCS
3E0N705	Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0N70M	Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0N805	Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0N80M	Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0P305	Introduction of Other Antineoplastic into Female Reproductive, Percutaneous Approach	Procedure	ICD-10-PCS
3E0P30M	Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Percutaneous Approach	Procedure	ICD-10-PCS
3E0P705	Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0P70M	Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

3E0P805	Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0P80M	Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0Q005	Introduction of Other Antineoplastic into Cranial Cavity and Brain, Open Approach	Procedure	ICD-10-PCS
3E0Q00M	Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Open Approach	Procedure	ICD-10-PCS
3E0Q305	Introduction of Other Antineoplastic into Cranial Cavity and Brain, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Q30M	Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Q705	Introduction of Other Antineoplastic into Cranial Cavity and Brain, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0Q70M	Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0R302	Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach	Procedure	ICD-10-PCS
3E0R303	Introduction of Low-dose Interleukin-2 into Spinal Canal, Percutaneous Approach	Procedure	ICD-10-PCS
3E0R305	Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach	Procedure	ICD-10-PCS
3E0R30M	Introduction of Antineoplastic, Monoclonal Antibody, into Spinal Canal, Percutaneous Approach	Procedure	ICD-10-PCS
3E0S302	Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach	Procedure	ICD-10-PCS
3E0S303	Introduction of Low-dose Interleukin-2 into Epidural Space, Percutaneous Approach	Procedure	ICD-10-PCS
3E0S305	Introduction of Other Antineoplastic into Epidural Space, Percutaneous Approach	Procedure	ICD-10-PCS
3E0S30M	Introduction of Antineoplastic, Monoclonal Antibody, into Epidural Space, Percutaneous Approach	Procedure	ICD-10-PCS
3E0U305	Introduction of Other Antineoplastic into Joints, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

3E0U30M	Introduction of Antineoplastic, Monoclonal Antibody, into Joints, Percutaneous Approach	Procedure	ICD-10-PCS
3E0V305	Introduction of Other Antineoplastic into Bones, Percutaneous Approach	Procedure	ICD-10-PCS
3E0V30M	Introduction of Antineoplastic, Monoclonal Antibody, into Bones, Percutaneous Approach	Procedure	ICD-10-PCS
3E0W305	Introduction of Other Antineoplastic into Lymphatics, Percutaneous Approach	Procedure	ICD-10-PCS
3E0W30M	Introduction of Antineoplastic, Monoclonal Antibody, into Lymphatics, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Y305	Introduction of Other Antineoplastic into Pericardial Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Y30M	Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Y705	Introduction of Other Antineoplastic into Pericardial Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0Y70M	Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic	Procedure	CPT-4
96402	Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic	Procedure	CPT-4
96409	Chemotherapy administration; intravenous, push technique, single or initial substance/drug	Procedure	CPT-4
96411	Chemotherapy administration; intravenous, push technique, each additional substance/drug (List separately in addition to code for primary procedure)	Procedure	CPT-4
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	Procedure	CPT-4
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)	Procedure	CPT-4
96416	Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

96417	Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)	Procedure	CPT-4
96420	CHEMOTX ADMIN INTRA-ART; PUSH TECH	Procedure	CPT-4
96422	CHEMOTX ADMIN INTRA-ART; INFUSION TECH TO 1 HR	Procedure	CPT-4
96423	Chemotherapy administration, intra-arterial; infusion technique, each additional hour up to 8 hours (List separately in addition to code for primary procedure)	Procedure	CPT-4
96425	Chemotherapy administration, intra-arterial; infusion technique, initiation of prolonged infusion (more than 8 hours), requiring the use of a portable or implantable pump	Procedure	CPT-4
96440	CHEMOTX-PLEURAL CAVITY-REQ & INCL THORACENTESIS	Procedure	CPT-4
96446	Chemotherapy administration into the peritoneal cavity via indwelling port or catheter	Procedure	CPT-4
96450	Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture	Procedure	CPT-4
96542	CHEMOTX INJ SUBARACH/INTRAVENTRIC-1/MX AGENTS	Procedure	CPT-4
96549	UNLISTED CHEMOTX PROC	Procedure	CPT-4
A9545	Iodine I-131 tositumomab, therapeutic, per treatment dose	Procedure	HCPCS
C1084	Denileukin diftitox, 300 mcg, ontak iv	Procedure	HCPCS
C1086	Temozolomide, 5 mg, temodar	Procedure	HCPCS
C1166	Injection, cytarabine liposome, per 10 mg	Procedure	HCPCS
C1167	Injection, epirubicin HCl, 2 mg	Procedure	HCPCS
C1178	Injection, busulfan, per 6 mg	Procedure	HCPCS
C9004	Injection, gemtuzumab ozogamicin, per 5 mg	Procedure	HCPCS
C9012	Injection, arsenic trioxide, per 1 mg/kg	Procedure	HCPCS
C9017	Lomustine, 10 mg	Procedure	HCPCS
C9021	Injection, obinutuzumab, 10 mg	Procedure	HCPCS
C9024	Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine	Procedure	HCPCS
C9042	Injection, bendamustine HCl (Belrapzo), 1 mg	Procedure	HCPCS
C9044	Injection, cemiplimab-rwlc, 1 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C9045	Injection, moxetumomab pasudotox-tdfk, 0.01 mg	Procedure	HCPCS
C9049	Injection, tagraxofusp-erzs, 10 mcg	Procedure	HCPCS
C9050	Injection, emapalumab-lzsg, 1 mg	Procedure	HCPCS
C9110	Injection, alemtuzumab, per 10 mg/ ml	Procedure	HCPCS
C9127	Injection, paclitaxel protein-bound particles, per 1 mg	Procedure	HCPCS
C9129	Injection, clofarabine, per 1 mg	Procedure	HCPCS
C9205	Injection, oxaliplatin, per 5 mg	Procedure	HCPCS
C9207	Injection, bortezomib, per 3.5 mg	Procedure	HCPCS
C9213	Injection, pemetrexed, per 10 mg	Procedure	HCPCS
C9214	Injection, bevacizumab, per 10 mg	Procedure	HCPCS
C9215	Injection, cetuximab, per 10 mg	Procedure	HCPCS
C9218	Injection, azacitidine, per 1 mg	Procedure	HCPCS
C9231	Injection, decitabine, per 1 mg	Procedure	HCPCS
C9235	Injection, panitumumab, 10 mg	Procedure	HCPCS
C9239	Injection, temsirolimus, 1 mg	Procedure	HCPCS
C9240	Injection, ixabepilone, 1 mg	Procedure	HCPCS
C9243	Injection, bendamustine hcl, 1 mg	Procedure	HCPCS
C9253	Injection, temozolomide, 1mg	Procedure	HCPCS
C9259	Injection, pralatrexate, 1 mg	Procedure	HCPCS
C9260	Injection, ofatumumab, 10 mg	Procedure	HCPCS
C9262	Fludarabine phosphate, oral, 1 mg	Procedure	HCPCS
C9265	Injection, romidepsin, 1 mg	Procedure	HCPCS
C9273	Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion	Procedure	HCPCS
C9276	Injection, cabazitaxel, 1 mg	Procedure	HCPCS
C9280	Injection, eribulin mesylate, 1 mg	Procedure	HCPCS
C9284	Injection, ipilimumab, 1 mg	Procedure	HCPCS
C9287	Injection, brentuximab vedotin, 1 mg	Procedure	HCPCS
C9289	Injection, asparaginase Erwinia chrysanthemi, 1,000 IU	Procedure	HCPCS
C9292	Injection, pertuzumab, 10 mg	Procedure	HCPCS
C9295	Injection, carfilzomib, 1 mg	Procedure	HCPCS
C9297	Injection, omacetaxine mepesuccinate, 0.01 mg	Procedure	HCPCS
C9414	Etoposide; oral, 50 mg, brand name	Procedure	HCPCS
C9415	Doxorubicin HCl, 10 mg, brand name	Procedure	HCPCS
C9417	Bleomycin sulfate, 15 units, brand name	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

C9418	Cisplatin, powder or solution, per 10 mg, brand name	Procedure	HCPCS
C9419	Injection, cladribine, per 1 mg, brand name	Procedure	HCPCS
C9420	Cyclophosphamide, 100 mg, brand name	Procedure	HCPCS
C9421	Cyclophosphamide, lyophilized, 100 mg, brand name	Procedure	HCPCS
C9422	Cytarabine, 100 mg, brand name	Procedure	HCPCS
C9423	Dacarbazine, 100 mg, brand name	Procedure	HCPCS
C9424	Daunorubicin, 10 mg	Procedure	HCPCS
C9425	Etoposide, 10 mg, brand name	Procedure	HCPCS
C9426	Floxuridine, 500 mg, brand name	Procedure	HCPCS
C9427	Ifosfamide, 1 gm, brand name	Procedure	HCPCS
C9429	Idarubicin HCl, 5 mg, brand name	Procedure	HCPCS
C9431	Paclitaxel, 30 mg, brand name	Procedure	HCPCS
C9432	Mitomycin, 5 mg, brand name	Procedure	HCPCS
C9433	Thiotepa, 15 mg, brand name	Procedure	HCPCS
C9437	Carmustine, brand name, 100 mg	Procedure	HCPCS
C9440	Vinorelbine tartrate, brand name, per 10 mg	Procedure	HCPCS
C9474	Injection, irinotecan liposome, 1 mg	Procedure	HCPCS
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D70.1	Agranulocytosis secondary to cancer chemotherapy	Diagnosis	ICD-10-CM
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion	Procedure	HCPCS
G3001	Administration and supply of tositumomab, 450 mg	Procedure	HCPCS
G9835	Trastuzumab administered within 12 months of diagnosis	Procedure	HCPCS
G9837	Trastuzumab not administered within 12 months of diagnosis	Procedure	HCPCS
J0202	Injection, alemtuzumab, 1 mg	Procedure	HCPCS
J0207	Injection, amifostine, 500 mg	Procedure	HCPCS
J0594	Injection, busulfan, 1 mg	Procedure	HCPCS
J0894	Injection, decitabine, 1 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

J7527	Everolimus, oral, 0.25 mg	Procedure	HCPCS
J8510	Busulfan; oral, 2 mg	Procedure	HCPCS
J8520	Capecitabine, oral, 150 mg	Procedure	HCPCS
J8521	Capecitabine, oral, 500 mg	Procedure	HCPCS
J8530	Cyclophosphamide, oral, 25 mg	Procedure	HCPCS
J8560	Etoposide, oral, 50 mg	Procedure	HCPCS
J8561	Everolimus, oral, 0.25 mg	Procedure	HCPCS
J8562	Fludarabine phosphate, oral, 10 mg	Procedure	HCPCS
J8565	Gefitinib, oral, 250 mg	Procedure	HCPCS
J8600	Melphalan, oral 2 mg	Procedure	HCPCS
J8610	Methotrexate, oral, 2.5 mg	Procedure	HCPCS
J8700	Temozolomide, oral, 5 mg	Procedure	HCPCS
J8705	Topotecan, oral, 0.25 mg	Procedure	HCPCS
J8999	Prescription drug, oral, chemotherapeutic, nos	Procedure	HCPCS
J9000	Injection, doxorubicin HCl, 10 mg	Procedure	HCPCS
J9001	Injection, doxorubicin HCl, all lipid formulations, 10 mg	Procedure	HCPCS
J9002	Injection, doxorubicin hydrochloride, liposomal, Doxil, 10 mg	Procedure	HCPCS
J9010	Injection, alemtuzumab, 10 mg	Procedure	HCPCS
J9015	Injection, aldesleukin, per single use vial	Procedure	HCPCS
J9017	Injection, arsenic trioxide, 1 mg	Procedure	HCPCS
J9019	Injection, asparaginase (Erwinaze), 1,000 IU	Procedure	HCPCS
J9020	Injection, asparaginase, not otherwise specified, 10,000 units	Procedure	HCPCS
J9025	Injection, azacitidine, 1 mg	Procedure	HCPCS
J9027	Injection, clofarabine, 1 mg	Procedure	HCPCS
J9033	Injection, bendamustine HCl (Treanda), 1 mg	Procedure	HCPCS
J9034	Injection, bendamustine HCl (Bendeka), 1 mg	Procedure	HCPCS
J9035	Injection, bevacizumab, 10 mg	Procedure	HCPCS
J9036	Injection, bendamustine hydrochloride, (Belrapzo/bendamustine), 1 mg	Procedure	HCPCS
J9040	Injection, bleomycin sulfate, 15 units	Procedure	HCPCS
J9041	Injection, bortezomib (Velcade), 0.1 mg	Procedure	HCPCS
J9042	Injection, brentuximab vedotin, 1 mg	Procedure	HCPCS
J9043	Injection, cabazitaxel, 1 mg	Procedure	HCPCS
J9045	Injection, carboplatin, 50 mg	Procedure	HCPCS
J9047	Injection, carfilzomib, 1 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

J9050	Injection, carmustine, 100 mg	Procedure	HCPCS
J9055	Injection, cetuximab, 10 mg	Procedure	HCPCS
J9057	Injection, copanlisib, 1 mg	Procedure	HCPCS
J9060	Injection, cisplatin, powder or solution, 10 mg	Procedure	HCPCS
J9062	Cisplatin, 50 mg	Procedure	HCPCS
J9065	Injection, cladribine, per 1 mg	Procedure	HCPCS
J9070	Cyclophosphamide, 100 mg	Procedure	HCPCS
J9080	Cyclophosphamide, 200 mg	Procedure	HCPCS
J9090	Cyclophosphamide, 500 mg	Procedure	HCPCS
J9091	Cyclophosphamide, 1 g	Procedure	HCPCS
J9092	Cyclophosphamide, 2 g	Procedure	HCPCS
J9093	Cyclophosphamide, lyophilized, 100 mg	Procedure	HCPCS
J9094	Cyclophosphamide, lyophilized, 200 mg	Procedure	HCPCS
J9095	Cyclophosphamide, lyophilized, 500 mg	Procedure	HCPCS
J9096	Cyclophosphamide, lyophilized, 1 g	Procedure	HCPCS
J9097	Cyclophosphamide, lyophilized, 2 g	Procedure	HCPCS
J9098	Injection, cytarabine liposome, 10 mg	Procedure	HCPCS
J9100	Cytarabine, 100 mg	Procedure	HCPCS
J9110	Injection, cytarabine, 500 mg	Procedure	HCPCS
J9118	Injection, calaspargase pegol-mknl, 10 units	Procedure	HCPCS
J9120	Injection, dactinomycin, 0.5 mg	Procedure	HCPCS
J9130	Dacarbazine, 100 mg	Procedure	HCPCS
J9140	Dacarbazine, 200 mg	Procedure	HCPCS
J9150	Injection, daunorubicin, 10 mg	Procedure	HCPCS
J9151	Injection, daunorubicin citrate, liposomal formulation, 10 mg	Procedure	HCPCS
J9153	Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine	Procedure	HCPCS
J9160	Injection, denileukin diftitox, 300 mcg	Procedure	HCPCS
J9170	Injection, docetaxel, 20 mg	Procedure	HCPCS
J9171	Injection, docetaxel, 1 mg	Procedure	HCPCS
J9173	Injection, durvalumab, 10 mg	Procedure	HCPCS
J9178	Injection, epirubicin HCl, 2 mg	Procedure	HCPCS
J9179	Injection, eribulin mesylate, 0.1 mg	Procedure	HCPCS
J9180	Epirubicin HCl, 50 mg	Procedure	HCPCS
J9181	Injection, etoposide, 10 mg	Procedure	HCPCS
J9182	Etoposide, 100 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

J9185	Injection, fludarabine phosphate, 50 mg	Procedure	HCPCS
J9190	Injection, fluorouracil, 500 mg	Procedure	HCPCS
J9200	Floxuridine, 500 mg	Procedure	HCPCS
J9201	Injection, gemcitabine HCl, not otherwise specified, 200 mg	Procedure	HCPCS
J9203	Injection, gemtuzumab ozogamicin, 0.1 mg	Procedure	HCPCS
J9205	Injection, irinotecan liposome, 1 mg	Procedure	HCPCS
J9206	Injection, irinotecan, 20 mg	Procedure	HCPCS
J9207	Injection, ixabepilone, 1 mg	Procedure	HCPCS
J9208	Injection, ifosfamide, 1 g	Procedure	HCPCS
J9211	Idarubicin HCl, 5 mg	Procedure	HCPCS
J9228	Injection, ipilimumab, 1 mg	Procedure	HCPCS
J9229	Injection, inotuzumab ozogamicin, 0.1 mg	Procedure	HCPCS
J9230	Injection, mechlorethamine HCl, (nitrogen mustard), 10 mg	Procedure	HCPCS
J9245	Injection, melphalan hydrochloride, not otherwise specified, 50 mg	Procedure	HCPCS
J9250	Methotrexate sodium, 5 mg	Procedure	HCPCS
J9260	Methotrexate sodium, 50 mg	Procedure	HCPCS
J9261	Injection, nelarabine, 50 mg	Procedure	HCPCS
J9262	Injection, omacetaxine mepesuccinate, 0.01 mg	Procedure	HCPCS
J9263	Injection, oxaliplatin, 0.5 mg	Procedure	HCPCS
J9264	Injection, paclitaxel protein-bound particles, 1 mg	Procedure	HCPCS
J9265	Injection, paclitaxel, 30 mg	Procedure	HCPCS
J9266	Injection, pegaspargase, per single dose vial	Procedure	HCPCS
J9267	Injection, paclitaxel, 1 mg	Procedure	HCPCS
J9268	Pentostatin, per 10 mg	Procedure	HCPCS
J9269	Injection, tagraxofusp-erzs, 10 mcg	Procedure	HCPCS
J9270	Plicamycin, 2.5 mg	Procedure	HCPCS
J9280	Mitomycin, 5 mg	Procedure	HCPCS
J9290	Mitomycin, 20 mg	Procedure	HCPCS
J9291	Mitomycin, 40 mg	Procedure	HCPCS
J9293	Injection, mitoxantrone HCl, per 5 mg	Procedure	HCPCS
J9300	Injection, gemtuzumab ozogamicin, 5 mg	Procedure	HCPCS
J9301	Injection, obinutuzumab, 10 mg	Procedure	HCPCS
J9302	Injection, ofatumumab, 10 mg	Procedure	HCPCS
J9303	Injection, panitumumab, 10 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

J9305	Injection, pemetrexed, NOS, 10 mg	Procedure	HCPCS
J9306	Injection, pertuzumab, 1 mg	Procedure	HCPCS
J9307	Injection, pralatrexate, 1 mg	Procedure	HCPCS
J9310	Injection, rituximab, 100 mg	Procedure	HCPCS
J9311	Injection, rituximab 10 mg and hyaluronidase	Procedure	HCPCS
J9312	Injection, rituximab, 10 mg	Procedure	HCPCS
J9315	Injection, romidepsin, 1 mg	Procedure	HCPCS
J9320	Streptozocin, 1 g	Procedure	HCPCS
J9328	Injection, temozolomide, 1 mg	Procedure	HCPCS
J9330	Injection, temsirolimus, 1 mg	Procedure	HCPCS
J9340	Thiotepa, 15 mg	Procedure	HCPCS
J9350	Injection, topotecan, 4 mg	Procedure	HCPCS
J9351	Injection, topotecan, 0.1 mg	Procedure	HCPCS
J9355	Injection, trastuzumab, 10 mg	Procedure	HCPCS
J9356	Injection, trastuzumab, 10 mg and hyaluronidase-oysk	Procedure	HCPCS
J9360	Injection, vinblastine sulfate, 1 mg	Procedure	HCPCS
J9370	Vincristine sulfate, 1 mg	Procedure	HCPCS
J9371	Injection, vincristine sulfate liposome, 1 mg	Procedure	HCPCS
J9375	Vincristine sulfate, 2 mg	Procedure	HCPCS
J9380	Vincristine sulfate, 5 mg	Procedure	HCPCS
J9390	Vinorelbine tartrate, per 10 mg	Procedure	HCPCS
J9999	Not otherwise classified, antineoplastic drugs	Procedure	HCPCS
Q2025	Fludarabine phosphate, oral, 1 mg	Procedure	HCPCS
Q2043	Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion	Procedure	HCPCS
Q2048	Injection, doxorubicin hydrochloride, liposomal, DOXIL, 10 mg	Procedure	HCPCS
Q2049	Injection, doxorubicin HCl, liposomal, imported Lipodox, 10 mg	Procedure	HCPCS
Q2050	Injection, doxorubicin HCl, liposomal, not otherwise specified, 10 mg	Procedure	HCPCS
Q5112	Injection, trastuzumab-dttb, biosimilar, (Ontruzant), 10 mg	Procedure	HCPCS
Q5113	Injection, trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Q5114	Injection, Trastuzumab-dkst, biosimilar, (Ogivri), 10 mg	Procedure	HCPCS
Q5115	Injection, rituximab-abbs, biosimilar, (Truxima), 10 mg	Procedure	HCPCS
Q5116	Injection, trastuzumab-qyyp, biosimilar, (Trazimera), 10 mg	Procedure	HCPCS
Q5117	Injection, trastuzumab-anns, biosimilar, (Kanjinti), 10 mg	Procedure	HCPCS
Q9979	Injection, Alemtuzumab, 1 mg	Procedure	HCPCS
S0087	Injection, alemtuzumab, 30 mg	Procedure	HCPCS
S0088	Imatinib, 100 mg	Procedure	HCPCS
S0108	Mercaptopurine, oral, 50 mg	Procedure	HCPCS
S0115	Bortezomib, 3.5 mg	Procedure	HCPCS
S0116	Bevacizumab, 100 mg	Procedure	HCPCS
S0168	Injection, azacitidine, 100 mg	Procedure	HCPCS
S0172	Chlorambucil, oral, 2 mg	Procedure	HCPCS
S0176	Hydroxyurea, oral, 500 mg	Procedure	HCPCS
S0178	Lomustine, oral, 10 mg	Procedure	HCPCS
S0182	Procarbazine HCl, oral, 50 mg	Procedure	HCPCS
T80.810	Extravasation of vesicant antineoplastic chemotherapy	Diagnosis	ICD-10-CM
T80.810A	Extravasation of vesicant antineoplastic chemotherapy, initial encounter	Diagnosis	ICD-10-CM
T80.810D	Extravasation of vesicant antineoplastic chemotherapy, subsequent encounter	Diagnosis	ICD-10-CM
XW03351	Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1	Procedure	ICD-10-PCS
XW033B3	Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3	Procedure	ICD-10-PCS
XW033C3	Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3	Procedure	ICD-10-PCS
XW033Q5	Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW033S5	Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

XW04351	Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1	Procedure	ICD-10-PCS
XW043B3	Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3	Procedure	ICD-10-PCS
XW043C3	Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3	Procedure	ICD-10-PCS
XW043Q5	Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW043S5	Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW0DXL5	Introduction of Erdafitinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW0DXR5	Introduction of Venetoclax Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW0DXT5	Introduction of Ruxolitinib into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW0DXV5	Introduction of Gilteritinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
Z51.1	Encounter for antineoplastic chemotherapy and immunotherapy	Diagnosis	ICD-10-CM
Z51.11	Encounter for antineoplastic chemotherapy	Diagnosis	ICD-10-CM
Z51.12	Encounter for antineoplastic immunotherapy	Diagnosis	ICD-10-CM
Immunosuppressant Therapeutic Agents			
3E030WL	Introduction of Immunosuppressive into Peripheral Vein, Open	Procedure	ICD-10-PCS
3E033WL	Introduction of Immunosuppressive into Peripheral Vein, Percutaneous	Procedure	ICD-10-PCS
3E040WL	Introduction of Immunosuppressive into Central Vein, Open	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

3E043WL	Introduction of Immunosuppressive into Central Vein, Percutaneous	Procedure	ICD-10-PCS
3E050WL	Introduction of Immunosuppressive into Peripheral Artery, Open	Procedure	ICD-10-PCS
3E053WL	Introduction of Immunosuppressive into Peripheral Artery, Percutaneous	Procedure	ICD-10-PCS
3E060WL	Introduction of Immunosuppressive into Central Artery, Open	Procedure	ICD-10-PCS
3E063WL	Introduction of Immunosuppressive into Central Artery, Percutaneous	Procedure	ICD-10-PCS
4153F	Combination peginterferon and ribavirin therapy prescribed (HEP-C)	Procedure	CPT-2
90378	Respiratory syncytial virus, monoclonal antibody, recombinant, for intramuscular use, 50 mg, each	Procedure	CPT-4
C9006	Injection, tacrolimus, per 5 mg (1 amp)	Procedure	HCPCS
C9020	Sirolimus tablet, 1 mg	Procedure	HCPCS
C9029	Injection, guselkumab, 1 mg	Procedure	HCPCS
C9042	Injection, bendamustine HCl (Belrapzo), 1 mg	Procedure	HCPCS
C9045	Injection, moxetumomab pasudotox-tdfk, 0.01 mg	Procedure	HCPCS
C9106	Sirolimus, per 1 mg/ml	Procedure	HCPCS
C9126	Injection natalizumab per 5 mg	Procedure	HCPCS
C9211	Injection, alefacept, for intravenous use, per 7.5 mg	Procedure	HCPCS
C9212	Injection, alefacept, for intramuscular use, per 7.5 mg	Procedure	HCPCS
C9230	Injection, abatacept, per 10 mg	Procedure	HCPCS
C9236	Injection, eculizumab, 10 mg	Procedure	HCPCS
C9249	Injection, certolizumab pegol, 1 mg	Procedure	HCPCS
C9261	Injection, ustekinumab, 1 mg	Procedure	HCPCS
C9264	Injection, tocilizumab, 1 mg	Procedure	HCPCS
C9286	Injection, belatacept, 1 mg	Procedure	HCPCS
C9436	Azathioprine, parenteral, brand name, per 100 mg	Procedure	HCPCS
C9438	Cyclosporine, oral, 100 mg, brand name	Procedure	HCPCS
C9487	Ustekinumab, for intravenous injection, 1 mg	Procedure	HCPCS
J0129	Injection, abatacept, 10 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)	Procedure	HCPCS
J0135	Injection, adalimumab, 20 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

J0215	Injection, alefacept, 0.5 mg	Procedure	HCPCS
J0480	Injection, basiliximab, 20 mg	Procedure	HCPCS
J0485	Injection, belatacept, 1 mg	Procedure	HCPCS
J0490	Injection, belimumab, 10 mg	Procedure	HCPCS
J0593	Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)	Procedure	HCPCS
J0638	Injection, canakinumab, 1 mg	Procedure	HCPCS
J0717	Injection, certolizumab pegol, 1 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)	Procedure	HCPCS
J0718	Injection, certolizumab pegol, 1 mg	Procedure	HCPCS
J0897	Injection, denosumab, 1 mg	Procedure	HCPCS
J1300	Injection, eculizumab, 10 mg	Procedure	HCPCS
J1303	Injection, ravulizumab-cwvz, 10 mg	Procedure	HCPCS
J1438	Injection, etanercept, 25 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)	Procedure	HCPCS
J1595	Injection, glatiramer acetate, 20 mg	Procedure	HCPCS
J1600	Injection, gold sodium thiomalate, up to 50 mg	Procedure	HCPCS
J1602	Injection, golimumab, 1 mg, for intravenous use	Procedure	HCPCS
J1628	Injection, guselkumab, 1 mg	Procedure	HCPCS
J1745	Injection, infliximab, excludes biosimilar, 10 mg	Procedure	HCPCS
J1825	Injection, interferon beta-1a, 33 mcg	Procedure	HCPCS
J1826	Injection, interferon beta-1a, 30 mcg	Procedure	HCPCS
J1830	Injection interferon beta-1b, 0.25 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)	Procedure	HCPCS
J2323	Injection, natalizumab, 1 mg	Procedure	HCPCS
J2350	Injection, ocrelizumab, 1 mg	Procedure	HCPCS
J2504	Injection, pegademase bovine, 25 IU	Procedure	HCPCS
J2793	Injection, rilonacept, 1 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

J2860	Injection, siltuximab, 10 mg	Procedure	HCPCS
J2910	Injection, aurothioglucose, up to 50 mg	Procedure	HCPCS
J3031	Injection, fremanezumab-vfrm, 1 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered)	Procedure	HCPCS
J3111	Injection, romosozumab-aqqg, 1 mg	Procedure	HCPCS
J3245	Injection, tildrakizumab, 1 mg	Procedure	HCPCS
J3262	Injection, tocilizumab, 1 mg	Procedure	HCPCS
J3357	Ustekinumab, for subcutaneous injection, 1 mg	Procedure	HCPCS
J3358	Ustekinumab, for intravenous injection, 1 mg	Procedure	HCPCS
J3380	Injection, vedolizumab, 1 mg	Procedure	HCPCS
J7500	Azathioprine, oral, 50 mg	Procedure	HCPCS
J7501	Azathioprine, parenteral, 100 mg	Procedure	HCPCS
J7502	Cyclosporine, oral, 100 mg	Procedure	HCPCS
J7503	Tacrolimus, extended release, (Envarsus XR), oral, 0.25 mg	Procedure	HCPCS
J7505	Muromonab-CD3, parenteral, 5 mg	Procedure	HCPCS
J7507	Tacrolimus, oral, per 1 mg	Procedure	HCPCS
J7508	Tacrolimus, extended release, (Astagraf XL), oral, 0.1 mg	Procedure	HCPCS
J7513	Daclizumab, parenteral, 25 mg	Procedure	HCPCS
J7515	Cyclosporine, oral, 25 mg	Procedure	HCPCS
J7516	Cyclosporine, parenteral, 250 mg	Procedure	HCPCS
J7517	Mycophenolate mofetil, oral, 250 mg	Procedure	HCPCS
J7520	Sirolimus, oral, 1 mg	Procedure	HCPCS
J7525	Tacrolimus, parenteral, 5 mg	Procedure	HCPCS
J7599	Immunosuppressive drug, not otherwise classified	Procedure	HCPCS
J9119	Injection, cemiplimab-rwlc, 1 mg	Procedure	HCPCS
J9204	Injection, mogamulizumab-kpkc, 1 mg	Procedure	HCPCS
J9210	Injection, emapalumab-lzsg, 1 mg	Procedure	HCPCS
J9212	Injection, interferon alfacon-1, recombinant, 1 mcg	Procedure	HCPCS
J9213	Injection, interferon, alfa-2a, recombinant, 3 million units	Procedure	HCPCS
J9214	Injection, interferon, alfa-2b, recombinant, 1 million units	Procedure	HCPCS
J9215	Injection, interferon, alfa-N3, (human leukocyte derived), 250,000 IU	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

J9216	Injection, interferon, gamma 1-b, 3 million units	Procedure	HCPCS
J9271	Injection, pembrolizumab, 1 mg	Procedure	HCPCS
K0119	Azathioprine, oral, tab, 50 mg	Procedure	HCPCS
K0120	Azathioprine, parenteral, 100 mg	Procedure	HCPCS
K0122	Cyclosporine, parenteral, 250 mg	Procedure	HCPCS
K0412	Mycophenolate mofetil, oral, 250 mg (CellCept)	Procedure	HCPCS
Q2010	Injection, glatiramer acetate, per dose	Procedure	HCPCS
Q2012	Injection, pegademase bovine, 25 IU	Procedure	HCPCS
Q2019	Injection, basiliximab, 20 mg	Procedure	HCPCS
Q2044	Injection, belimumab, 10 mg	Procedure	HCPCS
Q3025	Injection, interferon beta-1a, 11 mcg for intramuscular use	Procedure	HCPCS
Q3026	Injection, interferon beta-1a, 11 mcg for subcutaneous use	Procedure	HCPCS
Q3027	Injection, interferon beta-1a, 1 mcg for intramuscular use	Procedure	HCPCS
Q3028	Injection, interferon beta-1a, 1 mcg for subcutaneous use	Procedure	HCPCS
Q4079	Injection, natalizumab, 1 mg	Procedure	HCPCS
Q5102	Injection, infliximab, biosimilar, 10 mg	Procedure	HCPCS
Q5103	Injection, infliximab-dyyb, biosimilar, (Inflectra), 10 mg	Procedure	HCPCS
Q5104	Injection, infliximab-abda, biosimilar, (Renflexis), 10 mg	Procedure	HCPCS
Q5107	Injection, bevacizumab-awwb, biosimilar, (Mvasi), 10 mg	Procedure	HCPCS
Q5109	Injection, infliximab-qbtx, biosimilar, (Ixifi), 10 mg	Procedure	HCPCS
Q5112	Injection, trastuzumab-dttb, biosimilar, (Ontruzant), 10 mg	Procedure	HCPCS
Q5113	Injection, trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg	Procedure	HCPCS
Q5114	Injection, Trastuzumab-dkst, biosimilar, (Ogivri), 10 mg	Procedure	HCPCS
Q5115	Injection, rituximab-abbs, biosimilar, (Truxima), 10 mg	Procedure	HCPCS
Q5116	Injection, trastuzumab-qyyp, biosimilar, (Trazimera), 10 mg	Procedure	HCPCS
Q5117	Injection, trastuzumab-anns, biosimilar, (Kanjinti), 10 mg	Procedure	HCPCS
Q5118	Injection, bevacizumab-bvzr, biosimilar, (Zirabev), 10 mg	Procedure	HCPCS
Q5119	Injection, rituximab-pvvr, biosimilar, (RUXIENCE), 10 mg	Procedure	HCPCS
Q5121	Injection, infliximab-axxq, biosimilar, (AVSOLA), 10 mg	Procedure	HCPCS
Q9989	Ustekinumab, for intravenous injection, 1 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S0145	Injection, PEGylated interferon alfa-2A, 180 mcg per ml	Procedure	HCPCS
S0146	Injection, pegylated interferon alfa-2b, 10 mcg per 0.5 ml	Procedure	HCPCS
S0148	Injection, PEGylated interferon alfa-2B, 10 mcg	Procedure	HCPCS
S0162	Injection, efalizumab, 125 mg	Procedure	HCPCS
S0193	Injection alefacept, 7.5 mg (includes dose packaging)	Procedure	HCPCS
Steroid/Corticosteroid Diagnoses and Procedures and Dispensi			
J7509	Methylprednisolone, oral, per 4 mg	Procedure	HCPCS
J7510	Prednisolone, oral, per 5 mg	Procedure	HCPCS
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	Procedure	HCPCS
J8540	Dexamethasone, oral, 0.25 mg	Procedure	HCPCS
Z79.52	Long term (current) use of systemic steroids	Diagnosis	ICD-10-CM
Z92.241	Personal history of systemic steroid therapy	Diagnosis	ICD-10-CM
Organ Transplant Diagnoses and Procedures			
02Y	Heart and Great Vessels, Transplantation	Procedure	ICD-10-PCS
02YA	Transplantation / Heart	Procedure	ICD-10-PCS
02YA0Z0	Transplantation of Heart, Allogeneic, Open Approach	Procedure	ICD-10-PCS
02YA0Z1	Transplantation of Heart, Syngeneic, Open Approach	Procedure	ICD-10-PCS
02YA0Z2	Transplantation of Heart, Zooplastic, Open Approach	Procedure	ICD-10-PCS
07Y	Lymphatic and Hemic Systems, Transplantation	Procedure	ICD-10-PCS
07YP	Transplantation / Spleen	Procedure	ICD-10-PCS
07YP0Z0	Transplantation of Spleen, Allogeneic, Open Approach	Procedure	ICD-10-PCS
07YP0Z1	Transplantation of Spleen, Syngeneic, Open Approach	Procedure	ICD-10-PCS
07YP0Z2	Transplantation of Spleen, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0BY	Respiratory System, Transplantation	Procedure	ICD-10-PCS
0BYC	Transplantation / Upper Lung Lobe, Right	Procedure	ICD-10-PCS
0BYC0Z0	Transplantation of Right Upper Lung Lobe, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0BYC0Z1	Transplantation of Right Upper Lung Lobe, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0BYC0Z2	Transplantation of Right Upper Lung Lobe, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0BYD	Transplantation / Middle Lung Lobe, Right	Procedure	ICD-10-PCS
0BYD0Z0	Transplantation of Right Middle Lung Lobe, Allogeneic, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0BYD0Z1	Transplantation of Right Middle Lung Lobe, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0BYD0Z2	Transplantation of Right Middle Lung Lobe, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0BYF	Transplantation / Lower Lung Lobe, Right	Procedure	ICD-10-PCS
0BYF0Z0	Transplantation of Right Lower Lung Lobe, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0BYF0Z1	Transplantation of Right Lower Lung Lobe, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0BYF0Z2	Transplantation of Right Lower Lung Lobe, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0BYG	Transplantation / Upper Lung Lobe, Left	Procedure	ICD-10-PCS
0BYG0Z0	Transplantation of Left Upper Lung Lobe, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0BYG0Z1	Transplantation of Left Upper Lung Lobe, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0BYG0Z2	Transplantation of Left Upper Lung Lobe, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0BYH	Transplantation / Lung Lingula	Procedure	ICD-10-PCS
0BYH0Z0	Transplantation of Lung Lingula, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0BYH0Z1	Transplantation of Lung Lingula, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0BYH0Z2	Transplantation of Lung Lingula, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0BYJ	Transplantation / Lower Lung Lobe, Left	Procedure	ICD-10-PCS
0BYJ0Z0	Transplantation of Left Lower Lung Lobe, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0BYJ0Z1	Transplantation of Left Lower Lung Lobe, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0BYJ0Z2	Transplantation of Left Lower Lung Lobe, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0BYK	Transplantation / Lung, Right	Procedure	ICD-10-PCS
0BYK0Z0	Transplantation of Right Lung, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0BYK0Z1	Transplantation of Right Lung, Syngeneic, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0BYK0Z2	Transplantation of Right Lung, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0BYL	Transplantation / Lung, Left	Procedure	ICD-10-PCS
0BYL0Z0	Transplantation of Left Lung, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0BYL0Z1	Transplantation of Left Lung, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0BYL0Z2	Transplantation of Left Lung, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0BYM	Transplantation / Lungs, Bilateral	Procedure	ICD-10-PCS
0BYM0Z0	Transplantation of Bilateral Lungs, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0BYM0Z1	Transplantation of Bilateral Lungs, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0BYM0Z2	Transplantation of Bilateral Lungs, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0DY	Gastrointestinal System, Transplantation	Procedure	ICD-10-PCS
0DY5	Transplantation / Esophagus	Procedure	ICD-10-PCS
0DY50Z0	Transplantation of Esophagus, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0DY50Z1	Transplantation of Esophagus, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0DY50Z2	Transplantation of Esophagus, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0DY6	Transplantation / Stomach	Procedure	ICD-10-PCS
0DY60Z0	Transplantation of Stomach, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0DY60Z1	Transplantation of Stomach, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0DY60Z2	Transplantation of Stomach, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0DY8	Transplantation / Small Intestine	Procedure	ICD-10-PCS
0DY80Z0	Transplantation of Small Intestine, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0DY80Z1	Transplantation of Small Intestine, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0DY80Z2	Transplantation of Small Intestine, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0DYE	Transplantation / Large Intestine	Procedure	ICD-10-PCS
0DYE0Z0	Transplantation of Large Intestine, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0DYE0Z1	Transplantation of Large Intestine, Syngeneic, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

0DYE0Z2	Transplantation of Large Intestine, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0FY	Hepatobiliary System and Pancreas, Transplantation	Procedure	ICD-10-PCS
0FY0	Transplantation / Liver	Procedure	ICD-10-PCS
0FY00Z0	Transplantation of Liver, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0FY00Z1	Transplantation of Liver, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0FY00Z2	Transplantation of Liver, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0FYG	Transplantation / Pancreas	Procedure	ICD-10-PCS
0FYG0Z0	Transplantation of Pancreas, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0FYG0Z1	Transplantation of Pancreas, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0FYG0Z2	Transplantation of Pancreas, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0TY	Urinary System, Transplantation	Procedure	ICD-10-PCS
0TY0	Transplantation / Kidney, Right	Procedure	ICD-10-PCS
0TY00Z0	Transplantation of Right Kidney, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0TY00Z1	Transplantation of Right Kidney, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0TY00Z2	Transplantation of Right Kidney, Zooplastic, Open Approach	Procedure	ICD-10-PCS
0TY1	Transplantation / Kidney, Left	Procedure	ICD-10-PCS
0TY10Z0	Transplantation of Left Kidney, Allogeneic, Open Approach	Procedure	ICD-10-PCS
0TY10Z1	Transplantation of Left Kidney, Syngeneic, Open Approach	Procedure	ICD-10-PCS
0TY10Z2	Transplantation of Left Kidney, Zooplastic, Open Approach	Procedure	ICD-10-PCS
30230AZ	Transfusion of Embryonic Stem Cells into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230G1	Transfusion of Nonautologous Bone Marrow into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230G2	Transfusion of Allogeneic Related Bone Marrow into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230G3	Transfusion of Allogeneic Unrelated Bone Marrow into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230G4	Transfusion of Allogeneic Unspecified Bone Marrow into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

30230X1	Transfusion of Nonautologous Cord Blood Stem Cells into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230X2	Transfusion of Allogeneic Related Cord Blood Stem Cells into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230X3	Transfusion of Allogeneic Unrelated Cord Blood Stem Cells into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230X4	Transfusion of Allogeneic Unspecified Cord Blood Stem Cells into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230Y1	Transfusion of Nonautologous Hematopoietic Stem Cells into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230Y2	Transfusion of Allogeneic Related Hematopoietic Stem Cells into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230Y3	Transfusion of Allogeneic Unrelated Hematopoietic Stem Cells into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30230Y4	Transfusion of Allogeneic Unspecified Hematopoietic Stem Cells into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
30233AZ	Transfusion of Embryonic Stem Cells into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233G1	Transfusion of Nonautologous Bone Marrow into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233G2	Transfusion of Allogeneic Related Bone Marrow into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233G3	Transfusion of Allogeneic Unrelated Bone Marrow into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233G4	Transfusion of Allogeneic Unspecified Bone Marrow into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233X1	Transfusion of Nonautologous Cord Blood Stem Cells into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233X2	Transfusion of Allogeneic Related Cord Blood Stem Cells into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233X3	Transfusion of Allogeneic Unrelated Cord Blood Stem Cells into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233X4	Transfusion of Allogeneic Unspecified Cord Blood Stem Cells into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233Y1	Transfusion of Nonautologous Hematopoietic Stem Cells into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

30233Y2	Transfusion of Allogeneic Related Hematopoietic Stem Cells into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233Y3	Transfusion of Allogeneic Unrelated Hematopoietic Stem Cells into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30233Y4	Transfusion of Allogeneic Unspecified Hematopoietic Stem Cells into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30240AZ	Transfusion of Embryonic Stem Cells into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240G1	Transfusion of Nonautologous Bone Marrow into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240G2	Transfusion of Allogeneic Related Bone Marrow into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240G3	Transfusion of Allogeneic Unrelated Bone Marrow into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240G4	Transfusion of Allogeneic Unspecified Bone Marrow into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240X1	Transfusion of Nonautologous Cord Blood Stem Cells into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240X2	Transfusion of Allogeneic Related Cord Blood Stem Cells into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240X3	Transfusion of Allogeneic Unrelated Cord Blood Stem Cells into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240X4	Transfusion of Allogeneic Unspecified Cord Blood Stem Cells into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240Y0	Transfusion of Autologous Hematopoietic Stem Cells into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240Y1	Transfusion of Nonautologous Hematopoietic Stem Cells into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240Y2	Transfusion of Allogeneic Related Hematopoietic Stem Cells into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240Y3	Transfusion of Allogeneic Unrelated Hematopoietic Stem Cells into Central Vein, Open Approach	Procedure	ICD-10-PCS
30240Y4	Transfusion of Allogeneic Unspecified Hematopoietic Stem Cells into Central Vein, Open Approach	Procedure	ICD-10-PCS
30243AZ	Transfusion of Embryonic Stem Cells into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

30243G1	Transfusion of Nonautologous Bone Marrow into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243G2	Transfusion of Allogeneic Related Bone Marrow into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243G3	Transfusion of Allogeneic Unrelated Bone Marrow into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243G4	Transfusion of Allogeneic Unspecified Bone Marrow into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243X1	Transfusion of Nonautologous Cord Blood Stem Cells into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243X2	Transfusion of Allogeneic Related Cord Blood Stem Cells into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243X3	Transfusion of Allogeneic Unrelated Cord Blood Stem Cells into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243X4	Transfusion of Allogeneic Unspecified Cord Blood Stem Cells into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243Y1	Transfusion of Nonautologous Hematopoietic Stem Cells into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243Y2	Transfusion of Allogeneic Related Hematopoietic Stem Cells into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243Y3	Transfusion of Allogeneic Unrelated Hematopoietic Stem Cells into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30243Y4	Transfusion of Allogeneic Unspecified Hematopoietic Stem Cells into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
30250G1	Transfusion of Nonautologous Bone Marrow into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
30250X1	Transfusion of Nonautologous Cord Blood Stem Cells into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
30250Y1	Transfusion of Nonautologous Hematopoietic Stem Cells into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
30253G1	Transfusion of Nonautologous Bone Marrow into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
30253X1	Transfusion of Nonautologous Cord Blood Stem Cells into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
30253Y1	Transfusion of Nonautologous Hematopoietic Stem Cells into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

30260G1	Transfusion of Nonautologous Bone Marrow into Central Artery, Open Approach	Procedure	ICD-10-PCS
30260X1	Transfusion of Nonautologous Cord Blood Stem Cells into Central Artery, Open Approach	Procedure	ICD-10-PCS
30260Y1	Transfusion of Nonautologous Hematopoietic Stem Cells into Central Artery, Open Approach	Procedure	ICD-10-PCS
30263G1	Transfusion of Nonautologous Bone Marrow into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
30263X1	Transfusion of Nonautologous Cord Blood Stem Cells into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
30263Y1	Transfusion of Nonautologous Hematopoietic Stem Cells into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
32851	Lung transplant, single; without cardiopulmonary bypass	Procedure	CPT-4
32852	Lung transplant, single; with cardiopulmonary bypass	Procedure	CPT-4
32853	Lung transplant, double (bilateral sequential or en bloc); without cardiopulmonary bypass	Procedure	CPT-4
32854	Lung transplant, double (bilateral sequential or en bloc); with cardiopulmonary bypass	Procedure	CPT-4
33935	Heart-lung transplant with recipient cardiectomy-pneumonectomy	Procedure	CPT-4
33945	Heart transplant, with or without recipient cardiectomy	Procedure	CPT-4
38240	Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor	Procedure	CPT-4
38242	Allogeneic lymphocyte infusions	Procedure	CPT-4
38243	Hematopoietic progenitor cell (HPC); HPC boost	Procedure	CPT-4
44135	Intestinal allotransplantation; from cadaver donor	Procedure	CPT-4
44136	Intestinal allotransplantation; from living donor	Procedure	CPT-4
47135	Liver allotransplantation, orthotopic, partial or whole, from cadaver or living donor, any age	Procedure	CPT-4
47136	Liver allotransplantation; heterotopic, partial or whole, from cadaver or living donor, any age	Procedure	CPT-4
48554	Transplantation of pancreatic allograft	Procedure	CPT-4
50360	Renal allotransplantation, implantation of graft; excluding donor and recipient nephrectomy	Procedure	CPT-4
50365	Renal allotransplantation, implantation of graft; with recipient nephrectomy	Procedure	CPT-4
50366	Renal Homotransplantation, Implantation Of Graft	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

50370	Removal of transplanted renal allograft	Procedure	CPT-4
BT29	Computerized Tomography (CT Scan) / Kidney Transplant	Procedure	ICD-10-PCS
BT2900Z	Computerized Tomography (CT Scan) of Kidney Transplant using High Osmolar Contrast, Unenhanced and Enhanced	Procedure	ICD-10-PCS
BT290ZZ	Computerized Tomography (CT Scan) of Kidney Transplant using High Osmolar Contrast	Procedure	ICD-10-PCS
BT2910Z	Computerized Tomography (CT Scan) of Kidney Transplant using Low Osmolar Contrast, Unenhanced and Enhanced	Procedure	ICD-10-PCS
BT291ZZ	Computerized Tomography (CT Scan) of Kidney Transplant using Low Osmolar Contrast	Procedure	ICD-10-PCS
BT29Y0Z	Computerized Tomography (CT Scan) of Kidney Transplant using Other Contrast, Unenhanced and Enhanced	Procedure	ICD-10-PCS
BT29YZZ	Computerized Tomography (CT Scan) of Kidney Transplant using Other Contrast	Procedure	ICD-10-PCS
BT29ZZZ	Computerized Tomography (CT Scan) of Kidney Transplant	Procedure	ICD-10-PCS
BT39	Magnetic Resonance Imaging (MRI) / Kidney Transplant	Procedure	ICD-10-PCS
BT39Y0Z	Magnetic Resonance Imaging (MRI) of Kidney Transplant using Other Contrast, Unenhanced and Enhanced	Procedure	ICD-10-PCS
BT39YZZ	Magnetic Resonance Imaging (MRI) of Kidney Transplant using Other Contrast	Procedure	ICD-10-PCS
BT39ZZZ	Magnetic Resonance Imaging (MRI) of Kidney Transplant	Procedure	ICD-10-PCS
BT49	Ultrasonography / Kidney Transplant	Procedure	ICD-10-PCS
BT49ZZZ	Ultrasonography of Kidney Transplant	Procedure	ICD-10-PCS
D89.810	Acute graft-versus-host disease	Diagnosis	ICD-10-CM
D89.811	Chronic graft-versus-host disease	Diagnosis	ICD-10-CM
D89.812	Acute on chronic graft-versus-host disease	Diagnosis	ICD-10-CM
D89.813	Graft-versus-host disease, unspecified	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
S2053	Transplantation of small intestine and liver allografts	Procedure	HCPCS
S2054	Transplantation of multivisceral organs	Procedure	HCPCS
S2060	Lobar lung transplantation	Procedure	HCPCS
S2065	Simultaneous pancreas kidney transplantation	Procedure	HCPCS
S2142	Cord blood-derived stem-cell transplantation, allogeneic	Procedure	HCPCS
S2150	Bone marrow or blood-derived stem cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and posttransplant care in the global definition	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S2152	Solid organ(s), complete or segmental, single organ or combination of organs; deceased or living donor(s), procurement, transplantation, and related complications; including: drugs; supplies; hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services, and the number of days of pre- and posttransplant care in the global definition	Procedure	HCPCS
T86.00	Unspecified complication of bone marrow transplant	Diagnosis	ICD-10-CM
T86.01	Bone marrow transplant rejection	Diagnosis	ICD-10-CM
T86.02	Bone marrow transplant failure	Diagnosis	ICD-10-CM
T86.03	Bone marrow transplant infection	Diagnosis	ICD-10-CM
T86.09	Other complications of bone marrow transplant	Diagnosis	ICD-10-CM
T86.10	Unspecified complication of kidney transplant	Diagnosis	ICD-10-CM
T86.11	Kidney transplant rejection	Diagnosis	ICD-10-CM
T86.12	Kidney transplant failure	Diagnosis	ICD-10-CM
T86.13	Kidney transplant infection	Diagnosis	ICD-10-CM
T86.19	Other complication of kidney transplant	Diagnosis	ICD-10-CM
T86.20	Unspecified complication of heart transplant	Diagnosis	ICD-10-CM
T86.21	Heart transplant rejection	Diagnosis	ICD-10-CM
T86.22	Heart transplant failure	Diagnosis	ICD-10-CM
T86.23	Heart transplant infection	Diagnosis	ICD-10-CM
T86.290	Cardiac allograft vasculopathy	Diagnosis	ICD-10-CM
T86.298	Other complications of heart transplant	Diagnosis	ICD-10-CM
T86.30	Unspecified complication of heart-lung transplant	Diagnosis	ICD-10-CM
T86.31	Heart-lung transplant rejection	Diagnosis	ICD-10-CM
T86.32	Heart-lung transplant failure	Diagnosis	ICD-10-CM
T86.33	Heart-lung transplant infection	Diagnosis	ICD-10-CM
T86.39	Other complications of heart-lung transplant	Diagnosis	ICD-10-CM
T86.40	Unspecified complication of liver transplant	Diagnosis	ICD-10-CM
T86.41	Liver transplant rejection	Diagnosis	ICD-10-CM
T86.42	Liver transplant failure	Diagnosis	ICD-10-CM
T86.43	Liver transplant infection	Diagnosis	ICD-10-CM
T86.49	Other complications of liver transplant	Diagnosis	ICD-10-CM
T86.810	Lung transplant rejection	Diagnosis	ICD-10-CM
T86.811	Lung transplant failure	Diagnosis	ICD-10-CM
T86.812	Lung transplant infection	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

T86.818	Other complications of lung transplant	Diagnosis	ICD-10-CM
T86.819	Unspecified complication of lung transplant	Diagnosis	ICD-10-CM
T86.850	Intestine transplant rejection	Diagnosis	ICD-10-CM
T86.851	Intestine transplant failure	Diagnosis	ICD-10-CM
T86.852	Intestine transplant infection	Diagnosis	ICD-10-CM
T86.858	Other complications of intestine transplant	Diagnosis	ICD-10-CM
T86.859	Unspecified complication of intestine transplant	Diagnosis	ICD-10-CM
T86.890	Other transplanted tissue rejection	Diagnosis	ICD-10-CM
T86.891	Other transplanted tissue failure	Diagnosis	ICD-10-CM
T86.892	Other transplanted tissue infection	Diagnosis	ICD-10-CM
T86.898	Other complications of other transplanted tissue	Diagnosis	ICD-10-CM
T86.899	Unspecified complication of other transplanted tissue	Diagnosis	ICD-10-CM
T86.90	Unspecified complication of unspecified transplanted organ and tissue	Diagnosis	ICD-10-CM
T86.91	Unspecified transplanted organ and tissue rejection	Diagnosis	ICD-10-CM
T86.92	Unspecified transplanted organ and tissue failure	Diagnosis	ICD-10-CM
T86.93	Unspecified transplanted organ and tissue infection	Diagnosis	ICD-10-CM
T86.99	Other complications of unspecified transplanted organ and tissue	Diagnosis	ICD-10-CM
Y83.0	Surgical operation with transplant of whole organ as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure	Diagnosis	ICD-10-CM
Z48.21	Encounter for aftercare following heart transplant	Diagnosis	ICD-10-CM
Z48.22	Encounter for aftercare following kidney transplant	Diagnosis	ICD-10-CM
Z48.23	Encounter for aftercare following liver transplant	Diagnosis	ICD-10-CM
Z48.24	Encounter for aftercare following lung transplant	Diagnosis	ICD-10-CM
Z48.280	Encounter for aftercare following heart-lung transplant	Diagnosis	ICD-10-CM
Z48.288	Encounter for aftercare following multiple organ transplant	Diagnosis	ICD-10-CM
Z48.290	Encounter for aftercare following bone marrow transplant	Diagnosis	ICD-10-CM
Z48.298	Encounter for aftercare following other organ transplant	Diagnosis	ICD-10-CM
Z94.0	Kidney transplant status	Diagnosis	ICD-10-CM
Z94.1	Heart transplant status	Diagnosis	ICD-10-CM
Z94.2	Lung transplant status	Diagnosis	ICD-10-CM
Z94.3	Heart and lungs transplant status	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Z94.4	Liver transplant status	Diagnosis	ICD-10-CM
Z94.81	Bone marrow transplant status	Diagnosis	ICD-10-CM
Z94.82	Intestine transplant status	Diagnosis	ICD-10-CM
Z94.83	Pancreas transplant status	Diagnosis	ICD-10-CM
Z94.84	Stem cells transplant status	Diagnosis	ICD-10-CM
Z94.89	Other transplanted organ and tissue status	Diagnosis	ICD-10-CM
Z94.9	Transplanted organ and tissue status, unspecified	Diagnosis	ICD-10-CM
	Hyperlipidemia		
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
	Rheumatoid Arthritis/Osteoarthritis		
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.51	Distal interphalangeal psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.54	Psoriatic juvenile arthropathy	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM

M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM

M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM

M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM

M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM

M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM

M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM

M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
M08.842	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM
M08.849	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.851	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM

M08.852	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
M08.859	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.861	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM
M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM
M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.51	Unilateral post-traumatic osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.52	Unilateral post-traumatic osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.6	Other bilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.7	Other unilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.9	Osteoarthritis of hip, unspecified	Diagnosis	ICD-10-CM
M17.0	Bilateral primary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.10	Unilateral primary osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.11	Unilateral primary osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.12	Unilateral primary osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.2	Bilateral post-traumatic osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.31	Unilateral post-traumatic osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.32	Unilateral post-traumatic osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.4	Other bilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.5	Other unilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.9	Osteoarthritis of knee, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M18.0	Bilateral primary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.10	Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.11	Unilateral primary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.12	Unilateral primary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.30	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.4	Other bilateral secondary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.50	Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.51	Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.52	Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.9	Osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M19.011	Primary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.012	Primary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.019	Primary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.021	Primary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.022	Primary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.029	Primary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.031	Primary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.032	Primary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.039	Primary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.041	Primary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.042	Primary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.049	Primary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M19.071	Primary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.072	Primary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.A2	Non-radiographic axial spondyloarthritis of cervical region	Diagnosis	ICD-10-CM
M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.A4	Non-radiographic axial spondyloarthritis of thoracic region	Diagnosis	ICD-10-CM
M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.A6	Non-radiographic axial spondyloarthritis of lumbar region	Diagnosis	ICD-10-CM
M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region	Diagnosis	ICD-10-CM
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	Diagnosis	ICD-10-CM
M46.80	Other specified inflammatory spondylopathies, site unspecified	Diagnosis	ICD-10-CM
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M46.82	Other specified inflammatory spondylopathies, cervical region	Diagnosis	ICD-10-CM
M46.83	Other specified inflammatory spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M46.84	Other specified inflammatory spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M46.85	Other specified inflammatory spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M46.86	Other specified inflammatory spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M46.87	Other specified inflammatory spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M46.88	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.89	Other specified inflammatory spondylopathies, multiple sites in spine	Diagnosis	ICD-10-CM
M46.90	Unspecified inflammatory spondylopathy, site unspecified	Diagnosis	ICD-10-CM
M46.91	Unspecified inflammatory spondylopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.92	Unspecified inflammatory spondylopathy, cervical region	Diagnosis	ICD-10-CM
M46.93	Unspecified inflammatory spondylopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M46.94	Unspecified inflammatory spondylopathy, thoracic region	Diagnosis	ICD-10-CM
M46.95	Unspecified inflammatory spondylopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M46.96	Unspecified inflammatory spondylopathy, lumbar region	Diagnosis	ICD-10-CM
M46.97	Unspecified inflammatory spondylopathy, lumbosacral region	Diagnosis	ICD-10-CM
M46.98	Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.99	Unspecified inflammatory spondylopathy, multiple sites in spine	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M47.011	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM
M47.015	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM
M47.016	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021	Vertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022	Vertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029	Vertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.12	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.13	Other spondylosis with myelopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.14	Other spondylosis with myelopathy, thoracic region	Diagnosis	ICD-10-CM
M47.15	Other spondylosis with myelopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.16	Other spondylosis with myelopathy, lumbar region	Diagnosis	ICD-10-CM
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified	Diagnosis	ICD-10-CM
	Acquired Hypothyroidism		
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
	Glaucoma		
H40.001	Preglaucoma, unspecified, right eye	Diagnosis	ICD-10-CM
H40.002	Preglaucoma, unspecified, left eye	Diagnosis	ICD-10-CM
H40.003	Preglaucoma, unspecified, bilateral	Diagnosis	ICD-10-CM
H40.009	Preglaucoma, unspecified, unspecified eye	Diagnosis	ICD-10-CM
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM

H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.031	Anatomical narrow angle, right eye	Diagnosis	ICD-10-CM
H40.032	Anatomical narrow angle, left eye	Diagnosis	ICD-10-CM
H40.033	Anatomical narrow angle, bilateral	Diagnosis	ICD-10-CM
H40.039	Anatomical narrow angle, unspecified eye	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM

H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
	Osteoporosis		
M80.00XA	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.011A	Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.012A	Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.019A	Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.021A	Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.022A	Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.029A	Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.031A	Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.032A	Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM

M80.039A	Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.041A	Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.042A	Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.049A	Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.051A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.061A	Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.062A	Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.069A	Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.071A	Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.072A	Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.079A	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.08XA	Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0AXA	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M80.80XA	Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.811A	Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.812A	Other osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.819A	Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.821A	Other osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.822A	Other osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.829A	Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.831A	Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.832A	Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.839A	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.841A	Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.842A	Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.849A	Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.851A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.859A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.861A	Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.862A	Other osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M80.869A	Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.871A	Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.872A	Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.879A	Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.88XA	Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8AXA	Other osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M81.0	Age-related osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
M81.6	Localized osteoporosis [Lequesne]	Diagnosis	ICD-10-CM
M81.8	Other osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
	Anemia		
C94.6	Myelodysplastic disease, not elsewhere classified	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D50.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CM
D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
D50.8	Other iron deficiency anemias	Diagnosis	ICD-10-CM
D50.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CM
D51.1	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria	Diagnosis	ICD-10-CM
D51.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CM
D51.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CM
D51.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CM
D51.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D52.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CM
D52.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CM
D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CM
D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CM
D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CM
D53.2	Scorbutic anemia	Diagnosis	ICD-10-CM
D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM
	Benign Prostatic Hyperplasia		
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.3	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N42.83	Cyst of prostate	Diagnosis	ICD-10-CM
	Hip/Pelvic Fracture		
M80.051A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.851A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.859A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.350A	Stress fracture, pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.351A	Stress fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.352A	Stress fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.353A	Stress fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.359A	Stress fracture, hip, unspecified, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M84.451A	Pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.452A	Pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.453A	Pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.459A	Pathological fracture, hip, unspecified, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.550A	Pathological fracture in neoplastic disease, pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.551A	Pathological fracture in neoplastic disease, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.552A	Pathological fracture in neoplastic disease, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.553A	Pathological fracture in neoplastic disease, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.559A	Pathological fracture in neoplastic disease, hip, unspecified, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.650A	Pathological fracture in other disease, pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.651A	Pathological fracture in other disease, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.652A	Pathological fracture in other disease, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.653A	Pathological fracture in other disease, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M84.659A	Pathological fracture in other disease, hip, unspecified, initial encounter for fracture	Diagnosis	ICD-10-CM
M97.01XA	Periprosthetic fracture around internal prosthetic right hip joint, initial encounter	Diagnosis	ICD-10-CM
M97.02XA	Periprosthetic fracture around internal prosthetic left hip joint, initial encounter	Diagnosis	ICD-10-CM
S32.301A	Unspecified fracture of right ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.301B	Unspecified fracture of right ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S32.302A	Unspecified fracture of left ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.302B	Unspecified fracture of left ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.309A	Unspecified fracture of unspecified ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.309B	Unspecified fracture of unspecified ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.311A	Displaced avulsion fracture of right ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.311B	Displaced avulsion fracture of right ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.312A	Displaced avulsion fracture of left ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.312B	Displaced avulsion fracture of left ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.313A	Displaced avulsion fracture of unspecified ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.313B	Displaced avulsion fracture of unspecified ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.314A	Nondisplaced avulsion fracture of right ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.314B	Nondisplaced avulsion fracture of right ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.315A	Nondisplaced avulsion fracture of left ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.315B	Nondisplaced avulsion fracture of left ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.316A	Nondisplaced avulsion fracture of unspecified ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.316B	Nondisplaced avulsion fracture of unspecified ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.391A	Other fracture of right ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.391B	Other fracture of right ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S32.392A	Other fracture of left ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.392B	Other fracture of left ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.399A	Other fracture of unspecified ilium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.399B	Other fracture of unspecified ilium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.401A	Unspecified fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.401B	Unspecified fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.402A	Unspecified fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.402B	Unspecified fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.409A	Unspecified fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.409B	Unspecified fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.411A	Displaced fracture of anterior wall of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.411B	Displaced fracture of anterior wall of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.412A	Displaced fracture of anterior wall of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.412B	Displaced fracture of anterior wall of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.413A	Displaced fracture of anterior wall of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.413B	Displaced fracture of anterior wall of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.414A	Nondisplaced fracture of anterior wall of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.414B	Nondisplaced fracture of anterior wall of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S32.415A	Nondisplaced fracture of anterior wall of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.415B	Nondisplaced fracture of anterior wall of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.416A	Nondisplaced fracture of anterior wall of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.416B	Nondisplaced fracture of anterior wall of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.421A	Displaced fracture of posterior wall of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.421B	Displaced fracture of posterior wall of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.422A	Displaced fracture of posterior wall of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.422B	Displaced fracture of posterior wall of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.423A	Displaced fracture of posterior wall of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.423B	Displaced fracture of posterior wall of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.424A	Nondisplaced fracture of posterior wall of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.424B	Nondisplaced fracture of posterior wall of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.425A	Nondisplaced fracture of posterior wall of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.425B	Nondisplaced fracture of posterior wall of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.426A	Nondisplaced fracture of posterior wall of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.426B	Nondisplaced fracture of posterior wall of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.431A	Displaced fracture of anterior column [iliopubic] of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.431B	Displaced fracture of anterior column [iliopubic] of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S32.432A	Displaced fracture of anterior column [iliopubic] of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.432B	Displaced fracture of anterior column [iliopubic] of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.433A	Displaced fracture of anterior column [iliopubic] of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.433B	Displaced fracture of anterior column [iliopubic] of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.434A	Nondisplaced fracture of anterior column [iliopubic] of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.434B	Nondisplaced fracture of anterior column [iliopubic] of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.435A	Nondisplaced fracture of anterior column [iliopubic] of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.435B	Nondisplaced fracture of anterior column [iliopubic] of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.436A	Nondisplaced fracture of anterior column [iliopubic] of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.436B	Nondisplaced fracture of anterior column [iliopubic] of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.441A	Displaced fracture of posterior column [ilioischial] of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.441B	Displaced fracture of posterior column [ilioischial] of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.442A	Displaced fracture of posterior column [ilioischial] of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.442B	Displaced fracture of posterior column [ilioischial] of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.443A	Displaced fracture of posterior column [ilioischial] of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM

S32.443B	Displaced fracture of posterior column [ilioischial] of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.444A	Nondisplaced fracture of posterior column [ilioischial] of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.444B	Nondisplaced fracture of posterior column [ilioischial] of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.445A	Nondisplaced fracture of posterior column [ilioischial] of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.445B	Nondisplaced fracture of posterior column [ilioischial] of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.446A	Nondisplaced fracture of posterior column [ilioischial] of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.446B	Nondisplaced fracture of posterior column [ilioischial] of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.451A	Displaced transverse fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.451B	Displaced transverse fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.452A	Displaced transverse fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.452B	Displaced transverse fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.453A	Displaced transverse fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.453B	Displaced transverse fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.454A	Nondisplaced transverse fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.454B	Nondisplaced transverse fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.455A	Nondisplaced transverse fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.455B	Nondisplaced transverse fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S32.456A	Nondisplaced transverse fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.456B	Nondisplaced transverse fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.461A	Displaced associated transverse-posterior fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.461B	Displaced associated transverse-posterior fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.462A	Displaced associated transverse-posterior fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.462B	Displaced associated transverse-posterior fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.463A	Displaced associated transverse-posterior fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.463B	Displaced associated transverse-posterior fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.464A	Nondisplaced associated transverse-posterior fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.464B	Nondisplaced associated transverse-posterior fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.465A	Nondisplaced associated transverse-posterior fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.465B	Nondisplaced associated transverse-posterior fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.466A	Nondisplaced associated transverse-posterior fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.466B	Nondisplaced associated transverse-posterior fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.471A	Displaced fracture of medial wall of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.471B	Displaced fracture of medial wall of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S32.472A	Displaced fracture of medial wall of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.472B	Displaced fracture of medial wall of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.473A	Displaced fracture of medial wall of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.473B	Displaced fracture of medial wall of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.474A	Nondisplaced fracture of medial wall of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.474B	Nondisplaced fracture of medial wall of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.475A	Nondisplaced fracture of medial wall of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.475B	Nondisplaced fracture of medial wall of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.476A	Nondisplaced fracture of medial wall of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.476B	Nondisplaced fracture of medial wall of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.481A	Displaced dome fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.481B	Displaced dome fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.482A	Displaced dome fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.482B	Displaced dome fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.483A	Displaced dome fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.483B	Displaced dome fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.484A	Nondisplaced dome fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.484B	Nondisplaced dome fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S32.485A	Nondisplaced dome fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.485B	Nondisplaced dome fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.486A	Nondisplaced dome fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.486B	Nondisplaced dome fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.491A	Other specified fracture of right acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.491B	Other specified fracture of right acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.492A	Other specified fracture of left acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.492B	Other specified fracture of left acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.499A	Other specified fracture of unspecified acetabulum, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.499B	Other specified fracture of unspecified acetabulum, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.501A	Unspecified fracture of right pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.501B	Unspecified fracture of right pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.502A	Unspecified fracture of left pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.502B	Unspecified fracture of left pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.509A	Unspecified fracture of unspecified pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.509B	Unspecified fracture of unspecified pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.511A	Fracture of superior rim of right pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.511B	Fracture of superior rim of right pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S32.512A	Fracture of superior rim of left pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.512B	Fracture of superior rim of left pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.519A	Fracture of superior rim of unspecified pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.519B	Fracture of superior rim of unspecified pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.591A	Other specified fracture of right pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.591B	Other specified fracture of right pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.592A	Other specified fracture of left pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.592B	Other specified fracture of left pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.599A	Other specified fracture of unspecified pubis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.599B	Other specified fracture of unspecified pubis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.601A	Unspecified fracture of right ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.601B	Unspecified fracture of right ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.602A	Unspecified fracture of left ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.602B	Unspecified fracture of left ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.609A	Unspecified fracture of unspecified ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.609B	Unspecified fracture of unspecified ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.611A	Displaced avulsion fracture of right ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.611B	Displaced avulsion fracture of right ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S32.612A	Displaced avulsion fracture of left ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.612B	Displaced avulsion fracture of left ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.613A	Displaced avulsion fracture of unspecified ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.613B	Displaced avulsion fracture of unspecified ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.614A	Nondisplaced avulsion fracture of right ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.614B	Nondisplaced avulsion fracture of right ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.615A	Nondisplaced avulsion fracture of left ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.615B	Nondisplaced avulsion fracture of left ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.616A	Nondisplaced avulsion fracture of unspecified ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.616B	Nondisplaced avulsion fracture of unspecified ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.691A	Other specified fracture of right ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.691B	Other specified fracture of right ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.692A	Other specified fracture of left ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.692B	Other specified fracture of left ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.699A	Other specified fracture of unspecified ischium, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.699B	Other specified fracture of unspecified ischium, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.810A	Multiple fractures of pelvis with stable disruption of pelvic ring, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.810B	Multiple fractures of pelvis with stable disruption of pelvic ring, initial encounter for open fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S32.811A	Multiple fractures of pelvis with unstable disruption of pelvic ring, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.811B	Multiple fractures of pelvis with unstable disruption of pelvic ring, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.82XA	Multiple fractures of pelvis without disruption of pelvic ring, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.82XB	Multiple fractures of pelvis without disruption of pelvic ring, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.89XA	Fracture of other parts of pelvis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.89XB	Fracture of other parts of pelvis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S32.9XXA	Fracture of unspecified parts of lumbosacral spine and pelvis, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S32.9XXB	Fracture of unspecified parts of lumbosacral spine and pelvis, initial encounter for open fracture	Diagnosis	ICD-10-CM
S72.001A	Fracture of unspecified part of neck of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.001B	Fracture of unspecified part of neck of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.001C	Fracture of unspecified part of neck of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.002A	Fracture of unspecified part of neck of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.002B	Fracture of unspecified part of neck of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.002C	Fracture of unspecified part of neck of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.009A	Fracture of unspecified part of neck of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.009B	Fracture of unspecified part of neck of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.009C	Fracture of unspecified part of neck of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S72.011A	Unspecified intracapsular fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.011B	Unspecified intracapsular fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.011C	Unspecified intracapsular fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.012A	Unspecified intracapsular fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.012B	Unspecified intracapsular fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.012C	Unspecified intracapsular fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.019A	Unspecified intracapsular fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.019B	Unspecified intracapsular fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.019C	Unspecified intracapsular fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.021A	Displaced fracture of epiphysis (separation) (upper) of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.021B	Displaced fracture of epiphysis (separation) (upper) of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.021C	Displaced fracture of epiphysis (separation) (upper) of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.022A	Displaced fracture of epiphysis (separation) (upper) of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.022B	Displaced fracture of epiphysis (separation) (upper) of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.022C	Displaced fracture of epiphysis (separation) (upper) of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.023A	Displaced fracture of epiphysis (separation) (upper) of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S72.023B	Displaced fracture of epiphysis (separation) (upper) of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.023C	Displaced fracture of epiphysis (separation) (upper) of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.024A	Nondisplaced fracture of epiphysis (separation) (upper) of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.024B	Nondisplaced fracture of epiphysis (separation) (upper) of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.024C	Nondisplaced fracture of epiphysis (separation) (upper) of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.025A	Nondisplaced fracture of epiphysis (separation) (upper) of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.025B	Nondisplaced fracture of epiphysis (separation) (upper) of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.025C	Nondisplaced fracture of epiphysis (separation) (upper) of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.026A	Nondisplaced fracture of epiphysis (separation) (upper) of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.026B	Nondisplaced fracture of epiphysis (separation) (upper) of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.026C	Nondisplaced fracture of epiphysis (separation) (upper) of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.031A	Displaced midcervical fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.031B	Displaced midcervical fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.031C	Displaced midcervical fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S72.032A	Displaced midcervical fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.032B	Displaced midcervical fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.032C	Displaced midcervical fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.033A	Displaced midcervical fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.033B	Displaced midcervical fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.033C	Displaced midcervical fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.034A	Nondisplaced midcervical fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.034B	Nondisplaced midcervical fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.034C	Nondisplaced midcervical fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.035A	Nondisplaced midcervical fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.035B	Nondisplaced midcervical fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.035C	Nondisplaced midcervical fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.036A	Nondisplaced midcervical fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.036B	Nondisplaced midcervical fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.036C	Nondisplaced midcervical fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.041A	Displaced fracture of base of neck of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.041B	Displaced fracture of base of neck of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.041C	Displaced fracture of base of neck of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S72.042A	Displaced fracture of base of neck of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.042B	Displaced fracture of base of neck of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.042C	Displaced fracture of base of neck of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.043A	Displaced fracture of base of neck of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.043B	Displaced fracture of base of neck of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.043C	Displaced fracture of base of neck of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.044A	Nondisplaced fracture of base of neck of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.044B	Nondisplaced fracture of base of neck of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.044C	Nondisplaced fracture of base of neck of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.045A	Nondisplaced fracture of base of neck of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.045B	Nondisplaced fracture of base of neck of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.045C	Nondisplaced fracture of base of neck of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.046A	Nondisplaced fracture of base of neck of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.046B	Nondisplaced fracture of base of neck of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.046C	Nondisplaced fracture of base of neck of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.051A	Unspecified fracture of head of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.051B	Unspecified fracture of head of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S72.051C	Unspecified fracture of head of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.052A	Unspecified fracture of head of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.052B	Unspecified fracture of head of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.052C	Unspecified fracture of head of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.059A	Unspecified fracture of head of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.059B	Unspecified fracture of head of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.059C	Unspecified fracture of head of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.061A	Displaced articular fracture of head of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.061B	Displaced articular fracture of head of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.061C	Displaced articular fracture of head of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.062A	Displaced articular fracture of head of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.062B	Displaced articular fracture of head of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.062C	Displaced articular fracture of head of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.063A	Displaced articular fracture of head of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.063B	Displaced articular fracture of head of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.063C	Displaced articular fracture of head of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.064A	Nondisplaced articular fracture of head of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S72.064B	Nondisplaced articular fracture of head of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.064C	Nondisplaced articular fracture of head of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.065A	Nondisplaced articular fracture of head of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.065B	Nondisplaced articular fracture of head of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.065C	Nondisplaced articular fracture of head of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.066A	Nondisplaced articular fracture of head of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.066B	Nondisplaced articular fracture of head of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.066C	Nondisplaced articular fracture of head of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.091A	Other fracture of head and neck of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.091B	Other fracture of head and neck of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.091C	Other fracture of head and neck of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.092A	Other fracture of head and neck of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.092B	Other fracture of head and neck of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.092C	Other fracture of head and neck of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.099A	Other fracture of head and neck of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.099B	Other fracture of head and neck of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.099C	Other fracture of head and neck of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S72.101A	Unspecified trochanteric fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.101B	Unspecified trochanteric fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.101C	Unspecified trochanteric fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.102A	Unspecified trochanteric fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.102B	Unspecified trochanteric fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.102C	Unspecified trochanteric fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.109A	Unspecified trochanteric fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.109B	Unspecified trochanteric fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.109C	Unspecified trochanteric fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.111A	Displaced fracture of greater trochanter of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.111B	Displaced fracture of greater trochanter of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.111C	Displaced fracture of greater trochanter of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.112A	Displaced fracture of greater trochanter of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.112B	Displaced fracture of greater trochanter of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.112C	Displaced fracture of greater trochanter of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.113A	Displaced fracture of greater trochanter of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.113B	Displaced fracture of greater trochanter of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S72.113C	Displaced fracture of greater trochanter of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.114A	Nondisplaced fracture of greater trochanter of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.114B	Nondisplaced fracture of greater trochanter of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.114C	Nondisplaced fracture of greater trochanter of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.115A	Nondisplaced fracture of greater trochanter of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.115B	Nondisplaced fracture of greater trochanter of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.115C	Nondisplaced fracture of greater trochanter of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.116A	Nondisplaced fracture of greater trochanter of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.116B	Nondisplaced fracture of greater trochanter of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.116C	Nondisplaced fracture of greater trochanter of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.121A	Displaced fracture of lesser trochanter of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.121B	Displaced fracture of lesser trochanter of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.121C	Displaced fracture of lesser trochanter of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.122A	Displaced fracture of lesser trochanter of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.122B	Displaced fracture of lesser trochanter of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.122C	Displaced fracture of lesser trochanter of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S72.123A	Displaced fracture of lesser trochanter of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.123B	Displaced fracture of lesser trochanter of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.123C	Displaced fracture of lesser trochanter of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.124A	Nondisplaced fracture of lesser trochanter of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.124B	Nondisplaced fracture of lesser trochanter of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.124C	Nondisplaced fracture of lesser trochanter of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.125A	Nondisplaced fracture of lesser trochanter of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.125B	Nondisplaced fracture of lesser trochanter of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.125C	Nondisplaced fracture of lesser trochanter of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.126A	Nondisplaced fracture of lesser trochanter of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.126B	Nondisplaced fracture of lesser trochanter of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.126C	Nondisplaced fracture of lesser trochanter of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.131A	Displaced apophyseal fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.131B	Displaced apophyseal fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.131C	Displaced apophyseal fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.132A	Displaced apophyseal fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S72.132B	Displaced apophyseal fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.132C	Displaced apophyseal fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.133A	Displaced apophyseal fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.133B	Displaced apophyseal fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.133C	Displaced apophyseal fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.134A	Nondisplaced apophyseal fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.134B	Nondisplaced apophyseal fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.134C	Nondisplaced apophyseal fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.135A	Nondisplaced apophyseal fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.135B	Nondisplaced apophyseal fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.135C	Nondisplaced apophyseal fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.136A	Nondisplaced apophyseal fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.136B	Nondisplaced apophyseal fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.136C	Nondisplaced apophyseal fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.141A	Displaced intertrochanteric fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.141B	Displaced intertrochanteric fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.141C	Displaced intertrochanteric fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.142A	Displaced intertrochanteric fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S72.142B	Displaced intertrochanteric fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.142C	Displaced intertrochanteric fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.143A	Displaced intertrochanteric fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.143B	Displaced intertrochanteric fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.143C	Displaced intertrochanteric fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.144A	Nondisplaced intertrochanteric fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.144B	Nondisplaced intertrochanteric fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.144C	Nondisplaced intertrochanteric fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.145A	Nondisplaced intertrochanteric fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.145B	Nondisplaced intertrochanteric fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.145C	Nondisplaced intertrochanteric fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.146A	Nondisplaced intertrochanteric fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.146B	Nondisplaced intertrochanteric fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.146C	Nondisplaced intertrochanteric fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.21XA	Displaced subtrochanteric fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.21XB	Displaced subtrochanteric fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.21XC	Displaced subtrochanteric fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S72.22XA	Displaced subtrochanteric fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.22XB	Displaced subtrochanteric fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.22XC	Displaced subtrochanteric fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.23XA	Displaced subtrochanteric fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.23XB	Displaced subtrochanteric fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.23XC	Displaced subtrochanteric fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.24XA	Nondisplaced subtrochanteric fracture of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.24XB	Nondisplaced subtrochanteric fracture of right femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.24XC	Nondisplaced subtrochanteric fracture of right femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.25XA	Nondisplaced subtrochanteric fracture of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.25XB	Nondisplaced subtrochanteric fracture of left femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.25XC	Nondisplaced subtrochanteric fracture of left femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S72.26XA	Nondisplaced subtrochanteric fracture of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S72.26XB	Nondisplaced subtrochanteric fracture of unspecified femur, initial encounter for open fracture type I or II	Diagnosis	ICD-10-CM
S72.26XC	Nondisplaced subtrochanteric fracture of unspecified femur, initial encounter for open fracture type IIIA, IIIB, or IIIC	Diagnosis	ICD-10-CM
S79.001A	Unspecified physeal fracture of upper end of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.002A	Unspecified physeal fracture of upper end of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

S79.009A	Unspecified physeal fracture of upper end of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.011A	Salter-Harris Type I physeal fracture of upper end of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.012A	Salter-Harris Type I physeal fracture of upper end of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.019A	Salter-Harris Type I physeal fracture of upper end of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.091A	Other physeal fracture of upper end of right femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.092A	Other physeal fracture of upper end of left femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
S79.099A	Other physeal fracture of upper end of unspecified femur, initial encounter for closed fracture	Diagnosis	ICD-10-CM
	Cataract		
			10
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
H25.011	Cortical age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.012	Cortical age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.013	Cortical age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.019	Cortical age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.031	Anterior subcapsular polar age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.032	Anterior subcapsular polar age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.033	Anterior subcapsular polar age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.039	Anterior subcapsular polar age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.041	Posterior subcapsular polar age-related cataract, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H25.042	Posterior subcapsular polar age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.043	Posterior subcapsular polar age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.049	Posterior subcapsular polar age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.091	Other age-related incipient cataract, right eye	Diagnosis	ICD-10-CM
H25.092	Other age-related incipient cataract, left eye	Diagnosis	ICD-10-CM
H25.093	Other age-related incipient cataract, bilateral	Diagnosis	ICD-10-CM
H25.099	Other age-related incipient cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.10	Age-related nuclear cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.11	Age-related nuclear cataract, right eye	Diagnosis	ICD-10-CM
H25.12	Age-related nuclear cataract, left eye	Diagnosis	ICD-10-CM
H25.13	Age-related nuclear cataract, bilateral	Diagnosis	ICD-10-CM
H25.20	Age-related cataract, morgagnian type, unspecified eye	Diagnosis	ICD-10-CM
H25.21	Age-related cataract, morgagnian type, right eye	Diagnosis	ICD-10-CM
H25.22	Age-related cataract, morgagnian type, left eye	Diagnosis	ICD-10-CM
H25.23	Age-related cataract, morgagnian type, bilateral	Diagnosis	ICD-10-CM
H25.811	Combined forms of age-related cataract, right eye	Diagnosis	ICD-10-CM
H25.812	Combined forms of age-related cataract, left eye	Diagnosis	ICD-10-CM
H25.813	Combined forms of age-related cataract, bilateral	Diagnosis	ICD-10-CM
H25.819	Combined forms of age-related cataract, unspecified eye	Diagnosis	ICD-10-CM
H25.89	Other age-related cataract	Diagnosis	ICD-10-CM
H25.9	Unspecified age-related cataract	Diagnosis	ICD-10-CM
H26.001	Unspecified infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.002	Unspecified infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.003	Unspecified infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.009	Unspecified infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.011	Infantile and juvenile cortical, lamellar, or zonular cataract, right eye	Diagnosis	ICD-10-CM
H26.012	Infantile and juvenile cortical, lamellar, or zonular cataract, left eye	Diagnosis	ICD-10-CM
H26.013	Infantile and juvenile cortical, lamellar, or zonular cataract, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H26.019	Infantile and juvenile cortical, lamellar, or zonular cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.031	Infantile and juvenile nuclear cataract, right eye	Diagnosis	ICD-10-CM
H26.032	Infantile and juvenile nuclear cataract, left eye	Diagnosis	ICD-10-CM
H26.033	Infantile and juvenile nuclear cataract, bilateral	Diagnosis	ICD-10-CM
H26.039	Infantile and juvenile nuclear cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.041	Anterior subcapsular polar infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.042	Anterior subcapsular polar infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.043	Anterior subcapsular polar infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.049	Anterior subcapsular polar infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.051	Posterior subcapsular polar infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.052	Posterior subcapsular polar infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.053	Posterior subcapsular polar infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.059	Posterior subcapsular polar infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.061	Combined forms of infantile and juvenile cataract, right eye	Diagnosis	ICD-10-CM
H26.062	Combined forms of infantile and juvenile cataract, left eye	Diagnosis	ICD-10-CM
H26.063	Combined forms of infantile and juvenile cataract, bilateral	Diagnosis	ICD-10-CM
H26.069	Combined forms of infantile and juvenile cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.09	Other infantile and juvenile cataract	Diagnosis	ICD-10-CM
H26.101	Unspecified traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.102	Unspecified traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.103	Unspecified traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.109	Unspecified traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.111	Localized traumatic opacities, right eye	Diagnosis	ICD-10-CM
H26.112	Localized traumatic opacities, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H26.113	Localized traumatic opacities, bilateral	Diagnosis	ICD-10-CM
H26.119	Localized traumatic opacities, unspecified eye	Diagnosis	ICD-10-CM
H26.121	Partially resolved traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.122	Partially resolved traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.123	Partially resolved traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.129	Partially resolved traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.131	Total traumatic cataract, right eye	Diagnosis	ICD-10-CM
H26.132	Total traumatic cataract, left eye	Diagnosis	ICD-10-CM
H26.133	Total traumatic cataract, bilateral	Diagnosis	ICD-10-CM
H26.139	Total traumatic cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.20	Unspecified complicated cataract	Diagnosis	ICD-10-CM
H26.211	Cataract with neovascularization, right eye	Diagnosis	ICD-10-CM
H26.212	Cataract with neovascularization, left eye	Diagnosis	ICD-10-CM
H26.213	Cataract with neovascularization, bilateral	Diagnosis	ICD-10-CM
H26.219	Cataract with neovascularization, unspecified eye	Diagnosis	ICD-10-CM
H26.221	Cataract secondary to ocular disorders (degenerative) (inflammatory), right eye	Diagnosis	ICD-10-CM
H26.222	Cataract secondary to ocular disorders (degenerative) (inflammatory), left eye	Diagnosis	ICD-10-CM
H26.223	Cataract secondary to ocular disorders (degenerative) (inflammatory), bilateral	Diagnosis	ICD-10-CM
H26.229	Cataract secondary to ocular disorders (degenerative) (inflammatory), unspecified eye	Diagnosis	ICD-10-CM
H26.30	Drug-induced cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.31	Drug-induced cataract, right eye	Diagnosis	ICD-10-CM
H26.32	Drug-induced cataract, left eye	Diagnosis	ICD-10-CM
H26.33	Drug-induced cataract, bilateral	Diagnosis	ICD-10-CM
H26.40	Unspecified secondary cataract	Diagnosis	ICD-10-CM
H26.411	Soemmering's ring, right eye	Diagnosis	ICD-10-CM
H26.412	Soemmering's ring, left eye	Diagnosis	ICD-10-CM
H26.413	Soemmering's ring, bilateral	Diagnosis	ICD-10-CM
H26.419	Soemmering's ring, unspecified eye	Diagnosis	ICD-10-CM
H26.491	Other secondary cataract, right eye	Diagnosis	ICD-10-CM
H26.492	Other secondary cataract, left eye	Diagnosis	ICD-10-CM
H26.493	Other secondary cataract, bilateral	Diagnosis	ICD-10-CM
H26.499	Other secondary cataract, unspecified eye	Diagnosis	ICD-10-CM
H26.8	Other specified cataract	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

H26.9	Unspecified cataract	Diagnosis	ICD-10-CM
Q12.0	Congenital cataract	Diagnosis	ICD-10-CM
	Parkinsons Disease and Secondary Parkinsonism		
G20	Parkinson's disease	Diagnosis	ICD-10-CM
G21.11	Neuroleptic induced parkinsonism	Diagnosis	ICD-10-CM
G21.19	Other drug induced secondary parkinsonism	Diagnosis	ICD-10-CM
G21.3	Postencephalitic parkinsonism	Diagnosis	ICD-10-CM
G21.4	Vascular parkinsonism	Diagnosis	ICD-10-CM
G21.8	Other secondary parkinsonism	Diagnosis	ICD-10-CM
G21.9	Secondary parkinsonism, unspecified	Diagnosis	ICD-10-CM
G31.83	Neurocognitive disorder with Lewy bodies	Diagnosis	ICD-10-CM
	COVID-19 Diagnosis		
B97.29	Other coronavirus as the cause of diseases classified elsewhere	Diagnosis	ICD-10-CM
U07.1	COVID-19	Diagnosis	ICD-10-CM
	Remdesivir		
XW033E5	Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW043E5	Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
	Chloroquine		
J0390	Injection, chloroquine HCl, up to 250 mg	Procedure	HCPCS
	Azithromycin		
J0456	Injection, azithromycin, 500 mg	Procedure	HCPCS
Q0144	Azithromycin dihydrate, oral, capsules/powder, 1 g	Procedure	HCPCS
	Dexamethasone		
J1094	Injection, dexamethasone acetate, 1 mg	Procedure	HCPCS
J1100	Injection, dexamethasone sodium phosphate, 1 mg	Procedure	HCPCS
J8540	Dexamethasone, oral, 0.25 mg	Procedure	HCPCS
S0173	Dexamethasone, oral, 4 mg	Procedure	HCPCS
	Other Corticosteroids		
C9469	Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg	Procedure	HCPCS
G2112	Patient receiving <=5 mg daily prednisone (or equivalent), or RA activity is worsening, or glucocorticoid use is for less than 6 months	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

G2113	Patient receiving >5 mg daily prednisone (or equivalent) for longer than 6 months, and improvement or no change in disease activity	Procedure	HCPCS
G9467	Patients who have received or are receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills within the last twelve months	Procedure	HCPCS
G9468	Patient not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills	Procedure	HCPCS
G9469	Patients who have received or are receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 90 or greater consecutive days or a single prescription equating to 900 mg prednisone or greater for all fills	Procedure	HCPCS
G9470	Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills	Procedure	HCPCS
J0702	Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg	Procedure	HCPCS
J0704	Injection, betamethasone sodium phosphate, per 4 mg	Procedure	HCPCS
J1020	Injection, methylprednisolone acetate, 20 mg	Procedure	HCPCS
J1030	Injection, methylprednisolone acetate, 40 mg	Procedure	HCPCS
J1040	Injection, methylprednisolone acetate, 80 mg	Procedure	HCPCS
J1700	Injection, hydrocortisone acetate, up to 25 mg	Procedure	HCPCS
J1710	Injection, hydrocortisone sodium phosphate, up to 50 mg	Procedure	HCPCS
J1720	Injection, hydrocortisone sodium succinate, up to 100 mg	Procedure	HCPCS
J2650	Injection, prednisolone acetate, up to 1 ml	Procedure	HCPCS
J2920	Injection, methylprednisolone sodium succinate, up to 40 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	Procedure	HCPCS
J3300	Injection, triamcinolone acetonide, preservative free, 1 mg	Procedure	HCPCS
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	Procedure	HCPCS
J3302	Injection, triamcinolone diacetate, per 5 mg	Procedure	HCPCS
J3303	Injection, triamcinolone hexacetonide, per 5 mg	Procedure	HCPCS
J3304	Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg	Procedure	HCPCS
J7506	Prednisone, oral, per 5 mg	Procedure	HCPCS
J7509	Methylprednisolone, oral, per 4 mg	Procedure	HCPCS
J7510	Prednisolone, oral, per 5 mg	Procedure	HCPCS
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	Procedure	HCPCS
	Inhaled Corticosteroids		
J7622	Beclomethasone, inhalation solution, compounded product, administered through DME, unit dose form, per mg	Procedure	HCPCS
J7624	Bethamethasone, inhalation solution administered through DME, unit dose form, per mg	Procedure	HCPCS
J7626	Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, unit dose form, up to 0.5 mg	Procedure	HCPCS
J7627	Budesonide, inhalation solution, compounded product, administered through DME, unit dose form, up to 0.5 mg	Procedure	HCPCS
J7633	Budesonide, inhalation solution, FDA-approved final product, noncompounded, administered through DME, concentrated form, per 0.25 mg	Procedure	HCPCS
J7634	Budesonide, inhalation solution, compounded product, administered through DME, concentrated form, per 0.25 mg	Procedure	HCPCS
J7637	Dexamethasone, inhalation solution, compounded product, administered through DME, concentrated form, per mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

J7638	Dexamethasone, inhalation solution, compounded product, administered through DME, unit dose form, per mg	Procedure	HCPCS
J7641	Flunisolide, inhalation solution, compounded product, administered through DME, unit dose, per mg	Procedure	HCPCS
J7683	Triamcinolone, inhalation solution, compounded product, administered through DME, concentrated form, per mg	Procedure	HCPCS
J7684	Triamcinolone, inhalation solution, compounded product, administered through DME, unit dose form, per mg	Procedure	HCPCS
K0527	Triamcinolone, inhalation solution administered through DME, concentrated form, per milligram	Procedure	HCPCS
K0528	Triamcinolone, inhalation solution administered through DME, unit dose form, per milligram	Procedure	HCPCS
Baricitinib			
XW0DXM6	Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW0G7M6	Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6	Procedure	ICD-10-PCS
XW0H7M6	Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6	Procedure	ICD-10-PCS
Tocilizumab			
C9264	Injection, tocilizumab, 1 mg	Procedure	HCPCS
J3262	Injection, tocilizumab, 1 mg	Procedure	HCPCS
Bamlanivimab			
M0239	Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring	Procedure	HCPCS
Q0239	Injection, bamlanivimab, 700 mg	Procedure	HCPCS
XW033F6	Introduction of bamlanivimab monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6	Procedure	ICD-10-PCS
XW043F6	Introduction of bamlanivimab monoclonal antibody into central vein, percutaneous approach, new technology group 6	Procedure	ICD-10-PCS
Casirivimab/Imdevimab			

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

M0240	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion and post administration monitoring, subsequent repeat doses	Procedure	HCPCS
M0241	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency, subsequent repeat doses	Procedure	HCPCS
M0243	intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring	Procedure	HCPCS
M0244	Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency.	Procedure	HCPCS
Q0240	Injection, casirivimab and imdevimab, 600 mg	Procedure	HCPCS
Q0243	Injection, casirivimab and imdevimab, 2400 mg	Procedure	HCPCS
Q0244	Injection, casirivimab and imdevimab, 1200 mg	Procedure	HCPCS
XW033G6	Introduction of REGN-COV2 monoclonal antibody into peripheral vein, percutaneous approach, new technology group 6	Procedure	ICD-10-PCS
XW043G6	Introduction of REGN-COV2 monoclonal antibody into central vein, percutaneous approach, new technology group 6	Procedure	ICD-10-PCS
	Bamlanivimab/Etesevimab		
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	Procedure	HCPCS
M0246	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency.	Procedure	HCPCS
Q0245	Injection, bamlanivimab and etesevimab, 2100 mg	Procedure	HCPCS
XW033E6	Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW033F6	Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

XW043E6	Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW043F6	Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
	Sotrovimab		
M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	Procedure	HCPCS
M0248	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence	Procedure	HCPCS
Q0247	Injection, sotrovimab, 500 mg	Procedure	HCPCS
	Antidepressants		
4064F	Antidepressant pharmacotherapy prescribed (MDD, MDD ADOL)	Procedure	CPT-2
C9055	Injection, brexanolone, 1 mg	Procedure	HCPCS
G8126	Patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase	Procedure	HCPCS
G8129	Patient documented as being treated with antidepressant medication for at least 6 months continuous treatment phase	Procedure	HCPCS
G9194	Patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 180 day (6 month) continuation treatment phase	Procedure	HCPCS
J1320	Injection, amitriptyline HCl, up to 20 mg	Procedure	HCPCS
J1632	Injection, brexanolone, 1 mg	Procedure	HCPCS
J3270	Injection, imipramine hcl, up to 25 mg	Procedure	HCPCS
S0106	Bupropion HCl sustained release tablet, 150 mg, per bottle of 60 tablets	Procedure	HCPCS

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
Sickle Cell Disease	
crizanlizumab-tmca	Adakveo
voxelotor	Oxbryta
Cystic Fibrosis	
aztreonam lysine	Cayston
elexacaftor/tezacaftor/ivacaftor	Trikafta
ivacaftor	Kalydeco
lumacaftor/ivacaftor	Orkambi
mannitol	Bronchitol
tezacaftor/ivacaftor	Symdeko
tobramycin	Bethkis
tobramycin	Tobi Podhaler
tobramycin	tobramycin
tobramycin in 0.225 % sodium chloride	Tobi
tobramycin in 0.225 % sodium chloride	tobramycin in 0.225 % NaCl
tobramycin/nebulizer	Kitabis Pak
tobramycin/nebulizer	tobramycin with nebulizer
Obesity: Identified by Weight Management-Related Prescription	
amino acids/multivit-minerals/dietary supplement/protein sup	Optifast 70
benzphetamine HCl	Regimex
benzphetamine HCl	benzphetamine
diethylpropion HCl	diethylpropion
liraglutide	Saxenda
liraglutide	Victoza 2-Pak
liraglutide	Victoza 3-Pak
lorcaserin HCl	Belviq
lorcaserin HCl	Belviq XR
naltrexone HCl/bupropion HCl	Contrave
orlistat	Alli
orlistat	Xenical
phendimetrazine tartrate	Bontril PDM
phendimetrazine tartrate	phendimetrazine tartrate
phentermine HCl	Adipex-P
phentermine HCl	Lomaira
phentermine HCl	Suprenza
phentermine HCl	phentermine
phentermine HCl/topiramate	Qsymia
resveratrol/chromium pico/green tea/EGCG/caffeine/digestive3	Resveratrol Diet
Smoking: Identified by Smoking-Related Prescriptions	
nicotine	NTS Step 1
nicotine	Nicoderm CQ
nicotine	Nicotrol
nicotine	Nicotrol NS
nicotine	nicotine
nicotine bitartrate	Nicotine Tartrate
nicotine polacrilex	Nicorelief

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
nicotine polacrilex	Nicorette
nicotine polacrilex	Quit 2
nicotine polacrilex	Quit 4
nicotine polacrilex	Stop Smoking Aid
nicotine polacrilex	nicotine (polacrilex)
varenicline tartrate	Chantix
varenicline tartrate	Chantix Continuing Month Box
varenicline tartrate	Chantix Starting Month Box
varenicline tartrate	Tyrvaya
varenicline tartrate	varenicline
Chemo Therapeutic Agents/ Prescription	
ABEMACICLIB	VERZENIO
ACALABRUTINIB	CALQUENCE
ADO-TRASTUZUMAB EMTANSINE	KADCYLA
AFATINIB DIMALEATE	GILOTRIF
ALDESLEUKIN	PROLEUKIN
ALECTINIB HCL	ALECENSA
ALEMTUZUMAB	CAMPATH
ALEMTUZUMAB	LEMTRADA
ALPELISIB	PIQRAY 200MG DAILY DOSE
ALPELISIB	PIQRAY 250MG DAILY DOSE
ALPELISIB	PIQRAY 300MG DAILY DOSE
ALTRETAMINE	HEXALEN
ARSENIC TRIOXIDE	ARSENIC TRIOXIDE
ARSENIC TRIOXIDE	TRISENOX
ASPARAGINASE	ELSPAR
ASPARAGINASE ERWINIA CHRYSANTHEMI	ERWINAZE
ATEZOLIZUMAB	TECENTRIQ
AVAPRITINIB	AYVAKIT
AVELUMAB	BAVENCIO
AXICABTAGENE CILOLEUCEL	YESCARTA
AXITINIB	INLYTA
AZACITIDINE	AZACITIDINE
AZACITIDINE	ONUREG
AZACITIDINE	VIDAZA
BELANTAMAB MAFODOTIN/BLMF	BLENREP
BELINOSTAT	BELEODAQ
BENDAMUSTINE HCL	BELRAPZO
BENDAMUSTINE HCL	BENDAMUSTINE HYDROCHLORIDE
BENDAMUSTINE HCL	BENDEKA
BENDAMUSTINE HCL	TREANDA
BEVACIZUMAB	AVASTIN
BEVACIZUMAB/AWWB	MVASI
BEVACIZUMAB/BVZR	ZIRABEV
BEXAROTENE	BEXAROTENE
BEXAROTENE	TARGRETIN
BINIMETINIB	MEKTOVI
BLEOMYCIN SULF	BLEO 15K

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
BLEOMYCIN SULFATE	BLENOXANE
BLEOMYCIN SULFATE	BLEOMYCIN
BLEOMYCIN SULFATE	BLEOMYCIN SULFATE
BLINATUMOMAB	BLINCYTO
BORTEZOMIB	BORTEZOMIB
BORTEZOMIB	VELCADE
BOSUTINIB	BOSULIF
BRENTUXIMAB VEDOTIN	ADCETRIS
BREXUCABTAGENE AUTOLEUCEL	TECARTUS
BRIGATINIB	ALUNBRIG
BUSULFAN	BUSULFAN
BUSULFAN	BUSULFEX
BUSULFAN	MYLERAN
CABAZITAXEL	JEVTANA
CABOZANTINIB S-MALATE	CABOMETYX
CABOZANTINIB S-MALATE	COMETRIQ
CALASPARGASE PEGOL/MKNL	ASPARLAS
CAPECI	CAPECITABINE
CAPECITABINE	CAPECITABINE
CAPECITABINE	XELODA
CAPMATINIB HCL	TABRECTA
CARBOPLATIN	CARBOPLATIN
CARBOPLATIN	PARAPLATIN
CARFILZOMIB	KYPROLIS
CARMUSTINE	BICNU
CARMUSTINE	BICNU W/DILUENT ABSOLUTEETHANOL
CARMUSTINE	BiCNU
CARMUSTINE	CARMUSTINE
CARMUSTINE IN POLIFEPROSAN INTRACRANIAL IMPLANT WAFER	GLIADEL WAFER
CEMIPLIMAB-RWLC	LIBTAYO
CERITINIB	ZYKADIA
CETUXIMAB	ERBITUX
CHLORAMBUCIL	LEUKERAN
CISPLATIN	CISPLATIN
CISPLATIN	CISPLATIN AQ
CISPLATIN	PLATINOL AQ
CLADRIBINE	CLADRIBINE
CLADRIBINE	LEUSTATIN
CLOFARABINE	CLOFARABINE
CLOFARABINE	CLOLAR
COBIMETINIB FUMARATE	COTELLIC
COPANLISIB HCL	ALIQOPA
CRIZOTINIB	XALKORI
CYCLOPHOSPHAMIDE	CYCLOPHOSPHAMIDE
CYCLOPHOSPHAMIDE	CYTOXAN
CYCLOPHOSPHAMIDE	NEOSAR
CYTARABINE	CYTARABINE

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
CYTARABINE	CYTARABINEAQUEOUS
CYTARABINE	CYTOSAR-U
CYTARABINE	TARABINE PFS
CYTARABINE LIPOSOME	DEPOCYT
DABRAFENIB MESYLATE	TAFINLAR
DACARBAZINE	DACARBAZINE
DACARBAZINE	DTIC-DOME
DACOMITINIB	VIZIPDCO
DACTINOMYCIN	COSMEGEN
DACTINOMYCIN	DACTINOMYCIN
DARATUMUMAB	DARZALEX
DARATUMUMAB/HYALURONIDASE/FIHJ	DARZALEX FASPRO
DASATINIB	SPRYCEL
DAUNORUBICIN CITRATE LIPOSOME	DAUNOXOME
DAUNORUBICIN HCL	CERUBIDINE
DAUNORUBICIN HCL	DAUNORUBICIN HCL
DAUNORUBICIN HCL	DAUNORUBICIN HYDROCHLORIDE
DAUNORUBICIN-CYTARABINE LIPOSOME	VYXEOS
DECI	INQOVI
DECITABINE	DACOGEN
DECITABINE	DECITABINE
DENILEUKIN DIFTITOX	ONTAK
DINUTUXIMAB	UNITUXIN
DOCETAXEL	DOCEFREZ
DOCETAXEL	DOCETAXEL
DOCETAXEL	DOCETAXEL (NON- ALCOHOL FORMULA)
DOCETAXEL	DOCETAXEL (NON-ALCOHOL FORMULA)
DOCETAXEL	TAXOTERE
DOXORUBICIN HCL	ADRIAMYCIN
DOXORUBICIN HCL	ADRIAMYCIN PFS
DOXORUBICIN HCL	ADRIAMYCIN RDF
DOXORUBICIN HCL	DOXORUBICIN HCL
DOXORUBICIN HCL	DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HCL	RUBEX
DOXORUBICIN HCL	doxorubicin
DOXORUBICIN HCL LIPOSOMAL	DOXIL
DOXORUBICIN HCL LIPOSOMAL	DOXORUBICIN HCL LIPOSOME
DOXORUBICIN HCL LIPOSOMAL	DOXORUBICIN HYDROCHLORIDELIPOSOMAL
DOXORUBICIN HCL LIPOSOMAL	DOXORUBICIN HYDROCHLORIDELIPOSOME
DOXORUBICIN HCL LIPOSOMAL	LIPODOX
DOXORUBICIN HCL LIPOSOMAL	LIPODOX 50
DURVALUMAB	IMFINZI
DUVELISIB	COPIKTRA
ELOTUZUMAB	EMPLICITI
ENASIDENIB MESYLATE	IDHIFA
ENCORAFENIB	BRAFTOVI
ENFORTUMAB VEDOTIN/EJFV	PADCEV
ENTRECTINIB	ROZLYTREK

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
EPIRUBICIN HCL	ELLENCE
EPIRUBICIN HCL	EPIRUBICIN HCL
EPIRUBICIN HCL	EPIRUBICIN HYDROCHLORIDE
ERDAFITINIB	BALVERSA
ERIBULIN MESYLATE	HALAVEN
ERLOTINIB	TARCEVA
ERLOTINIB HCL	ERLOTINIB HYDROCHLORIDE
ETOPOSIDE	ETOPOSIDE
ETOPOSIDE	TOPOSAR
ETOPOSIDE	VEPESID
ETOPOSIDE PHOSPHATE	ETOPOPHOS
EVEROLIMUS	AFINITOR
EVEROLIMUS	AFINITOR DISPERZ
EVEROLIMUS	EVEROLIMUS
FAM/TRASTUZUMAB DERUXTECAN/NXKI	ENHERTU
FEDRATINIB HCL	INREBIC
FLOXURIDINE	FLOXURIDINE
FLOXURIDINE	FUDR
FLUDARABINE PHOSPHATE	FLUDARA
FLUDARABINE PHOSPHATE	FLUDARABINE
FLUDARABINE PHOSPHATE	FLUDARABINE PHOSPHATE
FLUDARABINE PHOSPHATE	OFORTA
FLUOROURACIL	ADRUCIL
FLUOROURACIL	FLUOROURACIL
FOSTAMATINIB DISODIUM	TAVALISSE
GEFITINIB	IRESSA
GEMCITABINE HCL	GEMCITABINE
GEMCITABINE HCL	GEMCITABINE HCL
GEMCITABINE HCL	GEMCITABINE HYDROCHLORIDE
GEMCITABINE HCL	GEMZAR
GEMCITABINE HCL-NACL	INFUGEM
GEMTUZUMAB OZOGAMICIN	MYLOTARG
GILTERITINIB FUMARATE	XOSPATA
GLASDEGIB MALEATE	DAURISMO
GLUCARPIDASE	VORAXAZE
HYDROXYUREA	HYDREA
HYDROXYUREA	HYDROXYUREA
HYDROXYUREA	MYLOCEL
IBRITUMOMAB TIUXETAN FOR INDIUM-111 (IN-111)	ZEVALIN IN-111
IBRITUMOMAB TIUXETAN FOR YTTRIUM/90 (Y/90)	ZEVALIN Y-90
IBRUTINIB	IMBRUVICA
IDARUBICIN HCL	IDAMYCIN PFS
IDARUBICIN HCL	IDARUBICIN
IDARUBICIN HCL	IDARUBICIN HCL
IDARUBICIN HCL	IDARUBICIN HYDROCHLORIDE
IDELALISIB	ZYDELIG
IFOSFAMIDE	IFEX
IFOSFAMIDE	IFOSFAMIDE

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
IFOSFAMIDE/MESNA	IFEX/MESNEX COMBO PACK
IFOSFAMIDE/MESNA	IFOSFAMIDE/MESNA
IMATINIB MESYLATE	GLEEVEC
IMATINIB MESYLATE	IMATINIB MESYLATE
INOTUZUMAB OZOGAMICIN	BESPONSA
INTERFERON ALFA-2A	ROFERON-A
INTERFERON ALFA-2B	INTRON A
INTERFERON ALFA-2B	INTRON-A
INTERFERON ALFA-2B	INTRON-A W/DILUENT
INTERFERON ALFA-N3	ALFERON N
INTERFERON GAMMA-1B	ACTIMMUNE
IPILIMUMAB	YERVOY
IRINOTECAN HCL	CAMPTOSAR
IRINOTECAN HCL	IRINOTECAN
IRINOTECAN HCL	IRINOTECAN HCL
IRINOTECAN HCL	IRINOTECAN HYDROCHLORIDE
IRINOTECAN HCL LIPOSOME	ONIVYDE
ISATUXIMAB/IRFC	SARCLISA
IVOSIDENIB	TIBSOVO
IXABEPILONE	IXEPDCA
IXABEPILONE	IXEPDCA KIT
IXAZOMIB CITRATE	NINLARO
LAPATINIB DITOSYLATE	LAPATINIB DITOSYLATE
LAPATINIB DITOSYLATE	TYKERB
LAROTRECTINIB SULFATE	VITRAKVI
LENVATINIB	LENVIMA 10MG DAILY DOSE
LENVATINIB	LENVIMA 12MG DAILY DOSE
LENVATINIB	LENVIMA 14MG DAILY DOSE
LENVATINIB	LENVIMA 18MG DAILY DOSE
LENVATINIB	LENVIMA 20MG DAILY DOSE
LENVATINIB	LENVIMA 24MG DAILY DOSE
LENVATINIB	LENVIMA 4 MG DAILY DOSE
LENVATINIB	LENVIMA 8MG DAILY DOSE
LISOCABTAGENE MARALEUCEL	BREYANZI
LOMUSTINE	CEENU
LOMUSTINE	GLEOSTINE
LOMUSTINE	LOMUSTINE
LORLATINIB	LORBRENA
LURBINECTEDIN	ZEPZELCA
MECHLORETHAMINE HCL	MUSTARGEN
MELPHALAN	ALKERAN
MELPHALAN	MELPHALAN
MELPHALAN HCL	ALKERAN
MELPHALAN HCL	EVOMELA
MELPHALAN HCL	MELPHALAN HCL
MELPHALAN HCL	MELPHALAN HYDROCHLORIDE
MERCAPTOPURINE	MERCAPTOPURINE
MERCAPTOPURINE	PURINETHOL

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
MERCAPTOPURINE	PURIXAN
METHOTREXATE	METHOTREXATE
METHOTREXATE	XATMEP
METHOTREXATE SODIUM	METHOTREXATE
METHOTREXATE SODIUM	METHOTREXATE SODIUM
METHOTREXATE SODIUM	METHOTREXATE SODIUM LPF
METHOTREXATE SODIUM	RHEUMATREX
METHOTREXATE SODIUM	TREXALL
METHOTREXATE SODIUM/PF	METHOTREXATE SODIUM (PF)
METHOTREXATE/PF	OTREXUP (PF)
METHOTREXATE/PF	RASUVO (PF)
MIDOSTAURIN	RYDAPT
MITOMYCIN	MITOMYCIN
MITOMYCIN	MUTAMYCIN
MITOXANTRONE	MITOXANTRONE HCL
MITOXANTRONE	NOVANTRONE
MOGAMULIZUMAB-KPKC	POTELIGEO
MOXETUMOMAB PASUDOTOX-TDFK	LUMOXITI
NAXITAMAB/GQGK	DANYELZA
NECITUMUMAB	PORTRAZZA
NELARABINE	ARRANON
NERATINIB MALEATE	NERLYNX
NILOTINIB	TASIGNA
NIRAPARIB TOSYLATE	ZEJULA
NIVOLUMAB	OPDIVO
OBINUTUZUMAB	GAZYVA
OFATUMUMAB	ARZERRA
OLAPARIB	LYNPARZA
OLARATUMAB	LARTRUVO
OMACETAXINE MEPESUCCINATE	SYNRIBO
OSIMERTINIB MESYLATE	TAGRISSO
OXALIPLATIN	ELOXATIN
OXALIPLATIN	OXALIPLATIN
PACLITAXEL	ABRAXANE
PACLITAXEL	ONXOL
PACLITAXEL	PACLITAXEL
PACLITAXEL	TAXOL
PALBOCICLIB	IBRANCE
PANITUMUMAB	VECTIBIX
PANOBINOSTAT LACTATE	FARYDAK
PAZOPANIB HCL	VOTRIENT
PEGASPARGASE	ONCASPAR
PEGINTERFERON ALFA-2B	SYLATRON
PEMBROLIZUMAB	KEYTRUDA
PEMETREXED DISODIUM	ALIMTA
PEMIGATINIB	PEMAZYRE
PENTOSTATIN	NIPENT
PENTOSTATIN	PENTOSTATIN

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
PERTUZUMAB	PERJETA
PERTUZUMAB/TRASTUZ/HYALURON/ZZXF	PHESGO
PEXIDARTINIB HCL	TURALIO
PLICAMYCIN	MITHRACIN
POLATUZUMAB VEDOTIN-PIIQ	POLIVY
POMALIDOMIDE	POMALYST
PONATINIB HCL	ICLUSIG
PRALATREXATE	FOLOTYN
PRALSETINIB	GAVRETO
PROCARBAZINE HCL	MATULANE
RAMUCIRUMAB	CYRAMZA
REGORAFENIB	STIVARGA
RIBOCICLIB SUCCINATE	KISQALI
RIBOCICLIB/LETROZOLE	KISQALI FEMARA 200 DOSE
RIBOCICLIB/LETROZOLE	KISQALI FEMARA 400 DOSE
RIBOCICLIB/LETROZOLE	KISQALI FEMARA 600 DOSE
RIPRETINIB	QINLOCK
RITUXIMAB	RITUXAN
RITUXIMAB-HYALURONIDASE HUMAN	RITUXAN HYCELA
RITUXIMAB/ABBS	TRUXIMA
RITUXIMAB/ARRX	RIABNI
RITUXIMAB/PVVR	RUXIENCE
ROMIDEPSIN	ISTODAX
ROMIDEPSIN	ISTODAX (OVERFILL)
ROMIDEPSIN	ROMIDEPSIN
RUCAPARIB CAMSYLATE	RUBRACA
RUXOLITINIB PHOSPHATE	JAKAFI
SACITUZUMAB GOVITECAN/HZIY	TRODELVY
SELINEXOR	XPOVIO 100 MG ONCE WEEKLY
SELINEXOR	XPOVIO 40 MG ONCE WEEKLY
SELINEXOR	XPOVIO 40 MG TWICE WEEKLY
SELINEXOR	XPOVIO 60 MG ONCE WEEKLY
SELINEXOR	XPOVIO 60 MG TWICE WEEKLY
SELINEXOR	XPOVIO 80 MG ONCE WEEKLY
SELINEXOR	XPOVIO 80 MG TWICE WEEKLY
SELPERCATINIB	RETEVMO
SELUMETINIB SULFATE	KOSELUGO
SIPULEUCEL-T	PROVENGE
SONIDEGIB PHOSPHATE	ODOMZO
SORAFENIB TOSYLATE	NEXAVAR
STREPTOZOCIN	ZANOSAR
SUNITINIB MALATE	SUTENT
TAFASITAMAB/CXIX	MONJUVI
TAGRAXOFUSP-ERZS	ELZONRIS
TALAZOPARIB TOSYLATE	TALZENNA
TALIMOGENE LAHERPAREPVEC	IMLYGIC
TAZEMETOSTAT HBR	TAZVERIK
TEMOZOLOMIDE	TEMODAR

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
TEMOZOLOMIDE	TEMOZOLOMIDE
TEMSIROLIMUS	TEMSIROLIMUS
TEMSIROLIMUS	TORISEL
TENIPOSIDE	TENIPOSIDE
TENIPOSIDE	VUMON
TEPOTINIB HCL	TEPMETKO
THIOGUANINE	TABLOID
THIOTEPA	TEPADINA
THIOTEPA	THIOPLEX
THIOTEPA	THIOTEPA
TISAGENLECLEUCEL-T	KYMRIAH
TOPOTECAN HCL	HYCAMTIN
TOPOTECAN HCL	TOPOTECAN HCL
TOPOTECAN HCL	TOPOTECAN HYDROCHLORIDE
TOPOTECAN HCL	TOPOTECAN HYDROCLORIDE
TOSITUMOMAB	BEXXAR
TRABECTEDIN	YONDELIS
TRAMETINIB DIMETHYL SULFOXIDE	MEKINIST
TRASTUZUMAB	HERCEPTIN
TRASTUZUMAB-HYALURONIDASE-OYSK	HERCPTIN HYLECTA
TRASTUZUMAB/ANNS	KANJINTI
TRASTUZUMAB/DKST	OGIVRI
TRASTUZUMAB/DTTB	ONTRUZANT
TRASTUZUMAB/PKRB	HERZUMA
TRASTUZUMAB/QYYP	TRAZIMERA
TRIFLURIDINE-TIPIRACIL	LONSURF
TRILACICLIB DIHYDROCHLORIDE	COSELA
TUCATINIB	TUKYSA
UMBRALISIB TOSYLATE	UKONIQ
URACIL MUSTARD	URACIL MUSTARD
VALRUBICIN	VALRUBICIN
VALRUBICIN	VALSTAR
VANDETANIB	CAPRELSA
VANDETANIB	VANDETANIB
VEMURAFENIB	ZELBORAF
VENETOCLAX	VENCLEXTA
VENETOCLAX	VENCLEXTA STARTING PACK
VINBLASTINE SULFATE	VINBLASTINE SULFATE
VINCRISTINE SULFATE	VINCASAR PFS
VINCRISTINE SULFATE	VINCRISTINE SULFATE
VINCRISTINE SULFATE LIPOSOME	MARQIBO
VINORELBINE TARTRATE	NAVELBINE
VINORELBINE TARTRATE	VINORELBINE TARTRATE
VISMODEGIB	ERIVEDGE
VORINOSTAT	ZOLINZA
ZANUBRUTINIB	BRUKINSA
ZIV-AFLIBERCEPT	ZALTRAP
Immunosuppressant Therapeutic Agents	

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
ABATACEPT	ORENCIA
ABATACEPT	ORENCIA CLICKJET
ADALIMUMAB	HUMIRA
ADALIMUMAB	HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK
ADALIMUMAB	HUMIRA PEN
ADALIMUMAB	HUMIRA PEN-CD/UC/HS STARTER
ADALIMUMAB	HUMIRA PEN-PSORIASIS STARTER
ANAKINRA	KINERET
ANTI/THYMOCYTE	THYMOGLOBULIN
APREMILAST	OTEZLA
AURANOFIN	RIDAURA
AUROTHIOGLUCOSE	AUROTHIOGLUCOSE
AUROTHIOGLUCOSE	SOLGANAL
AZATHIOPRINE	AZASAN
AZATHIOPRINE	AZATHIOPRINE
AZATHIOPRINE	AZATHIOPRINE SODIUM
AZATHIOPRINE	IMURAN
BARICITINIB	OLUMIANT
BASILIXIMAB	SIMULECT
BELATACEPT	NULOJIX
BELIMUMAB	BENLYSTA
CANAKINUMAB	ILARIS
CYCLOSPORINE	CYCLOSPORINE
CYCLOSPORINE	SANDIMMUNE
CYCLOSPORINE MODIFIED	CYCLOSPORINE MODIFIED
CYCLOSPORINE MODIFIED	GENGRAF
CYCLOSPORINE MODIFIED	NEORAL
DACLIZUMAB	ZENAPAX
EMAPALUMAB/LZSG	GAMIFANT
ETANERCEPT	ENBREL
ETANERCEPT	ENBREL MINI
ETANERCEPT	ENBREL SURECLICK
EVEROLIMUS	EVEROLIMUS
EVEROLIMUS	ZORTRESS
FINGOLIMOD HYDROCHLORIDE	GILENYA
GOLD SODIUM THIOMALATE	GOLD SODIUM THIOMALATE
GOLD SODIUM THIOMALATE	MYOCHRYSINE
GOLIMUMAB	SIMPONI
GOLIMUMAB	SIMPONI ARIA
INEBILIZUMAB/CDON	UPLIZNA
LEFLUNOMIDE	ARAVA
LEFLUNOMIDE	LEFLUNOMIDE
LENALIDOMIDE	REVLIMID
LYMPHOCYTE IMMUNE GLOBULIN ANTI/THYMOCYTE G	ATGAM
METHOTREXATE	RASUVO
METHOTREXATE	REDITREX
METHOTREXATE SODIUM	METHOTREXATE
METHOTREXATE SODIUM	RHEUMATREX

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
METHOTREXATE/PF	OTREXUP
MUROMONAB CD3	ORTHOCLONE OKT3
MYCOPHENOLATE MOFETIL	CELLCEPT
MYCOPHENOLATE MOFETIL	MYCOPHENOLATE MOFETIL
MYCOPHENOLATE MOFETIL HCL	CELLCEPT INTRAVENOUS
MYCOPHENOLATE MOFETIL HCL	MYCOPHENOLATE MOFETIL
MYCOPHENOLATE SODIUM	MYCOPHENOLIC ACID DR
MYCOPHENOLATE SODIUM	MYFORTIC
RILONACEPT	ARCALYST
SARILUMAB SUBCUTANEOUS	KEVZARA
SATRALIZUMAB/MWGE	ENSPRYNG
SIROLIMUS	RAPAMUNE
SIROLIMUS	SIROLIMUS
TACROLIMUS	ASTAGRAF XL
TACROLIMUS	ENVARSUS XR
TACROLIMUS	HECORIA
TACROLIMUS	PROGRAF
TACROLIMUS	TACROLIMUS
THALIDOMIDE	THALOMID
TOCILIZUMAB IV	ACTEMRA
TOCILIZUMAB SUBCUTANEOUS	ACTEMRA
TOCILIZUMAB SUBCUTANEOUS	ACTEMRA ACTPEN
TOFACITINIB CITRATE	XELJANZ
TOFACITINIB CITRATE	XELJANZ XR
TOFACITINIB CITRATE ORAL	XELJANZ
UPADACITINIB	RINVOQ
VOCLOSPORIN	LUPKYNIS
Steroid/Corticosteroid Diagnoses and Procedures and Dispensings	
NYSTATIN/HYDROCORTISONE/DIPHENHYDRAMINE HCL	FIRST-Duke's
NYSTATIN/TETRACYCLINE HCL/HYDROCORTISONE/DIPHENHYDRAMINE HCL	FIRST-Mary's Mouthwash
betamethasone acetate and sodium phos in sterile water/PF	betameth ac,sod phos(PF)-water
betamethasone acetate/betamethasone sodium	BSP-0820
betamethasone acetate/betamethasone sodium	Beta-1
betamethasone acetate/betamethasone sodium	Celestone Soluspan
betamethasone acetate/betamethasone sodium	Pod-Care 100C
betamethasone acetate/betamethasone sodium	ReadySharp Betamethasone
betamethasone acetate/betamethasone sodium	betamethasone acet,sod phos
betamethasone acetate/betamethasone sodium phosphate/water	betamethasone ace,sod phos-wtr
betamethasone sodium phosph in sterile water for injection	betamethasone sod phosph-water
budesonide	Entocort EC
budesonide	Ortikos
budesonide	Pulmicort
budesonide	Pulmicort Flexhaler
budesonide	Tarpeyo

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
budesonide	Uceris
budesonide	budesonide
budesonide/formoterol fumarate	Symbicort
budesonide/formoterol fumarate	budesonide-formoterol
budesonide/glycopyrrolate/formoterol fumarate	Breztri Aerosphere
bupivacaine HCl/dexamethasone sodium phos in sterile water	bupivacaine-dexameth in water
cortisone acetate	cortisone
deflazacort	Emflaza
dexamethasone	DexPak 10 day
dexamethasone	DexPak 13 Day
dexamethasone	DexPak 6 Day
dexamethasone	Dexabliss
dexamethasone	Dexamethasone Intensol
dexamethasone	Dxevo
dexamethasone	Hemady
dexamethasone	HiDex
dexamethasone	TaperDex
dexamethasone	ZCort
dexamethasone	dexamethasone
dexamethasone acetate and sodium phosphate in sterile water	dexamethasone ac, sod ph-water
dexamethasone acetate in sodium chloride, iso-osmotic	dexamethasone ace-NaCl,iso-osm
dexamethasone sodium phosphate	Dexonto
dexamethasone sodium phosphate	ReadySharp dexamethasone
dexamethasone sodium phosphate	dexamethasone sodium phosphate
dexamethasone sodium phosphate in 0.9 % sodium chloride	dexamethasone-0.9 % sod. chlor
dexamethasone sodium phosphate/PF	Active Injection Kit D (PF)
dexamethasone sodium phosphate/PF	DoubleDex (PF)
dexamethasone sodium phosphate/PF	MAS Care-Pak (PF)
dexamethasone sodium phosphate/PF	dexamethasone sodium phos (PF)
dexamethasone sodium phosphate/lidocaine HCl	Lidocidex-I
fludrocortisone acetate	fludrocortisone
hydrocortisone	Alkindi Sprinkle
hydrocortisone	Cortef
hydrocortisone	hydrocortisone
hydrocortisone sodium succinate	A-Hydrocort
hydrocortisone sodium succinate	Solu-Cortef
hydrocortisone sodium succinate/PF	Solu-Cortef Act-O-Vial (PF)
methylprednisolone	Medrol
methylprednisolone	Medrol (Pak)
methylprednisolone	Methylpred DP
methylprednisolone	methylprednisolone
methylprednisolone acetate	Depo-Medrol
methylprednisolone acetate	P-Care D40
methylprednisolone acetate	P-Care D80
methylprednisolone acetate	methylprednisolone acetate

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
methylprednisolone acetate in sodium chloride,iso-osmotic/PF	methylpred ac(PF)-NaCl,iso-osm
methylprednisolone acetate in sterile water for injection	methylprednisolone acet-water
methylprednisolone acetate/bupivacaine HCl in sterile water	methylprednisol ac-bupivac-wat
methylprednisolone sodium succinate	Solu-Medrol
methylprednisolone sodium succinate	methylprednisolone sodium succ
methylprednisolone sodium succinate/PF	Solu-Medrol (PF)
prednisolone	Millipred
prednisolone	Millipred DP
prednisolone	prednisolone
prednisolone sodium phosphate	Orapred ODT
prednisolone sodium phosphate	Pediapred
prednisolone sodium phosphate	Veripred 20
prednisolone sodium phosphate	prednisolone sodium phosphate
prednisone	Prednisone Intensol
prednisone	Rayos
prednisone	prednisone
triamcinolone acetonide	Kenalog
triamcinolone acetonide	Kenalog-80
triamcinolone acetonide	P-Care K40
triamcinolone acetonide	P-Care K80
triamcinolone acetonide	Pod-Care 100K
triamcinolone acetonide	Pro-C-Dure 5
triamcinolone acetonide	Pro-C-Dure 6
triamcinolone acetonide	Zilretta
triamcinolone acetonide	triamcinolone acetonide
triamcinolone acetonide in 0.9 % sodium chloride	triamcinolone aceton-0.9% NaCl
triamcinolone acetonide/0.9% sodium chloride/PF	triamcinol ac (PF) in 0.9%NaCl
triamcinolone acetonide/bupivacaine/in 0.9% sodium chloride	triamcinol ace-bupiv-0.9% NaCl
triamcinolone acetonide/lidocaine HCl	Lidocilone I
triamcinolone diacetate in 0.9 % sodium chloride	triamcinolone diacet-0.9% NaCl
triamcinolone diacetate in 0.9 % sodium chloride/PF	triamcinolone dia(PF)-0.9%NaCl
triamcinolone hexacetonide	Aristospan Intra-Articular
triamcinolone hexacetonide	Aristospan Intralesional
triamcinolone hexacetonide	Hexatrione
Lopinavir/Ritonavir	
LOPINAVIR/RITONAVIR	
Remdesivir	
REMDESIVIR	
REMDESIVIR (EMERGENCY USE AUTHORIZATION)	
REMDESIVIR FOR IV	
remdesivir	
Hydroxychloroquine	
hydroxychloroquine sulfate	Plaquenil
hydroxychloroquine sulfate	hydroxychloroquine
Chloroquine	

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
chloroquine phosphate	chloroquine phosphate
Azithromycin	
AZITHROMYCIN	
AZITHROMYCIN HYDROGEN CITRATE	
Ivermectin	
IVERMECTIN	
Dexamethasone	
BUPIVACAINE HCL/DEXAMETHASONE SODIUM PHOSPHATE IN STERILE WATER	
DEXAMETHASONE	
DEXAMETHASONE ACETATE	
DEXAMETHASONE ACETATE AND SODIUM PHOSPHATE IN STERILE WATER	
DEXAMETHASONE ACETATE IN SODIUM CHLORIDE, ISO/OSMOTIC	
DEXAMETHASONE ACETATE/SODIUM PHOSPHATE	
DEXAMETHASONE SODIUM PHOSPHATE	
DEXAMETHASONE SODIUM PHOSPHATE IN 0.9 % SODIUM CHLORIDE	
DEXAMETHASONE SODIUM PHOSPHATE PF/BUPIVACAINE 0.25%	
DEXAMETHASONE SODIUM PHOSPHATE/DEXTROSE	
DEXAMETHASONE SODIUM PHOSPHATE/LIDOCAINE HCL	
DEXAMETHASONE SODIUM PHOSPHATE/NACL	
DEXAMETHASONE SODIUM PHOSPHATE/PF	
DEXAMETHASONE/BUPIVACAINE HCL/EPINEPHRINE	
DEXAMETHASONE/SALIVA COLLECTION DEVICE	
dexamethasone	
dexamethasone sodium phosphate	
dexamethasone sodium phosphate/PF	
Other Corticosteroids	
NYSTATIN/HYDROCORTISONE/DIPHENHYDRAMINE HCL	FIRST-Duke's
NYSTATIN/TETRACYCLINE HCL/HYDROCORTISONE/DIPHENHYDRAMINE HCL	FIRST-Mary's Mouthwash
betamethasone acetate and sodium phos in sterile water/PF	betameth ac,sod phos(PF)-water
betamethasone acetate/betamethasone sodium	BSP-0820
betamethasone acetate/betamethasone sodium	Beta-1
betamethasone acetate/betamethasone sodium	Celestone Soluspan
betamethasone acetate/betamethasone sodium	Pod-Care 100C
betamethasone acetate/betamethasone sodium	ReadySharp Betamethasone
betamethasone acetate/betamethasone sodium	betamethasone acet,sod phos
betamethasone acetate/betamethasone sodium phosphate/water	betamethasone ace,sod phos-wtr
betamethasone sodium phosph in sterile water for injection	betamethasone sod phosph-water
cortisone acetate	cortisone
fludrocortisone acetate	fludrocortisone

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
hydrocortisone	Alkindi Sprinkle
hydrocortisone	Cortef
hydrocortisone	hydrocortisone
hydrocortisone sodium succinate	A-Hydrocort
hydrocortisone sodium succinate	Solu-Cortef
hydrocortisone sodium succinate/PF	Solu-Cortef Act-O-Vial (PF)
methylprednisolone	Medrol
methylprednisolone	Medrol (Pak)
methylprednisolone	Methylpred DP
methylprednisolone	methylprednisolone
methylprednisolone acetate	Depo-Medrol
methylprednisolone acetate	P-Care D40
methylprednisolone acetate	P-Care D80
methylprednisolone acetate	methylprednisolone acetate
methylprednisolone acetate in sodium chloride,iso-osmotic/PF	methylpred ac(PF)-NaCl,iso-osm
methylprednisolone acetate in sterile water for injection	methylprednisolone acet-water
methylprednisolone acetate/bupivacaine HCl in sterile water	methylprednisol ac-bupivac-wat
methylprednisolone sodium succinate	Solu-Medrol
methylprednisolone sodium succinate	methylprednisolone sodium succ
methylprednisolone sodium succinate/PF	Solu-Medrol (PF)
prednisolone	Millipred
prednisolone	Millipred DP
prednisolone	prednisolone
prednisolone sodium phosphate	Orapred ODT
prednisolone sodium phosphate	Pediapred
prednisolone sodium phosphate	Veripred 20
prednisolone sodium phosphate	prednisolone sodium phosphate
prednisone	Prednisone Intensol
prednisone	Rayos
prednisone	prednisone
triamcinolone acetonide	Kenalog
triamcinolone acetonide	Kenalog-80
triamcinolone acetonide	P-Care K40
triamcinolone acetonide	P-Care K80
triamcinolone acetonide	Pod-Care 100K
triamcinolone acetonide	Pro-C-Dure 5
triamcinolone acetonide	Pro-C-Dure 6
triamcinolone acetonide	Zilretta
triamcinolone acetonide	triamcinolone acetonide
triamcinolone acetonide in 0.9 % sodium chloride	triamcinolone aceton-0.9% NaCl
triamcinolone acetonide/0.9% sodium chloride/PF	triamcinol ac (PF) in 0.9%NaCl
triamcinolone acetonide/bupivacaine/in 0.9% sodium chloride	triamcinol ace-bupiv-0.9% NaCl
triamcinolone acetonide/lidocaine HCl	Lidocilone I
triamcinolone diacetate in 0.9 % sodium chloride	triamcinolone diacet-0.9% NaCl
triamcinolone diacetate in 0.9 % sodium chloride/PF	triamcinolone dia(PF)-0.9%NaCl

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
triamcinolone hexacetonide	Aristospan Intra-Articular
triamcinolone hexacetonide	Aristospan Intralesional
triamcinolone hexacetonide	Hexatrione
Inhaled Corticosteroids	
beclomethasone dipropionate	Qvar RediHaler
budesonide	Pulmicort
budesonide	Pulmicort Flexhaler
budesonide	budesonide
budesonide/formoterol fumarate	Symbicort
budesonide/formoterol fumarate	budesonide-formoterol
budesonide/glycopyrrolate/formoterol fumarate	Breztri Aerosphere
ciclesonide	Alvesco
fluticasone furoate	Arnuity Ellipta
fluticasone furoate/umeclidinium bromide/vilanterol trifenat	Trelegy Ellipta
fluticasone furoate/vilanterol trifenatate	Breo Ellipta
fluticasone furoate/vilanterol trifenatate	fluticasone furoate-vilanterol
fluticasone propionate	ArmonAir Digihaler
fluticasone propionate	Flovent Diskus
fluticasone propionate	Flovent HFA
fluticasone propionate	fluticasone propionate
fluticasone propionate/salmeterol xinafoate	Advair Diskus
fluticasone propionate/salmeterol xinafoate	Advair HFA
fluticasone propionate/salmeterol xinafoate	AirDuo Digihaler
fluticasone propionate/salmeterol xinafoate	AirDuo RespiClick
fluticasone propionate/salmeterol xinafoate	Wixela Inhub
fluticasone propionate/salmeterol xinafoate	fluticasone propion-salmeterol
mometasone furoate	Asmanex HFA
mometasone furoate	Asmanex Twisthaler
mometasone furoate/formoterol fumarate	Dulera
Paxlovid	
nirmatrelvir/ritonavir	Paxlovid (EUA)
Baricitinib	
BARICITINIB	
Tocilizumab	
tocilizumab	Actemra
tocilizumab	Actemra ACTPen
Bamlanivimab	
Bamlanivimab	Bamlanivimab
Casirivimab/Imdevimab	
Casirivimab	
Casirivimab/Imdevimab	
Imdevimab	
casirivimab-imdevimab	
Bamlanivimab/Etesevimab	
Bamlanivimab	Bamlanivimab
Etesevimab	etesevimab
Sotrovimab	

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
Sotrovimab injection 500mg/8ml	sotrovimab
NSAIDs	
NAPROXEN	Napro
NAPROXEN	Naproderm
amlodipine besylate/celecoxib	Consensi
bromfenac sodium	BromSite
bromfenac sodium	Prolensa
bromfenac sodium	bromfenac
bupivacaine/ketorolac/ketamine	bupivacaine-ketorolac-ketamine
bupivacaine/meloxicam	Zynrelef
celecoxib	Celebrex
celecoxib	Elyxyb
celecoxib	celecoxib
celecoxib/capsaicin/methyl salicylate/menthol	NuDroxiPAK
chlorpheniramine maleate/phenylephrine HCl/ibuprofen	Advil Allergy-Congestion Rlf
chlorpheniramine maleate/pseudoephedrine HCl/ibuprofen	Advil Allergy Sinus
dexamethasone sod ph/moxifloxacin HCl/ketorolac/sod chlor/PF	dexamet-moxifl-ketoro-NaCl(PF)
diclofenac epolamine	Flector
diclofenac epolamine	Licart
diclofenac epolamine	diclofenac epolamine
diclofenac potassium	Cambia
diclofenac potassium	Cataflam
diclofenac potassium	Lofena
diclofenac potassium	Zipsor
diclofenac potassium	diclofenac potassium
diclofenac sodium	Arthritis Pain (diclofenac)
diclofenac sodium	Diclo Gel
diclofenac sodium	Diclofono
diclofenac sodium	Dicloprep-100
diclofenac sodium	Diclozor
diclofenac sodium	Pennsaid
diclofenac sodium	Solaraze
diclofenac sodium	VennGel One
diclofenac sodium	Voltaren
diclofenac sodium	Voltaren Arthritis Pain
diclofenac sodium	Voltaren-XR
diclofenac sodium	diclofenac sodium
diclofenac sodium/capsaicin	CapsFenac Pak
diclofenac sodium/capsaicin	Dicloheal-60
diclofenac sodium/capsaicin	Diclopak
diclofenac sodium/capsaicin	Flexipak
diclofenac sodium/capsaicin	Inavix
diclofenac sodium/capsaicin	NuDiclo SoluPAK
diclofenac sodium/capsaicin	NuDiclo TabPAK
diclofenac sodium/capsaicin	Pennsaicin
diclofenac sodium/capsaicin/methyl salicylate/menthol	NuDroxiPAK DSDR-50

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
diclofenac sodium/capsaicin/methyl salicylate/menthol	NuDroxiPAK DSDR-75
diclofenac sodium/capsicum oleoresin	Capsinac
diclofenac sodium/capsicum oleoresin	DermacinRx Lexitral
diclofenac sodium/capsicum oleoresin	Diclofex DC
diclofenac sodium/capsicum oleoresin	Diclosaicin
diclofenac sodium/capsicum oleoresin	Diclotral
diclofenac sodium/capsicum oleoresin	Iclofenac CP
diclofenac sodium/capsicum oleoresin	Inflammacin
diclofenac sodium/capsicum oleoresin	Kapzin DC
diclofenac sodium/capsicum oleoresin	Lexitral PharmaPak II
diclofenac sodium/capsicum oleoresin	Sure Result DSS Premium Pack
diclofenac sodium/capsicum oleoresin	Xelitral
diclofenac sodium/capsicum oleoresin	Xenaflamm
diclofenac sodium/capsicum oleoresin	Ziclopro
diclofenac sodium/hyaluronate sodium/niacinamide	Roaoxia
diclofenac sodium/hyaluronate sodium/niacinamide	diclofenac-hyaluronate-niacin
diclofenac sodium/kinesiology tape	Clofenax
diclofenac sodium/kinesiology tape	Diclo Gel-Xrylix Sheet
diclofenac sodium/kinesiology tape	Lexixryl
diclofenac sodium/kinesiology tape	Profinac
diclofenac sodium/kinesiology tape	Xrylix (diclofenac-kines tape)
diclofenac sodium/kinesiology tape	Xrylix II
diclofenac sodium/lidocaine	Lidovix
diclofenac sodium/lidocaine HCl/kinesiology tape	TriXylitral
diclofenac sodium/lidocaine/methyl salicylate/camphor	Diclovix
diclofenac sodium/menthol	DiThol
diclofenac sodium/menthol/camphor	Diclotrex
diclofenac sodium/menthol/camphor	Diclotrex II
diclofenac sodium/menthol/camphor	Inflatherm(diclofenac-menthol)
diclofenac sodium/menthol/kinesiology tape	DiMentho
diclofenac sodium/menthol/kinesiology tape	Diclovix M
diclofenac sodium/methyl salicylate/menthol	DicloPR
diclofenac sodium/methyl salicylate/menthol	Varophen (diclofenac)
diclofenac sodium/methyl salicylate/menthol/camphor	Inflamma-K
diclofenac sodium/misoprostol	Arthrotec 50
diclofenac sodium/misoprostol	Arthrotec 75
diclofenac sodium/misoprostol	diclofenac-misoprostol
diclofenac sodium/silicone, adhesive	Solaravix
diclofenac sodium/trolamine salicylate	Inflatherm (diclofenac-trolam)
diclofenac submicronized	Zorvolex
diclofenac submicronized	diclofenac submicronized
etodolac	Lodine
etodolac	etodolac
etodolac/capsaicin/methyl salicylate/menthol	NuDroxiPAK E-400
fenoprofen calcium	Fenortho
fenoprofen calcium	Nalfon
fenoprofen calcium	ProFeno
fenoprofen calcium	fenoprofen

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
flurbiprofen	flurbiprofen
flurbiprofen sodium	flurbiprofen sodium
hydrocodone/ibuprofen	Ibudone
hydrocodone/ibuprofen	hydrocodone-ibuprofen
ibuprofen	Addaprin
ibuprofen	Advil
ibuprofen	Advil Junior Strength
ibuprofen	Advil Liqui-Gel
ibuprofen	Advil Migraine
ibuprofen	Caldolor
ibuprofen	Children's Advil
ibuprofen	Children's Ibuprofen
ibuprofen	Children's Motrin
ibuprofen	Children's Motrin Jr Strength
ibuprofen	Children's Profen IB
ibuprofen	I-Prin
ibuprofen	IBU
ibuprofen	IBU-200
ibuprofen	Ibuprofen IB
ibuprofen	Ibuprofen Jr Strength
ibuprofen	Infant's Advil
ibuprofen	Infant's Ibuprofen
ibuprofen	Infant's Motrin
ibuprofen	Infants ProfenIB
ibuprofen	Motrin IB
ibuprofen	Provil
ibuprofen	Wal-Profen
ibuprofen	ibuprofen
ibuprofen lysine/PF	NeoProfen (ibuprofen lysn)(PF)
ibuprofen lysine/PF	ibuprofen lysine (PF)
ibuprofen/acetaminophen	Advil Dual Action
ibuprofen/capsaicin/methyl salicylate/menthol	NuDroxiPAK I-800
ibuprofen/diphenhydramine HCl	Advil PM Liqui-Gels
ibuprofen/diphenhydramine HCl	Ibuprofen PM
ibuprofen/diphenhydramine citrate	Advil PM
ibuprofen/diphenhydramine citrate	Ibuprofen PM
ibuprofen/diphenhydramine citrate	Motrin PM
ibuprofen/famotidine	Duexis
ibuprofen/famotidine	ibuprofen-famotidine
ibuprofen/glycerin	Ibupak
ibuprofen/irritants counter-irritants combination no.2	Comfort Pac-Ibuprofen
ibuprofen/oxycodone HCl	ibuprofen-oxycodone
ibuprofen/phenylephrine HCl	Advil Sinus Congestion-Pain
ibuprofen/phenylephrine HCl	Congestion Relief (ibuprof-PE)
ibuprofen/phenylephrine HCl	Sudafed PE Head Congestn-Pain
ibuprofen/pseudoephedrine HCl	Advil Cold and Sinus
ibuprofen/pseudoephedrine HCl	Cold and Sinus Pain Relief
ibuprofen/pseudoephedrine HCl	Cold-Sinus Relief

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
ibuprofen/pseudoephedrine HCl	Cold-Sinus Relief (ibuprofen)
ibuprofen/pseudoephedrine HCl	Ibuprofen Cold-Sinus(with PSE)
ibuprofen/pseudoephedrine HCl	Wal-Profen Cold-Sinus
ibuprofen/pseudoephedrine HCl	Wal-Profen D Cold and Sinus
indomethacin	Indocin
indomethacin	indomethacin
indomethacin sodium	indomethacin sodium
indomethacin, submicronized	Tivorbex
indomethacin, submicronized	indomethacin submicronized
ketoprofen	Frotek
ketoprofen	ketoprofen
ketoprofen, micronized	Frotek
ketorolac tromethamine	Acular
ketorolac tromethamine	Acular LS
ketorolac tromethamine	ReadySharp ketorolac
ketorolac tromethamine	Sprix
ketorolac tromethamine	ketorolac
ketorolac tromethamine/PF	Acuvail (PF)
ketorolac/norflurane and pentafluoropropane (HFC 245fa)	Toronova II SUIK
ketorolac/norflurane and pentafluoropropane (HFC 245fa)	Toronova SUIK
meclofenamate sodium	meclofenamate
mefenamic acid	mefenamic acid
meloxicam	Anjeso
meloxicam	Mobic
meloxicam	Qmiiz ODT
meloxicam	meloxicam
meloxicam, submicronized	Vivlodex
meloxicam, submicronized	meloxicam submicronized
meloxicam/irritants counter-irritants combination no.2	Comfort Pac-Meloxicam
nabumetone	Relafen
nabumetone	Relafen DS
nabumetone	nabumetone
nabumetone/capsaicin/methyl salicylate/menthol	NuDroxiPAK N-500
naproxen	EC-Naprosyn
naproxen	EC-Naproxen
naproxen	Naprosyn
naproxen	naproxen
naproxen sodium	Aleve
naproxen sodium	All Day Pain Relief
naproxen sodium	All Day Relief
naproxen sodium	Anaprox DS
naproxen sodium	Flanax (naproxen)
naproxen sodium	Mediproxen
naproxen sodium	Midol (naproxen)
naproxen sodium	Naprelan CR
naproxen sodium	Wal-Proxen
naproxen sodium	naproxen sodium
naproxen sodium/diphenhydramine HCl	Aleve PM

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
naproxen sodium/diphenhydramine HCl	Naproxen PM
naproxen sodium/pseudoephedrine HCl	Aleve Cold and Sinus
naproxen sodium/pseudoephedrine HCl	Aleve Sinus and Headache
naproxen sodium/pseudoephedrine HCl	Aleve-D Sinus and Cold
naproxen sodium/pseudoephedrine HCl	Aleve-D Sinus and Headache
naproxen sodium/pseudoephedrine HCl	All Day Pain Relief Sinus,Cold
naproxen sodium/pseudoephedrine HCl	Sinus and Cold-D
naproxen sodium/pseudoephedrine HCl	Sudafed Sinus 12Hr Pressr-Pain
naproxen/esomeprazole magnesium	Vimovo
naproxen/esomeprazole magnesium	naproxen-esomeprazole
naproxen/irritant counter-irritant combination no.2	Comfort Pac-Naproxen
nepafenac	Ilevro
nepafenac	Nevanac
oxaprozin	Daypro
oxaprozin	oxaprozin
phenylephrine HCl/ketorolac tromethamine	Omidria
piroxicam	Feldene
piroxicam	piroxicam
prednisolone acetate/bromfenac sodium	prednisolone acetate-bromfenac
prednisolone acetate/gatifloxacin/bromfenac sodium	prednisol ace-gatiflox-bromfen
prednisolone acetate/moxifloxacin HCl/bromfenac sodium	prednisolone-moxiflox-bromfen
prednisolone acetate/moxifloxacin HCl/nepafenac	prednisolone-moxiflo-nepafenac
prednisolone acetate/nepafenac	prednisolone acetate-nepafenac
prednisolone sodium phosphate/bromfenac sodium	prednisolone sod ph-bromfenac
prednisolone sodium phosphate/gatifloxacin/bromfenac sodium	prednisoln sp-gatiflox-bromfen
prednisolone sodium phosphate/moxifloxacin HCl/bromfenac sod	prednisoln sp-moxiflox-bromfen
ropivacaine HCl/clonidine HCl/ketorolac tromethamine	ropivacaine-clonidin-ketorolac
ropivacaine HCl/epinephrine/clonidine HCl/ketorolac trometh	ropivacaine-epi-clonid-ketorol
ropivacaine/ketorolac/ketamine	ropivacaine-ketorolac-ketamine
sulindac	sulindac
sumatriptan succinate/naproxen sodium	Treximet
sumatriptan succinate/naproxen sodium	sumatriptan-naproxen
tolmetin sodium	tolmetin
tramadol HCl/celecoxib	Seglentis
tropicamide/proparacaine/phenylephrine/ketorolac in water	Mydriatic4(trop-prop-PE-ktrlc)
tropicamide/proparacaine/phenylephrine/ketorolac in water	tropic-proparacai-pe-ketor-wat
Antidepressants	
St. John's wort	Alterra
St. John's wort	Centrum Herbals St Johns Wort
St. John's wort	Kira St. John's Wort
St. John's wort	Movana
St. John's wort	Quanterra Emotional
St. John's wort	St. John's wort

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
amitriptyline HCl	Elavil
amitriptyline HCl	Vanatrip
amitriptyline HCl	amitriptyline
amitriptyline HCl/chlordiazepoxide	Limbitrol
amitriptyline HCl/chlordiazepoxide	Limbitrol DS
amitriptyline HCl/chlordiazepoxide	amitriptyline-chlordiazepoxide
amoxapine	Asendin
amoxapine	amoxapine
brexanolone	Zulresso
bupropion HBr	Aplenzin
bupropion HCl	Budeprion SR
bupropion HCl	Budeprion XL
bupropion HCl	Forfivo XL
bupropion HCl	Wellbutrin
bupropion HCl	Wellbutrin SR
bupropion HCl	Wellbutrin XL
bupropion HCl	bupropion HCl
bupropion HCl/dietary supplement combination no.15	Appbutamone-D
bupropion HCl/dietary supplement combination no.16	Appbutamone
citalopram hydrobromide	Celexa
citalopram hydrobromide	citalopram
clomipramine HCl	Anafranil
clomipramine HCl	clomipramine
desipramine HCl	Norpramin
desipramine HCl	desipramine
desvenlafaxine	Khedezla
desvenlafaxine	desvenlafaxine
desvenlafaxine fumarate	desvenlafaxine fumarate
desvenlafaxine succinate	Pristiq
desvenlafaxine succinate	desvenlafaxine succinate
dextromethorphan HBr/bupropion HCl	Auvelity
doxepin HCl	Adapin
doxepin HCl	Silenor
doxepin HCl	Sinequan
doxepin HCl	doxepin
duloxetine HCl	Cymbalta
duloxetine HCl	Drizalma Sprinkle
duloxetine HCl	Irenka
duloxetine HCl	duloxetine
escitalopram oxalate	Lexapro
escitalopram oxalate	escitalopram oxalate
esketamine HCl	Spravato
fluoxetine HCl	Prozac
fluoxetine HCl	Prozac Weekly
fluoxetine HCl	Rapiflux
fluoxetine HCl	Sarafem
fluoxetine HCl	Selfemra
fluoxetine HCl	fluoxetine

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
fluoxetine HCl/dietary supplement no.17	Gaboxetine
fluoxetine HCl/dietary supplement no.8	Sentroxatine
fluvoxamine maleate	Luvox
fluvoxamine maleate	Luvox CR
fluvoxamine maleate	fluvoxamine
imipramine HCl	Tofranil
imipramine HCl	imipramine HCl
imipramine pamoate	Tofranil-PM
imipramine pamoate	imipramine pamoate
isocarboxazid	Marplan
levomilnacipran HCl	Fetzima
maprotiline HCl	Ludiomil
maprotiline HCl	maprotiline
milnacipran HCl	Savella
mirtazapine	Remeron
mirtazapine	Remeron SolTab
mirtazapine	mirtazapine
nefazodone HCl	Serzone
nefazodone HCl	nefazodone
nortriptyline HCl	Aventyl
nortriptyline HCl	Pamelor
nortriptyline HCl	nortriptyline
olanzapine/fluoxetine HCl	Symbyax
olanzapine/fluoxetine HCl	olanzapine-fluoxetine
paroxetine HCl	Paxil
paroxetine HCl	Paxil CR
paroxetine HCl	paroxetine HCl
paroxetine mesylate	Pexeva
perphenazine/amitriptyline HCl	Duo-Vil 2-10
perphenazine/amitriptyline HCl	Duo-Vil 2-25
perphenazine/amitriptyline HCl	Etrafon 2-10
perphenazine/amitriptyline HCl	Etrafon 2-25
perphenazine/amitriptyline HCl	Etrafon Forte 4-25
perphenazine/amitriptyline HCl	Triavil 2-10
perphenazine/amitriptyline HCl	Triavil 2-25
perphenazine/amitriptyline HCl	Triavil 4-25
perphenazine/amitriptyline HCl	perphenazine-amitriptyline
phenelzine sulfate	Nardil
phenelzine sulfate	phenelzine
protriptyline HCl	Vivactil
protriptyline HCl	protriptyline
selegiline	Emsam
sertraline HCl	Zoloft
sertraline HCl	sertraline
tranylcypromine sulfate	Parnate
tranylcypromine sulfate	tranylcypromine
trazodone HCl	Desyrel
trazodone HCl	Oleptro ER

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
trazodone HCl	trazodone
trazodone HCl/dietary supplement no.8	Trazamine
trimipramine maleate	Surmontil
trimipramine maleate	trimipramine
venlafaxine HCl	Effexor
venlafaxine HCl	Effexor XR
venlafaxine HCl	venlafaxine
venlafaxine besylate	venlafaxine besylate
vilazodone HCl	Viibryd
vilazodone HCl	vilazodone
vortioxetine hydrobromide	Brintellix
vortioxetine hydrobromide	Trintellix

Appendix F. Technical Specifications Used for this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v13.0.1 to assess vaccine data in the Sentinel Distributed Database (SDD).

Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 183 days
Post-index enrollment requirement: 0 days
Post-episode enrollment requirement for Type 2 analyses: 0 days
Enrollment gap: 45 days
Age groups: 0-6 months, 6 months-4 years, 5-11, 12-15, 16-39, 40-64, and ≥ 65 years
Index Distribution Macro for Phase 1: Turn on
Envelope macro: Turn off envelope. No reclassification. (2)

							Exposure			
	Run	Scenario	Group	Query Period	Stratifications	Distribution of Index	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:
r01	1	With at least one COVID-19 vaccine	11/01/2020 - latest available data	-Sex -Year -Year month -Agegroup - Geographic region (states) -agegroup*Year Month	Y	First dose of COVID-19 vaccine (Any brand)	First valid exposure episodes during query period	0	n/a	Y

Appendix F. Technical Specifications Used for this Request

r02	2	With at least two COVID-19 vaccine	11/01/2020 - latest available data	- agegroup*Calendar Month -Sex - Geographic region (states)	Y	First dose of COVID-19 vaccine (Any brand)	First valid exposure episodes during query period	0	n/a	Y
r03	3	Pfizer-Pfizer combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Pfizer brand)	First valid exposure episodes during query period	0	n/a	Y

Appendix F. Technical Specifications Used for this Request

r03	4	Moderna-Moderna combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Moderna brand)	First valid exposure episodes during query period	0	n/a	Y
r03	5	Jannsen-Jannsen combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Jannsen_Jannsen)	First valid exposure episodes during query period	0	n/a	Y
r03	6	Other-Other combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Novavax or Unspecified)	First valid exposure episodes during query period	0	n/a	Y
r03	7	Pfizer-Moderna combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Pfizer brand)	First valid exposure episodes during query period	0	n/a	Y

Appendix F. Technical Specifications Used for this Request

r03	8	Moderna-Pfizer combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Moderna brand)	First valid exposure episodes during query period	0	n/a	Y
r03	9	Pfizer-Other combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Pfizer brand)	First valid exposure episodes during query period	0	n/a	Y
r03	10	Pfizer-Jannsen combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Pfizer brand)	First valid exposure episodes during query period	0	n/a	Y
r03	11	Moderna-Jannsen combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Moderna brand)	First valid exposure episodes during query period	0	n/a	Y

Appendix F. Technical Specifications Used for this Request

r03	12	Moderna-Other combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Moderna brand)	First valid exposure episodes during query period	0	n/a	Y
r03	13	Jannsen-Moderna combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Jannsen)	First valid exposure episodes during query period	0	n/a	Y
r03	14	Jannsen-Pfizer combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Jannsen)	First valid exposure episodes during query period	0	n/a	Y
r03	15	Jannsen-Other combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Jannsen)	First valid exposure episodes during query period	0	n/a	Y

Appendix F. Technical Specifications Used for this Request

r03	16	Other-Moderna combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Novavax or Unspecified)	First valid exposure episodes during query period	0	n/a	Y
r03	17	Other-Pfizer combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Novavax or Unspecified)	First valid exposure episodes during query period	0	n/a	Y
r03	18	Other-Jannsen combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Novavax or Unspecified)	First valid exposure episodes during query period	0	n/a	Y

Appendix F. Technical Specifications Used for this Request

r03	19	Claims-Claim combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Claims: NDC and PX codes)	First valid exposure episodes during query period	0	n/a	Y
r03	20	IIS-IIS combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (IIS: CVX codes)	First valid exposure episodes during query period	0	n/a	Y

Appendix F. Technical Specifications Used for this Request

r03	21	Claim-IIS combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Claims: NDC and PX codes)	First valid exposure episodes during query period	0	n/a	Y
r03	22	IIS-Claims combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (IIS: CVX codes)	First valid exposure episodes during query period	0	n/a	Y

Appendix F. Technical Specifications Used for this Request

r03	23	Claims-Claims and IIS combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Claims: NDC and PX codes)	First valid exposure episodes during query period	0	n/a	Y
r03	24	IIS-IIS and Claims combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (IIS: CVX codes)	First valid exposure episodes during query period	0	n/a	Y

Appendix F. Technical Specifications Used for this Request

r03	25	IIS and Claims-IIS combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Claims)	First valid exposure episodes during query period	0	n/a	Y
r03	26	IIS and Claims-Claims combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Claims)	First valid exposure episodes during query period	0	n/a	Y

Appendix F. Technical Specifications Used for this Request

r03	27	IIS and Claims-IIS and Claims combination for first and second COVID-19 vaccines	11/01/2020 - latest available data	-	-	First dose of COVID-19 vaccine (Claims)	First valid exposure episodes during query period	0	n/a	Y
r04	28	Booster defined as 3rd dose in all individuals	09/01/2021 - latest available data	- Sex - Geographic State region - **agegroup*Calendar Month**	-	3rd dose of the pfizer and moderna COVID-19 vaccine that qualifies as a booster for non-immunocompromised individuals	First valid exposure episodes during query period	0	n/a	Y

Appendix F. Technical Specifications Used for this Request

r04	29	Booster defined as 4th dose in immunocompromised individuals	09/01/2021 - latest available data	-	-	4th dose of the pfizer and moderna COVID-19 vaccine that qualifies as a booster including immunocompromised individuals	First valid exposure episodes during query period	0	n/a	Y
r04	30	Booster defined as 3rd dose in non-immunocompromised individuals	09/01/2021 - latest available data	-	-	3rd dose of the pfizer and moderna COVID-19 vaccine that qualifies as a booster excluding immunocompromised individuals	First valid exposure episodes during query period	0	n/a	Y

Appendix F. Technical Specifications Used for this Request

r04	31	Evidence of any COVID-19 brand that specifies "booster" or "bivalent"	09/01/2021 - latest available data	- Sex - Geographic State region - **agegroup*Calendar Month**	-	Evidence of one COVID vaccine codes of any brand that specifies "booster" or "bivalent"	First valid exposure episodes during query period	0	n/a	Y

ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360.

NDC codes are checked against First Data Bank's FDB MedKnowledge®.

Appendix F. Technical Specifications Used for this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v13.0.1 to assess vaccine data in the Sentinel Distributed Database (SDD).

Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 183 days
Post-index enrollment requirement: 0 days
Post-episode enrollment requirement for Type 2 analyses: 0 days
Enrollment gap: 45 days
Age groups: 0-6 months, 6 months-4 years, 5-11, 12-15, 16-39, 40-64, and ≥ 65 years
Index Distribution Macro for Phase 1: Turn on
Envelope macro: Turn off envelope. No reclassification. (2)

			Exposure								
	Run	Scenario	Build Episodes on Point Exposure?	Treatment episode gap	Exposure episode extension	Minimum exposure episode duration	Minimum days supplied	Maximum exposure episode duration	Care setting	Principal diagnosis position	Forced supply to attach to dispensings
r01	1	With at least one COVID-19 vaccine						Any care setting	N/A	N/A	Y

Appendix F. Technical Specifications Used for this Request

r02	2	With at least two COVID-19 vaccine		Any care setting	N/A	N/A	Y
r03	3	Pfizer-Pfizer combination for first and second COVID-19 vaccines		Any care setting	N/A	N/A	N

Appendix F. Technical Specifications Used for this Request

r03	4	Moderna-Moderna combination for first and second COVID-19 vaccines	Any care setting	N/A	N/A	N
r03	5	Jannsen-Jannsen combination for first and second COVID-19 vaccines	Any care setting	N/A	N/A	N
r03	6	Other-Other combination for first and second COVID-19 vaccines	Any care setting	N/A	N/A	N
r03	7	Pfizer-Moderna combination for first and second COVID-19 vaccines	Any care setting	N/A	N/A	N

Appendix F. Technical Specifications Used for this Request						
r03	8	Moderna-Pfizer combination for first and second COVID-19 vaccines	Any care setting	N/A	N/A	N
r03	9	Pfizer-Other combination for first and second COVID-19 vaccines	Any care setting	N/A	N/A	N
r03	10	Pfizer-Jannsen combination for first and second COVID-19 vaccines	Any care setting	N/A	N/A	N
r03	11	Moderna-Jannsen combination for first and second COVID-19 vaccines	Any care setting	N/A	N/A	N

Appendix F. Technical Specifications Used for this Request

r03	12	Moderna-Other combination for first and second COVID-19 vaccines	Any care setting	N/A	N/A	N
r03	13	Jannsen-Moderna combination for first and second COVID-19 vaccines	Any care setting	N/A	N/A	N
r03	14	Jannsen-Pfizer combination for first and second COVID-19 vaccines	Any care setting	N/A	N/A	N
r03	15	Jannsen-Other combination for first and second COVID-19 vaccines	Any care setting	N/A	N/A	N

Appendix F. Technical Specifications Used for this Request

r03	16	Other-Moderna combination for first and second COVID-19 vaccines	Any care setting	N/A	N/A	N
r03	17	Other-Pfizer combination for first and second COVID-19 vaccines	Any care setting	N/A	N/A	N
r03	18	Other-Jannsen combination for first and second COVID-19 vaccines	Any care setting	N/A	N/A	N

Appendix F. Technical Specifications Used for this Request

r03	19	Claims-Claim combination for first and second COVID-19 vaccines		Any care setting	N/A	N/A	N
r03	20	IIS-IIS combination for first and second COVID-19 vaccines		Any care setting	N/A	N/A	N

Appendix F. Technical Specifications Used for this Request

r03	21	Claim-IIS combination for first and second COVID-19 vaccines	—	Any care setting	N/A	N/A	N
r03	22	IIS-Claims combination for first and second COVID-19 vaccines	—	Any care setting	N/A	N/A	N

Appendix F. Technical Specifications Used for this Request

r03	23	Claims-Claims and IIS combination for first and second COVID-19 vaccines		Any care setting	N/A	N/A	N
r03	24	IIS-IIS and Claims combination for first and second COVID-19 vaccines		Any care setting	N/A	N/A	N

Appendix F. Technical Specifications Used for this Request							
r03	25	IIS and Claims-IIS combination for first and second COVID-19 vaccines	———	Any care setting	N/A	N/A	N
r03	26	IIS and Claims-Claims combination for first and second COVID-19 vaccines	———	Any care setting	N/A	N/A	N

Appendix F. Technical Specifications Used for this Request

r03	27	IIS and Claims-IIS and Claims combination for first and second COVID-19 vaccines		Any care setting	N/A	N/A	N
r04	28	Booster defined as 3rd dose in all individuals		Any care setting	N/A	N/A	Y

Appendix F. Technical Specifications Used for this Request

r04	29	Booster defined as 4th dose in immunocompromised individuals	Any care setting	N/A	N/A	N
r04	30	Booster defined as 3rd dose in non-immunocompromised individuals	Any care setting	N/A	N/A	N

Appendix F. Technical Specifications Used for this Request

r04	31	Evidence of any COVID-19 brand that specifies "booster" or "bivalent"		Any care setting	N/A	N/A	N

ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360.
NDC codes are checked against First Data Bank's FDB MedKnowledge®.

Appendix F. Technical Specifications Used for this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v13.0.1 to assess vaccine data in the Sentinel Distributed Database (SDD).

Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 183 days
Post-index enrollment requirement: 0 days
Post-episode enrollment requirement for Type 2 analyses: 0 days
Enrollment gap: 45 days
Age groups: 0-6 months, 6 months-4 years, 5-11, 12-15, 16-39, 40-64, and ≥ 65 years
Index Distribution Macro for Phase 1: Turn on
Envelope macro: Turn off envelope. No reclassification. (2)

			Exposure			Inclusion/Exclusion Criteria						
	Run	Scenario	Output Baseline Table	Censor treatment episode at evidence of:	Follow-Up Time Categories:	Inclusion/ Exclusion group	Criteria	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end	Exclude evidence of days supply if inclusion/exclusion evaluation period includes dispensings
r01	1	With at least one COVID-19 vaccine	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A

Appendix F. Technical Specifications Used for this Request

r02	2	With at least two COVID-19 vaccine	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
					COVID-19 vaccine (any brand)	Exclusion	Any	Any	1	4	Yes - looking at dispensing date only, not days supply	N/A
					COVID-19 vaccine (any brand)	Inclusion	Any	Any	5	latest value (i.e., the end of enrollment)	Yes - looking at dispensing date only, not days supply	N/A
r03	3	Pfizer-Pfizer combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A

Appendix F. Technical Specifications Used for this Request

r03	4	Moderna-Moderna combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
r03	5	Jannsen-Jannsen combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
r03	6	Other-Other combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
r03	7	Pfizer-Moderna combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A

Appendix F. Technical Specifications Used for this Request

r03	8	Moderna-Pfizer combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
r03	9	Pfizer-Other combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
r03	10	Pfizer-Jannsen combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
r03	11	Moderna-Jannsen combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A

Appendix F. Technical Specifications Used for this Request

r03	12	Moderna-Other combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
r03	13	Jannsen-Moderna combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
r03	14	Jannsen-Pfizer combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
r03	15	Jannsen-Other combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A

Appendix F. Technical Specifications Used for this Request

r03	16	Other-Moderna combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
r03	17	Other-Pfizer combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
r03	18	Other-Jannsen combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
					COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A

Appendix F. Technical Specifications Used for this Request

r03	19	Claims-Claim combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	**OR**							
					COVID-19 vaccine (IIS)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	latest value (i.e., the end of enrollment)	Yes - looking at dispensing date only, not days supply	N/A
r03	20	IIS-IIS combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
					OR							
					COVID-19 vaccine (Claims)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	latest value (i.e., the end of enrollment)	Yes - looking at dispensing date only, not days supply	N/A

Appendix F. Technical Specifications Used for this Request

r03	21	Claim-IIS combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
					OR							
					COVID-19 vaccine (IIS)	Exclusion	Any	Any	0	0	Yes - looking at dispensing date only, not days supply	N/A
r03	22	IIS-Claims combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of	-1	Yes - looking at dispensing date only, not	N/A
					OR							
					COVID-19 vaccine (Claims)	Exclusion	Any	Any	0	0	Yes - looking at dispensing date only, not days supply	N/A

Appendix F. Technical Specifications Used for this Request

r03	23	Claims-Claims and IIS combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
					OR							
					COVID-19 vaccine (IIS)	Exclusion	Any	Any	0	0	Yes - looking at dispensing date only, not days supply	N/A
r03	24	IIS-IIS and Claims combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
					OR							
					COVID-19 vaccine (Claims)	Exclusion	Any	Any	0	0	Yes - looking at dispensing date only, not days supply	N/A

Appendix F. Technical Specifications Used for this Request

r03	25	IIS and Claims-IIS combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
					COVID-19 vaccine (IIS)	Inclusion	Any	Any	0	0	Yes - looking at dispensing date only, not days supply	N/A
r03	26	IIS and Claims-Claims combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
					COVID-19 vaccine (IIS)	Inclusion	Any	Any	0	0	Yes - looking at dispensing date only, not days supply	N/A

Appendix F. Technical Specifications Used for this Request

r03	27	IIS and Claims-IIS and Claims combination for first and second COVID-19 vaccines	*Death; *Disenrollment; * DP end date; *Query end date;	1-10 days, 11-17 days, 18-21 days, 22-24 days, 25-27 days, 28-40 days, 41-50 days, 51-60 days, 61+ days	COVID-19 vaccine (any brand)	Exclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply	N/A
					COVID-19 vaccine (IIS)	Inclusion	Any	Any	0	0	Yes - looking at dispensing date only, not days supply	N/A
r04	28	Booster defined as 3rd dose in all individuals	*Death; *Disenrollment; * DP end date; *Query end date;	-	Evidence of **two** COVID vaccine codes of any brand that are 4 days apart **[Booster_twoprev]**	inclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-4	Yes - looking at dispensing date only, not days supply	1

Appendix F. Technical Specifications Used for this Request

r04	29	Booster defined as 4th dose in immunocompromised individuals	*Death; *Disenrollment; * DP end date; *Query end date;	-		inclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply
						inclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-4	
r04	30	Booster defined as 3rd dose in non-immunocompromised individuals	*Death; *Disenrollment; * DP end date; *Query end date;			**exclusion**	Any	Any	Earlier value (i.e., the start of enrollment)	-1	Yes - looking at dispensing date only, not days supply
						inclusion	Any	Any	Earlier value (i.e., the start of enrollment)	-4	

Appendix F. Technical Specifications Used for this Request

r04	31	Evidence of any COVID-19 brand that specifies "booster" or "bivalent"	*Death; *Disenrollment; * DP end date; *Query end date;	-	-	-	-	-	-	-	-	-

ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360.
NDC codes are checked against First Data Bank's FDB MedKnowledge®.

Appendix F. Technical Specifications Used for this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool v13.0.1 to assess vaccine data in the Sentinel Distributed Database (SDD).

Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 183 days
Post-index enrollment requirement: 0 days
Post-episode enrollment requirement for Type 2 analyses: 0 days
Enrollment gap: 45 days
Age groups: 0-6 months, 6 months-4 years, 5-11, 12-15, 16-39, 40-64, and ≥ 65 years
Index Distribution Macro for Phase 1: Turn on
Envelope macro: Turn off envelope. No reclassification. (2)

			Inclusion/Exclusion Criteria	Event Outcome						
	Run	Scenario	Number of instances the criteria should be found in evaluation period	Event	Incident event washout period	Incident w/ respect to:	Care setting	Principal diagnosis position	Exclude evidence of days supply if event washout includes dispensings	Event de-duplication
r01	1	With at least one COVID-19 vaccine	Second dose of COVID-19 vaccine (Combo: SecondCovid_Vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)

Appendix F. Technical Specifications Used for this Request

r02	2	With at least two COVID-19 vaccine	Second dose of COVID-19 vaccine (Combo: SecondCovid_Vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
r03	3	Pfizer-Pfizer combination for first and second COVID-19 vaccines	Second dose of Pfizer COVID-19 vaccine (pfizertwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)

Appendix F. Technical Specifications Used for this Request

r03	4	Moderna-Moderna combination for first and second COVID-19 vaccines	Second dose of Moderna COVID-19 vaccine (modernatwo_vax	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
r03	5	Jannsen-Jannsen combination for first and second COVID-19 vaccines	Second dose of Jannsen COVID-19 vaccine (jantwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
r03	6	Other-Other combination for first and second COVID-19 vaccines	Second dose of Novavax or Unspecified COVID-19 vaccine (othertwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
r03	7	Pfizer-Moderna combination for first and second COVID-19 vaccines	Second dose of Moderna COVID-19 vaccine	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)

Appendix F. Technical Specifications Used for this Request

r03	8	Moderna-Pfizer combination for first and second COVID-19 vaccines	Second dose of Pfizer COVID-19 vaccine	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
r03	9	Pfizer-Other combination for first and second COVID-19 vaccines	Second dose of Novavax or Unspecified COVID-19 vaccine (othertwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
r03	10	Pfizer-Jannsen combination for first and second COVID-19 vaccines	Second dose of Jannsen COVID-19 vaccine (jantwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
r03	11	Moderna-Jannsen combination for first and second COVID-19 vaccines	Second dose of Jannsen COVID-19 vaccine (jantwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)

Appendix F. Technical Specifications Used for this Request										
r03	12	Moderna-Other combination for first and second COVID-19 vaccines	Second dose of Novavax or Unspecified COVID-19 vaccine (othertwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
r03	13	Jannsen-Moderna combination for first and second COVID-19 vaccines	Second dose of Moderna COVID-19 vaccine (modernatwo_vax	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
r03	14	Jannsen-Pfizer combination for first and second COVID-19 vaccines	Second dose of Pfizer COVID-19 vaccine (pfizertwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
r03	15	Jannsen-Other combination for first and second COVID-19 vaccines	Second dose of Novavax or Unspecified COVID-19 vaccine (othertwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)

Appendix F. Technical Specifications Used for this Request										
r03	16	Other-Moderna combination for first and second COVID-19 vaccines	Second dose of Moderna COVID-19 vaccine (modernatwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
r03	17	Other-Pfizer combination for first and second COVID-19 vaccines	Second dose of Pfizer COVID-19 vaccine (pfizertwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
r03	18	Other-Jannsen combination for first and second COVID-19 vaccines	Second dose of Janssen COVID-19 vaccine (jantwo_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)

Appendix F. Technical Specifications Used for this Request									
r03	19	Claims-Claim combination for first and second COVID-19 vaccines	**Second dose of Claims only COVID-19 vaccine (claimsiis_vax)**	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
r03	20	IIS-IIS combination for first and second COVID-19 vaccines	**Second dose of IIS only COVID-19 vaccine (iisclaims_vax)**	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)

Appendix F. Technical Specifications Used for this Request

r03	21	Claim-IIS combination for first and second COVID-19 vaccines	Second dose of COVID-19 vaccine (IIS) (iisclaims_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
r03	22	IIS-Claims combination for first and second COVID-19 vaccines	Second dose of COVID-19 vaccine (Claims) (claimsiis_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)

Appendix F. Technical Specifications Used for this Request

r03	23	Claims-Claims and IIS combination for first and second COVID-19 vaccines	Second dose of COVID-19 vaccine (Claims and IIS) (bothclaimsiis_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
r03	24	IIS-IIS and Claims combination for first and second COVID-19 vaccines	Second dose of COVID-19 vaccine (IIS and Claims) (bothclaimsiis_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)

Appendix F. Technical Specifications Used for this Request										
r03	25	IIS and Claims-IIS combination for first and second COVID-19 vaccines	Second dose of COVID-19 vaccine (IIS) (iisclaims_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
r03	26	IIS and Claims-Claims combination for first and second COVID-19 vaccines	Second dose of COVID-19 vaccine (Claims) (claimsiis_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)

Appendix F. Technical Specifications Used for this Request

r03	27	IIS and Claims-IIS and Claims combination for first and second COVID-19 vaccines	Second dose of COVID-19 vaccine (IIS and Claims) (bothclaimsiis_vax)	0	N/A	Any care setting	N/A	N/A	De-duplicates occurrences of the same event code and code type on the same day	5 (Start on index date)
r04	28	Booster defined as 3rd dose in all individuals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Appendix F. Technical Specifications Used for this Request

r04	29	Booster defined as 4th dose in immunocompromised individuals	N/A	N/A	N/A	N/A	N/A	N/A	N/A
r04	30	Booster defined as 3rd dose in non-immunocompromised individuals	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Appendix F. Technical Specifications Used for this Request

r04	31	Evidence of any COVID-19 brand that specifies "booster" or "bivalent"	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360.
NDC codes are checked against First Data Bank's FDB MedKnowledge®.
N/A: Not Applicable

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

	Baseline Characteristics			
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**
Demographics				
Age (continuous, and categorical)	-	02	N/A	N/A
Sex	-	02	N/A	N/A
Race	-	02	N/A	N/A
Ethnicity	-	02	N/A	N/A
Year	-	02	N/A	N/A
COVID-19 Vaccination				
Duplicated COVID-19 vaccines (having evidence of days with COVID-19 vaccine codes within ≤4 days of first code)				
Duplicated	COVAR1	02	N/A	Any
COVID vaccine brand for the first observed record				
Pfizer at index	COVAR2	02	N/A	Any
Moderna at index	COVAR3	02	N/A	Any
Jannsen at index	COVAR4	02	N/A	Any
Novavax at index	COVAR5	02	N/A	Any
Unspecified at index	COVAR6	02	N/A	Any
Other (including Janssen, Novavax, and Unspecified) at index	COVAR7	02	N/A	N/A
Pfizer 1-4 days after the index date	COVAR8	02	N/A	Any
Moderna 1-4 days after the index date	COVAR9	02	N/A	Any
Jannsen 1-4 days after the index date	COVAR10	02	N/A	Any
Novavax 1-4 days after the index date	COVAR11	02	N/A	Any
Unspecified 1-4 days after the index date	COVAR12	02	N/A	Any
Other (including Janssen, Novavax, and Unspecified) 1-4 days after the index date	COVAR13	02	N/A	N/A
Having both Pfizer and Moderna at the index	COVAR14	02	COVAR2 and COVAR3	N/A
Having both Pfizer and Other at the index	COVAR15	02	COVAR2 and COVAR7	N/A
Having both Moderna and Other at the index	COVAR16	02	COVAR3 and COVAR7	N/A
Having both Pfizer and Moderna 1-4 days after the index date	COVAR17	02	COVAR8 and COVAR9	N/A
Having both Pfizer and Other 1-4 days after the index date	COVAR18	02	COVAR8 and COVAR13	N/A
Having both Moderna and Other 1-4 days after the index date	COVAR19	02	COVAR9 and COVAR13	N/A
COVID vaccine brand for the first observed record, With no evidence of having other brands on the same day				

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

	Baseline Characteristics			
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**
Only Pfizer at index	COVAR20	02	COVAR2 AND NOT (COVAR3 or COVAR4 or COVAR5 or COVAR6)	N/A
Only Moderna at index	COVAR21	02	COVAR3 AND NOT (COVAR2 or COVAR4 or COVAR5 or COVAR6)	N/A
Only Jannsen at index	COVAR22	02	COVAR4 AND NOT (COVAR2 or COVAR3 or COVAR5 or COVAR6)	N/A
Only Novavax at index	COVAR23	02	COVAR5 AND NOT (COVAR2 or COVAR3 or COVAR4 or COVAR6)	N/A
Only Unspecified at index	COVAR24	02	COVAR6 AND NOT (COVAR2 or COVAR3 or COVAR4 or COVAR5)	N/A
Only Other (including Janssen, Novavax, and Unspecified) at index	COVAR25	02	COVAR7 AND NOT (COVAR2 or COVAR3)	N/A
COVID vaccine code type for the first observed record				
Insurance claims data (NDC/CPT/HCPCS codes) only at index date	COVAR26	02	N/A	Any
State-based Immunization Information Systems (IIS) (CVX codes) only at index date	COVAR27	02	N/A	Any
Insurance claims data (NDC/CPT/HCPCS codes) 1-4 days after the index date	COVAR28	02	N/A	Any
State-based Immunization Information Systems (IIS) (CVX codes) 1-4 days after the index date	COVAR29	02	N/A	Any
Having both state-based Immunization Information Systems (IIS) (CVX codes) and insurance claims data (NDC/CPT/HCPCS codes) at the index date	COVAR30	02	COVAR26 and COVAR27	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

	Baseline Characteristics			
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**
Having both state-based Immunization Information Systems (IIS) (CVX codes) and insurance claims data (NDC/CPT/HCPCS codes) 1-4 days after the index date	COVAR31	02	COVAR28 and COVAR29	N/A
COVID vaccine code type for the first observed record, With no evidence of having other types of code				
Only Insurance claims data (NDC/CPT/HCPCS codes) only at index date	COVAR32	02	COVAR26 AND NOT COVAR27	N/A
Only State-based Immunization Information Systems (IIS) (CVX codes) only at index date	COVAR33	02	COVAR27 AND NOT COVAR26	N/A
COVID vaccine for the first observed record; monovalent or bivalent (only Pfizer and Moderna)				
Monovalent at index date	COVAR34	02	N/A	Any
Bivalent at index date	COVAR35	02	N/A	Any
Monovalent 1-4 days after the index date	COVAR36	02	N/A	Any
Bivalent 1-4 days after the index date	COVAR37	02	N/A	Any
Having both Monovalent and Bivalent at index date	COVAR38	02	COVAR34 and COVAR35	N/A
Having Monovalent and Bivalent 1-4 days after the index date	COVAR39	02	COVAR36 and COVAR37	N/A
COVID vaccine for the first observed record; monovalent or bivalent (only Pfizer and Moderna), With no evidence of having another type of vaccine				
Only Monovalent at index date	COVAR40	02	COVAR34 AND NOT COVAR35	N/A
Only Bivalent at index date	COVAR41	02	COVAR35 AND NOT COVAR34	N/A
COVID vaccine for the first observed record; whether the "dose1" is mentioned in the code description				
CovVax_dose1	COVAR42	02	N/A	Any
COVID vaccine for the second observed record; whether the "dose2" is mentioned in the code description				
CovVax_dose2	COVAR43	02	N/A	Any
COVID vaccine Numbers (unique days with a code associated with a vaccine)				
With at least one COVID-19 vaccine codes	COVAR44	02	N/A	Any
With at least two COVID-19 vaccine codes in two separate days	COVAR45	02	N/A	Any
With at least three COVID-19 vaccine codes in three separate days	COVAR46	02	N/A	Any
With at least four COVID-19 vaccine codes in four separate days	COVAR47	02	N/A	Any

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

	Baseline Characteristics			
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**
With one COVID-19 vaccine	COVAR48	02	COVAR44 AND NOT COVAR45	N/A
With two COVID-19 vaccine in two separate days	COVAR49	02	COVAR45 AND NOT COVAR46	N/A
With three COVID-19 vaccine in three separate days	COVAR50	02	COVAR46 AND NOT COVAR47	N/A
High-risk comorbidities for severe COVID-19 infection [2]				
Pre-index				
Reactive Airway and Lung Diseases	COVAR51	02	N/A	Any
Other Chronic Respiratory Diseases (e.g., Pneumonia and Bronchitis)	COVAR52	02	N/A	Any
Sickle Cell Disease	COVAR53	02	N/A	Any
Liver disease (severe/moderate)	COVAR54	02	N/A	Any
Tuberculosis	COVAR55	02	N/A	Any
Cystic fibrosis	COVAR56	02	N/A	Any
Congenital or Acquired Heart Disease	COVAR57	02	N/A	Any
Lung Cancer (ccw)	COVAR58	02	N/A	IP*, IS* or
	COVAR59	02	N/A	AV*, ED* OA*
	COVAR60	02	COVAR58 or COVAR59	N/A
Breast Cancer (ccw)	COVAR61	02	N/A	IP*, IS* or
	COVAR62	02	N/A	AV*, ED* OA*
	COVAR63	02	COVAR61 or COVAR62	N/A
Colorectal Cancer (ccw)	COVAR64	02	N/A	IP*, IS* or
	COVAR65	02	N/A	AV*, ED* OA*
	COVAR66	02	COVAR64 or COVAR65	N/A
Prostate Cancer (ccw)	COVAR67	02	N/A	IP*, IS* or
	COVAR68	02	N/A	AV*, ED* OA*
	COVAR69	02	COVAR67 or COVAR68	N/A
Endometrial Cancer (ccw)	COVAR70	02	N/A	IP*, IS* or

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

	Baseline Characteristics			
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**
	COVAR71	02	N/A	AV*, ED* OA*
	COVAR72	02	COVAR70 or COVAR71	N/A
Other cancer	COVAR73	02	N/A	Any
Asthma (ccw)	COVAR74	02	N/A	IP*, IS*, or
	COVAR75	02	N/A	AV*, ED* OA*
	COVAR76	02	COVAR74 or COVAR75	N/A
COPD and Bronchiectasis (ccw)	COVAR77	02	N/A	IP*, IS*, or
	COVAR78	02	N/A	AV*, ED* OA*
	COVAR79	02	COVAR77 or COVAR78	N/A
Diabetes (types 1 and 2) (ccw)	COVAR80	02	N/A	IP*, IS* or
	COVAR81	02	N/A	AV*, ED*, OA*
	COVAR82	02	COVAR80 or COVAR81	N/A
Chronic Kidney Disease (ccw)	COVAR83	02	N/A	IP*, IS*, or
	COVAR84	02	N/A	AV*, ED* OA*
	COVAR85	02	COVAR83 or COVAR84	N/A
Hypertension (ccw)	COVAR86	02	N/A	IP*, IS* or
	COVAR87	02	N/A	AV*, ED*, OA*
	COVAR88	02	COVAR86 or COVAR87	N/A
Acute Myocardial Infarction (ccw)	COVAR89	02	N/A	IPP, IPS
Atrial Fibrillation (ccw)	COVAR90	02	N/A	IPP, IPS or
	COVAR91	02	N/A	AV*, ED*, OA*
	COVAR92	02	COVAR90 or COVAR91	N/A
Heart Failure (ccw)	COVAR93	02	N/A	IP*, AV*, ED*, OA*

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

	Baseline Characteristics			
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**
Ischemic Heart Disease (ccw)	COVAR94	02	N/A	Any
Stroke/Transient Ischemic Attack (TIA) (ccw)	COVAR95	02	N/A	IP*
	COVAR96	02	N/A	AV*, ED*, OA*
	COVAR97	02	COVAR95 or COVAR96	N/A
History of Cardiac Arrest	COVAR98	02	N/A	Any
History of Coronary Angioplasty or Bypass	COVAR99	02	N/A	Any
Alzheimer's disease, dementia, and conditions (ccw)	COVAR100	02	N/A	Any
Depression (ccw)	COVAR101	02	N/A	Any
Bipolar, or Other Depressive Mood Disorders	COVAR102	02	N/A	Any
ADHD	COVAR103	02	N/A	Any
Cerebral palsy	COVAR104	02	N/A	Any
Spinal cord injuries	COVAR105	02	N/A	Any
Down syndrome	COVAR106	02	N/A	Any
Alcohol Abuse or Dependence	COVAR107	02	N/A	Any
Drug Abuse or Dependence	COVAR108	02	N/A	Any
Obesity: diagnosed or identified by weight management procedures	COVAR109	02	N/A	Any
Obesity: identified by weight management-related prescriptions	COVAR110	02	N/A	Any
Overweight	COVAR111	02	N/A	Any
Obesity/overweight	COVAR112	02	COVAR109 or COVAR110 or COVAR111	N/A
Smoking: diagnosed or identified by smoking cessation procedures	COVAR113	02	N/A	Any
Smoking: identified by smoking-related prescriptions	COVAR114	02	N/A	Any
Smoking	COVAR115	02	COVAR113 or COVAR114	N/A
HIV/AIDS	COVAR116	02	N/A	Any
Hematological Malignancy	COVAR117	02	N/A	Any
Treatment-Independent Immune Deficiencies	COVAR118	02	N/A	Any
Dialysis	COVAR119	02	N/A	Any
Chemo Therapeutic Agents/ Diagnoses and Procedures	COVAR120	02	N/A	Any
Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures	COVAR121	02	N/A	Any

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

			Baseline Characteristics	
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**
Steroid/Corticosteroid Diagnoses and Procedures and Dispensing	COVAR122	02	N/A	Any
Organ Transplant Diagnoses and Procedures	COVAR123	02	N/A	Any
Solid Malignancies	COVAR124	02	N/A	Any
Immunocompromised	COVAR125	02	COVAR116 or COVAR117 or COVAR118 or COVAR119 or COVAR120 or COVAR121 or COVAR122 or COVAR123 or COVAR124	N/A
Other general Health Indicators [2]				
Pre-index				
Hyperlipidemia (ccw)	COVAR126	02	N/A	IP*, IS* or
	COVAR127	02	N/A	AV*, ED*, OA*
	COVAR128	02	COVAR126 or COVAR127	N/A
Rheumatoid Arthritis/Osteoarthritis (ccw)	COVAR129	02	N/A	Any
Acquired Hypothyroidism (ccw)	COVAR130	02	N/A	IP*, IS*, or
	COVAR131	02	N/A	AV*, ED* OA*
	COVAR132	02	COVAR130 or COVAR131	N/A
Glaucoma (ccw)	COVAR133	02	N/A	AV*, ED*, OA*
Osteoporosis (ccw)	COVAR134	02	N/A	IP*, IS*, or
	COVAR135	02	N/A	AV*, ED* OA*
	COVAR136	02	COVAR134 or COVAR135	N/A
Anemia (ccw)	COVAR137	02	N/A	Any
Benign Prostatic Hyperplasia (ccw)	COVAR138	02	N/A	IP*, IS*, or
	COVAR139	02	N/A	AV*, ED* OA*

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

	Baseline Characteristics			
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**
	COVAR140	02	COVAR138 or COVAR139	N/A
Hip/Pelvic Fracture (ccw)	COVAR141	02	N/A	Any
Cataract (ccw)	COVAR142	02	N/A	AV*, ED*, OA*
Parkinson's Disease and Secondary Parkinsonism (ccw)	COVAR143	02	N/A	IP*, IS*, or
	COVAR144	02	N/A	AV*, ED* OA*
	COVAR145	02	COVAR143 or COVAR144	N/A
COVID-19 diagnosis/Treatments				
Pre-index				
COVID-19 diagnosis	COVAR146	02	N/A	Any
Lopinavir/Ritonavir	COVAR147	02	N/A	Any
Remdesivir	COVAR148	02	N/A	Any
Hydroxychloroquine	COVAR149	02	N/A	Any
Chloroquine	COVAR150	02	N/A	Any
Azithromycin	COVAR151	02	N/A	Any
Ivermectin	COVAR152	02	N/A	Any
Dexamethasone	COVAR153	02	N/A	Any
Other Corticosteroids	COVAR154	02	N/A	Any
Inhaled Corticosteroids	COVAR155	02	N/A	Any
Paxlovid	COVAR156	02	N/A	Any
Baricitinib	COVAR157	02	N/A	Any
Tocilizumab	COVAR158	02	N/A	Any
Bamlanivimab	COVAR159	02	N/A	Any
Casirivimab/Imdevimab	COVAR160	02	N/A	Any
Bamlanivimab/Etesevimab	COVAR161	02	N/A	Any
Sotrovimab	COVAR162	02	N/A	Any
NSAIDs	COVAR163	02	N/A	Any
Antidepressants	COVAR164	02	N/A	Any
Post-index				
COVID-19 diagnosis	COVAR165	02	N/A	Any
Lopinavir/Ritonavir	COVAR166	02	N/A	Any

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

	Baseline Characteristics			
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**
Remdesivir	COVAR167	02	N/A	Any
Hydroxychloroquine	COVAR168	02	N/A	Any
Chloroquine	COVAR169	02	N/A	Any
Azithromycin	COVAR170	02	N/A	Any
Ivermectin	COVAR171	02	N/A	Any
Dexamethasone	COVAR172	02	N/A	Any
Other Corticosteroids	COVAR173	02	N/A	Any
Inhaled Corticosteroids	COVAR174	02	N/A	Any
Paxlovid	COVAR175	02	N/A	Any
Baricitinib	COVAR176	02	N/A	Any
Tocilizumab	COVAR177	02	N/A	Any
Bamlanivimab	COVAR178	02	N/A	Any
Casirivimab/Imdevimab	COVAR179	02	N/A	Any
Bamlanivimab/Etesevimab	COVAR180	02	N/A	Any
Sotrovimab	COVAR181	02	N/A	Any
NSAIDs	COVAR182	02	N/A	Any
Antidepressants	COVAR183	02	N/A	Any
Comorbidity score				
Charlson/Elixhauser comorbidity scores		02	N/A	Any
Health Service Utilization Intensity Metrics				
Mean number of ambulatory encounters	-	02	N/A	AV*
Mean number of emergency room encounters	-	02	N/A	ED*
Mean number of inpatient hospital encounters	-	02	N/A	IP*
Mean number of non-acute institutional encounters	-	02	N/A	IS*
Mean number of other ambulatory encounters	-	02	N/A	OA*
Mean number of filled prescriptions	-	02	N/A	N/A
Mean number of generics dispensed	-	02	N/A	N/A
Mean number of unique drug classes dispensed	-	02	N/A	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

	Baseline Characteristics			
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**

***The wildcard symbol (*) can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.**
The (P) at the end of the care setting refers to the primary diagnosis position, while the (S) refers to the secondary diagnosis position. This indicates that only the first or second diagnosis on the claims should be used for specified codes. For example, IPP (Inpatient Primary) uses the first diagnosis position, and IPS (Inpatient Scondary) uses the second diagnosis position.

[1]Caresetting/ Principal Diagnosis
Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

[2] Specified chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse (CCW) algorithms.

Reference: Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. https://www.ccwdata.org/web/guest/condition-categories

N/A: Not Applicable

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

Baseline Characteristics					
Code Category	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
Demographics					
N/A	0	0	N/A	N/A	N/A
N/A	0	0	N/A	N/A	N/A
N/A	0	0	N/A	N/A	N/A
N/A	0	0	N/A	N/A	N/A
N/A	0	0	N/A	N/A	N/A
COVID-19 Vaccination					
Duplicated COVID-19 vaccines (having evidence of days with COVID-19 vaccine codes within ≤4 days of first code)					
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1	4	No	1	N/A
COVID vaccine brand for the first observed record					
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

Baseline Characteristics					
Code Category	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
N/A	0	0	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1	4	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1	4	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1	4	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1	4	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1	4	N/A	1	N/A
N/A	1	4	N/A	1	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

Baseline Characteristics					
Code Category	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
COVID vaccine brand for the first observed record, With no evidence of having other brands on the same day					
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
COVID vaccine code type for the first observed record					
*Drug Code	0	0	N/A	1	N/A
*Procedure Code (CPT/HCPCS codes)					
*Procedure Code (CVX)	0	0	N/A	1	N/A
*Drug Code	1	4	N/A	1	N/A
*Procedure Code (CPT/HCPCS codes)					
*Procedure Code (CVX)	1	4	N/A	1	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

Baseline Characteristics					
Code Category	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
COVID vaccine code type for the first observed record, With no evidence of having other types of code					
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
COVID vaccine for the first observed record; monovalent or bivalent (only Pfizer and Moderna)					
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1	4	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	1	4	N/A	1	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

Baseline Characteristics					
Code Category	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
COVID vaccine for the first observed record; monovalent or bivalent (only Pfizer and Moderna), With no evidence of having another type of vaccine					
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
COVID vaccine for the first observed record; whether the "dose1" is mentioned in the code description					
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
COVID vaccine for the second observed record; whether the "dose2" is mentioned in the code description					
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	5	latest available data	N/A	1	N/A
*Procedure Code (CPT/HCPCS codes)					

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

Baseline Characteristics					
Code Category	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
*Procedure Code (CVX)	0	latest available data	N/A	1	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	latest available data	N/A	2	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	latest available data	N/A	3	N/A
*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	latest available data	N/A	4	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
N/A	N/A	N/A	N/A	N/A	N/A
High-risk comorbidities for severe COVID-19 infection					
Pre-index					
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

Baseline Characteristics					
Code Category	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

Baseline Characteristics					
Code Category	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	Earliest available data	0	N/A	1	N/A
*Diagnosis/procedure Codes	Earliest available data	0	N/A	1	N/A
*Diagnosis/procedure Codes	Earliest available data	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Drug Code	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Drug codes	-183	0	N/A	1	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

Baseline Characteristics					
Code Category	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
*Diagnosis/procedure Codes *Drug codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes *Drug codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes *Drug codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
N/A	N/A	N/A	N/A	N/A	N/A
Other general Health Indicators [2]					
Pre-index					
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Diagnosis/procedure Codes	-183	0	N/A	2	N/A
N/A	N/A	N/A	N/A	N/A	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

Baseline Characteristics					
Code Category	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
COVID-19 diagnosis/Treatments					
Pre-index					
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
*Drug/procedure Codes	-183	0	No	1	N/A
Post-index					
*Diagnosis/procedure Codes	1	183	N/A	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

Baseline Characteristics					
Code Category	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
*Drug/procedure Codes	1	183	No	1	N/A
Comorbidity score					
*Diagnosis/procedure Codes	-183	0	N/A	1	N/A
Health Service Utilization Intensity Metrics					
N/A	-183	0	N/A	N/A	N/A
N/A	-183	0	N/A	N/A	N/A
N/A	-183	0	N/A	N/A	N/A
N/A	-183	0	N/A	N/A	N/A
N/A	-183	0	N/A	N/A	N/A
N/A	-183	0	N/A	N/A	N/A
N/A	-183	0	N/A	N/A	N/A
N/A	-183	0	N/A	N/A	N/A

***The wildcard symbol (*) can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.**
The (P) at the end of the care setting refers to the primary diagnosis position, while the (S) refers to the secondary diagnosis position. This indicates that only the first or second diagnosis on the claims should be used for specified codes. For example, IPP (Inpatient Primary) uses the first diagnosis position, and IPS (Inpatient Scondary) uses the second diagnosis position.

[1]Caresetting/ Principal Diagnosis

Appendix G r01. Specifications Defining Parameters for Baseline Characteristics for run01 for this Request

Baseline Characteristics					
Code Category	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.
Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

[2] Specified chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse (CCW) algorithms.
Reference: Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. https://www.ccwdata.org/web/guest/condition-categories

N/A: Not Applicable

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start	Evaluation period end
Demographics							
Age (continuous, and categorical)	-	02	N/A	N/A	N/A	0	0
Sex	-	02	N/A	N/A	N/A	0	0
Race	-	02	N/A	N/A	N/A	0	0
Ethnicity	-	02	N/A	N/A	N/A	0	0
Year	-	02	N/A	N/A	N/A	0	0
COVID-19 Vaccination							
COVID vaccine brand for the first observed record							
Pfizer at index	COVAR2	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0
Moderna at index	COVAR3	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0
Jannsen at index	COVAR4	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0
Novavax at index	COVAR5	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0
Unspecified at index	COVAR6	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0
Other (including Janssen, Novavax, and Unspecified) at index	COVAR7	02	N/A	N/A	N/A	0	0
Having both Pfizer and Moderna at the index	COVAR14	02	COVAR2 and COVAR3	N/A	N/A	N/A	N/A
Having both Pfizer and Other at the index	COVAR15	02	COVAR2 and COVAR7	N/A	N/A	N/A	N/A
Having both Moderna and Other at the index	COVAR16	02	COVAR3 and COVAR7	N/A	N/A	N/A	N/A

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start	Evaluation period end
COVID vaccine brand for the first observed record, With no evidence of having other brands on the same day							
Only Pfizer at index	COVAR20	02	COVAR2 AND NOT (COVAR3 or COVAR4 or COVAR5 or COVAR6)	N/A	N/A	N/A	N/A
Only Moderna at index	COVAR21	02	COVAR3 AND NOT (COVAR2 or COVAR4 or COVAR5 or COVAR6)	N/A	N/A	N/A	N/A
Only Jannsen at index	COVAR22	02	COVAR4 AND NOT (COVAR2 or COVAR3 or COVAR5 or COVAR6)	N/A	N/A	N/A	N/A
Only Novavax at index	COVAR23	02	COVAR5 AND NOT (COVAR2 or COVAR3 or COVAR4 or COVAR6)	N/A	N/A	N/A	N/A
Only Unspecified at index	COVAR24	02	COVAR6 AND NOT (COVAR2 or COVAR3 or COVAR4 or COVAR5)	N/A	N/A	N/A	N/A
Only Other (including Janssen, Novavax, and Unspecified) at index	COVAR25	02	COVAR7 AND NOT (COVAR2 or COVAR3)	N/A	N/A	N/A	N/A
COVID vaccine code type for the first observed record							

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start	Evaluation period end
Insurance claims data (NDC/CPT/HCPCS codes) only at index date	COVAR26	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes)	0	0
State-based Immunization Information Systems (IIS) (CVX codes) only at index date	COVAR27	02	N/A	Any	*Procedure Code (CVX)	0	0
Having both state-based Immunization Information Systems (IIS) (CVX codes) and insurance claims data (NDC/CPT/HCPCS codes) at the index date	COVAR30	02	COVAR26 and COVAR27	N/A	N/A	N/A	N/A
COVID vaccine code type for the first observed record, With no evidence of having other types of code							
Only Insurance claims data (NDC/CPT/HCPCS codes) only at index date	COVAR32	02	COVAR26 AND NOT COVAR27	N/A	N/A	N/A	N/A
Only State-based Immunization Information Systems (IIS) (CVX codes) only at index date	COVAR33	02	COVAR27 AND NOT COVAR26	N/A	N/A	N/A	N/A
COVID vaccine for the first observed record; monovalent or bivalent (only Pfizer and Moderna)							
Monovalent at index date	COVAR34	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0
Bivalent at index date	COVAR35	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0
Having both Monovalent and Bivalent at index date	COVAR38	02	COVAR34 and COVAR35	N/A	N/A	N/A	N/A

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start	Evaluation period end
COVID vaccine for the first observed record; monovalent or bivalent (only Pfizer and Moderna), With no evidence of having another type of vaccine							
Only Monovalent at index date	COVAR40	02	COVAR34 AND NOT COVAR35	N/A	N/A	N/A	N/A
Only Bivalent at index date	COVAR41	02	COVAR35 AND NOT COVAR34	N/A	N/A	N/A	N/A
COVID vaccine for the first observed record; whether the "dose1" is mentioned in the code description							
CovVax_dose1	COVAR42	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0
COVID vaccine for the second observed record; whether the "dose2" is mentioned in the code description							
CovVax_dose2	COVAR43	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	5	latest available data
COVID vaccine Numbers (unique days with a code associated with a vaccine)					*Procedure Code (CPT/HCPCS codes)		
With at least one COVID-19 vaccine codes	COVAR44	02	N/A	Any	*Procedure Code (CVX)	0	latest available data

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start	Evaluation period end
With at least two COVID-19 vaccine codes in two separate days	COVAR45	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	latest available data
With at least three COVID-19 vaccine codes in three separate days	COVAR46	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	latest available data
With at least four COVID-19 vaccine codes in four separate days	COVAR47	02	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	latest available data
With one COVID-19 vaccine	COVAR48	02	COVAR44 AND NOT COVAR45	N/A	N/A	N/A	N/A
With two COVID-19 vaccine in two separate days	COVAR49	02	COVAR45 AND NOT COVAR46	N/A	N/A	N/A	N/A
With three COVID-19 vaccine in three separate days	COVAR50	02	COVAR46 AND NOT COVAR47	N/A	N/A	N/A	N/A
High-risk comorbidities for severe COVID-19 infection [2]							
Pre-index							
Reactive Airway and Lung Diseases	COVAR51	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Other Chronic Respiratory Diseases (e.g., Pneumonia and Bronchitis)	COVAR52	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Sickle Cell Disease	COVAR53	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Liver disease (severe/moderate)	COVAR54	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Tuberculosis	COVAR55	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Cystic fibrosis	COVAR56	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Congenital or Acquired Heart Disease	COVAR57	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Lung Cancer (ccw)	COVAR58	02	N/A	IP*, IS* or	*Diagnosis/procedure Codes	-183	0
	COVAR59	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183	0
	COVAR60	02	COVAR58 or COVAR59	N/A	N/A	N/A	N/A
Breast Cancer (ccw)	COVAR61	02	N/A	IP*, IS* or	*Diagnosis/procedure Codes	-183	0
	COVAR62	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183	0
	COVAR63	02	COVAR61 or COVAR62	N/A	N/A	N/A	N/A
Colorectal Cancer (ccw)	COVAR64	02	N/A	IP*, IS* or	*Diagnosis/procedure Codes	-183	0
	COVAR65	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183	0
	COVAR66	02	COVAR64 or COVAR65	N/A	N/A	N/A	N/A

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start	Evaluation period end
Prostate Cancer (ccw)	COVAR67	02	N/A	IP*, IS* or	*Diagnosis/procedure Codes	-183	0
	COVAR68	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183	0
	COVAR69	02	COVAR67 or COVAR68	N/A	N/A	N/A	N/A
Endometrial Cancer (ccw)	COVAR70	02	N/A	IP*, IS* or	*Diagnosis/procedure Codes	-183	0
	COVAR71	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183	0
	COVAR72	02	COVAR70 or COVAR71	N/A	N/A	N/A	N/A
Other cancer	COVAR73	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Asthma (ccw)	COVAR74	02	N/A	IP*, IS*, or	*Diagnosis/procedure Codes	-183	0
	COVAR75	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183	0
	COVAR76	02	COVAR74 or COVAR75	N/A	N/A	N/A	N/A
COPD and Bronchiectasis (ccw)	COVAR77	02	N/A	IP*, IS*, or	*Diagnosis/procedure Codes	-183	0
	COVAR78	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183	0
	COVAR79	02	COVAR77 or COVAR78	N/A	N/A	N/A	N/A
Diabetes (types 1 and 2) (ccw)	COVAR80	02	N/A	IP*, IS* or	*Diagnosis/procedure Codes	-183	0
	COVAR81	02	N/A	AV*, ED*, OA*	*Diagnosis/procedure Codes	-183	0
	COVAR82	02	COVAR80 or COVAR81	N/A	N/A	N/A	N/A
Chronic Kidney Disease (ccw)	COVAR83	02	N/A	IP*, IS*, or	*Diagnosis/procedure Codes	-183	0
	COVAR84	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183	0
	COVAR85	02	COVAR83 or COVAR84	N/A	N/A	N/A	N/A
Hypertension (ccw)	COVAR86	02	N/A	IP*, IS* or	*Diagnosis/procedure Codes	-183	0
	COVAR87	02	N/A	AV*, ED*, OA*	*Diagnosis/procedure Codes	-183	0
	COVAR88	02	COVAR86 or COVAR87	N/A	N/A	N/A	N/A
Acute Myocardial Infarction (ccw)	COVAR89	02	N/A	IPP, IPS	*Diagnosis/procedure Codes	-183	0
Atrial Fibrillation (ccw)	COVAR90	02	N/A	IPP, IPS or	*Diagnosis/procedure Codes	-183	0
	COVAR91	02	N/A	AV*, ED*, OA*	*Diagnosis/procedure Codes	-183	0
	COVAR92	02	COVAR90 or COVAR91	N/A	N/A	N/A	N/A
Heart Failure (ccw)	COVAR93	02	N/A	IP*, AV*, ED*, OA*	*Diagnosis/procedure Codes	-183	0

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start	Evaluation period end
Ischemic Heart Disease (ccw)	COVAR94	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Stroke/Transient Ischemic Attack (TIA) (ccw)	COVAR95	02	N/A	IP*	*Diagnosis/procedure Codes	-183	0
	COVAR96	02	N/A	AV*, ED*, OA*	*Diagnosis/procedure Codes	-183	0
	COVAR97	02	COVAR95 or COVAR96	N/A	N/A	N/A	N/A
History of Cardiac Arrest	COVAR98	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
History of Coronary Angioplasty or Bypass	COVAR99	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Alzheimer's disease, dementia, and conditions (ccw)	COVAR100	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Depression (ccw)	COVAR101	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Bipolar, or Other Depressive Mood Disorders	COVAR102	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
ADHD	COVAR103	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Cerebral palsy	COVAR104	02	N/A	Any	*Diagnosis/procedure Codes	Earliest available data	0
Spinal cord injuries	COVAR105	02	N/A	Any	*Diagnosis/procedure Codes	Earliest available data	0
Down syndrome	COVAR106	02	N/A	Any	*Diagnosis/procedure Codes	Earliest available data	0
Alcohol Abuse or Dependence	COVAR107	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Drug Abuse or Dependence	COVAR108	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Obesity: diagnosed or identified by weight management procedures	COVAR109	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Obesity: identified by weight management-related prescriptions	COVAR110	02	N/A	Any	*Drug Code	-183	0
Overweight	COVAR111	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Obesity/overweight	COVAR112	02	COVAR109 or COVAR110 or COVAR111	N/A	N/A	N/A	N/A
Smoking: diagnosed or identified by smoking cessation procedures	COVAR113	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Smoking: identified by smoking-related prescriptions	COVAR114	02	N/A	Any	*Drug codes	-183	0
Smoking	COVAR115	02	COVAR113 or COVAR114	N/A	N/A	N/A	N/A
HIV/AIDS	COVAR116	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Hematological Malignancy	COVAR117	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Treatment-Independent Immune Deficiencies	COVAR118	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Dialysis	COVAR119	02	N/A	Any	*Diagnosis/procedure Codes	-183	0

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start	Evaluation period end
Chemo Therapeutic Agents/ Diagnoses and Procedures	COVAR120	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures	COVAR121	02	N/A	Any	*Diagnosis/procedure Codes *Drug codes	-183	0
Steroid/Corticosteroid Diagnoses and Procedures and Dispensing	COVAR122	02	N/A	Any	*Diagnosis/procedure Codes *Drug codes	-183	0
Organ Transplant Diagnoses and Procedures	COVAR123	02	N/A	Any	*Diagnosis/procedure Codes *Drug codes	-183	0
Solid Malignancies	COVAR124	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Immunocompromised	COVAR125	02	COVAR116 or COVAR117 or COVAR118 or COVAR119 or COVAR120 or COVAR121 or COVAR122 or COVAR123 or COVAR124	N/A	N/A	N/A	N/A
Other general Health Indicators [2]							
Pre-index							
Hyperlipidemia (ccw)	COVAR126	02	N/A	IP*, IS* or	*Diagnosis/procedure Codes	-183	0
	COVAR127	02	N/A	AV*, ED*, OA*	*Diagnosis/procedure Codes	-183	0
	COVAR128	02	COVAR126 or COVAR127	N/A	N/A	N/A	N/A
Rheumatoid Arthritis/Osteoarthritis (ccw)	COVAR129	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Acquired Hypothyroidism (ccw)	COVAR130	02	N/A	IP*, IS*, or	*Diagnosis/procedure Codes	-183	0
	COVAR131	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183	0
	COVAR132	02	COVAR130 or COVAR131	N/A	N/A	N/A	N/A
Glaucoma (ccw)	COVAR133	02	N/A	AV*, ED*, OA*	*Diagnosis/procedure Codes	-183	0
Osteoporosis (ccw)	COVAR134	02	N/A	IP*, IS*, or	*Diagnosis/procedure Codes	-183	0
	COVAR135	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183	0
	COVAR136	02	COVAR134 or COVAR135	N/A	N/A	N/A	N/A
Anemia (ccw)	COVAR137	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Benign Prostatic Hyperplasia (ccw)	COVAR138	02	N/A	IP*, IS*, or	*Diagnosis/procedure Codes	-183	0
	COVAR139	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183	0

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start	Evaluation period end
	COVAR140	02	COVAR138 or COVAR139	N/A	N/A	N/A	N/A
Hip/Pelvic Fracture (ccw)	COVAR141	02	N/A	Any	*Diagnosis/procedure Code	-183	0
Cataract (ccw)	COVAR142	02	N/A	AV*, ED*, OA*	*Diagnosis/procedure Codes	-183	0
Parkinson's Disease and Secondary Parkinsonism (ccw)	COVAR143	02	N/A	IP*, IS*, or	*Diagnosis/procedure Codes	-183	0
	COVAR144	02	N/A	AV*, ED* OA*	*Diagnosis/procedure Codes	-183	0
	COVAR145	02	COVAR143 or COVAR144	N/A	N/A	N/A	N/A
COVID-19 diagnosis/Treatments							
Pre-index							
COVID-19 diagnosis	COVAR146	02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Lopinavir/Ritonavir	COVAR147	02	N/A	Any	*Drug/procedure Codes	-183	0
Remdesivir	COVAR148	02	N/A	Any	*Drug/procedure Codes	-183	0
Hydroxychloroquine	COVAR149	02	N/A	Any	*Drug/procedure Codes	-183	0
Chloroquine	COVAR150	02	N/A	Any	*Drug/procedure Codes	-183	0
Azithromycin	COVAR151	02	N/A	Any	*Drug/procedure Codes	-183	0
Ivermectin	COVAR152	02	N/A	Any	*Drug/procedure Codes	-183	0
Dexamethasone	COVAR153	02	N/A	Any	*Drug/procedure Codes	-183	0
Other Corticosteroids	COVAR154	02	N/A	Any	*Drug/procedure Codes	-183	0
Inhaled Corticosteroids	COVAR155	02	N/A	Any	*Drug/procedure Codes	-183	0
Paxlovid	COVAR156	02	N/A	Any	*Drug/procedure Codes	-183	0
Baricitinib	COVAR157	02	N/A	Any	*Drug/procedure Codes	-183	0
Tocilizumab	COVAR158	02	N/A	Any	*Drug/procedure Codes	-183	0
Bamlanivimab	COVAR159	02	N/A	Any	*Drug/procedure Codes	-183	0
Casirivimab/Imdevimab	COVAR160	02	N/A	Any	*Drug/procedure Codes	-183	0
Bamlanivimab/Etesevimab	COVAR161	02	N/A	Any	*Drug/procedure Codes	-183	0
Sotrovimab	COVAR162	02	N/A	Any	*Drug/procedure Codes	-183	0
NSAIDs	COVAR163	02	N/A	Any	*Drug/procedure Codes	-183	0
Antidepressants	COVAR164	02	N/A	Any	*Drug/procedure Codes	-183	0
Post-index							
COVID-19 diagnosis	COVAR165	02	N/A	Any	*Diagnosis/procedure Codes	1	183
Lopinavir/Ritonavir	COVAR166	02	N/A	Any	*Drug/procedure Codes	1	183
Remdesivir	COVAR167	02	N/A	Any	*Drug/procedure Codes	1	183
Hydroxychloroquine	COVAR168	02	N/A	Any	*Drug/procedure Codes	1	183
Chloroquine	COVAR169	02	N/A	Any	*Drug/procedure Codes	1	183
Azithromycin	COVAR170	02	N/A	Any	*Drug/procedure Codes	1	183
Ivermectin	COVAR171	02	N/A	Any	*Drug/procedure Codes	1	183
Dexamethasone	COVAR172	02	N/A	Any	*Drug/procedure Codes	1	183
Other Corticosteroids	COVAR173	02	N/A	Any	*Drug/procedure Codes	1	183
Inhaled Corticosteroids	COVAR174	02	N/A	Any	*Drug/procedure Codes	1	183
Paxlovid	COVAR175	02	N/A	Any	*Drug/procedure Codes	1	183
Baricitinib	COVAR176	02	N/A	Any	*Drug/procedure Codes	1	183
Tocilizumab	COVAR177	02	N/A	Any	*Drug/procedure Codes	1	183
Bamlanivimab	COVAR178	02	N/A	Any	*Drug/procedure Codes	1	183
Casirivimab/Imdevimab	COVAR179	02	N/A	Any	*Drug/procedure Codes	1	183
Bamlanivimab/Etesevimab	COVAR180	02	N/A	Any	*Drug/procedure Codes	1	183

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start	Evaluation period end
Sotrovimab	COVAR181	02	N/A	Any	*Drug/procedure Codes	1	183
NSAIDs	COVAR182	02	N/A	Any	*Drug/procedure Codes	1	183
Antidepressants	COVAR183	02	N/A	Any	*Drug/procedure Codes	1	183
Comorbidity Score							
Charlson/Elixhauser comorbidity scores		02	N/A	Any	*Diagnosis/procedure Codes	-183	0
Health Service Utilization Intensity Metrics							
Mean number of ambulatory encounters	-	02	N/A	AV*	N/A	-183	0
Mean number of emergency room encounters	-	02	N/A	ED*	N/A	-183	0
Mean number of inpatient hospital encounters	-	02	N/A	IP*	N/A	-183	0
Mean number of non-acute institutional encounters	-	02	N/A	IS*	N/A	-183	0
Mean number of other ambulatory encounters	-	02	N/A	OA*	N/A	-183	0
Mean number of filled prescriptions	-	02	N/A	N/A	N/A	-183	0
Mean number of generics dispensed	-	02	N/A	N/A	N/A	-183	0
Mean number of unique drug classes dispensed	-	02	N/A	N/A	N/A	-183	0

***The wildcard symbol (*) can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.**

[1]Caresetting/ Principal Diagnosis

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) **-** diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

~ Specified chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse (CCW) algorithms.

Reference: Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. https://www.ccwdata.org/web/guest/condition-categories

N/A: Not Applicable

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
Demographics										
Age (continuous, and categorical)	-	N/A	N/A	N/A	N/A	N/A	N/A	N/A	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
Sex	-	N/A	N/A	N/A	N/A	N/A	N/A	N/A		
Race	-	N/A	N/A	N/A	N/A	N/A	N/A	N/A		
Ethnicity	-	N/A	N/A	N/A	N/A	N/A	N/A	N/A		
Year	-	N/A	N/A	N/A	N/A	N/A	N/A	N/A		
COVID-19 Vaccination										
COVID vaccine brand for the first observed record					Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
Pfizer at index	COVAR2	N/A	1	N/A						
Moderna at index	COVAR3	N/A	1	N/A						
Jannsen at index	COVAR4	N/A	1	N/A						
Novavax at index	COVAR5	N/A	1	N/A						
Unspecified at index	COVAR6	N/A	1	N/A						
Other (including Janssen, Novavax, and Unspecified) at index	COVAR7	N/A	1	N/A						
Having both Pfizer and Moderna at the index	COVAR14	N/A	N/A	N/A						
Having both Pfizer and Other at the index	COVAR15	N/A	N/A	N/A						
Having both Moderna and Other at the index	COVAR16	N/A	N/A	N/A						

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
COVID vaccine brand for the first observed record, With no evidence of having other brands on the same day					Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
Only Pfizer at index	COVAR20	N/A	N/A	N/A						
Only Moderna at index	COVAR21	N/A	N/A	N/A						
Only Jannsen at index	COVAR22	N/A	N/A	N/A						
Only Novavax at index	COVAR23	N/A	N/A	N/A						
Only Unspecified at index	COVAR24	N/A	N/A	N/A						
Only Other (including Janssen, Novavax, and Unspecified) at index	COVAR25	N/A	N/A	N/A						
COVID vaccine code type for the first observed record					Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
Insurance claims data (NDC/CPT/HCPCS codes) only at index date	COVAR26	N/A	1	N/A						

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**	**Minimum cumulative dose**	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
State-based Immunization Information Systems (IIS) (CVX codes) only at index date	COVAR27	N/A	1	N/A						
Having both state-based Immunization Information Systems (IIS) (CVX codes) and insurance claims data (NDC/CPT/HCPCS codes) at the index date	COVAR30	N/A	N/A	N/A						
COVID vaccine code type for the first observed record, With no evidence of having other types of code					Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
Only Insurance claims data (NDC/CPT/HCPCS codes) only at index date	COVAR32	N/A	N/A	N/A						
Only State-based Immunization Information Systems (IIS) (CVX codes) only at index date	COVAR33	N/A	N/A	N/A						

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
COVID vaccine for the first observed record; monovalent or bivalent (only Pfizer and Moderna)					Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
Monovalent at index date	COVAR34	N/A	1	N/A						
Bivalent at index date	COVAR35	N/A	1	N/A						
Having both Monovalent and Bivalent at index date	COVAR38	N/A	N/A	N/A						
COVID vaccine for the first observed record; monovalent or bivalent (only Pfizer and Moderna), With no evidence of having another type of vaccine					Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
Only Monovalent at index date	COVAR40	N/A	N/A	N/A						
Only Bivalent at index date	COVAR41	N/A	N/A	N/A						

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
COVID vaccine for the first observed record; whether the "dose1" is mentioned in the code description					Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
CovVax_dose1	COVAR42	N/A	1	N/A						
COVID vaccine for the second observed record; whether the "dose2" is mentioned in the code description					Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
CovVax_dose2	COVAR43	N/A	1	N/A						
COVID vaccine Numbers (unique days with a code associated with a vaccine)										
With at least one COVID-19 vaccine codes	COVAR44	N/A	1	N/A						
With at least two COVID-19 vaccine codes in two separate days	COVAR45	N/A	2	N/A						
With at least three COVID-19 vaccine codes in three separate days	COVAR46	N/A	3	N/A						

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
With at least four COVID-19 vaccine codes in four separate days	COVAR47	N/A	4	N/A						
With one COVID-19 vaccine	COVAR48	N/A	N/A	N/A						
With two COVID-19 vaccine in two separate days	COVAR49	N/A	N/A	N/A						
With three COVID-19 vaccine in three separate days	COVAR50	N/A	N/A	N/A						
High-risk comorbidities for severe COVID-19 infection [2]										
Pre-index										
Reactive Airway and Lung Diseases	COVAR51	N/A	1	N/A						
Other Chronic Respiratory Diseases (e.g., Pneumonia and Bronchitis)	COVAR52	N/A	1	N/A						
Sickle Cell Disease	COVAR53	N/A	1	N/A						
Liver disease (severe/moderate)	COVAR54	N/A	1	N/A						
Tuberculosis	COVAR55	N/A	1	N/A						
Cystic fibrosis	COVAR56	N/A	1	N/A						
Congenital or Acquired Heart Disease	COVAR57	N/A	1	N/A						
Lung Cancer (ccw)	COVAR58	N/A	1	N/A						
	COVAR59	N/A	2	N/A						
	COVAR60	N/A	N/A	N/A						
Breast Cancer (ccw)	COVAR61	N/A	1	N/A						
	COVAR62	N/A	2	N/A						
	COVAR63	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Colorectal Cancer (ccw)	COVAR64	N/A	1	N/A						
	COVAR65	N/A	2	N/A						
	COVAR66	N/A	N/A	N/A						
Prostate Cancer (ccw)	COVAR67	N/A	1	N/A						
	COVAR68	N/A	2	N/A						
	COVAR69	N/A	N/A	N/A						
Endometrial Cancer (ccw)	COVAR70	N/A	1	N/A						

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**	**Minimum cumulative dose**	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
	COVAR71	N/A	2	N/A						
	COVAR72	N/A	N/A	N/A						
Other cancer	COVAR73	N/A	1	N/A						
Asthma (ccw)	COVAR74	N/A	1	N/A						
	COVAR75	N/A	2	N/A						
	COVAR76	N/A	N/A	N/A						
COPD and Bronchiectasis (ccw)	COVAR77	N/A	1	N/A						
	COVAR78	N/A	2	N/A						
	COVAR79	N/A	N/A	N/A						
Diabetes (types 1 and 2) (ccw)	COVAR80	N/A	1	N/A						
	COVAR81	N/A	2	N/A						
	COVAR82	N/A	N/A	N/A						
Chronic Kidney Disease (ccw)	COVAR83	N/A	1	N/A						
	COVAR84	N/A	2	N/A						
	COVAR85	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Hypertension (ccw)	COVAR86	N/A	1	N/A						
	COVAR87	N/A	2	N/A						
	COVAR88	N/A	N/A	N/A						
Acute Myocardial Infarction (ccw)	COVAR89	N/A	1	N/A						
Atrial Fibrillation (ccw)	COVAR90	N/A	1	N/A						
	COVAR91	N/A	2	N/A						
	COVAR92	N/A	N/A	N/A						
Heart Failure (ccw)	COVAR93	N/A	1	N/A						
Ischemic Heart Disease (ccw)	COVAR94	N/A	1	N/A						
Stroke/Transient Ischemic Attack (TIA) (ccw)	COVAR95	N/A	1	N/A						
	COVAR96	N/A	2	N/A						
	COVAR97	N/A	N/A	N/A						
History of Cardiac Arrest	COVAR98	N/A	1	N/A						
History of Coronary Angioplasty or Bypass	COVAR99	N/A	1	N/A						
Alzheimer's disease, dementia, and conditions (ccw)	COVAR100	N/A	1	N/A						

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
Depression (ccw)	COVAR101	N/A	1	N/A						
Bipolar, or Other Depressive Mood Disorders	COVAR102	N/A	1	N/A						
ADHD	COVAR103	N/A	1	N/A						
Cerebral palsy	COVAR104	N/A	1	N/A						
Spinal cord injuries	COVAR105	N/A	1	N/A						
Down syndrome	COVAR106	N/A	1	N/A						
Alcohol Abuse or Dependence	COVAR107	N/A	1	N/A						
Drug Abuse or Dependence	COVAR108	N/A	1	N/A						
Obesity: diagnosed or identified by weight management procedures	COVAR109	N/A	1	N/A						
Obesity: identified by weight management-related prescriptions	COVAR110	N/A	1	N/A						
Overweight	COVAR111	N/A	1	N/A						
Obesity/overweight	COVAR112	N/A	N/A	N/A						
Smoking: diagnosed or identified by smoking cessation procedures	COVAR113	N/A	1	N/A						
Smoking: identified by smoking-related prescriptions	COVAR114	N/A	1	N/A						
Smoking	COVAR115	N/A	N/A	N/A						
HIV/AIDS	COVAR116	N/A	1	N/A						
Hematological Malignancy	COVAR117	N/A	1	N/A						
Treatment-Independent Immune Deficiencies	COVAR118	N/A	1	N/A						
Dialysis	COVAR119	N/A	1	N/A						
Chemo Therapeutic Agents/ Diagnoses and Procedures	COVAR120	N/A	1	N/A						
Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures	COVAR121	N/A	1	N/A						

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**	**Minimum cumulative dose**	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
Steroid/Corticosteroid Diagnoses and Procedures and Dispensing	COVAR122	N/A	1	N/A						
Organ Transplant Diagnoses and Procedures	COVAR123	N/A	1	N/A						
Solid Malignancies	COVAR124	N/A	1	N/A						
Immunocompromised	COVAR125	N/A	N/A	N/A						
Other general Health Indicators [2]										
Pre-index										
Hyperlipidemia (ccw)	COVAR126	N/A	1	N/A						
	COVAR127	N/A	2	N/A						
	COVAR128	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Rheumatoid Arthritis/Osteoarthritis (ccw)	COVAR129	N/A	2	N/A						
Acquired Hypothyroidism (ccw)	COVAR130	N/A	1	N/A						
	COVAR131	N/A	2	N/A						
	COVAR132	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Glaucoma (ccw)	COVAR133	N/A	1	N/A						
Osteoporosis (ccw)	COVAR134	N/A	1	N/A						
	COVAR135	N/A	2	N/A						
	COVAR136	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Anemia (ccw)	COVAR137	N/A	1	N/A						
Benign Prostatic Hyperplasia (ccw)	COVAR138	N/A	1	N/A						
	COVAR139	N/A	2	N/A						
	COVAR140	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Hip/Pelvic Fracture (ccw)	COVAR141	N/A	1	N/A						
Cataract (ccw)	COVAR142	N/A	1	N/A						
Parkinson's Disease and Secondary Parkinsonism (ccw)	COVAR143	N/A	1	N/A						
	COVAR144	N/A	2	N/A						
	COVAR145	N/A	N/A	N/A						
COVID-19 diagnosis/Treatments										
Pre-index										

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**	**Minimum cumulative dose**	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
COVID-19 diagnosis	COVAR146	N/A	1	N/A	N/A	N/A	N/A	N/A	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
Lopinavir/Ritonavir	COVAR147	No	1	N/A						
Remdesivir	COVAR148	No	1	N/A						
Hydroxychloroquine	COVAR149	No	1	N/A	N/A	N/A	N/A	N/A		
Chloroquine	COVAR150	No	1	N/A	N/A	N/A	N/A	N/A		
Azithromycin	COVAR151	No	1	N/A	N/A	N/A	N/A	N/A		
Ivermectin	COVAR152	No	1	N/A	N/A	N/A	N/A	N/A		
Dexamethasone	COVAR153	No	1	N/A	N/A	N/A	N/A	N/A		
Other Corticosteroids	COVAR154	No	1	N/A	N/A	N/A	N/A	N/A		
Inhaled Corticosteroids	COVAR155	No	1	N/A	N/A	N/A	N/A	N/A		
Paxlovid	COVAR156	No	1	N/A	N/A	N/A	N/A	N/A		
Baricitinib	COVAR157	No	1	N/A	N/A	N/A	N/A	N/A		
Tocilizumab	COVAR158	No	1	N/A	N/A	N/A	N/A	N/A		
Bamlanivimab	COVAR159	No	1	N/A						
Casirivimab/Imdevimab	COVAR160	No	1	N/A						
Bamlanivimab/Etesevimab	COVAR161	No	1	N/A						
Sotrovimab	COVAR162	No	1	N/A						
NSAIDs	COVAR163	No	1	N/A	N/A	N/A	N/A	N/A		
Antidepressants	COVAR164	No	1	N/A	N/A	N/A	N/A	N/A		
Post-index										
COVID-19 diagnosis	COVAR165	N/A	1	N/A	N/A	N/A	N/A	N/A		
Lopinavir/Ritonavir	COVAR166	No	1	N/A						
Remdesivir	COVAR167	No	1	N/A	N/A	N/A	N/A	N/A		
Hydroxychloroquine	COVAR168	No	1	N/A	N/A	N/A	N/A	N/A		
Chloroquine	COVAR169	No	1	N/A						
Azithromycin	COVAR170	No	1	N/A						
Ivermectin	COVAR171	No	1	N/A						
Dexamethasone	COVAR172	No	1	N/A						
Other Corticosteroids	COVAR173	No	1	N/A						
Inhaled Corticosteroids	COVAR174	No	1	N/A						
Paxlovid	COVAR175	No	1	N/A						
Baricitinib	COVAR176	No	1	N/A						
Tocilizumab	COVAR177	No	1	N/A						
Bamlanivimab	COVAR178	No	1	N/A						

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics

Covariate	Covariate Number	Exclude evidence of days supply if covariate includes dispensings	Number of instances the covariate should be found in evaluation period	Minimum Days Supplied	Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values
Casirivimab/Imdevimab	COVAR179	No	1	N/A						
Bamlanivimab/Etesevimab	COVAR180	No	1	N/A						
Sotrovimab	COVAR181	No	1	N/A						
NSAIDs	COVAR182	No	1	N/A						
Antidepressants	COVAR183	No	1	N/A						
Comorbidity Score										
Charlson/Elixhauser comorbidity scores		N/A	1	N/A						
Health Service Utilization Intensity Metrics										
Mean number of ambulatory encounters	-	N/A	N/A	N/A	N/A	N/A	N/A	N/A	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
Mean number of emergency room encounters	-	N/A	N/A	N/A	N/A	N/A	N/A	N/A		
Mean number of inpatient hospital encounters	-	N/A	N/A	N/A	N/A	N/A	N/A	N/A		
Mean number of non-acute institutional encounters	-	N/A	N/A	N/A	N/A	N/A	N/A	N/A		
Mean number of other ambulatory encounters	-	N/A	N/A	N/A	N/A	N/A	N/A	N/A		
Mean number of filled prescriptions	-	N/A	N/A	N/A	N/A	N/A	N/A	N/A		
Mean number of generics dispensed	-	N/A	N/A	N/A						
Mean number of unique drug classes dispensed	-	N/A	N/A	N/A						

***The wildcard symbol (*) can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.**

[1]Caresetting/ Principal Diagnosis

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Appendix G r02. Specifications Defining Parameters for Baseline Characteristics for run02 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Exclude evidence of days supply if covariate includes dispensings**	**Number of instances the covariate should be found in evaluation period**	**Minimum Days Supplied**	**Minimum cumulative dose**	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

[2] Specified chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse (CCW) algorithms.

Reference: Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. https://www.ccwdata.org/web/guest/condition-categories

N/A: Not Applicable

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
Demographics										
Age (continuous, and categorical)	-	04	N/A	N/A	N/A	0	0	N/A	N/A	N/A
Sex	-	04	N/A	N/A	N/A	0	0	N/A	N/A	N/A
Race	-	04	N/A	N/A	N/A	0	0	N/A	N/A	N/A
Ethnicity	-	04	N/A	N/A	N/A	0	0	N/A	N/A	N/A
Year	-	04	N/A	N/A	N/A	0	0	N/A	N/A	N/A
COVID-19 Vaccination										
COVID vaccine brand for the third or fourth observed record (depends on if they are from immunocompromised or non-immunocompromised cohorts)										
Pfizer at index	COVAR1	04	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
Moderna at index	COVAR2	04	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
COVID vaccine code type for the third or fourth observed record (depends on if they are from immunocompromised or non-immunocompromised cohorts)										

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
Insurance claims data (NDC/CPT/HCPCS codes) only at index date	COVAR3	04	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes)	0	0	N/A	1	N/A
State-based Immunization Information Systems (IIS) (CVX codes) only at index date	COVAR4	04	N/A	Any	*Procedure Code (CVX)	0	0	N/A	1	N/A
COVID vaccine for the third or fourth observed record (depends on if they are from immunocompromised or non-immunocompromised cohorts); monovalent or bivalent (only Pfizer and Moderna)										
Monovalent at index date	COVAR5	04	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
Bivalent at index date	COVAR6	04	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	instances the covariate should be found in evaluation period	Minimum Days Supplied
COVID vaccine for the third or fourth observed record (depends on if they are from immunocompromised or non-immunocompromised cohorts); whether the "Booster" or "Bivalent" is mentioned in the code description										
CovVax_Booster_1	COVAR7	04	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	0	0	N/A	1	N/A
COVID vaccine for the observed record after the third or fourth record (depends on if they are from immunocompromised or non-immunocompromised cohorts); whether the "Booster" or "Bivalent" is mentioned in the code description										
CovVax_Booster_2	COVAR8	04	N/A	Any	*Drug Code *Procedure Code (CPT/HCPCS codes) *Procedure Code (CVX)	4	latest available data	N/A	1	N/A
High-risk comorbidities for severe COVID-19 infection [2]										
Pre-index										
Reactive Airway and Lung Diseases	COVAR16	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Other Chronic Respiratory Diseases (e.g., Pneumonia and Bronchitis)	COVAR17	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
Sickle Cell Disease	COVAR18	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Liver disease (severe/moderate)	COVAR19	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Tuberculosis	COVAR20	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Cystic fibrosis	COVAR21	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Congenital or Acquired Heart Disease	COVAR22	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Lung Cancer (ccw)	COVAR23	04	N/A	IP*, IS* or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR24	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR25	04	COVAR23 or COVAR24	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Breast Cancer (ccw)	COVAR26	04	N/A	IP*, IS* or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR27	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR28	04	COVAR26 or COVAR27	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Colorectal Cancer (ccw)	COVAR29	04	N/A	IP*, IS* or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR30	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR31	04	COVAR29 or COVAR30	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Prostate Cancer (ccw)	COVAR32	04	N/A	IP*, IS* or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR33	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR34	04	COVAR32 or COVAR33	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
Endometrial Cancer (ccw)	COVAR35	04	N/A	IP*, IS* or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR36	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR37	04	COVAR35 or COVAR36	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other cancer	COVAR38	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Asthma (ccw)	COVAR39	04	N/A	IP*, IS*, or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR40	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR41	04	COVAR39 or COVAR40	N/A	N/A	N/A	N/A	N/A	N/A	N/A
COPD and Bronchiectasis (ccw)	COVAR42	04	N/A	IP*, IS*, or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR43	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR44	04	COVAR42 or COVAR43	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diabetes (types 1 and 2) (ccw)	COVAR45	04	N/A	IP*, IS* or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR46	04	N/A	AV*, ED*, OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR47	04	COVAR45 or COVAR46	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Chronic Kidney Disease (ccw)	COVAR48	04	N/A	IP*, IS*, or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR49	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR50	04	COVAR48 or COVAR49	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Hypertension (ccw)	COVAR51	04	N/A	IP*, IS* or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	instances the covariate should be found in evaluation period	Minimum Days Supplied
	COVAR52	04	N/A	AV*, ED*, OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR53	04	COVAR51 or COVAR52	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Acute Myocardial Infarction (ccw)	COVAR54	04	N/A	IPP, IPS	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Atrial Fibrillation (ccw)	COVAR55	04	N/A	IPP, IPS or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR56	04	N/A	AV*, ED*, OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR57	04	COVAR55 or COVAR56	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Heart Failure (ccw)	COVAR58	04	N/A	IP*, AV*, ED*, OA*	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Ischemic Heart Disease (ccw)	COVAR59	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Stroke/Transient Ischemic Attack (TIA) (ccw)	COVAR60	04	N/A	IP*	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR61	04	N/A	AV*, ED*, OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR62	04	COVAR60 or COVAR61	N/A	N/A	N/A	N/A	N/A	N/A	N/A
History of Cardiac Arrest	COVAR63	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
History of Coronary Angioplasty or Bypass	COVAR64	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Alzheimer's disease, dementia, and c	COVAR65	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Depression (ccw)	COVAR66	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Bipolar, or Other Depressive Mood Disorders	COVAR67	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
ADHD	COVAR68	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
Cerebral palsy	COVAR69	04	N/A	Any	*Diagnosis/ procedure Codes	Earliest available data	0	N/A	1	N/A
Spinal cord injuries	COVAR70	04	N/A	Any	*Diagnosis/ procedure Codes	Earliest available data	0	N/A	1	N/A
Down syndrome	COVAR71	04	N/A	Any	*Diagnosis/ procedure Codes	Earliest available data	0	N/A	1	N/A
Alcohol Abuse or Dependence	COVAR72	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Drug Abuse or Dependence	COVAR73	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Obesity: diagnosed or identified by weight management procedures	COVAR74	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Obesity: identified by weight management-related prescriptions	COVAR75	04	N/A	Any	*Drug Code	-183	0	N/A	1	N/A
Overweight	COVAR76	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Obesity/overweight	COVAR77	04	COVAR74 or COVAR75 or COVAR76	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Smoking: diagnosed or identified by smoking cessation procedures	COVAR78	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Smoking: identified by smoking-related prescriptions	COVAR79	04	N/A	Any	*Drug codes	-183	0	N/A	1	N/A
Smoking	COVAR80	04	COVAR78 or COVAR79	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HIV/AIDS	COVAR81	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
Hematological Malignancy	COVAR82	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Treatment-Independent Immune Deficiencies	COVAR83	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Dialysis	COVAR84	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Chemo Therapeutic Agents/ Diagnoses and Procedures	COVAR85	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures	COVAR86	04	N/A	Any	*Diagnosis/ procedure Codes *Drug codes	-183	0	N/A	1	N/A
Steroid/Corticosteroid Diagnoses and Procedures and Dispensing	COVAR87	04	N/A	Any	*Diagnosis/ procedure Codes *Drug codes	-183	0	N/A	1	N/A
Organ Transplant Diagnoses and Procedures	COVAR88	04	N/A	Any	*Diagnosis/ procedure Codes *Drug codes	-183	0	N/A	1	N/A
Solid Malignancies	COVAR89	02	N/A	Any	*Diagnosis/ procedure Codes *Drug codes	-183	0	N/A	1	N/A
Immunocompromised	COVAR90	01	COVAR81 or COVAR82 or COVAR83 or COVAR84 or COVAR85 or COVAR86 or COVAR87 or COVAR88 or COVAR89	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other general Health Indicators [2]										
Pre-index										
Hyperlipidemia (ccw)	COVAR91	04	N/A	IP*, IS* or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	instances the covariate should be found in evaluation period	Minimum Days Supplied
	COVAR92	04	N/A	AV*, ED*, OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR93	04	COVAR91 or COVAR92	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Rheumatoid Arthritis/Osteoarthritis (ccw)	COVAR94	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
Acquired Hypothyroidism (ccw)	COVAR95	04	N/A	IP*, IS*, or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR96	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR97	04	COVAR95 or COVAR96	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Glaucoma (ccw)	COVAR98	04	N/A	AV*, ED*, OA*	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Osteoporosis (ccw)	COVAR99	04	N/A	IP*, IS*, or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR100	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR101	04	COVAR99 or COVAR100	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Anemia (ccw)	COVAR102	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Benign Prostatic Hyperplasia (ccw)	COVAR103	04	N/A	IP*, IS*, or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR104	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR105	04	COVAR103 or COVAR104	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Hip/Pelvic Fracture (ccw)	COVAR106	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Cataract (ccw)	COVAR107	04	N/A	AV*, ED*, OA*	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
Parkinson's Disease and Secondary Parkinsonism (ccw)	COVAR108	04	N/A	IP*, IS*, or	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
	COVAR109	04	N/A	AV*, ED* OA*	*Diagnosis/ procedure Codes	-183	0	N/A	2	N/A
	COVAR110	04	COVAR108 or COVAR109	N/A	N/A	N/A	N/A	N/A	N/A	N/A
COVID-19 diagnosis/Treatments										
Pre-index										
COVID-19 diagnosis	COVAR111	04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Lopinavir/Ritonavir	COVAR112	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Remdesivir	COVAR113	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Hydroxychloroquine	COVAR114	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Chloroquine	COVAR115	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Azithromycin	COVAR116	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Ivermectin	COVAR117	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Dexamethasone	COVAR118	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Other Corticosteroids	COVAR119	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Inhaled Corticosteroids	COVAR120	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Paxlovid	COVAR121	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	instances the covariate should be found in evaluation period	Minimum Days Supplied
Baricitinib	COVAR122	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Tocilizumab	COVAR123	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Bamlanivimab	COVAR124	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Casirivimab/Imdevimab	COVAR125	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Bamlanivimab/Etesevimab	COVAR126	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Sotrovimab	COVAR127	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
NSAIDs	COVAR128	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Antidepressants	COVAR129	04	N/A	Any	*Drug/procedure Codes	-183	0	No	1	N/A
Post-index										
COVID-19 diagnosis	COVAR130	04	N/A	Any	*Diagnosis/ procedure Codes	1	183	N/A	1	N/A
Lopinavir/Ritonavir	COVAR131	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Remdesivir	COVAR132	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Hydroxychloroquine	COVAR133	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Chloroquine	COVAR134	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Azithromycin	COVAR135	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Ivermectin	COVAR136	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Dexamethasone	COVAR137	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	**Covariate Number**	**Cohort (scenarios)**	**Combo Covariate Components**	**Care setting/ Principal diagnosis[1]**	**Code Category**	**Evaluation period start**	**Evaluation period end**	**Exclude evidence of days supply if covariate includes dispensings**	**instances the covariate should be found in evaluation period**	**Minimum Days Supplied**
Other Corticosteroids	COVAR138	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Inhaled Corticosteroids	COVAR139	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Paxlovid	COVAR140	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Baricitinib	COVAR141	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Tocilizumab	COVAR142	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Bamlanivimab	COVAR143	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Casirivimab/Imdevimab	COVAR144	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Bamlanivimab/Etesevimab	COVAR145	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Sotrovimab	COVAR146	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
NSAIDs	COVAR147	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Antidepressants	COVAR148	04	N/A	Any	*Drug/procedure Codes	1	183	No	1	N/A
Comorbidity score										
Charlson/Elixhauser comorbidity scores		04	N/A	Any	*Diagnosis/ procedure Codes	-183	0	N/A	1	N/A
Health Service Utilization Intensity Metrics										
Mean number of ambulatory encounters	-	04	N/A	AV*	N/A	-183	0	N/A	N/A	N/A
Mean number of emergency room encounters	-	04	N/A	ED*	N/A	-183	0	N/A	N/A	N/A
Mean number of inpatient hospital encounters	-	04	N/A	IP*	N/A	-183	0	N/A	N/A	N/A

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	instances the covariate should be found in evaluation period	Minimum Days Supplied
Mean number of non-acute institutional encounters	-	04	N/A	IS*	N/A	-183	0	N/A	N/A	N/A
Mean number of other ambulatory encounters	-	04	N/A	OA*	N/A	-183	0	N/A	N/A	N/A
Mean number of filled prescriptions	-	04	N/A	N/A	N/A	-183	0	N/A	N/A	N/A
Mean number of generics dispensed	-	04	N/A	N/A	N/A	-183	0	N/A	N/A	N/A
Mean number of unique drug classes	-	04	N/A	N/A	N/A	-183	0	N/A	N/A	N/A

***The wildcard symbol (*) can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.**

The (P) at the end of the care setting refers to the primary diagnosis position, while the (S) refers to the secondary diagnosis position. This indicates that only the first or second diagnosis on the claims should be used for specified codes. For example, IPP (Inpatient Primary) uses the first diagnosis position, and IPS (Inpatient Scondary) uses the second diagnosis position.

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics										
Covariate	Covariate Number	Cohort (scenarios)	Combo Covariate Components	Care setting/ Principal diagnosis[1]	Code Category	Evaluation period start	Evaluation period end	Exclude evidence of days supply if covariate includes dispensings	instances the covariate should be found in evaluation period	Minimum Days Supplied

[1]Caresetting/ Principal Diagnosis
- Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.
- Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.
- Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.
- Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.
- Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

[2] Specified chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse (CCW) algorithms.
Reference: Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. https://www.ccwdata.org/web/guest/condition-categories
N/A: Not Applicable

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics							
Covariate	**Covariate Number**	**Minimum cumulative dose**	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
Demographics							
Age (continuous, and categorical)	-	N/A	N/A	N/A	N/A	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
Sex	-	N/A	N/A	N/A	N/A		
Race	-	N/A	N/A	N/A	N/A		
Ethnicity	-	N/A	N/A	N/A	N/A		
Year	-	N/A	N/A	N/A	N/A		
COVID-19 Vaccination							
COVID vaccine brand for the third or fourth observed record (depends on if they are from immunocompromised or non-immunocompromised cohorts)		Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
Pfizer at index	COVAR1						
Moderna at index	COVAR2						
COVID vaccine code type for the third or fourth observed record		Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

		Baseline Characteristics					
Covariate	**Covariate Number**	**Minimum cumulative dose**	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
Insurance claims data (NDC/CPT/HCPCS codes) only at index date	COVAR3						
State-based Immunization Information Systems (IIS) (CVX codes) only at index date	COVAR4						
COVID vaccine for the third or fourth observed record (depends on if they are from immunocompromised or non-immunocompromised cohorts); monovalent or bivalent (only Pfizer and Moderna)		Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
Monovalent at index date	COVAR5						
Bivalent at index date	COVAR6						

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics							
Covariate	**Covariate Number**	**Minimum cumulative dose**	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
COVID vaccine for the third or fourth observed record (depends on if they are from immunocompromised or non-immunocompromised cohorts); whether the "Booster" or "Bivalent" is mentioned in the code description		Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
CovVax_Booster_1	COVAR7						
COVID vaccine for the observed record after the third or fourth record (depends on if they are from immunocompromised or non-immunocompromised cohorts); whether the "Booster" or "Bivalent" is mentioned in the code description		Numeric and units specified	Numeric and units specified	Numeric and units specified	Numeric specified; Indicates a forced supply that should be attached to the NDC to replaced the inclusion/exclusion code's RxSup value	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
CovVax_Booster_2	COVAR8						
High-risk comorbidities for severe COVID-19 infection [2]							
Pre-index							
Reactive Airway and Lung Diseases	COVAR16						
Other Chronic Respiratory Diseases (e.g., Pneumonia and Bronchitis)	COVAR17						
Sickle Cell Disease	COVAR18						
Liver disease (severe/moderate)	COVAR19						
Tuberculosis	COVAR20						

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

		Baseline Characteristics					
Covariate	**Covariate Number**	**Minimum cumulative dose**	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
Cystic fibrosis	COVAR21						
Congenital or Acquired Heart Disease	COVAR22						
Lung Cancer (ccw)	COVAR23						
	COVAR24						
	COVAR25						
Breast Cancer (ccw)	COVAR26						
	COVAR27						
	COVAR28	N/A	N/A	N/A	N/A	N/A	N/A
Colorectal Cancer (ccw)	COVAR29						
	COVAR30						
	COVAR31						
Prostate Cancer (ccw)	COVAR32						
	COVAR33						
	COVAR34						
Endometrial Cancer (ccw)	COVAR35						
	COVAR36						
	COVAR37						
Other cancer	COVAR38						
Asthma (ccw)	COVAR39						
	COVAR40						
	COVAR41						
COPD and Bronchiectasis (ccw)	COVAR42						
	COVAR43						
	COVAR44						
Diabetes (types 1 and 2) (ccw)	COVAR45						
	COVAR46						
	COVAR47						
Chronic Kidney Disease (ccw)	COVAR48						
	COVAR49						
	COVAR50	N/A	N/A	N/A	N/A	N/A	N/A
Hypertension (ccw)	COVAR51						
	COVAR52						
	COVAR53						
Acute Myocardial Infarction (ccw)	COVAR54						

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

		Baseline Characteristics					
Covariate	**Covariate Number**	**Minimum cumulative dose**	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
Atrial Fibrillation (ccw)	COVAR55 COVAR56 COVAR57						
Heart Failure (ccw)	COVAR58						
Ischemic Heart Disease (ccw)	COVAR59						
Stroke/Transient Ischemic Attack (TIA) (ccw)	COVAR60 COVAR61 COVAR62						
History of Cardiac Arrest	COVAR63						
History of Coronary Angioplasty or Bypass	COVAR64						
Alzheimer's disease, dementia, and c	COVAR65						
Depression (ccw)	COVAR66						
Bipolar, or Other Depressive Mood Disorders	COVAR67						
ADHD	COVAR68						
Cerebral palsy	COVAR69						
Spinal cord injuries	COVAR70						
Down syndrome	COVAR71						
Alcohol Abuse or Dependence	COVAR72						
Drug Abuse or Dependence	COVAR73						
Obesity: diagnosed or identified by weight management procedures	COVAR74						
Obesity: identified by weight management-related prescriptions	COVAR75						
Overweight	COVAR76						
Obesity/overweight	COVAR77						
Smoking: diagnosed or identified by smoking cessation procedures	COVAR78						
Smoking: identified by smoking-related prescriptions	COVAR79						

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

		Baseline Characteristics					
Covariate	**Covariate Number**	**Minimum cumulative dose**	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
Smoking	COVAR80						
HIV/AIDS	COVAR81						
Hematological Malignancy	COVAR82						
Treatment-Independent Immune Deficiencies	COVAR83						
Dialysis	COVAR84						
Chemo Therapeutic Agents/ Diagnoses and Procedures	COVAR85						
Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures	COVAR86						
Steroid/Corticosteroid Diagnoses and Procedures and Dispensing	COVAR87						
Organ Transplant Diagnoses and Procedures	COVAR88						
Solid Malignancies	COVAR89						
Immunocompromised	COVAR90						
Other general Health Indicators [2]							
Pre-index							
Hyperlipidemia (ccw)	COVAR91						
	COVAR92						
	COVAR93	N/A	N/A	N/A	N/A	N/A	N/A
Rheumatoid Arthritis/Osteoarthritis (ccw)	COVAR94						
Acquired Hypothyroidism (ccw)	COVAR95						
	COVAR96						
	COVAR97	N/A	N/A	N/A	N/A	N/A	N/A
Glaucoma (ccw)	COVAR98						
Osteoporosis (ccw)	COVAR99						
	COVAR100						
	COVAR101	N/A	N/A	N/A	N/A	N/A	N/A
Anemia (ccw)	COVAR102						
Benign Prostatic Hyperplasia (ccw)	COVAR103						
	COVAR104						

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

Baseline Characteristics							
Covariate	**Covariate Number**	**Minimum cumulative dose**	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
	COVAR105	N/A	N/A	N/A	N/A	N/A	N/A
Hip/Pelvic Fracture (ccw)	COVAR106						
Cataract (ccw)	COVAR107						
Parkinson's Disease and Secondary	COVAR108						
Parkinsonism (ccw)	COVAR109						
	COVAR110						
COVID-19 diagnosis/Treatments							
Pre-index							
COVID-19 diagnosis	COVAR111	N/A	N/A	N/A	N/A	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
Lopinavir/Ritonavir	COVAR112						
Remdesivir	COVAR113						
Hydroxychloroquine	COVAR114	N/A	N/A	N/A	N/A		
Chloroquine	COVAR115	N/A	N/A	N/A	N/A		
Azithromycin	COVAR116	N/A	N/A	N/A	N/A		
Ivermectin	COVAR117	N/A	N/A	N/A	N/A		
Dexamethasone	COVAR118	N/A	N/A	N/A	N/A		
Other Corticosteroids	COVAR119	N/A	N/A	N/A	N/A		
Inhaled Corticosteroids	COVAR120	N/A	N/A	N/A	N/A		
Paxlovid	COVAR121	N/A	N/A	N/A	N/A		
Baricitinib	COVAR122	N/A	N/A	N/A	N/A		
Tocilizumab	COVAR123	N/A	N/A	N/A	N/A		
Bamlanivimab	COVAR124						
Casirivimab/Imdevimab	COVAR125						
Bamlanivimab/Etesevimab	COVAR126						
Sotrovimab	COVAR127						
NSAIDs	COVAR128	N/A	N/A	N/A	N/A		
Antidepressants	COVAR129	N/A	N/A	N/A	N/A		
Post-index							
COVID-19 diagnosis	COVAR130	N/A	N/A	N/A	N/A		
Lopinavir/Ritonavir	COVAR131						
Remdesivir	COVAR132	N/A	N/A	N/A	N/A		
Hydroxychloroquine	COVAR133	N/A	N/A	N/A	N/A		

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

		Baseline Characteristics					
Covariate	**Covariate Number**	**Minimum cumulative dose**	**Minimum average daily dose**	**Maximum average daily dose**	**Forced supply to attach to dispensings**	**Lab date selection algorithm**	**Lab Result Values**
Chloroquine	COVAR134						
Azithromycin	COVAR135						
Ivermectin	COVAR136						
Dexamethasone	COVAR137						
Other Corticosteroids	COVAR138						
Inhaled Corticosteroids	COVAR139						
Paxlovid	COVAR140						
Baricitinib	COVAR141						
Tocilizumab	COVAR142						
Bamlanivimab	COVAR143						
Casirivimab/Imdevimab	COVAR144						
Bamlanivimab/Etesevimab	COVAR145						
Sotrovimab	COVAR146						
NSAIDs	COVAR147						
Antidepressants	COVAR148						
Comorbidity score							
Charlson/Elixhauser comorbidity scores							
Health Service Utilization Intensity Metrics							
Mean number of ambulatory encounters	-	N/A	N/A	N/A	N/A	*Single (e.g., L) *Hierarchy (e.g., LOR)	Specify the lab result value or lab result range
Mean number of emergency room encounters	-	N/A	N/A	N/A	N/A		
Mean number of inpatient hospital encounters	-	N/A	N/A	N/A	N/A		
Mean number of non-acute institutional encounters	-	N/A	N/A	N/A	N/A		
Mean number of other ambulatory encounters	-	N/A	N/A	N/A	N/A		
Mean number of filled prescriptions	-	N/A	N/A	N/A	N/A		
Mean number of generics dispensed	-						
Mean number of unique drug classes	-						

Appendix G r04. Specifications Defining Parameters for Baseline Characteristics for run04 for this Request

		Baseline Characteristics					
Covariate	Covariate Number	Minimum cumulative dose	Minimum average daily dose	Maximum average daily dose	Forced supply to attach to dispensings	Lab date selection algorithm	Lab Result Values

***The wildcard symbol (*) can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.**
The (P) at the end of the care setting refers to the primary diagnosis position, while the (S) refers to the secondary diagnosis position. This indicates that only the first or second diagnosis on the claims should be used for specified codes. For example, IPP (Inpatient Primary) uses the first diagnosis position, and IPS (Inpatient Scondary) uses the second diagnosis position.

[1]Caresetting/ Principal Diagnosis
- Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.
- Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.
- Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.
- Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.
- Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

[2] Specified chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse (CCW) algorithms.
Reference: Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. https://www.ccwdata.org/web/guest/condition-categories
N/A: Not Applicable

Appendix H. Design Diagram Used for this Request



***Covariates:

Window I: Age, year, race, sex, ethnicity, COVID-19 vaccine brand/type of code, etc.

Window II: High-risk comorbidities for severe COVID-19 infection, General Health Indicators, and COVID-19 diagnosis/Treatment

Window III: COVID-19 diagnosis/Treatment

Appendix H. Design Diagram Used for this Request



***Covariates:

Window I: Age, year, race, sex, ethnicity, COVID-19 vaccine brand/type of code, etc.

Window II: High-risk comorbidities for severe COVID-19 infection, General Health Indicators, and COVID-19 diagnosis/Treatment

Window III: COVID-19 diagnosis/Treatment

Appendix H. Design Diagram Used for this Request



***Covariates:

Window I: Age, year, race, sex, ethnicity, Geographic regions, COVID-19 vaccine brand/type of code, etc.

Window II: High-risk comorbidities for severe COVID-19 infection, General Health Indicators, COVID-19 diagnosis/Treatments, and COVID-19 diagnosis/Treatment

Window III: High-risk comorbidities for severe COVID-19 infection, General Health Indicators, COVID-19 diagnosis/Treatments, and COVID-19 diagnosis/Treatment

Appendix H. Design Diagram Used for this Request



Immunocompromised: including any evidence of HIV/AIDS, Hematological Malignancy, Treatment-Independent Immune Deficiencies, Dialysis, Chemo Therapeutic Agents/ Diagnoses and Procedures, Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures, Steroid Diagnoses and Procedures, Organ Transplant Diagnoses and Procedures, or Solid Malignancies any time before index.

Appendix H. Design Diagram Used for this Request



Immunocompromised: including any evidence of HIV/AIDS, Hematological Malignancy, Treatment-Independent Immune Deficiencies, Dialysis, Chemo Therapeutic Agents/ Diagnoses and Procedures, Immunosuppressant Therapeutic Agents/ Diagnoses and Procedures, Steroid Diagnoses and Procedures, Organ Transplant Diagnoses and Procedures, or Solid Malignancies any time before index.

Appendix H. Design Diagram Used for this Request